

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number  
**WO 03/024392 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(US). **WU, Thomas, D.**; 113 Elsie Street, San Francisco, CA 94110 (US). **ZHANG, Zemin**; 876 Taurus Drive, Foster City, CA 94404 (US).

(21) International Application Number: PCT/US02/28859

(22) International Filing Date:  
11 September 2002 (11.09.2002)

(74) Agents: **KRESNAK, Mark, T.** et al.; c/o Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/323,268	18 September 2001 (18.09.2001)	US
60/339,227	19 October 2001 (19.10.2001)	US
60/336,827	7 November 2001 (07.11.2001)	US
60/331,906	20 November 2001 (20.11.2001)	US
60/345,444	2 January 2002 (02.01.2002)	US
60/369,724	3 April 2002 (03.04.2002)	US
60/404,809	19 August 2002 (19.08.2002)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(72) Inventors: **FRANTZ, Gretchen**; 135 San Benito Way, San Francisco, CA 94127 (US). **HILLAN, Kenneth, J.**; 64 Seward Street, San Francisco, CA 94114 (US). **PHILLIPS, Heidi, S.**; 15 Pine Avenue, San Carlos, CA 94070 (US). **POLAKIS, Paul**; 1449 Cortez Avenue, Burlingame, CA 94010 (US). **SPENCER, Susan, D.**; 2395 Paradise Drive, Tiburon, CA 94920 (US). **WILLIAMS, P., Mickey**; 509 Alto Avenue, Half Moon Bay, CA 94019

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

(57) Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.



WO 03/024392 A2

## COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

### FIELD OF THE INVENTION

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

### BACKGROUND OF THE INVENTION

Malignant tumors (cancers) are the second leading cause of death in the United States, after heart disease (Boring et al., *CA Cancer J. Clin.* 43:7 (1993)). Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread via the blood or lymphatic system to regional lymph nodes and to distant sites via a process called metastasis. In a cancerous state, a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.

In attempts to discover effective cellular targets for cancer diagnosis and therapy, researchers have sought to identify transmembrane or otherwise membrane-associated polypeptides that are specifically expressed on the surface of one or more particular type(s) of cancer cell as compared to on one or more normal non-cancerous cell(s). Often, such membrane-associated polypeptides are more abundantly expressed on the surface of the cancer cells as compared to on the surface of the non-cancerous cells. The identification of such tumor-associated cell surface antigen polypeptides has given rise to the ability to specifically target cancer cells for destruction via antibody-based therapies. In this regard, it is noted that antibody-based therapy has proved very effective in the treatment of certain cancers. For example, HERCEPTIN® and RITUXAN® (both from Genentech Inc., South San Francisco, California) are antibodies that have been used successfully to treat breast cancer and non-Hodgkin's lymphoma, respectively. More specifically, HERCEPTIN® is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) proto-oncogene. HER2 protein overexpression is observed in 25-30% of primary breast cancers. RITUXAN® is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. Both these antibodies are recombinantly produced in CHO cells.

In other attempts to discover effective cellular targets for cancer diagnosis and therapy, researchers have sought to identify (1) non-membrane-associated polypeptides that are specifically produced by one or more particular type(s) of cancer cell(s) as compared to by one or more particular type(s) of non-cancerous normal cell(s), (2) polypeptides that are produced by cancer cells at an expression level that is significantly higher than that of one or more normal non-cancerous cell(s), or (3) polypeptides whose expression is specifically limited to only a single (or very limited number of different) tissue type(s) in both the cancerous and non-cancerous state

(e.g., normal prostate and prostate tumor tissue). Such polypeptides may remain intracellularly located or may be secreted by the cancer cell. Moreover, such polypeptides may be expressed not by the cancer cell itself, but rather by cells which produce and/or secrete polypeptides having a potentiating or growth-enhancing effect on cancer cells. Such secreted polypeptides are often proteins that provide cancer cells with a growth advantage over normal cells and include such things as, for example, angiogenic factors, cellular adhesion factors, growth factors, and the like. Identification of antagonists of such non-membrane associated polypeptides would be expected to serve as effective therapeutic agents for the treatment of such cancers. Furthermore, identification of the expression pattern of such polypeptides would be useful for the diagnosis of particular cancers in mammals.

Despite the above identified advances in mammalian cancer therapy, there is a great need for additional diagnostic and therapeutic agents capable of detecting the presence of tumor in a mammal and for effectively inhibiting neoplastic cell growth, respectively. Accordingly, it is an objective of the present invention to identify: (1) cell membrane-associated polypeptides that are more abundantly expressed on one or more type(s) of cancer cell(s) as compared to on normal cells or on other different cancer cells, (2) non-membrane-associated polypeptides that are specifically produced by one or more particular type(s) of cancer cell(s) (or by other cells that produce polypeptides having a potentiating effect on the growth of cancer cells) as compared to by one or more particular type(s) of non-cancerous normal cell(s), (3) non-membrane-associated polypeptides that are produced by cancer cells at an expression level that is significantly higher than that of one or more normal non-cancerous cell(s), or (4) polypeptides whose expression is specifically limited to only a single (or very limited number of different) tissue type(s) in both a cancerous and non-cancerous state (e.g., normal prostate and prostate tumor tissue), and to use those polypeptides, and their encoding nucleic acids, to produce compositions of matter useful in the therapeutic treatment and diagnostic detection of cancer in mammals. It is also an objective of the present invention to identify cell membrane-associated, secreted or intracellular polypeptides whose expression is limited to a single or very limited number of tissues, and to use those polypeptides, and their encoding nucleic acids, to produce compositions of matter useful in the therapeutic treatment and diagnostic detection of cancer in mammals.

## SUMMARY OF THE INVENTION

### A. Embodiments

In the present specification, Applicants describe for the first time the identification of various cellular polypeptides (and their encoding nucleic acids or fragments thereof) which are expressed to a greater degree on the surface of or by one or more types of cancer cell(s) as compared to on the surface of or by one or more types of normal non-cancer cells. Alternatively, such polypeptides are expressed by cells which produce and/or secrete polypeptides having a potentiating or growth-enhancing effect on cancer cells. Again alternatively, such polypeptides may not be overexpressed by tumor cells as compared to normal cells of the same tissue type, but rather may be specifically expressed by both tumor cells and normal cells of only a single or very limited number of tissue types (preferably tissues which are not essential for life, e.g., prostate, etc.). All of the above polypeptides are herein referred to as Tumor-associated Antigenic Target polypeptides ("TAT" polypeptides) and are expected to serve as effective targets for cancer therapy and diagnosis in mammals.

Accordingly, in one embodiment of the present invention, the invention provides an isolated nucleic acid molecule having a nucleotide sequence that encodes a tumor-associated antigenic target polypeptide or fragment thereof (a "TAT" polypeptide).

In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length TAT polypeptide amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule comprising the coding sequence of a full-length TAT polypeptide cDNA as disclosed herein, the coding sequence of a TAT polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length TAT polypeptide amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In further aspects, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule that encodes the same mature polypeptide encoded by the full-length coding region of any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect of the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a TAT polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide(s) are disclosed herein. Therefore, soluble extracellular domains of the herein described TAT polypeptides are contemplated.

In other aspects, the present invention is directed to isolated nucleic acid molecules which hybridize to (a) a nucleotide sequence encoding a TAT polypeptide having a full-length amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length TAT polypeptide amino acid sequence as disclosed herein, or (b) the complement of the nucleotide sequence of (a). In this regard, an embodiment of the present invention is directed to fragments of a full-length TAT polypeptide coding sequence, or the complement thereof, as disclosed herein, that may find use as, for example, hybridization probes useful as, for example, diagnostic probes, antisense



oligonucleotide probes, or for encoding fragments of a full-length TAT polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-TAT polypeptide antibody, a TAT binding oligopeptide or other small organic molecule that binds to a TAT polypeptide. Such nucleic acid fragments are usually at least about 5 nucleotides in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a TAT polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the TAT polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which TAT polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such novel fragments of TAT polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the TAT polypeptide fragments encoded by these nucleotide molecule fragments, preferably those TAT polypeptide fragments that comprise a binding site for an anti-TAT antibody, a TAT binding oligopeptide or other small organic molecule that binds to a TAT polypeptide.

In another embodiment, the invention provides isolated TAT polypeptides encoded by any of the isolated nucleic acid sequences hereinabove identified.

In a certain aspect, the invention concerns an isolated TAT polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity, to a TAT polypeptide having a full-length amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide protein, with or without the signal peptide, as disclosed herein, an amino acid sequence encoded by any of the nucleic acid sequences disclosed herein or any other specifically defined fragment of a full-length TAT polypeptide amino acid sequence as disclosed herein.

In a further aspect, the invention concerns an isolated TAT polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity, to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein.

In a specific aspect, the invention provides an isolated TAT polypeptide without the N-terminal signal sequence and/or without the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the TAT polypeptide and recovering

the TAT polypeptide from the cell culture.

Another aspect of the invention provides an isolated TAT polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the TAT polypeptide and recovering the TAT polypeptide from the cell culture.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cells comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli* cells, or yeast cells. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides isolated chimeric polypeptides comprising any of the herein described TAT polypeptides fused to a heterologous (non-TAT) polypeptide. Example of such chimeric molecules comprise any of the herein described TAT polypeptides fused to a heterologous polypeptide such as, for example, an epitope tag sequence or a Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, single-chain antibody or antibody that competitively inhibits the binding of an anti-TAT polypeptide antibody to its respective antigenic epitope. Antibodies of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies of the present invention may optionally be produced in CHO cells or bacterial cells and preferably induce death of a cell to which they bind. For diagnostic purposes, the antibodies of the present invention may be detectably labeled, attached to a solid support, or the like.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described antibodies. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli* cells, or yeast cells. A process for producing any of the herein described antibodies is further provided and comprises culturing host cells under conditions suitable for expression of the desired antibody and recovering the desired antibody from the cell culture.

In another embodiment, the invention provides oligopeptides ("TAT binding oligopeptides") which bind, preferably specifically, to any of the above or below described TAT polypeptides. Optionally, the TAT binding oligopeptides of the present invention may be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The TAT binding oligopeptides of the present invention may optionally be produced in CHO cells or bacterial cells and preferably induce death of a cell to which they bind. For diagnostic purposes, the TAT binding oligopeptides of the present invention may be detectably labeled, attached to a solid support, or the like.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described TAT binding oligopeptides. Host cell comprising any such vector are also provided.

By way of example, the host cells may be CHO cells, *E. coli* cells, or yeast cells. A process for producing any of the herein described TAT binding oligopeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired oligopeptide and recovering the desired oligopeptide from the cell culture.

5 In another embodiment, the invention provides small organic molecules ("TAT binding organic molecules") which bind, preferably specifically, to any of the above or below described TAT polypeptides. Optionally, the TAT binding organic molecules of the present invention may be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The TAT binding organic molecules of the present invention preferably induce death of a cell to which they bind. For diagnostic purposes, the TAT binding organic molecules  
10 of the present invention may be detectably labeled, attached to a solid support, or the like.

In a still further embodiment, the invention concerns a composition of matter comprising a TAT polypeptide as described herein, a chimeric TAT polypeptide as described herein, an anti-TAT antibody as described herein, a TAT binding oligopeptide as described herein, or a TAT binding organic molecule as described herein, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

15 In yet another embodiment, the invention concerns an article of manufacture comprising a container and a composition of matter contained within the container, wherein the composition of matter may comprise a TAT polypeptide as described herein, a chimeric TAT polypeptide as described herein, an anti-TAT antibody as described herein, a TAT binding oligopeptide as described herein, or a TAT binding organic molecule as described herein. The article may further optionally comprise a label affixed to the container, or a package insert included  
20 with the container, that refers to the use of the composition of matter for the therapeutic treatment or diagnostic detection of a tumor.

Another embodiment of the present invention is directed to the use of a TAT polypeptide as described herein, a chimeric TAT polypeptide as described herein, an anti-TAT polypeptide antibody as described herein, a TAT binding oligopeptide as described herein, or a TAT binding organic molecule as described herein, for the  
25 preparation of a medicament useful in the treatment of a condition which is responsive to the TAT polypeptide, chimeric TAT polypeptide, anti-TAT polypeptide antibody, TAT binding oligopeptide, or TAT binding organic molecule.

#### B. Additional Embodiments

Another embodiment of the present invention is directed to a method for inhibiting the growth of a cell  
30 that expresses a TAT polypeptide, wherein the method comprises contacting the cell with an antibody, an oligopeptide or a small organic molecule that binds to the TAT polypeptide, and wherein the binding of the antibody, oligopeptide or organic molecule to the TAT polypeptide causes inhibition of the growth of the cell expressing the TAT polypeptide. In preferred embodiments, the cell is a cancer cell and binding of the antibody, oligopeptide or organic molecule to the TAT polypeptide causes death of the cell expressing the TAT polypeptide.  
35 Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TAT binding oligopeptides and TAT binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic

agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and TAT binding oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

Yet another embodiment of the present invention is directed to a method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a TAT polypeptide, wherein the method comprises administering to the mammal a therapeutically effective amount of an antibody, an oligopeptide or a small organic molecule that binds to the TAT polypeptide, thereby resulting in the effective therapeutic treatment of the tumor. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TAT binding oligopeptides and TAT binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

Yet another embodiment of the present invention is directed to a method of determining the presence of a TAT polypeptide in a sample suspected of containing the TAT polypeptide, wherein the method comprises exposing the sample to an antibody, oligopeptide or small organic molecule that binds to the TAT polypeptide and determining binding of the antibody, oligopeptide or organic molecule to the TAT polypeptide in the sample, wherein the presence of such binding is indicative of the presence of the TAT polypeptide in the sample. Optionally, the sample may contain cells (which may be cancer cells) suspected of expressing the TAT polypeptide. The antibody, TAT binding oligopeptide or TAT binding organic molecule employed in the method may optionally be detectably labeled, attached to a solid support, or the like.

A further embodiment of the present invention is directed to a method of diagnosing the presence of a tumor in a mammal, wherein the method comprises detecting the level of expression of a gene encoding a TAT polypeptide (a) in a test sample of tissue cells obtained from said mammal, and (b) in a control sample of known normal non-cancerous cells of the same tissue origin or type, wherein a higher level of expression of the TAT polypeptide in the test sample, as compared to the control sample, is indicative of the presence of tumor in the mammal from which the test sample was obtained.

Another embodiment of the present invention is directed to a method of diagnosing the presence of a tumor in a mammal, wherein the method comprises (a) contacting a test sample comprising tissue cells obtained from the mammal with an antibody, oligopeptide or small organic molecule that binds to a TAT polypeptide and (b) detecting the formation of a complex between the antibody, oligopeptide or small organic molecule and the TAT polypeptide in the test sample, wherein the formation of a complex is indicative of the presence of a tumor in the mammal. Optionally, the antibody, TAT binding oligopeptide or TAT binding organic molecule employed is detectably labeled, attached to a solid support, or the like, and/or the test sample of tissue cells is obtained from an individual suspected of having a cancerous tumor.

Yet another embodiment of the present invention is directed to a method for treating or preventing a cell proliferative disorder associated with altered, preferably increased, expression or activity of a TAT polypeptide, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist

of a TAT polypeptide. Preferably, the cell proliferative disorder is cancer and the antagonist of the TAT polypeptide is an anti-TAT polypeptide antibody, TAT binding oligopeptide, TAT binding organic molecule or antisense oligonucleotide. Effective treatment or prevention of the cell proliferative disorder may be a result of direct killing or growth inhibition of cells that express a TAT polypeptide or by antagonizing the cell growth potentiating activity of a TAT polypeptide.

5 Yet another embodiment of the present invention is directed to a method of binding an antibody, oligopeptide or small organic molecule to a cell that expresses a TAT polypeptide, wherein the method comprises contacting a cell that expresses a TAT polypeptide with said antibody, oligopeptide or small organic molecule under conditions which are suitable for binding of the antibody, oligopeptide or small organic molecule to said TAT polypeptide and allowing binding therebetween.

10 Other embodiments of the present invention are directed to the use of (a) a TAT polypeptide, (b) a nucleic acid encoding a TAT polypeptide or a vector or host cell comprising that nucleic acid, (c) an anti-TAT polypeptide antibody, (d) a TAT-binding oligopeptide, or (e) a TAT-binding small organic molecule in the preparation of a medicament useful for (i) the therapeutic treatment or diagnostic detection of a cancer or tumor, or (ii) the therapeutic treatment or prevention of a cell proliferative disorder.

15 Another embodiment of the present invention is directed to a method for inhibiting the growth of a cancer cell, wherein the growth of said cancer cell is at least in part dependent upon the growth potentiating effect(s) of a TAT polypeptide (wherein the TAT polypeptide may be expressed either by the cancer cell itself or a cell that produces polypeptide(s) that have a growth potentiating effect on cancer cells), wherein the method comprises contacting the TAT polypeptide with an antibody, an oligopeptide or a small organic molecule that binds to the TAT polypeptide, thereby antagonizing the growth-potentiating activity of the TAT polypeptide and, in turn, inhibiting the growth of the cancer cell. Preferably the growth of the cancer cell is completely inhibited. Even more preferably, binding of the antibody, oligopeptide or small organic molecule to the TAT polypeptide induces the death of the cancer cell. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TAT binding oligopeptides and TAT binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin, an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and TAT binding oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

25 Yet another embodiment of the present invention is directed to a method of therapeutically treating a tumor in a mammal, wherein the growth of said tumor is at least in part dependent upon the growth potentiating effect(s) of a TAT polypeptide, wherein the method comprises administering to the mammal a therapeutically effective amount of an antibody, an oligopeptide or a small organic molecule that binds to the TAT polypeptide, thereby antagonizing the growth potentiating activity of said TAT polypeptide and resulting in the effective therapeutic treatment of the tumor. Optionally, the antibody is a monoclonal antibody, antibody fragment, chimeric antibody, humanized antibody, or single-chain antibody. Antibodies, TAT binding oligopeptides and TAT binding organic molecules employed in the methods of the present invention may optionally be conjugated to a growth inhibitory agent or cytotoxic agent such as a toxin, including, for example, a maytansinoid or calicheamicin,

an antibiotic, a radioactive isotope, a nucleolytic enzyme, or the like. The antibodies and oligopeptides employed in the methods of the present invention may optionally be produced in CHO cells or bacterial cells.

C. Further Additional Embodiments

In yet further embodiments, the invention is directed to the following set of potential claims for this application:

1. Isolated nucleic acid having a nucleotide sequence that has at least 80% nucleic acid sequence identity to:

(a) a DNA molecule encoding the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) a DNA molecule encoding the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) a DNA molecule encoding an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) a DNA molecule encoding an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119);

(f) the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(g) the complement of (a), (b), (c), (d), (e) or (f).

2. Isolated nucleic acid having:

(a) a nucleotide sequence that encodes the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) a nucleotide sequence that encodes the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) a nucleotide sequence that encodes an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) a nucleotide sequence that encodes an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119);

(f) the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(g) the complement of (a), (b), (c), (d), (e) or (f).

3. Isolated nucleic acid that hybridizes to:

(a) a nucleic acid that encodes the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) a nucleic acid that encodes the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) a nucleic acid that encodes an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) a nucleic acid that encodes an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119);

(f) the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(g) the complement of (a), (b), (c), (d), (e) or (f).

4. The nucleic acid of Claim 3, wherein the hybridization occurs under stringent conditions.

5. The nucleic acid of Claim 3 which is at least about 5 nucleotides in length.

6. An expression vector comprising the nucleic acid of Claim 1, 2 or 3.

7. The expression vector of Claim 6, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

8. A host cell comprising the expression vector of Claim 7.

9. The host cell of Claim 8 which is a CHO cell, an *E. coli* cell or a yeast cell.

10. A process for producing a polypeptide comprising culturing the host cell of Claim 8 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.

11. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

12. An isolated polypeptide having:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

13. A chimeric polypeptide comprising the polypeptide of Claim 11 or 12 fused to a heterologous polypeptide.

14. The chimeric polypeptide of Claim 13, wherein said heterologous polypeptide is an epitope tag sequence or an Fc region of an immunoglobulin.

15. An isolated antibody that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

16. An isolated antibody that binds to a polypeptide having:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;



(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

17. The antibody of Claim 15 or 16 which is a monoclonal antibody.

18. The antibody of Claim 15 or 16 which is an antibody fragment.

19. The antibody of Claim 15 or 16 which is a chimeric or a humanized antibody.

20. The antibody of Claim 15 or 16 which is conjugated to a growth inhibitory agent.

21. The antibody of Claim 15 or 16 which is conjugated to a cytotoxic agent.

22. The antibody of Claim 21, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

23. The antibody of Claim 21, wherein the cytotoxic agent is a toxin.

24. The antibody of Claim 23, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

25. The antibody of Claim 23, wherein the toxin is a maytansinoid.

26. The antibody of Claim 15 or 16 which is produced in bacteria.

27. The antibody of Claim 15 or 16 which is produced in CHO cells.

28. The antibody of Claim 15 or 16 which induces death of a cell to which it binds.

29. The antibody of Claim 15 or 16 which is detectably labeled.

30. An isolated nucleic acid having a nucleotide sequence that encodes the antibody of Claim 15 or 16.

31. An expression vector comprising the nucleic acid of Claim 30 operably linked to control sequences recognized by a host cell transformed with the vector.

32. A host cell comprising the expression vector of Claim 31.

33. The host cell of Claim 32 which is a CHO cell, an *E. coli* cell or a yeast cell.

34. A process for producing an antibody comprising culturing the host cell of Claim 32 under conditions suitable for expression of said antibody and recovering said antibody from the cell culture.

35. An isolated oligopeptide that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

36. An isolated oligopeptide that binds to a polypeptide having:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequences shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

37. The oligopeptide of Claim 35 or 36 which is conjugated to a growth inhibitory agent.

38. The oligopeptide of Claim 35 or 36 which is conjugated to a cytotoxic agent.

39. The oligopeptide of Claim 38, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

40. The oligopeptide of Claim 38, wherein the cytotoxic agent is a toxin.

41. The oligopeptide of Claim 40, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

42. The oligopeptide of Claim 40, wherein the toxin is a maytansinoid.

43. The oligopeptide of Claim 35 or 36 which induces death of a cell to which it binds.

44. The oligopeptide of Claim 35 or 36 which is detectably labeled.

45. A TAT binding organic molecule that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

46. The organic molecule of Claim 45 that binds to a polypeptide having:

5 (a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

10 (c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

15 (e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

47. The organic molecule of Claim 45 or 46 which is conjugated to a growth inhibitory agent.

48. The organic molecule of Claim 45 or 46 which is conjugated to a cytotoxic agent.

20 49. The organic molecule of Claim 48, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

50. The organic molecule of Claim 48, wherein the cytotoxic agent is a toxin.

51. The organic molecule of Claim 50, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

25 52. The organic molecule of Claim 50, wherein the toxin is a maytansinoid.

53. The organic molecule of Claim 45 or 46 which induces death of a cell to which it binds.

54. The organic molecule of Claim 45 or 46 which is detectably labeled.

55. A composition of matter comprising:

30 (a) the polypeptide of Claim 11;

(b) the polypeptide of Claim 12;

(c) the chimeric polypeptide of Claim 13;

(d) the antibody of Claim 15;

(e) the antibody of Claim 16;

(f) the oligopeptide of Claim 35;

35 (g) the oligopeptide of Claim 36;

(h) the TAT binding organic molecule of Claim 45; or

(i) the TAT binding organic molecule of Claim 46; in combination with a carrier.

56. The composition of matter of Claim 55, wherein said carrier is a pharmaceutically acceptable carrier.

57. An article of manufacture comprising:

(a) a container; and

(b) the composition of matter of Claim 55 contained within said container.

58. The article of manufacture of Claim 57 further comprising a label affixed to said container, or a package insert included with said container, referring to the use of said composition of matter for the therapeutic treatment of or the diagnostic detection of a cancer.

59. A method of inhibiting the growth of a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein, the binding of said antibody, oligopeptide or organic molecule to said protein thereby causing an inhibition of growth of said cell.

60. The method of Claim 59, wherein said antibody is a monoclonal antibody.

61. The method of Claim 59, wherein said antibody is an antibody fragment.

62. The method of Claim 59, wherein said antibody is a chimeric or a humanized antibody.

63. The method of Claim 59, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

64. The method of Claim 59, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

65. The method of Claim 64, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

66. The method of Claim 64, wherein the cytotoxic agent is a toxin.

67. The method of Claim 66, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

68. The method of Claim 66, wherein the toxin is a maytansinoid.

69. The method of Claim 59, wherein said antibody is produced in bacteria.

70. The method of Claim 59, wherein said antibody is produced in CHO cells.

71. The method of Claim 59, wherein said cell is a cancer cell.

72. The method of Claim 71, wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent.

73. The method of Claim 71, wherein said cancer cell is selected from the group consisting of a breast cancer cell, a colorectal cancer cell, a lung cancer cell, an ovarian cancer cell, a central nervous system cancer cell, a liver cancer cell, a bladder cancer cell, a pancreatic cancer cell, a cervical cancer cell, a melanoma cell and a leukemia cell.

74. The method of Claim 71, wherein said protein is more abundantly expressed by said cancer cell as compared to a normal cell of the same tissue origin.

75. The method of Claim 59 which causes the death of said cell.

76. The method of Claim 59, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

77. A method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising administering to said mammal a therapeutically effective amount of an antibody, oligopeptide or organic molecule that binds to said protein, thereby effectively treating said mammal.

78. The method of Claim 77, wherein said antibody is a monoclonal antibody.

79. The method of Claim 77, wherein said antibody is an antibody fragment.

80. The method of Claim 77, wherein said antibody is a chimeric or a humanized antibody.

81. The method of Claim 77, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

82. The method of Claim 77, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

83. The method of Claim 82, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

84. The method of Claim 82, wherein the cytotoxic agent is a toxin.

85. The method of Claim 84, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

86. The method of Claim 84, wherein the toxin is a maytansinoid.

87. The method of Claim 77, wherein said antibody is produced in bacteria.

88. The method of Claim 77, wherein said antibody is produced in CHO cells.

89. The method of Claim 77, wherein said tumor is further exposed to radiation treatment or a chemotherapeutic agent.

90. The method of Claim 77, wherein said tumor is a breast tumor, a colorectal tumor, a lung tumor, an ovarian tumor, a central nervous system tumor, a liver tumor, a bladder tumor, a pancreatic tumor, or a cervical tumor.

91. The method of Claim 77, wherein said protein is more abundantly expressed by the cancerous cells of said tumor as compared to a normal cell of the same tissue origin.

92. The method of Claim 77, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

93. A method of determining the presence of a protein in a sample suspected of containing said protein, wherein said protein has at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising exposing said sample to an antibody, oligopeptide or organic molecule that binds to said protein and determining binding of said antibody, oligopeptide or organic molecule to said protein in said sample, wherein binding of the antibody, oligopeptide or organic molecule to said protein is indicative of the presence of said protein in said sample.

94. The method of Claim 93, wherein said sample comprises a cell suspected of expressing said protein.

95. The method of Claim 94, wherein said cell is a cancer cell.

96. The method of Claim 93, wherein said antibody, oligopeptide or organic molecule is detectably labeled.

97. The method of Claim 93, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

98. A method of diagnosing the presence of a tumor in a mammal, said method comprising determining the level of expression of a gene encoding a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

5 (b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

10 (d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

15 (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), in a test sample of tissue cells obtained from said mammal and in a control sample of known normal cells of the same tissue origin, wherein a higher level of expression of said protein in the test sample, as compared to the control sample, is indicative of the presence of tumor in the mammal from which the test sample was obtained.

99. The method of Claim 98, wherein the step of determining the level of expression of a gene encoding said protein comprises employing an oligonucleotide in an *in situ* hybridization or RT-PCR analysis.

20 100. The method of Claim 98, wherein the step determining the level of expression of a gene encoding said protein comprises employing an antibody in an immunohistochemistry or Western blot analysis.

101. The method of Claim 98, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

25 (b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

30 (d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

35 (f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).



102. A method of diagnosing the presence of a tumor in a mammal, said method comprising contacting a test sample of tissue cells obtained from said mammal with an antibody, oligopeptide or organic molecule that binds to a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

5 (b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

10 (d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

15 (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), and detecting the formation of a complex between said antibody, oligopeptide or organic molecule and said protein in the test sample, wherein the formation of a complex is indicative of the presence of a tumor in said mammal.

103. The method of Claim 102, wherein said antibody, oligopeptide or organic molecule is detectably labeled.

20 104. The method of Claim 102, wherein said test sample of tissue cells is obtained from an individual suspected of having a cancerous tumor.

105. The method of Claim 102, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

25 (b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

30 (d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

35 106. A method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising administering to a subject in need of such treatment an effective amount of an antagonist of said protein, thereby effectively treating or preventing said cell proliferative disorder.

107. The method of Claim 106, wherein said cell proliferative disorder is cancer.

108. The method of Claim 106, wherein said antagonist is an anti-TAT polypeptide antibody, TAT binding oligopeptide, TAT binding organic molecule or antisense oligonucleotide.

109. A method of binding an antibody, oligopeptide or organic molecule to a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein and allowing the binding of the antibody, oligopeptide or organic molecule to said protein to occur, thereby binding said antibody, oligopeptide or organic molecule to said cell.

110. The method of Claim 109, wherein said antibody is a monoclonal antibody.

111. The method of Claim 109, wherein said antibody is an antibody fragment.

112. The method of Claim 109, wherein said antibody is a chimeric or a humanized antibody.

113. The method of Claim 109, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

114. The method of Claim 109, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

5 115. The method of Claim 114, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

116. The method of Claim 114, wherein the cytotoxic agent is a toxin.

117. The method of Claim 116, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

118. The method of Claim 116, wherein the toxin is a maytansinoid.

10 119. The method of Claim 109, wherein said antibody is produced in bacteria.

120. The method of Claim 109, wherein said antibody is produced in CHO cells.

121. The method of Claim 109, wherein said cell is a cancer cell.

122. The method of Claim 121, wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent.

15 123. The method of Claim 121, wherein said cancer cell is selected from the group consisting of a breast cancer cell, a colorectal cancer cell, a lung cancer cell, an ovarian cancer cell, a central nervous system cancer cell, a liver cancer cell, a bladder cancer cell, a pancreatic cancer cell, a cervical cancer cell, a melanoma cell and a leukemia cell.

20 124. The method of Claim 123, wherein said protein is more abundantly expressed by said cancer cell as compared to a normal cell of the same tissue origin.

125. The method of Claim 109 which causes the death of said cell.

126. Use of a nucleic acid as claimed in any of Claims 1 to 5 or 30 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

25 127. Use of a nucleic acid as claimed in any of Claims 1 to 5 or 30 in the preparation of a medicament for treating a tumor.

128. Use of a nucleic acid as claimed in any of Claims 1 to 5 or 30 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

129. Use of an expression vector as claimed in any of Claims 6, 7 or 31 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

30 130. Use of an expression vector as claimed in any of Claims 6, 7 or 31 in the preparation of medicament for treating a tumor.

131. Use of an expression vector as claimed in any of Claims 6, 7 or 31 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

35 132. Use of a host cell as claimed in any of Claims 8, 9, 32, or 33 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

133. Use of a host cell as claimed in any of Claims 8, 9, 32 or 33 in the preparation of a medicament for treating a tumor.

134. Use of a host cell as claimed in any of Claims 8, 9, 32 or 33 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

135. Use of a polypeptide as claimed in any of Claims 11 to 14 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

5 136. Use of a polypeptide as claimed in any of Claims 11 to 14 in the preparation of a medicament for treating a tumor.

137. Use of a polypeptide as claimed in any of Claims 11 to 14 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

138. Use of an antibody as claimed in any of Claims 15 to 29 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

10 139. Use of an antibody as claimed in any of Claims 15 to 29 in the preparation of a medicament for treating a tumor.

140. Use of an antibody as claimed in any of Claims 15 to 29 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

15 141. Use of an oligopeptide as claimed in any of Claims 35 to 44 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

142. Use of an oligopeptide as claimed in any of Claims 35 to 44 in the preparation of a medicament for treating a tumor.

143. Use of an oligopeptide as claimed in any of Claims 35 to 44 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

20 144. Use of a TAT binding organic molecule as claimed in any of Claims 45 to 54 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

145. Use of a TAT binding organic molecule as claimed in any of Claims 45 to 54 in the preparation of a medicament for treating a tumor.

25 146. Use of a TAT binding organic molecule as claimed in any of Claims 45 to 54 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

147. Use of a composition of matter as claimed in any of Claims 55 or 56 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

148. Use of a composition of matter as claimed in any of Claims 55 or 56 in the preparation of a medicament for treating a tumor.

30 149. Use of a composition of matter as claimed in any of Claims 55 or 56 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

150. Use of an article of manufacture as claimed in any of Claims 57 or 58 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

35 151. Use of an article of manufacture as claimed in any of Claims 57 or 58 in the preparation of a medicament for treating a tumor.

152. Use of an article of manufacture as claimed in any of Claims 57 or 58 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

153. A method for inhibiting the growth of a cell, wherein the growth of said cell is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, thereby inhibiting the growth of said cell.

154. The method of Claim 153, wherein said cell is a cancer cell.

155. The method of Claim 153, wherein said protein is expressed by said cell.

156. The method of Claim 153, wherein the binding of said antibody, oligopeptide or organic molecule to said protein antagonizes a cell growth-potentiating activity of said protein.

157. The method of Claim 153, wherein the binding of said antibody, oligopeptide or organic molecule to said protein induces the death of said cell.

158. The method of Claim 153, wherein said antibody is a monoclonal antibody.

159. The method of Claim 153, wherein said antibody is an antibody fragment.

160. The method of Claim 153, wherein said antibody is a chimeric or a humanized antibody.

161. The method of Claim 153, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

162. The method of Claim 153, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

163. The method of Claim 162, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

164. The method of Claim 162, wherein the cytotoxic agent is a toxin.

165. The method of Claim 164, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

166. The method of Claim 164, wherein the toxin is a maytansinoid.

167. The method of Claim 153, wherein said antibody is produced in bacteria.

168. The method of Claim 153, wherein said antibody is produced in CHO cells.

169. The method of Claim 153, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

5 (c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

10 (e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

15 170. A method of therapeutically treating a tumor in a mammal, wherein the growth of said tumor is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

20 (b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

25 (e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

30 (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, thereby effectively treating said tumor.

171. The method of Claim 170, wherein said protein is expressed by cells of said tumor.

172. The method of Claim 170, wherein the binding of said antibody, oligopeptide or organic molecule to said protein antagonizes a cell growth-potentiating activity of said protein.

173. The method of Claim 170, wherein said antibody is a monoclonal antibody.

35 174. The method of Claim 170, wherein said antibody is an antibody fragment.

175. The method of Claim 170, wherein said antibody is a chimeric or a humanized antibody.

176. The method of Claim 170, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

177. The method of Claim 170, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

178. The method of Claim 177, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

179. The method of Claim 177, wherein the cytotoxic agent is a toxin.

180. The method of Claim 179, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

181. The method of Claim 179, wherein the toxin is a maytansinoid.

182. The method of Claim 170, wherein said antibody is produced in bacteria.

183. The method of Claim 170, wherein said antibody is produced in CHO cells.

184. The method of Claim 170, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

Yet further embodiments of the present invention will be evident to the skilled artisan upon a reading of the present specification.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a TAT207 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA67962".

Figure 2 shows a nucleotide sequence (SEQ ID NO:2) of a TAT177 cDNA, wherein SEQ ID NO:2 is a clone designated herein as "DNA77507".

Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a TAT235 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA87993".

Figure 4 shows a nucleotide sequence (SEQ ID NO:4) of a TAT234 cDNA, wherein SEQ ID NO:4 is a clone designated herein as "DNA92980".

Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a TAT239 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA96792".

Figure 6 shows a nucleotide sequence (SEQ ID NO:6) of a TAT193 cDNA, wherein SEQ ID NO:6 is a clone designated herein as "DNA96964".

Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a TAT233 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA105792".

Figure 8 shows a nucleotide sequence (SEQ ID NO:8) of a TAT226 cDNA, wherein SEQ ID NO:8 is a clone designated herein as "DNA119474".

Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a TAT199 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA142915".

Figures 10A-B show a nucleotide sequence (SEQ ID NO:10) of a TAT204 cDNA, wherein SEQ ID NO:10 is a clone designated herein as "DNA150491".

Figures 11A-B show a nucleotide sequence (SEQ ID NO:11) of a TAT248 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA280351".

Figure 12 shows a nucleotide sequence (SEQ ID NO:12) of a TAT232 cDNA, wherein SEQ ID NO:12 is a clone designated herein as "DNA150648".

Figure 13 shows a nucleotide sequence (SEQ ID NO:13) of a TAT219 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA172500".

Figure 14 shows a nucleotide sequence (SEQ ID NO:14) of a TAT224 cDNA, wherein SEQ ID NO:14 is a clone designated herein as "DNA179651".

Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a TAT237 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA207698".

Figure 16 shows a nucleotide sequence (SEQ ID NO:16) of a TAT178 cDNA, wherein SEQ ID NO:16 is a clone designated herein as "DNA208551".

Figures 17A-B show a nucleotide sequence (SEQ ID NO:17) of a TAT198 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA210159".

Figures 18A-B show a nucleotide sequence (SEQ ID NO:18) of a TAT194 cDNA, wherein SEQ ID NO:18 is a clone designated herein as "DNA225706".

Figures 19A-B show a nucleotide sequence (SEQ ID NO:19) of a TAT223 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA225793".

Figure 20 shows a nucleotide sequence (SEQ ID NO:20) of a TAT196 cDNA, wherein SEQ ID NO:20 is a clone designated herein as "DNA225796".

Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a TAT236 cDNA, wherein SEQ ID NO:21 is a clone designated herein as "DNA225886".

Figure 22 shows a nucleotide sequence (SEQ ID NO:22) of a TAT195 cDNA, wherein SEQ ID NO:22 is a clone designated herein as "DNA225943".

Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a TAT203 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA226283".



Figures 24A-B show a nucleotide sequence (SEQ ID NO:24) of a TAT200 cDNA, wherein SEQ ID NO:24 is a clone designated herein as "DNA226589".

Figures 25A-B show a nucleotide sequence (SEQ ID NO:25) of a TAT205 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA226622".

5 Figures 26A-B show a nucleotide sequence (SEQ ID NO:26) of a TAT185 cDNA, wherein SEQ ID NO:26 is a clone designated herein as "DNA226717".

Figures 27A-B show a nucleotide sequence (SEQ ID NO:27) of a TAT225 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA227162".

Figure 28 shows a nucleotide sequence (SEQ ID NO:28) of a TAT247 cDNA, wherein SEQ ID NO:28 is a clone designated herein as "DNA277804".

10 Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a TAT197 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA227545".

Figure 30 shows a nucleotide sequence (SEQ ID NO:30) of a TAT175 cDNA, wherein SEQ ID NO:30 is a clone designated herein as "DNA227611".

15 Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a TAT208 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA261021".

Figure 32 shows a nucleotide sequence (SEQ ID NO:32) of a TAT174 cDNA, wherein SEQ ID NO:32 is a clone designated herein as "DNA233034".

Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a TAT214 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA266920".

20 Figure 34 shows a nucleotide sequence (SEQ ID NO:34) of a TAT220 cDNA, wherein SEQ ID NO:34 is a clone designated herein as "DNA266921".

Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a TAT221 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA266922".

25 Figure 36 shows a nucleotide sequence (SEQ ID NO:36) of a TAT201 cDNA, wherein SEQ ID NO:36 is a clone designated herein as "DNA234441".

Figures 37A-B show a nucleotide sequence (SEQ ID NO:37) of a TAT179 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA234834".

Figure 38 shows a nucleotide sequence (SEQ ID NO:38) of a TAT216 cDNA, wherein SEQ ID NO:38 is a clone designated herein as "DNA247587".

30 Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a TAT218 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA255987".

Figure 40 shows a nucleotide sequence (SEQ ID NO:40) of a TAT206 cDNA, wherein SEQ ID NO:40 is a clone designated herein as "DNA56041".

35 Figures 41A-B show a nucleotide sequence (SEQ ID NO:41) of a TAT374 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA257845".

Figure 42 shows a nucleotide sequence (SEQ ID NO:42) of a TAT209 cDNA, wherein SEQ ID NO:42 is a clone designated herein as "DNA260655".

Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a TAT192 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA260945".

Figure 44 shows a nucleotide sequence (SEQ ID NO:44) of a TAT180 cDNA, wherein SEQ ID NO:44 is a clone designated herein as "DNA247476".

Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a TAT375 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA260990".

Figure 46 shows a nucleotide sequence (SEQ ID NO:46) of a TAT181 cDNA, wherein SEQ ID NO:46 is a clone designated herein as "DNA261001".

Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a TAT176 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA261013".

Figure 48 shows a nucleotide sequence (SEQ ID NO:48) of a TAT184 cDNA, wherein SEQ ID NO:48 is a clone designated herein as "DNA262144".

Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a TAT182 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA266928".

Figures 50A-B show a nucleotide sequence (SEQ ID NO:50) of a TAT213 cDNA, wherein SEQ ID NO:50 is a clone designated herein as "DNA267342".

Figures 51A-C show a nucleotide sequence (SEQ ID NO:51) of a TAT217 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA267626".

Figure 52 shows a nucleotide sequence (SEQ ID NO:52) of a TAT222 cDNA, wherein SEQ ID NO:52 is a clone designated herein as "DNA268035".

Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a TAT202 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA268334".

Figure 54 shows a nucleotide sequence (SEQ ID NO:54) of a TAT215 cDNA, wherein SEQ ID NO:54 is a clone designated herein as "DNA269238".

Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a TAT238 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA272578".

Figure 56 shows a nucleotide sequence (SEQ ID NO:56) of a TAT212 cDNA, wherein SEQ ID NO:56 is a clone designated herein as "DNA277797".

Figure 57 shows the amino acid sequence (SEQ ID NO:57) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:2 shown in Figure 2.

Figure 59 shows the amino acid sequence (SEQ ID NO:59) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:4 shown in Figure 4.

Figure 61 shows the amino acid sequence (SEQ ID NO:61) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.

Figure 62 shows the amino acid sequence (SEQ ID NO:62) derived from the coding sequence of SEQ ID NO:6 shown in Figure 6.

Figure 63 shows the amino acid sequence (SEQ ID NO:63) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

5 Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:8 shown in Figure 8.

Figure 65 shows the amino acid sequence (SEQ ID NO:65) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.

Figure 66 shows the amino acid sequence (SEQ ID NO:66) derived from the coding sequence of SEQ ID NO:10 shown in Figures 10A-B.

10 Figure 67 shows the amino acid sequence (SEQ ID NO:67) derived from the coding sequence of SEQ ID NO:11 shown in Figures 11A-B.

Figure 68 shows the amino acid sequence (SEQ ID NO:68) derived from the coding sequence of SEQ ID NO:12 shown in Figure 12.

15 Figure 69 shows the amino acid sequence (SEQ ID NO:69) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.

Figure 70 shows the amino acid sequence (SEQ ID NO:70) derived from the coding sequence of SEQ ID NO:14 shown in Figure 14.

Figure 71 shows the amino acid sequence (SEQ ID NO:71) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

20 Figure 72 shows the amino acid sequence (SEQ ID NO:72) derived from the coding sequence of SEQ ID NO:16 shown in Figure 16.

Figure 73 shows the amino acid sequence (SEQ ID NO:73) derived from the coding sequence of SEQ ID NO:17 shown in Figures 17A-B.

25 Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:18 shown in Figures 18A-B.

Figure 75 shows the amino acid sequence (SEQ ID NO:75) derived from the coding sequence of SEQ ID NO:19 shown in Figures 19A-B.

Figure 76 shows the amino acid sequence (SEQ ID NO:76) derived from the coding sequence of SEQ ID NO:20 shown in Figure 20.

30 Figure 77 shows the amino acid sequence (SEQ ID NO:77) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

Figure 78 shows the amino acid sequence (SEQ ID NO:78) derived from the coding sequence of SEQ ID NO:22 shown in Figure 22.

35 Figure 79 shows the amino acid sequence (SEQ ID NO:79) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

Figure 80 shows the amino acid sequence (SEQ ID NO:80) derived from the coding sequence of SEQ ID NO:24 shown in Figures 24A-B.

Figure 81 shows the amino acid sequence (SEQ ID NO:81) derived from the coding sequence of SEQ ID NO:25 shown in Figures 25A-B.

Figure 82 shows the amino acid sequence (SEQ ID NO:82) derived from the coding sequence of SEQ ID NO:26 shown in Figures 26A-B.

5 Figure 83 shows the amino acid sequence (SEQ ID NO:83) derived from the coding sequence of SEQ ID NO:27 shown in Figures 27A-B.

Figure 84 shows the amino acid sequence (SEQ ID NO:84) derived from the coding sequence of SEQ ID NO:28 shown in Figure 28.

Figure 85 shows the amino acid sequence (SEQ ID NO:85) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

10 Figure 86 shows the amino acid sequence (SEQ ID NO:86) derived from the coding sequence of SEQ ID NO:30 shown in Figure 30.

Figure 87 shows the amino acid sequence (SEQ ID NO:87) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.

15 Figure 88 shows the amino acid sequence (SEQ ID NO:88) derived from the coding sequence of SEQ ID NO:32 shown in Figure 32.

Figure 89 shows the amino acid sequence (SEQ ID NO:89) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

Figure 90 shows the amino acid sequence (SEQ ID NO:90) derived from the coding sequence of SEQ ID NO:34 shown in Figure 34.

20 Figure 91 shows the amino acid sequence (SEQ ID NO:91) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

Figure 92 shows the amino acid sequence (SEQ ID NO:92) derived from the coding sequence of SEQ ID NO:36 shown in Figure 36.

25 Figure 93 shows the amino acid sequence (SEQ ID NO:93) derived from the coding sequence of SEQ ID NO:37 shown in Figures 37A-B.

Figure 94 shows the amino acid sequence (SEQ ID NO:94) derived from the coding sequence of SEQ ID NO:38 shown in Figure 38.

Figure 95 shows the amino acid sequence (SEQ ID NO:95) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39.

30 Figure 96 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:40 shown in Figure 40.

Figure 97 shows the amino acid sequence (SEQ ID NO:97) derived from the coding sequence of SEQ ID NO:41 shown in Figures 41A-B.

35 Figure 98 shows the amino acid sequence (SEQ ID NO:98) derived from the coding sequence of SEQ ID NO:42 shown in Figure 42.

Figure 99 shows the amino acid sequence (SEQ ID NO:99) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.

Figure 100 shows the amino acid sequence (SEQ ID NO:100) derived from the coding sequence of SEQ ID NO:44 shown in Figure 44.

Figure 101 shows the amino acid sequence (SEQ ID NO:101) derived from the coding sequence of SEQ ID NO:45 shown in Figure 45.

5 Figure 102 shows the amino acid sequence (SEQ ID NO:102) derived from the coding sequence of SEQ ID NO:46 shown in Figure 46.

Figure 103 shows the amino acid sequence (SEQ ID NO:103) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.

Figure 104 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO:48 shown in Figure 48.

10 Figure 105 shows the amino acid sequence (SEQ ID NO:105) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.

Figure 106 shows the amino acid sequence (SEQ ID NO:106) derived from the coding sequence of SEQ ID NO:50 shown in Figures 50A-B.

15 Figures 107A-B show the amino acid sequence (SEQ ID NO:107) derived from the coding sequence of SEQ ID NO:51 shown in Figures 51A-C.

Figure 108 shows the amino acid sequence (SEQ ID NO:108) derived from the coding sequence of SEQ ID NO:52 shown in Figure 52.

Figure 109 shows the amino acid sequence (SEQ ID NO:109) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.

20 Figure 110 shows the amino acid sequence (SEQ ID NO:110) derived from the coding sequence of SEQ ID NO:54 shown in Figure 54.

Figure 111 shows the amino acid sequence (SEQ ID NO:111) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.

25 Figure 112 shows the amino acid sequence (SEQ ID NO:112) derived from the coding sequence of SEQ ID NO:56 shown in Figure 56.

Figure 113 shows a nucleotide sequence (SEQ ID NO:113) of a TAT376 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "DNA304853".

Figure 114 shows the amino acid sequence (SEQ ID NO:114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 113.

30 Figure 115 shows a nucleotide sequence (SEQ ID NO:115) of a TAT377 cDNA, wherein SEQ ID NO:115 is a clone designated herein as "DNA304854".

Figure 116 shows the amino acid sequence (SEQ ID NO:116) derived from the coding sequence of SEQ ID NO:115 shown in Figure 115.

35 Figure 117 shows a nucleotide sequence (SEQ ID NO:117) of a TAT378 cDNA, wherein SEQ ID NO:117 is a clone designated herein as "DNA304855".

Figure 118 shows the amino acid sequence (SEQ ID NO:118) derived from the coding sequence of SEQ ID NO:117 shown in Figure 117.

Figures 119A-B show a nucleotide sequence (SEQ ID NO:119) of a TAT379 cDNA, wherein SEQ ID NO:119 is a clone designated herein as "DNA287971".

Figure 120 shows the amino acid sequence (SEQ ID NO:120) derived from the coding sequence of SEQ ID NO:119 shown in Figures 119A-B.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

### I. Definitions

The terms "TAT polypeptide" and "TAT" as used herein and when immediately followed by a numerical designation, refer to various polypeptides, wherein the complete designation (i.e., TAT/number) refers to specific polypeptide sequences as described herein. The terms "TAT/number polypeptide" and "TAT/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides, polypeptide variants and fragments of native sequence polypeptides and polypeptide variants (which are further defined herein). The TAT polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "TAT polypeptide" refers to each individual TAT/number polypeptide disclosed herein. All disclosures in this specification which refer to the "TAT polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, formation of TAT binding oligopeptides to or against, formation of TAT binding organic molecules to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "TAT polypeptide" also includes variants of the TAT/number polypeptides disclosed herein.

A "native sequence TAT polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding TAT polypeptide derived from nature. Such native sequence TAT polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence TAT polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific TAT polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In certain embodiments of the invention, the native sequence TAT polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons (if indicated) are shown in bold font and underlined in the figures. Nucleic acid residues indicated as "N" in the accompanying figures are any nucleic acid residue. However, while the TAT polypeptides disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the TAT polypeptides.

The TAT polypeptide "extracellular domain" or "ECD" refers to a form of the TAT polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a TAT polypeptide ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such

domains. It will be understood that any transmembrane domains identified for the TAT polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a TAT polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

The approximate location of the "signal peptides" of the various TAT polypeptides disclosed herein may be shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

"TAT polypeptide variant" means a TAT polypeptide, preferably an active TAT polypeptide, as defined herein having at least about 80% amino acid sequence identity with a full-length native sequence TAT polypeptide sequence as disclosed herein, a TAT polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a TAT polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length TAT polypeptide sequence as disclosed herein (such as those encoded by a nucleic acid that represents only a portion of the complete coding sequence for a full-length TAT polypeptide). Such TAT polypeptide variants include, for instance, TAT polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a TAT polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity, to a full-length native sequence TAT polypeptide sequence as disclosed herein, a TAT polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a TAT polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length TAT polypeptide sequence as disclosed herein. Ordinarily, TAT variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600 amino acids in length, or more. Optionally, TAT variant polypeptides will have no more than one conservative amino acid substitution as compared to the native TAT polypeptide sequence, alternatively no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitution

as compared to the native TAT polypeptide sequence.

"Percent (%) amino acid sequence identity" with respect to the TAT polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific TAT polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "TAT", wherein "TAT" represents the amino acid sequence of a hypothetical TAT polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "TAT" polypeptide of interest is being compared, and "X", "Y" and "Z" each represent different hypothetical amino acid residues. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.



"TAT variant polynucleotide" or "TAT variant nucleic acid sequence" means a nucleic acid molecule which encodes a TAT polypeptide, preferably an active TAT polypeptide, as defined herein and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence TAT polypeptide sequence as disclosed herein, a full-length native sequence TAT polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a TAT polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length TAT polypeptide sequence as disclosed herein (such as those encoded by a nucleic acid that represents only a portion of the complete coding sequence for a full-length TAT polypeptide). Ordinarily, a TAT variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence TAT polypeptide sequence as disclosed herein, a full-length native sequence TAT polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a TAT polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-length TAT polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

Ordinarily, TAT variant polynucleotides are at least about 5 nucleotides in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length.

"Percent (%) nucleic acid sequence identity" with respect to TAT-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the TAT nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "TAT-DNA", wherein "TAT-DNA" represents a hypothetical TAT-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "TAT-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides. Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

In other embodiments, TAT variant polynucleotides are nucleic acid molecules that encode a TAT polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length TAT polypeptide as disclosed herein. TAT variant polypeptides may be those that are encoded by a TAT variant polynucleotide.

The term "full-length coding region" when used in reference to a nucleic acid encoding a TAT polypeptide refers to the sequence of nucleotides which encode the full-length TAT polypeptide of the invention (which is often shown between start and stop codons, inclusive thereof, in the accompanying figures). The term "full-length coding region" when used in reference to an ATCC deposited nucleic acid refers to the TAT polypeptide-encoding portion of the cDNA that is inserted into the vector deposited with the ATCC (which is often shown between start and stop codons, inclusive thereof, in the accompanying figures).

"Isolated," when used to describe the various TAT polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the TAT polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" TAT polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) overnight hybridization in a solution that employs 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution,

sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with a 10 minute wash at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) followed by a 10 minute high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a TAT polypeptide or anti-TAT antibody fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

"Active" or "activity" for the purposes herein refers to form(s) of a TAT polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring TAT, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring TAT other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring TAT and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring TAT.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native TAT polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native TAT polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native TAT polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a TAT polypeptide may comprise contacting a TAT polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the TAT polypeptide.

"Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully "treated" for a TAT polypeptide-expressing cancer if, after receiving a therapeutic amount of an anti-TAT antibody, TAT binding

oligopeptide or TAT binding organic molecule according to the methods of the present invention, the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells or absence of the cancer cells; reduction in the tumor size; inhibition (i.e., slow to some extent and preferably stop) of cancer cell infiltration into peripheral organs including the spread of cancer into soft tissue and bone; inhibition (i.e., slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. To the extent the anti-TAT antibody or TAT binding oligopeptide may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. Reduction of these signs or symptoms may also be felt by the patient.

The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and/or determining the response rate (RR). Metastasis can be determined by staging tests and by bone scan and tests for calcium level and other enzymes to determine spread to the bone. CT scans can also be done to look for spread to the pelvis and lymph nodes in the area. Chest X-rays and measurement of liver enzyme levels by known methods are used to look for metastasis to the lungs and liver, respectively. Other routine methods for monitoring the disease include transrectal ultrasonography (TRUS) and transrectal needle biopsy (TRNB).

For bladder cancer, which is a more localized cancer, methods to determine progress of disease include urinary cytologic evaluation by cystoscopy, monitoring for presence of blood in the urine, visualization of the urothelial tract by sonography or an intravenous pyelogram, computed tomography (CT) and magnetic resonance imaging (MRI). The presence of distant metastases can be assessed by CT of the abdomen, chest x-rays, or radionuclide imaging of the skeleton.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

"Mammal" for purposes of the treatment of, alleviating the symptoms of or diagnosis of a cancer refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming

counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®.

By "solid phase" or "solid support" is meant a non-aqueous matrix to which an antibody, TAT binding oligopeptide or TAT binding organic molecule of the present invention can adhere or attach. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a TAT polypeptide, an antibody thereto or a TAT binding oligopeptide) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

A "small" molecule or "small" organic molecule is defined herein to have a molecular weight below about 500 Daltons.

An "effective amount" of a polypeptide, antibody, TAT binding oligopeptide, TAT binding organic molecule or an agonist or antagonist thereof as disclosed herein is an amount sufficient to carry out a specifically stated purpose. An "effective amount" may be determined empirically and in a routine manner, in relation to the stated purpose.

The term "therapeutically effective amount" refers to an amount of an antibody, polypeptide, TAT binding oligopeptide, TAT binding organic molecule or other drug effective to "treat" a disease or disorder in a subject or mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. See the definition herein of "treating". To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.

A "growth inhibitory amount" of an anti-TAT antibody, TAT polypeptide, TAT binding oligopeptide or TAT binding organic molecule is an amount capable of inhibiting the growth of a cell, especially tumor, e.g., cancer cell, either *in vitro* or *in vivo*. A "growth inhibitory amount" of an anti-TAT antibody, TAT polypeptide, TAT binding oligopeptide or TAT binding organic molecule for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner.

A "cytotoxic amount" of an anti-TAT antibody, TAT polypeptide, TAT binding oligopeptide or TAT binding organic molecule is an amount capable of causing the destruction of a cell, especially tumor, e.g., cancer cell, either *in vitro* or *in vivo*. A "cytotoxic amount" of an anti-TAT antibody, TAT polypeptide, TAT binding oligopeptide or TAT binding organic molecule for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner.

The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-TAT monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-TAT antibody compositions with polypeptopic specificity, polyclonal antibodies, single chain anti-TAT antibodies, and fragments of anti-TAT antibodies (see below) as long as they exhibit the desired biological or immunological activity. The term "immunoglobulin" (Ig) is used interchangeable with antibody herein.

5 An "isolated antibody" is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99%  
10 by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

15 The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains (an IgM antibody consists of 5 of the basic heterotetramer unit along with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages comprising 2-5 of the basic 4-chain units along with J chain). In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to a H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide  
20 bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain ( $V_H$ ) followed by three constant domains ( $C_H$ ) for each of the  $\alpha$  and  $\gamma$  chains and four  $C_H$  domains for  $\mu$  and  $\epsilon$  isotypes. Each L chain has at the N-terminus, a variable domain ( $V_L$ ) followed by a constant domain ( $C_L$ ) at its other end. The  $V_L$  is aligned with the  $V_H$  and the  $C_L$  is aligned with the first constant domain of the heavy chain ( $C_H1$ ). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains. The pairing of a  $V_H$  and  $V_L$  together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th edition, Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.

30 The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains ( $C_H$ ), immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated  $\alpha$ ,  $\delta$ ,  $\epsilon$ ,  $\gamma$ , and  $\mu$ , respectively. The  $\gamma$  and  $\alpha$  classes are further divided into subclasses on the basis of  
35 relatively minor differences in  $C_H$  sequence and function, e.g., humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

The term "variable" refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino acids long. The variable domains of native heavy and light chains each comprise four FRs, largely adopting a  $\beta$ -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the  $\beta$ -sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g. around about residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the  $V_L$ , and around about 1-35 (H1), 50-65 (H2) and 95-102 (H3) in the  $V_H$ ; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (e.g. residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the  $V_L$ , and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the  $V_H$ ; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al., Nature, 256:495 (1975), or may be made using recombinant DNA methods in bacterial, eukaryotic animal or plant cells (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example.

The monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological



activity (see U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc), and human constant region sequences.

5 An "intact" antibody is one which comprises an antigen-binding site as well as a C<sub>L</sub> and at least heavy chain constant domains, C<sub>H</sub>1, C<sub>H</sub>2 and C<sub>H</sub>3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. Preferably, the intact antibody has one or more effector functions.

10 "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (see U.S. Patent No. 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

15 Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire L chain along with the variable region domain of the H chain (V<sub>H</sub>), and the first constant domain of one heavy chain (C<sub>H</sub>1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')<sub>2</sub> fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the C<sub>H</sub>1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein 20 for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

25 The Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types of cells.

30 "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

35 "Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that comprise the V<sub>H</sub> and V<sub>L</sub> antibody domains connected into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, *infra*.

The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10 residues) between the V<sub>H</sub> and V<sub>L</sub> domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the V<sub>H</sub> and V<sub>L</sub> domains of the two antibodies are present on different polypeptide chains. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

"Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992).

A "species-dependent antibody," e.g., a mammalian anti-human IgE antibody, is an antibody which has a stronger binding affinity for an antigen from a first mammalian species than it has for a homologue of that antigen from a second mammalian species. Normally, the species-dependent antibody "bind specifically" to a human antigen (i.e., has a binding affinity (K<sub>d</sub>) value of no more than about  $1 \times 10^{-7}$  M, preferably no more than about  $1 \times 10^{-8}$  and most preferably no more than about  $1 \times 10^{-9}$  M) but has a binding affinity for a homologue of the antigen from a second non-human mammalian species which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen. The species-dependent antibody can be of any of the various types of antibodies as defined above, but preferably is a humanized or human antibody.

A "TAT binding oligopeptide" is an oligopeptide that binds, preferably specifically, to a TAT polypeptide as described herein. TAT binding oligopeptides may be chemically synthesized using known oligopeptide synthesis methodology or may be prepared and purified using recombinant technology. TAT binding oligopeptides are usually at least about 5 amino acids in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids in length or more, wherein such oligopeptides that are capable of binding, preferably specifically, to a TAT polypeptide as described herein. TAT binding oligopeptides may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening oligopeptide libraries for oligopeptides that are capable of

specifically binding to a polypeptide target are well known in the art (see, e.g., U.S. Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 81:3998-4002 (1984); Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 82:178-182 (1985); Geysen et al., in Synthetic Peptides as Antigens, 130-149 (1986); Geysen et al., J. Immunol. Meth., 102:259-274 (1987); Schoofs et al., J. Immunol., 140:611-616 (1988), Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378; Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J.D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363, and Smith, G. P. (1991) Current Opin. Biotechnol., 2:668).

A "TAT binding organic molecule" is an organic molecule other than an oligopeptide or antibody as defined herein that binds, preferably specifically, to a TAT polypeptide as described herein. TAT binding organic molecules may be identified and chemically synthesized using known methodology (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). TAT binding organic molecules are usually less than about 2000 daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 daltons in size, wherein such organic molecules that are capable of binding, preferably specifically, to a TAT polypeptide as described herein may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening organic molecule libraries for molecules that are capable of binding to a polypeptide target are well known in the art (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585).

An antibody, oligopeptide or other organic molecule "which binds" an antigen of interest, e.g. a tumor-associated polypeptide antigen target, is one that binds the antigen with sufficient affinity such that the antibody, oligopeptide or other organic molecule is useful as a diagnostic and/or therapeutic agent in targeting a cell or tissue expressing the antigen, and does not significantly cross-react with other proteins. In such embodiments, the extent of binding of the antibody, oligopeptide or other organic molecule to a "non-target" protein will be less than about 10% of the binding of the antibody, oligopeptide or other organic molecule to its particular target protein as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA). With regard to the binding of an antibody, oligopeptide or other organic molecule to a target molecule, the term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. The term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a  $K_d$  for the target of at least about  $10^{-4}$  M, alternatively at least about  $10^{-5}$  M, alternatively at least about  $10^{-6}$  M, alternatively at least about  $10^{-7}$  M, alternatively at least about  $10^{-8}$  M, alternatively at least about  $10^{-9}$  M, alternatively at least about  $10^{-10}$  M, alternatively at least about  $10^{-11}$  M, alternatively at least about  $10^{-12}$  M, or greater. In one embodiment, the term "specific binding" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially

binding to any other polypeptide or polypeptide epitope.

An antibody, oligopeptide or other organic molecule that "inhibits the growth of tumor cells expressing a TAT polypeptide" or a "growth inhibitory" antibody, oligopeptide or other organic molecule is one which results in measurable growth inhibition of cancer cells expressing or overexpressing the appropriate TAT polypeptide. The TAT polypeptide may be a transmembrane polypeptide expressed on the surface of a cancer cell or may be a polypeptide that is produced and secreted by a cancer cell. Preferred growth inhibitory anti-TAT antibodies, oligopeptides or organic molecules inhibit growth of TAT-expressing tumor cells by greater than 20%, preferably from about 20% to about 50%, and even more preferably, by greater than 50% (e.g., from about 50% to about 100%) as compared to the appropriate control, the control typically being tumor cells not treated with the antibody, oligopeptide or other organic molecule being tested. In one embodiment, growth inhibition can be measured at an antibody concentration of about 0.1 to 30  $\mu\text{g/ml}$  or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells to the antibody. Growth inhibition of tumor cells *in vivo* can be determined in various ways such as is described in the Experimental Examples section below. The antibody is growth inhibitory *in vivo* if administration of the anti-TAT antibody at about 1  $\mu\text{g/kg}$  to about 100 mg/kg body weight results in reduction in tumor size or tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days.

An antibody, oligopeptide or other organic molecule which "induces apoptosis" is one which induces programmed cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). The cell is usually one which overexpresses a TAT polypeptide. Preferably the cell is a tumor cell, e.g., a prostate, breast, ovarian, stomach, endometrial, lung, kidney, colon, bladder cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl serine (PS) translocation can be measured by annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells. Preferably, the antibody, oligopeptide or other organic molecule which induces apoptosis is one which results in about 2 to 50 fold, preferably about 5 to 50 fold, and most preferably about 10 to 50 fold, induction of annexin binding relative to untreated cell in an annexin binding assay.

Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxic cells (e.g., Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are absolutely required for such killing. The primary cells for mediating ADCC, NK cells, express Fc $\gamma$ RIII only, whereas monocytes express Fc $\gamma$ RI, Fc $\gamma$ RII and Fc $\gamma$ RIII. FcR expression on hematopoietic cells is summarized in Table 3 on

page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. (USA) 95:652-656 (1998).

5 "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (see review M. in Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those 10 to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).

"Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least FcγRIII and perform ADCC effector function. Examples of human leukocytes 20 which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source, e.g., from blood.

"Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component 25 of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), may be performed.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, 30 lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland 35 carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma and B-cell lymphoma, brain, as well as head and neck

cancer, and associated metastases.

The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.

"Tumor", as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

5 An antibody, oligopeptide or other organic molecule which "induces cell death" is one which causes a viable cell to become nonviable. The cell is one which expresses a TAT polypeptide, preferably a cell that overexpresses a TAT polypeptide as compared to a normal cell of the same tissue type. The TAT polypeptide may be a transmembrane polypeptide expressed on the surface of a cancer cell or may be a polypeptide that is produced and secreted by a cancer cell. Preferably, the cell is a cancer cell, e.g., a breast, ovarian, stomach, endometrial, 10 salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell. Cell death *in vitro* may be determined in the absence of complement and immune effector cells to distinguish cell death induced by antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). Thus, the assay for cell death may be performed using heat inactivated serum (i.e., in the absence of complement) and in the absence of immune effector cells. To determine whether the antibody, oligopeptide or other organic molecule is able to induce cell 15 death, loss of membrane integrity as evaluated by uptake of propidium iodide (PI), trypan blue (see Moore et al. Cytotechnology 17:1-11 (1995)) or 7AAD can be assessed relative to untreated cells. Preferred cell death-inducing antibodies, oligopeptides or other organic molecules are those which induce PI uptake in the PI uptake assay in BT474 cells.

A "TAT-expressing cell" is a cell which expresses an endogenous or transfected TAT polypeptide either 20 on the cell surface or in a secreted form. A "TAT-expressing cancer" is a cancer comprising cells that have a TAT polypeptide present on the cell surface or that produce and secrete a TAT polypeptide. A "TAT-expressing cancer" optionally produces sufficient levels of TAT polypeptide on the surface of cells thereof, such that an anti-TAT antibody, oligopeptide or other organic molecule can bind thereto and have a therapeutic effect with respect to the cancer. In another embodiment, a "TAT-expressing cancer" optionally produces and secretes sufficient 25 levels of TAT polypeptide, such that an anti-TAT antibody, oligopeptide or other organic molecule antagonist can bind thereto and have a therapeutic effect with respect to the cancer. With regard to the latter, the antagonist may be an antisense oligonucleotide which reduces, inhibits or prevents production and secretion of the secreted TAT polypeptide by tumor cells. A cancer which "overexpresses" a TAT polypeptide is one which has significantly higher levels of TAT polypeptide at the cell surface thereof, or produces and secretes, compared to 30 a noncancerous cell of the same tissue type. Such overexpression may be caused by gene amplification or by increased transcription or translation. TAT polypeptide overexpression may be determined in a diagnostic or prognostic assay by evaluating increased levels of the TAT protein present on the surface of a cell, or secreted by the cell (e.g., via an immunohistochemistry assay using anti-TAT antibodies prepared against an isolated TAT polypeptide which may be prepared using recombinant DNA technology from an isolated nucleic acid encoding 35 the TAT polypeptide; FACS analysis, etc.). Alternatively, or additionally, one may measure levels of TAT polypeptide-encoding nucleic acid or mRNA in the cell, e.g., via fluorescent *in situ* hybridization using a nucleic acid based probe corresponding to a TAT-encoding nucleic acid or the complement thereof; (FISH; see

WO98/45479 published October, 1998), Southern blotting, Northern blotting, or polymerase chain reaction (PCR) techniques, such as real time quantitative PCR (RT-PCR). One may also study TAT polypeptide overexpression by measuring shed antigen in a biological fluid such as serum, e.g. using antibody-based assays (see also, e.g., U.S. Patent No. 4,933,294 issued June 12, 1990; WO91/05264 published April 18, 1991; U.S. Patent 5,401,638 issued March 28, 1995; and Sias et al., *J. Immunol. Methods* 132:73-80 (1990)). Aside from the above assays, various *in vivo* assays are available to the skilled practitioner. For example, one may expose cells within the body of the patient to an antibody which is optionally labeled with a detectable label, e.g., a radioactive isotope, and binding of the antibody to cells in the patient can be evaluated, e.g., by external scanning for radioactivity or by analyzing a biopsy taken from a patient previously exposed to the antibody.

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody, oligopeptide or other organic molecule so as to generate a "labeled" antibody, oligopeptide or other organic molecule. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., At<sup>211</sup>, I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup>, Re<sup>186</sup>, Re<sup>188</sup>, Sm<sup>153</sup>, Bi<sup>212</sup>, P<sup>32</sup> and radioactive isotopes of Lu), chemotherapeutic agents e.g. methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below. A tumoricidal agent causes destruction of tumor cells.

A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially a TAT-expressing cancer cell, either *in vitro* or *in vivo*. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of TAT-expressing cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents

such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami et al. (WB Saunders: Philadelphia, 1995), especially p. 13. The taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.

"Doxorubicin" is an anthracycline antibiotic. The full chemical name of doxorubicin is (8S-cis)-10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexapyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione.

The term "cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- $\alpha$  and - $\beta$ ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- $\beta$ ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- $\alpha$  and TGF- $\beta$ ; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon - $\alpha$ , - $\beta$ , and - $\gamma$ ; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; a tumor necrosis factor such as TNF- $\alpha$  or TNF- $\beta$ ; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.



**Table 1**

```

/*
*
* C-C increased from 12 to 15
* Z is average of EQ
5  * B is average of ND
* match with stop is _M; stop-stop = 0; J (joker) match = 0
*/
#define _M      -8      /* value of a match with a stop */

10  int      _day[26][26] = {
/* A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
/* A */      { 2, 0, -2, 0, 0, -4, 1, -1, -1, 0, -1, -2, -1, 0, _M, 1, 0, -2, 1, 1, 0, 0, -6, 0, -3, 0},
/* B */      { 0, 3, -4, 3, 2, -5, 0, 1, -2, 0, 0, -3, -2, 2, _M, -1, 1, 0, 0, 0, 0, -2, -5, 0, -3, 1},
/* C */      {-2, -4, 15, -5, -5, -4, -3, -3, -2, 0, -5, -6, -5, -4, _M, -3, -5, -4, 0, -2, 0, -2, -8, 0, 0, -5},
15  /* D */      { 0, 3, -5, 4, 3, -6, 1, 1, -2, 0, 0, -4, -3, 2, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 2},
/* E */      { 0, 2, -5, 3, 4, -5, 0, 1, -2, 0, 0, -3, -2, 1, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 3},
/* F */      {-4, -5, -4, -6, -5, 9, -5, -2, 1, 0, -5, 2, 0, -4, _M, -5, -5, -4, -3, -3, 0, -1, 0, 0, 7, -5},
/* G */      { 1, 0, -3, 1, 0, -5, 5, -2, -3, 0, -2, -4, -3, 0, _M, -1, -1, -3, 1, 0, 0, -1, -7, 0, -5, 0},
/* H */      {-1, 1, -3, 1, 1, -2, -2, 6, -2, 0, 0, -2, -2, 2, _M, 0, 3, 2, -1, -1, 0, -2, -3, 0, 0, 2},
20  /* I */      {-1, -2, -2, -2, -2, 1, -3, -2, 5, 0, -2, 2, 2, -2, _M, -2, -2, -2, -1, 0, 0, 4, -5, 0, -1, -2},
/* J */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* K */      {-1, 0, -5, 0, 0, -5, -2, 0, -2, 0, 5, -3, 0, 1, _M, -1, 1, 3, 0, 0, 0, -2, -3, 0, -4, 0},
/* L */      {-2, -3, -6, -4, -3, 2, -4, -2, 2, 0, -3, 6, 4, -3, _M, -3, -2, -3, -3, -1, 0, 2, -2, 0, -1, -2},
/* M */      {-1, -2, -5, -3, -2, 0, -3, -2, 2, 0, 0, 4, 6, -2, _M, -2, -1, 0, -2, -1, 0, 2, -4, 0, -2, -1},
25  /* N */      { 0, 2, -4, 2, 1, -4, 0, 2, -2, 0, 1, -3, -2, 2, _M, -1, 1, 0, 1, 0, 0, -2, -4, 0, -2, 1},
/* O */      { _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, 0, _M, _M, _M, _M, _M, _M, _M, _M, _M},
/* P */      { 1, -1, -3, -1, -1, -5, -1, 0, -2, 0, -1, -3, -2, -1, _M, 6, 0, 0, 1, 0, 0, -1, -6, 0, -5, 0},
/* Q */      { 0, 1, -5, 2, 2, -5, -1, 3, -2, 0, 1, -2, -1, 1, _M, 0, 4, 1, -1, -1, 0, -2, -5, 0, -4, 3},
/* R */      {-2, 0, -4, -1, -1, -4, -3, 2, -2, 0, 3, -3, 0, 0, _M, 0, 1, 6, 0, -1, 0, -2, 2, 0, -4, 0},
30  /* S */      { 1, 0, 0, 0, 0, -3, 1, -1, -1, 0, 0, -3, -2, 1, _M, 1, -1, 0, 2, 1, 0, -1, -2, 0, -3, 0},
/* T */      { 1, 0, -2, 0, 0, -3, 0, -1, 0, 0, 0, -1, -1, 0, _M, 0, -1, -1, 1, 3, 0, 0, -5, 0, -3, 0},
/* U */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */      { 0, -2, -2, -2, -2, -1, -1, -2, 4, 0, -2, 2, 2, -2, _M, -1, -2, -2, -1, 0, 0, 4, -6, 0, -2, -2},
/* W */      {-6, -5, -8, -7, -7, 0, -7, -3, -5, 0, -3, -2, -4, -4, _M, -6, -5, 2, -2, -5, 0, -6, 17, 0, 0, -6},
35  /* X */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */      {-3, -3, 0, -4, -4, 7, -5, 0, -1, 0, -4, -1, -2, -2, _M, -5, -4, -4, -3, -3, 0, -2, 0, 0, 10, -4},
/* Z */      { 0, 1, -5, 2, 3, -5, 0, 2, -2, 0, 0, -2, -1, 1, _M, 0, 3, 0, 0, 0, 0, -2, -6, 0, -4, 4}
};

40

45

50

```

**Table 1 (cont')**

```

/*
*/
#include <stdio.h>
#include <ctype.h>

5
#define MAXJMP      16      /* max jumps in a diag */
#define MAXGAP      24      /* don't continue to penalize gaps larger than this */
#define JMPS        1024    /* max jmps in an path */
#define MX          4       /* save if there's at least MX-1 bases since last jmp */

10
#define DMAT         3       /* value of matching bases */
#define DMIS         0       /* penalty for mismatched bases */
#define DINS0        8       /* penalty for a gap */
#define DINS1        1       /* penalty per base */
15
#define PINS0        8       /* penalty for a gap */
#define PINS1        4       /* penalty per residue */

struct jmp {
    short            n[MAXJMP]; /* size of jmp (neg for dely) */
    unsigned short   x[MAXJMP]; /* base no. of jmp in seq x */
}; /* limits seq to 2^16 -1 */

20
struct diag {
    int              score;      /* score at last jmp */
    long             offset;     /* offset of prev block */
    short            ijmp;       /* current jmp index */
    struct jmp        jp;        /* list of jmps */
};

25
struct path {
    int              spc;        /* number of leading spaces */
    short            n[JMPS]; /* size of jmp (gap) */
    int              x[JMPS]; /* loc of jmp (last elem before gap) */
};

30
char          *ofile;          /* output file name */
char          *namex[2];       /* seq names: getseqs() */
char          *prog;           /* prog name for err msgs */
char          *seqx[2];        /* seqs: getseqs() */
40
int           dmax;             /* best diag: nw() */
int           dmax0;           /* final diag */
int           dna;             /* set if dna: main() */
int           endgaps;         /* set if penalizing end gaps */
int           gapx, gapy;       /* total gaps in seqs */
45
int           len0, len1;       /* seq lens */
int           ngapx, ngapy;     /* total size of gaps */
int           smax;            /* max score: nw() */
int           *xbm;            /* bitmap for matching */
long          offset;          /* current offset in jmp file */
50
struct        diag             *dx; /* holds diagonals */
struct        path             pp[2]; /* holds path for seqs */

char          *calloc(), *malloc(), *index(), *strcpy();
char          *getseq(), *g_calloc();

```

Table 1 (cont')

```

/* Needleman-Wunsch alignment program
*
* usage: progs file1 file2
* where file1 and file2 are two dna or two protein sequences.
5 * The sequences can be in upper- or lower-case and may contain ambiguity
* Any lines beginning with ';', '>' or '<' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
* Output is in the file "align.out"
10 *
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650
*/

#include "nw.h"
15 #include "day.h"

static _dbval[26] = {
    1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};

20 static _pbval[26] = {
    1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
    1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
25 1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)                                main
30     int      ac;
     char      *av[];
{
    prog = av[0];
    if (ac != 3) {
35         fprintf(stderr, "usage: %s file1 file2\n", prog);
         fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
         fprintf(stderr, "The sequences can be in upper- or lower-case\n");
         fprintf(stderr, "Any lines beginning with ';' or '<' are ignored\n");
         fprintf(stderr, "Output is in the file \"align.out\"\n");
         exit(1);
40     }
    namex[0] = av[1];
    namex[1] = av[2];
    seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
45     xbm = (dna)? _dbval : _pbval;

    endgaps = 0;                            /* 1 to penalize endgaps */
    ofile = "align.out";                    /* output file */

50     nw();                                /* fill in the matrix, get the possible jmps */
    readjmps();                             /* get the actual jmps */
    print();                                /* print stats, alignment */

    cleanup(0);                             /* unlink any tmp files */

```

**Table 1 (cont')**

```

/* do the alignment, return best score: main()
* dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
* pro: PAM 250 values
* When scores are equal, we prefer mismatches to any gap, prefer
5 * a new gap to extending an ongoing gap, and prefer a gap in seqx
* to a gap in seq y.
*/
nw()
{
10     char      *px, *py;          /* seqs and ptrs */
    int         *ndely, *dely;      /* keep track of dely */
    int         ndelx, delx;        /* keep track of delx */
    int         *tmp;              /* for swapping row0, row1 */
    int         mis;               /* score for each type */
15     int         ins0, ins1;       /* insertion penalties */
    register    id;                /* diagonal index */
    register    ij;                /* jmp index */
    register    *col0, *col1;       /* score for curr, last row */
    register    xx, yy;            /* index into seqs */
20
    dx = (struct diag *)g_calloc("to get diags", len0+len1+1, sizeof(struct diag));
    ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
    dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
    col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
25     col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
    ins0 = (dna)? DINS0 : PINS0;
    ins1 = (dna)? DINS1 : PINS1;
    smax = -10000;
    if (endgaps) {
30         for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
            col0[yy] = dely[yy] = col0[yy-1] - ins1;
            ndely[yy] = yy;
        }
        col0[0] = 0;          /* Waterman Bull Math Biol 84 */
35     }
    else
        for (yy = 1; yy <= len1; yy++)
            dely[yy] = -ins0;

    /* fill in match matrix
    */
40     for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
        /* initialize first entry in col
        */
        if (endgaps) {
45             if (xx == 1)
                col1[0] = delx = -(ins0+ins1);
            else
                col1[0] = delx = col0[0] - ins1;
            ndelx = xx;
50         }
        else {
            col1[0] = 0;
            delx = -ins0;
            ndelx = 0;
55         }
    }

```

**Table 1 (cont')**

...nw

```

for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
    mis = col0[yy-1];
    if (dna)
        mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
    else
        mis += _day[*px-'A'][*py-'A'];

    /* update penalty for del in x seq;
    * favor new del over ongong del
    * ignore MAXGAP if weighting endgaps
    */
    if (endgaps || ndely[yy] < MAXGAP) {
        if (col0[yy] - ins0 >= dely[yy]) {
            dely[yy] = col0[yy] - (ins0+ins1);
            ndely[yy] = 1;
        } else {
            dely[yy] -= ins1;
            ndely[yy]++;
        }
    } else {
        if (col0[yy] - (ins0+ins1) >= dely[yy]) {
            dely[yy] = col0[yy] - (ins0+ins1);
            ndely[yy] = 1;
        } else
            ndely[yy]++;
    }

    /* update penalty for del in y seq;
    * favor new del over ongong del
    */
    if (endgaps || ndelx < MAXGAP) {
        if (col1[yy-1] - ins0 >= delx) {
            delx = col1[yy-1] - (ins0+ins1);
            ndelx = 1;
        } else {
            delx -= ins1;
            ndelx++;
        }
    } else {
        if (col1[yy-1] - (ins0+ins1) >= delx) {
            delx = col1[yy-1] - (ins0+ins1);
            ndelx = 1;
        } else
            ndelx++;
    }

    /* pick the maximum score; we're favoring
    * mis over any del and delx over dely
    */

    id = xx - yy + len1 - 1;
    if (mis >= delx && mis >= dely[yy])
        col1[yy] = mis;

```

...nw

**Table 1 (cont')**

```

else if (delx >= dely[yy]) {
    coll[yy] = delx;
    ij = dx[id].ijmp;
    if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
5      && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
        dx[id].ijmp++;
        if (++ij >= MAXJMP) {
            writejms(id);
            ij = dx[id].ijmp = 0;
10          dx[id].offset = offset;
            offset += sizeof(struct jmp) + sizeof(offset);
        }
    }
    dx[id].jp.n[ij] = ndelx;
15    dx[id].jp.x[ij] = xx;
    dx[id].score = delx;
}
else {
    coll[yy] = dely[yy];
    ij = dx[id].ijmp;
20    if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
        && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
        dx[id].ijmp++;
        if (++ij >= MAXJMP) {
25          writejms(id);
            ij = dx[id].ijmp = 0;
            dx[id].offset = offset;
            offset += sizeof(struct jmp) + sizeof(offset);
        }
    }
30    dx[id].jp.n[ij] = -ndely[yy];
    dx[id].jp.x[ij] = xx;
    dx[id].score = dely[yy];
}
35    if (xx == len0 && yy < len1) {
        /* last col
        */
        if (endgaps)
            coll[yy] -= ins0+ins1*(len1-yy);
40        if (coll[yy] > smax) {
            smax = coll[yy];
            dmax = id;
        }
    }
}
45    if (endgaps && xx < len0)
        coll[yy-1] -= ins0+ins1*(len0-xx);
    if (coll[yy-1] > smax) {
        smax = coll[yy-1];
50        dmax = id;
    }
    tmp = col0; col0 = coll; coll = tmp;
}
(void) free((char *)ndely);
(void) free((char *)dely);
55 (void) free((char *)col0);
(void) free((char *)coll);
}

```

Table 1 (cont')

```

/*
*
* print() -- only routine visible outside this module
*
5  * static:
* getmat() -- trace back best path, count matches: print()
* pr_align() -- print alignment of described in array p[]: print()
* dumpblock() -- dump a block of lines with numbers, stars: pr_align()
* nums() -- put out a number line: dumpblock()
10 * putline() -- put out a line (name, [num], seq, [num]): dumpblock()
* stars() -- put a line of stars: dumpblock()
* stripname() -- strip any path and prefix from a seqname
*/

15 #include "nw.h"

#define SPC      3
#define P_LINE  256      /* maximum output line */
#define P_SPC    3        /* space between name or num and seq */

20 extern  _day[26][26];
int      olen;           /* set output line length */
FILE     *fx;            /* output file */

25 print()
{
    int      lx, ly, firstgap, lastgap;      /* overlap */

    if ((fx = fopen(ofile, "w")) == 0) {
30         fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1);
    }
    fprintf(fx, "<first sequence: %s (length = %d)\n", namex[0], len0);
    fprintf(fx, "<second sequence: %s (length = %d)\n", namex[1], len1);
35     olen = 60;
    lx = len0;
    ly = len1;
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) {      /* leading gap in x */
40         pp[0].spc = firstgap = len1 - dmax - 1;
        ly -= pp[0].spc;
    }
    else if (dmax > len1 - 1) { /* leading gap in y */
        pp[1].spc = firstgap = dmax - (len1 - 1);
45         lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) {     /* trailing gap in x */
        lastgap = len0 - dmax0 - 1;
        lx -= lastgap;
50     }
    else if (dmax0 > len0 - 1) { /* trailing gap in y */
        lastgap = dmax0 - (len0 - 1);
        ly -= lastgap;
    }
55     getmat(lx, ly, firstgap, lastgap);
    pr_align();
}

```

**print**

**Table 1 (cont')**

```

/*
 * trace back the best path, count matches
 */
static
5 getmat(lx, ly, firstgap, lastgap)                                getmat
    int      lx, ly;                      /* "core" (minus endgaps) */
    int      firstgap, lastgap;           /* leading trailing overlap */
{
    int      nm, i0, i1, siz0, siz1;
10    char      outx[32];
    double    pct;
    register  n0, n1;
    register char *p0, *p1;
    /* get total matches, score
15    */
    i0 = i1 = siz0 = siz1 = 0;
    p0 = seqx[0] + pp[1].spc;
    p1 = seqx[1] + pp[0].spc;
    n0 = pp[1].spc + 1;
20    n1 = pp[0].spc + 1;
    nm = 0;
    while ( *p0 && *p1 ) {
        if (siz0) {
            p1++;
25            n1++;
            siz0--;
        }
        else if (siz1) {
            p0++;
30            n0++;
            siz1--;
        }
        else {
            if (xbm[*p0-'A']&xbm[*p1-'A'])
35                nm++;
            if (n0++ == pp[0].x[i0])
                siz0 = pp[0].n[i0++];
            if (n1++ == pp[1].x[i1])
                siz1 = pp[1].n[i1++];
40            p0++;
            p1++;
        }
    }

45    /* pct homology:
    * if penalizing endgaps, base is the shorter seq
    * else, knock off overhangs and take shorter core
    */
    if (endgaps)
50        lx = (len0 < len1)? len0 : len1;
    else
        lx = (lx < ly)? lx : ly;
    pct = 100.*((double)nm)/((double)lx);
    fprintf(fx, "\n");
55    fprintf(fx, "<%d match%s in an overlap of %d: %.2f percent similarity\n",
        nm, (nm == 1)? "" : "es", lx, pct);

```



**Table 1 (cont')****...getmat**

```

fprintf(fx, "<gaps in first sequence: %d", gapx);
if (gapx) {
    (void) sprintf(outx, " (%d %s%s)",
        ngapx, (dna)? "base": "residue", (ngapx == 1)? "" : "s");
    fprintf(fx, "%s", outx);
}
fprintf(fx, ", gaps in second sequence: %d", gapy);
if (gapy) {
    (void) sprintf(outx, " (%d %s%s)",
        ngapy, (dna)? "base": "residue", (ngapy == 1)? "" : "s");
    fprintf(fx, "%s", outx);
}
if (dna)
    fprintf(fx,
        "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
        smax, DMAT, DMIS, DINS0, DINS1);
else
    fprintf(fx,
        "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
        smax, PINS0, PINS1);
if (endgaps)
    fprintf(fx,
        "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
        firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s",
        lastgap, (dna)? "base" : "residue", (lastgap == 1)? "" : "s");
else
    fprintf(fx, "<endgaps not penalized\n");
}
static      nm;          /* matches in core -- for checking */
static      lmax;        /* lengths of stripped file names */
static      ij[2];       /* jmp index for a path */
static      nc[2];       /* number at start of current line */
static      ni[2];       /* current elem number -- for gapping */
static      siz[2];
static char *ps[2];      /* ptr to current element */
static char *po[2];      /* ptr to next output char slot */
static char out[2][P_LINE]; /* output line */
static char star[P_LINE]; /* set by stars() */
/*
* print alignment of described in struct path pp[]
*/
static
pr_align()
{
    int      nn;          /* char count */
    int      more;
    register i;

    for (i = 0, lmax = 0; i < 2; i++) {
        nn = stripname(namex[i]);
        if (nn > lmax)
            lmax = nn;
        nc[i] = 1;
        ni[i] = 1;
        siz[i] = ij[i] = 0;
        ps[i] = seqx[i];
        po[i] = out[i];
    }

```

**pr\_align**

**Table 1 (cont')**

```

for (nn = nm = 0, more = 1; more; ) {
    for (i = more = 0; i < 2; i++) {
        /*
5         * do we have more of this sequence?
        */
        if (!*ps[i])
            continue;
        more++;
10        if (pp[i].spc) { /* leading space */
            *po[i]++ = ' ';
            pp[i].spc--;
        }
        else if (siz[i]) { /* in a gap */
15            *po[i]++ = '-';
            siz[i]--;
        }
        else { /* we're putting a seq element
                */
20            *po[i] = *ps[i];
            if (islower(*ps[i]))
                *ps[i] = toupper(*ps[i]);

            po[i]++;
            ps[i]++;
25            /*
            * are we at next gap for this seq?
            */
            if (ni[i] == pp[i].x[ij[i]]) {
30                /*
                * we need to merge all gaps
                * at this location
                */
                siz[i] = pp[i].n[ij[i]++];
                while (ni[i] == pp[i].x[ij[i]])
35                    siz[i] += pp[i].n[ij[i]++];
            }
            ni[i]++;
        }
    }
40    if (++nn == olen || !more && nn) {
        dumpblock();
        for (i = 0; i < 2; i++)
            po[i] = out[i];
        nn = 0;
45    }
}

/*
* dump a block of lines, including numbers, stars: pr_align()
*/
50 static
dumpblock()
{
    register i;
55    for (i = 0; i < 2; i++)
        *po[i]-- = '\0';
}

```

...pr\_align

dumpblock

Table 1 (cont')

...dumpblock

```

5      (void) putc('\n', fx);
      for (i = 0; i < 2; i++) {
          if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' ')) {
              if (i == 0)
                  nums(i);
              if (i == 0 && *out[1])
                  stars();
              putline(i);
10         if (i == 0 && *out[1])
                fprintf(fx, star);
              if (i == 1)
                  nums(i);
          }
15     }
}
/*
 * put out a number line: dumpblock()
 */
20 static
nums(ix)
    int    ix;        /* index in out[] holding seq line */
{
    char    nline[P_LINE];
25     register i, j;
    register char *pn, *px, *py;
    for (pn = nline, i = 0; i < lmax+P_SPC; i++, pn++)
        *pn = ' ';
    for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
30         if (*py == ' ' || *py == '-')
            *pn = ' ';
        else {
            if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                j = (i < 0)? -i : i;
35                 for (px = pn; j; j /= 10, px--)
                    *px = j%10 + '0';
                if (i < 0)
                    *px = '-';
            }
            else
40                 *pn = ' ';
            i++;
        }
    }
45     *pn = '\0';
    nc[ix] = i;
    for (pn = nline; *pn; pn++)
        (void) putc(*pn, fx);
    (void) putc('\n', fx);
50 }
/*
 * put out a line (name, [num], seq, [num]): dumpblock()
 */
static
55 putline(ix)
    int    ix;
    {

```

nums

putline

Table 1 (cont')

...putline

```

5      int          i;
      register char *px;

      for (px = namex[ix], i = 0; *px && *px != '!'; px++, i++)
          (void) putc(*px, fx);
      for (; i < lmax+P_SPC; i++)
          (void) putc(' ', fx);

10     /* these count from 1:
       * ni[] is current element (from 1)
       * nc[] is number at start of current line
       */
15     for (px = out[ix]; *px; px++)
          (void) putc(*px&0x7F, fx);
      (void) putc('\n', fx);
  }

20  /*
   * put a line of stars (seqs always in out[0], out[1]): dumpblock()
   */
   static
25  stars()
  {
      int          i;
      register char *p0, *p1, cx, *px;

30     if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
        !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
          return;
      px = star;
      for (i = lmax+P_SPC; i; i--)
35         *px++ = ' ';

      for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
          if (isalpha(*p0) && isalpha(*p1)) {

40                 if (xbm[*p0-'A']&xbm[*p1-'A']) {
                        cx = '*';
                        nm++;
                    }
                    else if (!dna && _day[*p0-'A'][*p1-'A'] > 0)
45                         cx = '!';
                    else
                        cx = ' ';
                }
                else
50                 cx = ' ';
                *px++ = cx;
            }
      *px++ = '\n';
      *px = '\0';
55  }

```

stars

Table 1 (cont')

```

/*
 * strip path or prefix from pn, return len: pr_align()
 */
static
5 stripname(pn)                                     stripname
    char    *pn;    /* file name (may be path) */
{
    register char    *px, *py;
10     py = 0;
    for (px = pn; *px; px++)
        if (*px == '/')
            py = px + 1;
    if (py)
15     (void) strcpy(pn, py);
    return(strlen(pn));
}
20

```

Table 1 (cont')

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
 * g_calloc() -- calloc() with error checkin
5  * readjumps() -- get the good jumps, from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file: nw()
 */
#include "nw.h"
#include <sys/file.h>

10 char    *jname = "/tmp/homgXXXXXXX";          /* tmp file for jumps */
FILE      *fj;
int        cleanup();                          /* cleanup tmp file */
long       lseek();

15 /*
 * remove any tmp file if we blow
 */
cleanup(i)                                     cleanup
{
    int      i;

    if (fj)
        (void) unlink(jname);
    exit(i);
}

25 /*
 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
30 char    *
getseq(file, len)                             getseq
{
    char    *file;    /* file name */
    int      *len;    /* seq len */

    {
35         char    line[1024], *pseq;
        register char *px, *py;
        int      natgc, tlen;
        FILE      *fp;
        if ((fp = fopen(file, "r")) == 0) {
40             fprintf(stderr, "%s: can't read %s\n", prog, file);
            exit(1);
        }
        tlen = natgc = 0;
        while (fgets(line, 1024, fp)) {
45             if (*line == ';' || *line == '<' || *line == '>')
                continue;
            for (px = line; *px != '\n'; px++)
                if (isupper(*px) || islower(*px))
                    tlen++;
50         }
        if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
            fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
            exit(1);
        }
        pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';
55

```

**Table 1 (cont')****...getseq**

```

py = pseq + 4;
*len = tlen;
rewind(fp);
5 while (fgets(line, 1024, fp)) {
    if (*line == ';' || *line == '<' || *line == '>')
        continue;
    for (px = line; *px != '\n'; px++) {
10         if (isupper(*px))
            *py++ = *px;
        else if (islower(*px))
            *py++ = toupper(*px);
        if (index("ATGCU", *(py-1)))
            natgc++;
15     }
}
*py++ = '\0';
*py = '\0';
(void) fclose(fp);
20 dna = natgc > (tlen/3);
return(pseq+4);
}
char *
g_calloc(msg, nx, sz)
25 char *msg; /* program, calling routine */
int nx, sz; /* number and size of elements */
{
    char *px, *calloc();
    if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
30         if (*msg) {
            fprintf(stderr, "%s: g_calloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
            exit(1);
        }
    }
    return(px);
35 }

/*
* get final jmps from dx[] or tmp file, set pp[], reset dmax: main()
*/
40 readjmps()
{
    int fd = -1;
    int siz, i0, i1;
45 register i, j, xx;
    if (fj) {
        (void) fclose(fj);
        if ((fd = open(jname, O_RDONLY, 0)) < 0) {
            fprintf(stderr, "%s: can't open() %s\n", prog, jname);
50             cleanup(1);
        }
    }
    for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; ; i++) {
        while (1) {
55             for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)
                ;

```

**g\_calloc****readjmps**

**Table 1 (cont')****...readjumps**

```

5      if (j < 0 && dx[dmax].offset && fj) {
          (void) lseek(fd, dx[dmax].offset, 0);
          (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
          (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
          dx[dmax].ijmp = MAXJMP-1;
      }
      else
          break;
10     if (i >= JMPS) {
        fprintf(stderr, "%s: too many gaps in alignment\n", prog);
        cleanup(1);
    }
    if (j >= 0) {
        siz = dx[dmax].jp.n[j];
        xx = dx[dmax].jp.x[j];
        dmax += siz;
        if (siz < 0) { /* gap in second seq */
            pp[1].n[i1] = -siz;
            xx += siz;
            /* id = xx - yy + len1 - 1 */
            pp[1].x[i1] = xx - dmax + len1 - 1;
            gapy++;
            ngapy -= siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
            i1++;
        }
        else if (siz > 0) { /* gap in first seq */
            pp[0].n[i0] = siz;
            pp[0].x[i0] = xx;
            gapx++;
            ngapx += siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
            i0++;
        }
    }
    else
        break;
40 }
    /* reverse the order of jumps */
    for (j = 0, i0--; j < i0; j++, i0--) {
        i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
        i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
    }
    for (j = 0, i1--; j < i1; j++, i1--) {
        i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
        i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
    }
50     if (fd >= 0)
        (void) close(fd);
    if (fj) {
        (void) unlink(jname);
        fj = 0;
        offset = 0;
55 }

```



Table 1 (cont')

	/*	
	* write a filled jmp struct offset of the prev one (if any): nw()	
	*/	
5	writejumps(ix)	<b>writejumps</b>
	int    ix;	
	{	
	char    *mktemp();	
10	if (!fj) {	
	if (mktemp(jname) < 0) {	
	fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname);	
	cleanup(1);	
	}	
15	if ((fj = fopen(jname, "w")) == 0) {	
	fprintf(stderr, "%s: can't write %s\n", prog, jname);	
	exit(1);	
	}	
20	}	
	(void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);	
	(void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);	
	}	

**Table 2**

TAT	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXXXYYYYYYY	(Length = 12 amino acids)

5      % amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the TAT polypeptide) =

10      5 divided by 15 = 33.3%

**Table 3**

15	TAT	XXXXXXXXXXXX	(Length = 10 amino acids)
	Comparison Protein	XXXXXXXXYYYYZZYZ	(Length = 15 amino acids)

% amino acid sequence identity =

20      (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the TAT polypeptide) =

5 divided by 10 = 50%

**Table 4**

25	TAT-DNA	NNNNNNNNNNNNNN	(Length = 14 nucleotides)
	Comparison DNA	NNNNNNLLLLLLLLLL	(Length = 16 nucleotides)

% nucleic acid sequence identity =

30

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the TAT-DNA nucleic acid sequence) =

6 divided by 14 = 42.9%

**Table 5**

TAT-DNA	NNNNNNNNNNNNNN	(Length = 12 nucleotides)
Comparison DNA	NNNNLLLVV	(Length = 9 nucleotides)

5      % nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the TAT-DNA nucleic acid sequence) =

10      4 divided by 12 = 33.3%

## II.                      Compositions and Methods of the Invention

### A.                      Anti-TAT Antibodies

15      In one embodiment, the present invention provides anti-TAT antibodies which may find use herein as therapeutic and/or diagnostic agents. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

#### 1.                      Polyclonal Antibodies

20      Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen (especially when synthetic peptides are used) to a protein that is immunogenic in the species to be immunized. For example, the antigen can be conjugated to keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl<sub>2</sub>, or R<sup>1</sup>N=C=NR, where R and R<sup>1</sup> are different alkyl groups.

25      Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 µg or 5 µg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and the serum is assayed for antibody titer. Animals  
30      are boosted until the titer plateaus. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

#### 2.                      Monoclonal Antibodies

35      Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. After

immunization, lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium which medium preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells (also referred to as fusion partner). For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the selective culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred fusion partner myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a selective medium that selects against the unfused parental cells. Preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 and derivatives e.g., X63-Ag8-653 cells available from the American Type Culture Collection, Manassas, Virginia, USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); and Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis described in Munson et al., Anal. Biochem., 107:220 (1980).

Once hybridoma cells that produce antibodies of the desired specificity, affinity, and/or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal e.g., by i.p. injection of the cells into mice.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (e.g., using protein A or protein G-Sepharose) or ion-exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, etc.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce

antibody protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., Curr. Opinion in Immunol., 5:256-262 (1993) and Plückthun, Immunol. Revs. 130:151-188 (1992).

In a further embodiment, monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., Bio/Technology, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nuc. Acids. Res. 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA that encodes the antibody may be modified to produce chimeric or fusion antibody polypeptides, for example, by substituting human heavy chain and light chain constant domain ( $C_H$  and  $C_L$ ) sequences for the homologous murine sequences (U.S. Patent No. 4,816,567; and Morrison, et al., Proc. Natl Acad. Sci. USA, 81:6851 (1984)), or by fusing the immunoglobulin coding sequence with all or part of the coding sequence for a non-immunoglobulin polypeptide (heterologous polypeptide). The non-immunoglobulin polypeptide sequences can substitute for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

### 3. Human and Humanized Antibodies

The anti-TAT antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-

human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeven et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity and HAMA response (human anti-mouse antibody) when the antibody is intended for human therapeutic use. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human V domain sequence which is closest to that of the rodent is identified and the human framework region (FR) within it accepted for the humanized antibody (Sims et al., J. Immunol. 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987)). Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993)).

It is further important that antibodies be humanized with retention of high binding affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

Various forms of a humanized anti-TAT antibody are contemplated. For example, the humanized antibody may be an antibody fragment, such as a Fab, which is optionally conjugated with one or more cytotoxic agent(s) in order to generate an immunoconjugate. Alternatively, the humanized antibody may be an intact antibody, such as an intact IgG1 antibody.

As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described

that the homozygous deletion of the antibody heavy-chain joining region ( $J_H$ ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno. 7:33 (1993); U.S. Patent Nos. 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); 5,545,807; and WO 97/17852.

Alternatively, phage display technology (McCafferty et al., Nature 348:552-553 [1990]) can be used to produce human antibodies and antibody fragments *in vitro*, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats, reviewed in, e.g., Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol. 222:581-597 (1991), or Griffith et al., EMBO J. 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905.

As discussed above, human antibodies may also be generated by *in vitro* activated B cells (see U.S. Patents 5,567,610 and 5,229,275).

#### 4. Antibody fragments

In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors.

Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from *E. coli*, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form  $F(ab')_2$  fragments (Carter et al., Bio/Technology 10:163-167 (1992)). According to another approach,  $F(ab')_2$  fragments can be isolated directly from recombinant host cell culture. Fab and  $F(ab')_2$  fragment with increased *in vivo* half-life comprising a salvage receptor binding epitope residues are described in U.S. Patent No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No.

5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced nonspecific binding during in vivo use. sFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineering, ed. Borrebaeck, supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

#### 5. Bispecific Antibodies

Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of a TAT protein as described herein. Other such antibodies may combine a TAT binding site with a binding site for another protein. Alternatively, an anti-TAT arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD3), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16), so as to focus and localize cellular defense mechanisms to the TAT-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express TAT. These antibodies possess a TAT-binding arm and an arm which binds the cytotoxic agent (e.g., saporin, anti-interferon-α, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')<sub>2</sub> bispecific antibodies).

WO 96/16673 describes a bispecific anti-ErbB2/anti-FcγRIII antibody and U.S. Patent No. 5,837,234 discloses a bispecific anti-ErbB2/anti-FcγRI antibody. A bispecific anti-ErbB2/Fcα antibody is shown in WO98/02463. U.S. Patent No. 5,821,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody.

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al., EMBO J. 10:3655-3659 (1991).

According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least part of the hinge, C<sub>H</sub>2, and C<sub>H</sub>3 regions. It is preferred to have the first heavy-chain constant region (C<sub>H</sub>1) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios have no significant affect



on the yield of the desired chain combination.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology 121:210 (1986).

According to another approach described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the C<sub>H</sub>3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175: 217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets. Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture

have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a V<sub>H</sub> connected to a V<sub>L</sub> by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V<sub>H</sub> and V<sub>L</sub> domains of one fragment are forced to pair with the complementary V<sub>L</sub> and V<sub>H</sub> domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol., 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

#### 6. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### 7. Multivalent Antibodies

A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. The antibodies of the present invention can be multivalent antibodies (which are other than of the IgM class) with three or more antigen binding sites (e.g. tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. The preferred multivalent antibody herein comprises (or consists of) three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide chain(s) may comprise VD1-(X1)<sub>n</sub>-VD2-(X2)<sub>n</sub>-Fc, wherein VD1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, X1 and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fc region chain. The multivalent antibody herein preferably further comprises at least two (and preferably four) light chain variable domain polypeptides. The multivalent antibody herein may,

for instance, comprise from about two to about eight light chain variable domain polypeptides. The light chain variable domain polypeptides contemplated here comprise a light chain variable domain and, optionally, further comprise a CL domain.

#### 8. Effector Function Engineering

It may be desirable to modify the antibody of the invention with respect to effector function, e.g., so as to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al., Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design 3:219-230 (1989). To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope-into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, or IgG<sub>4</sub>) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

#### 9. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include <sup>212</sup>Bi, <sup>131</sup>I, <sup>131</sup>In, <sup>90</sup>Y, and <sup>186</sup>Re. Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyl-diethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of

radionucleotide to the antibody. See WO94/11026.

Conjugates of an antibody and one or more small molecule toxins, such as a calicheamicin, maytansinoids, a trichothene, and CC1065, and the derivatives of these toxins that have toxin activity, are also contemplated herein.

#### Maytansine and maytansinoids

5 In one preferred embodiment, an anti-TAT antibody (full length or fragments) of the invention is conjugated to one or more maytansinoid molecules.

Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub *Maytenus serrata* (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters  
10 (U.S. Patent No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, the disclosures of which are hereby expressly incorporated by reference.

#### Maytansinoid-antibody conjugates

15 In an attempt to improve their therapeutic index, maytansine and maytansinoids have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference. Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) described immunoconjugates comprising a maytansinoid designated DM1 linked to the  
20 monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an *in vivo* tumor growth assay. Chari et al., Cancer Research 52:127-131 (1992) describe immunoconjugates in which a maytansinoid was conjugated via a disulfide linker to the murine antibody A7 binding to an antigen on human colon cancer cell lines, or to another murine monoclonal antibody TA.1 that binds the HER-2/*neu* oncogene. The cytotoxicity of the TA.1-  
25 maytansinoid conjugate was tested *in vitro* on the human breast cancer cell line SK-BR-3, which expresses  $3 \times 10^5$  HER-2 surface antigens per cell. The drug conjugate achieved a degree of cytotoxicity similar to the free maytansinoid drug, which could be increased by increasing the number of maytansinoid molecules per antibody molecule. The A7-maytansinoid conjugate showed low systemic cytotoxicity in mice.

#### Anti-TAT polypeptide antibody-maytansinoid conjugates (immunoconjugates)

30 Anti-TAT antibody-maytansinoid conjugates are prepared by chemically linking an anti-TAT antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. An average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody, although even one molecule of toxin/antibody would be expected to enhance cytotoxicity over the use  
35 of naked antibody. Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural sources. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020 and in the other patents and nonpatent publications referred to hereinabove. Preferred maytansinoids are maytansinol

and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.

There are many linking groups known in the art for making antibody-maytansinoid conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 or EP Patent 0 425 235 B1, and Chari et al., Cancer Research 52:127-131 (1992). The linking groups include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred.

Conjugates of the antibody and maytansinoid may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Carlsson et al., Biochem. J. 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP) to provide for a disulfide linkage.

The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In a preferred embodiment, the linkage is formed at the C-3 position of maytansinol or a maytansinol analogue.

#### Calicheamicin

Another immunoconjugate of interest comprises an anti-TAT antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. patents 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296 (all to American Cyanamid Company). Structural analogues of calicheamicin which may be used include, but are not limited to,  $\gamma_1^I$ ,  $\alpha_2^I$ ,  $\alpha_3^I$ , N-acetyl- $\gamma_1^I$ , PSAG and  $\theta_1^I$  (Hinman et al., Cancer Research 53:3336-3342 (1993), Lode et al., Cancer Research 58:2925-2928 (1998) and the aforementioned U.S. patents to American Cyanamid). Another anti-tumor drug that the antibody can be conjugated is QFA which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody mediated internalization greatly enhances their cytotoxic effects.

#### Other cytotoxic agents

Other antitumor agents that can be conjugated to the anti-TAT antibodies of the invention include BCNU, streptozocin, vincristine and 5-fluorouracil, the family of agents known collectively LL-E33288 complex described in U.S. patents 5,053,394, 5,770,710, as well as esperamicins (U.S. patent 5,877,296).

Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, for example, WO 93/21232 published October 28, 1993.

The present invention further contemplates an immunoconjugate formed between an antibody and a compound with nucleolytic activity (e.g., a ribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

For selective destruction of the tumor, the antibody may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated anti-TAT antibodies. Examples include  $\text{At}^{211}$ ,  $\text{I}^{131}$ ,  $\text{I}^{125}$ ,  $\text{Y}^{90}$ ,  $\text{Re}^{186}$ ,  $\text{Re}^{188}$ ,  $\text{Sm}^{153}$ ,  $\text{Bi}^{212}$ ,  $\text{P}^{32}$ ,  $\text{Pb}^{212}$  and radioactive isotopes of Lu. When the conjugate is used for diagnosis, it may comprise a radioactive atom for scintigraphic studies, for example  $\text{tc}^{99\text{m}}$  or  $\text{I}^{123}$ , or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

The radio- or other labels may be incorporated in the conjugate in known ways. For example, the peptide may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen. Labels such as  $\text{tc}^{99\text{m}}$  or  $\text{I}^{123}$ ,  $\text{Re}^{186}$ ,  $\text{Re}^{188}$  and  $\text{In}^{111}$  can be attached via a cysteine residue in the peptide. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes other methods in detail.

Conjugates of the antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Research 52:127-131 (1992); U.S. Patent No. 5,208,020) may be used.

Alternatively, a fusion protein comprising the anti-TAT antibody and cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. The length of DNA may comprise respective regions encoding

the two portions of the conjugate either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.

In yet another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a radionucleotide).

#### 10. Immunoliposomes

The anti-TAT antibodies disclosed herein may also be formulated as immunoliposomes. A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and WO97/38731 published October 23, 1997. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem. 257:286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst. 81(19):1484 (1989).

#### B. TAT Binding Oligopeptides

TAT binding oligopeptides of the present invention are oligopeptides that bind, preferably specifically, to a TAT polypeptide as described herein. TAT binding oligopeptides may be chemically synthesized using known oligopeptide synthesis methodology or may be prepared and purified using recombinant technology. TAT binding oligopeptides are usually at least about 5 amino acids in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids in length or more, wherein such oligopeptides that are capable of binding, preferably specifically, to a TAT polypeptide as described herein. TAT binding oligopeptides may be identified without undue experimentation using well known techniques.

In this regard, it is noted that techniques for screening oligopeptide libraries for oligopeptides that are capable of specifically binding to a polypeptide target are well known in the art (see, e.g., U.S. Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 81:3998-4002 (1984); Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 82:178-182 (1985); Geysen et al., in Synthetic Peptides as Antigens, 130-149 (1986); Geysen et al., J. Immunol. Meth., 102:259-274 (1987); Schoofs et al., J. Immunol., 140:611-616 (1988), Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378; Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363, and Smith, G.

P. (1991) Current Opin. Biotechnol., 2:668).

In this regard, bacteriophage (phage) display is one well known technique which allows one to screen large oligopeptide libraries to identify member(s) of those libraries which are capable of specifically binding to a polypeptide target. Phage display is a technique by which variant polypeptides are displayed as fusion proteins to the coat protein on the surface of bacteriophage particles (Scott, J.K. and Smith, G. P. (1990) Science 249: 386).

5 The utility of phage display lies in the fact that large libraries of selectively randomized protein variants (or randomly cloned cDNAs) can be rapidly and efficiently sorted for those sequences that bind to a target molecule with high affinity. Display of peptide (Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378) or protein (Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363) libraries on phage have  
10 been used for screening millions of polypeptides or oligopeptides for ones with specific binding properties (Smith, G. P. (1991) Current Opin. Biotechnol., 2:668). Sorting phage libraries of random mutants requires a strategy for constructing and propagating a large number of variants, a procedure for affinity purification using the target receptor, and a means of evaluating the results of binding enrichments. U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,689, and 5,663,143.

15 Although most phage display methods have used filamentous phage, lambdoid phage display systems (WO 95/34683; U.S. 5,627,024), T4 phage display systems (Ren, Z-J. et al. (1998) Gene 215:439; Zhu, Z. (1997) CAN 33:534; Jiang, J. et al. (1997) can 128:44380; Ren, Z-J. et al. (1997) CAN 127:215644; Ren, Z-J. (1996) Protein Sci. 5:1833; Efimov, V. P. et al. (1995) Virus Genes 10:173) and T7 phage display systems (Smith, G. P. and Scott, J.K. (1993) Methods in Enzymology, 217, 228-257; U.S. 5,766,905) are also known.

20 Many other improvements and variations of the basic phage display concept have now been developed. These improvements enhance the ability of display systems to screen peptide libraries for binding to selected target molecules and to display functional proteins with the potential of screening these proteins for desired properties. Combinatorial reaction devices for phage display reactions have been developed (WO 98/14277) and phage display libraries have been used to analyze and control bimolecular interactions (WO 98/20169; WO  
25 98/20159) and properties of constrained helical peptides (WO 98/20036). WO 97/35196 describes a method of isolating an affinity ligand in which a phage display library is contacted with one solution in which the ligand will bind to a target molecule and a second solution in which the affinity ligand will not bind to the target molecule, to selectively isolate binding ligands. WO 97/46251 describes a method of biopanning a random phage display library with an affinity purified antibody and then isolating binding phage, followed by a micropanning process  
30 using microplate wells to isolate high affinity binding phage. The use of *Staphylococcus aureus* protein A as an affinity tag has also been reported (Li et al. (1998) Mol Biotech., 9:187). WO 97/47314 describes the use of substrate subtraction libraries to distinguish enzyme specificities using a combinatorial library which may be a phage display library. A method for selecting enzymes suitable for use in detergents using phage display is described in WO 97/09446. Additional methods of selecting specific binding proteins are described in U.S. Patent  
35 Nos. 5,498,538, 5,432,018, and WO 98/15833.

Methods of generating peptide libraries and screening these libraries are also disclosed in U.S. Patent Nos. 5,723,286, 5,432,018, 5,580,717, 5,427,908, 5,498,530, 5,770,434, 5,734,018, 5,698,426, 5,763,192, and 5,723,323.



### C. TAT Binding Organic Molecules

TAT binding organic molecules are organic molecules other than oligopeptides or antibodies as defined herein that bind, preferably specifically, to a TAT polypeptide as described herein. TAT binding organic molecules may be identified and chemically synthesized using known methodology (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). TAT binding organic molecules are usually less than about 2000 daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 daltons in size, wherein such organic molecules that are capable of binding, preferably specifically, to a TAT polypeptide as described herein may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening organic molecule libraries for molecules that are capable of binding to a polypeptide target are well known in the art (see, e.g., PCT Publication Nos. WO00/00823 and WO00/39585). TAT binding organic molecules may be, for example, aldehydes, ketones, oximes, hydrazones, semicarbazones, carbazides, primary amines, secondary amines, tertiary amines, N-substituted hydrazines, hydrazides, alcohols, ethers, thiols, thioethers, disulfides, carboxylic acids, esters, amides, ureas, carbamates, carbonates, ketals, thioketals, acetals, thioacetals, aryl halides, aryl sulfonates, alkyl halides, alkyl sulfonates, aromatic compounds, heterocyclic compounds, anilines, alkenes, alkynes, diols, amino alcohols, oxazolidines, oxazolines, thiazolidines, thiazolines, enamines, sulfonamides, epoxides, aziridines, isocyanates, sulfonyl chlorides, diazo compounds, acid chlorides, or the like.

### D. Screening for Anti-TAT Antibodies, TAT Binding Oligopeptides and TAT Binding Organic Molecules With the Desired Properties

Techniques for generating antibodies, oligopeptides and organic molecules that bind to TAT polypeptides have been described above. One may further select antibodies, oligopeptides or other organic molecules with certain biological characteristics, as desired.

The growth inhibitory effects of an anti-TAT antibody, oligopeptide or other organic molecule of the invention may be assessed by methods known in the art, e.g., using cells which express a TAT polypeptide either endogenously or following transfection with the TAT gene. For example, appropriate tumor cell lines and TAT-transfected cells may be treated with an anti-TAT monoclonal antibody, oligopeptide or other organic molecule of the invention at various concentrations for a few days (e.g., 2-7) days and stained with crystal violet or MTT or analyzed by some other colorimetric assay. Another method of measuring proliferation would be by comparing <sup>3</sup>H-thymidine uptake by the cells treated in the presence or absence of an anti-TAT antibody, TAT binding oligopeptide or TAT binding organic molecule of the invention. After treatment, the cells are harvested and the amount of radioactivity incorporated into the DNA quantitated in a scintillation counter. Appropriate positive controls include treatment of a selected cell line with a growth inhibitory antibody known to inhibit growth of that cell line. Growth inhibition of tumor cells *in vivo* can be determined in various ways known in the art. Preferably, the tumor cell is one that overexpresses a TAT polypeptide. Preferably, the anti-TAT antibody, TAT binding oligopeptide or TAT binding organic molecule will inhibit cell proliferation of a TAT-expressing tumor cell *in vitro* or *in vivo* by about 25-100% compared to the untreated tumor cell, more preferably, by about 30-100%, and even more preferably by about 50-100% or 70-100%, in one embodiment, at an antibody concentration of about 0.5 to 30 µg/ml. Growth inhibition can be measured at an antibody concentration of about 0.5 to 30 µg/ml or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells

to the antibody. The antibody is growth inhibitory *in vivo* if administration of the anti-TAT antibody at about 1 µg/kg to about 100 mg/kg body weight results in reduction in tumor size or reduction of tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days.

To select for an anti-TAT antibody, TAT binding oligopeptide or TAT binding organic molecule which induces cell death, loss of membrane integrity as indicated by, e.g., propidium iodide (PI), trypan blue or 7AAD uptake may be assessed relative to control. A PI uptake assay can be performed in the absence of complement and immune effector cells. TAT polypeptide-expressing tumor cells are incubated with medium alone or medium containing the appropriate anti-TAT antibody (e.g., at about 10µg/ml), TAT binding oligopeptide or TAT binding organic molecule. The cells are incubated for a 3 day time period. Following each treatment, cells are washed and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell clumps. Tubes then receive PI (10µg/ml). Samples may be analyzed using a FACSCAN® flow cytometer and FACSCONVERT® CellQuest software (Becton Dickinson). Those anti-TAT antibodies, TAT binding oligopeptides or TAT binding organic molecules that induce statistically significant levels of cell death as determined by PI uptake may be selected as cell death-inducing anti-TAT antibodies, TAT binding oligopeptides or TAT binding organic molecules.

To screen for antibodies, oligopeptides or other organic molecules which bind to an epitope on a TAT polypeptide bound by an antibody of interest, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. This assay can be used to determine if a test antibody, oligopeptide or other organic molecule binds the same site or epitope as a known anti-TAT antibody. Alternatively, or additionally, epitope mapping can be performed by methods known in the art. For example, the antibody sequence can be mutagenized such as by alanine scanning, to identify contact residues. The mutant antibody is initially tested for binding with polyclonal antibody to ensure proper folding. In a different method, peptides corresponding to different regions of a TAT polypeptide can be used in competition assays with the test antibodies or with a test antibody and an antibody with a characterized or known epitope.

#### E. Antibody Dependent Enzyme Mediated Prodrug Therapy (ADEPT)

The antibodies of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Patent No. 4,975,278.

The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to convert it into its more active, cytotoxic form.

Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β-galactosidase and neuraminidase useful for

converting glycosylated prodrugs into free drugs;  $\beta$ -lactamase useful for converting drugs derivatized with  $\beta$ -lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328:457-458 (1987)).

5 Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.

The enzymes of this invention can be covalently bound to the anti-TAT antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature 312:604-608 (1984)).

#### F. Full-Length TAT Polypeptides

The present invention also provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as TAT polypeptides. In particular, cDNAs (partial and full-length) encoding various TAT polypeptides have been identified and isolated, as disclosed in further detail in the Examples below.

As disclosed in the Examples below, various cDNA clones have been deposited with the ATCC. The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods in the art. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the TAT polypeptides and encoding nucleic acids described herein, in some cases, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.

#### G. Anti-TAT Antibody and TAT Polypeptide Variants

In addition to the anti-TAT antibodies and full-length native sequence TAT polypeptides described herein, it is contemplated that anti-TAT antibody and TAT polypeptide variants can be prepared. Anti-TAT antibody and TAT polypeptide variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA, and/or by synthesis of the desired antibody or polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the anti-TAT antibody or TAT polypeptide, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the anti-TAT antibodies and TAT polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the antibody or polypeptide that results in a change in the amino acid sequence as compared with the native sequence antibody or polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the anti-TAT antibody or TAT polypeptide. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the anti-TAT antibody or TAT

polypeptide with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

Anti-TAT antibody and TAT polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native antibody or protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the anti-TAT antibody or TAT polypeptide.

Anti-TAT antibody and TAT polypeptide fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating antibody or polypeptide fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired antibody or polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, anti-TAT antibody and TAT polypeptide fragments share at least one biological and/or immunological activity with the native anti-TAT antibody or TAT polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

	Original Residue	Exemplary Substitutions	Preferred Substitutions
5	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
10	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
15	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
20	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the anti-TAT antibody or TAT polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)]

or other known techniques can be performed on the cloned DNA to produce the anti-TAT antibody or TAT polypeptide variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244:1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

Any cysteine residue not involved in maintaining the proper conformation of the anti-TAT antibody or TAT polypeptide also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the anti-TAT antibody or TAT polypeptide to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

A particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and human TAT polypeptide. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

Nucleic acid molecules encoding amino acid sequence variants of the anti-TAT antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the anti-TAT antibody.

#### H. Modifications of Anti-TAT Antibodies and TAT Polypeptides

Covalent modifications of anti-TAT antibodies and TAT polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of an anti-TAT

antibody or TAT polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the anti-TAT antibody or TAT polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking anti-TAT antibody or TAT polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-TAT antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimideate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the anti-TAT antibody or TAT polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the antibody or polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence anti-TAT antibody or TAT polypeptide (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence anti-TAT antibody or TAT polypeptide. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Glycosylation of antibodies and other polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Addition of glycosylation sites to the anti-TAT antibody or TAT polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original anti-TAT antibody or TAT polypeptide (for O-linked glycosylation sites). The anti-TAT antibody or TAT polypeptide amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the anti-TAT antibody or TAT polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the anti-TAT antibody or TAT polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the anti-TAT antibody or TAT polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of anti-TAT antibody or TAT polypeptide comprises linking the antibody or polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. The antibody or polypeptide also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980).

The anti-TAT antibody or TAT polypeptide of the present invention may also be modified in a way to form chimeric molecules comprising an anti-TAT antibody or TAT polypeptide fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the anti-TAT antibody or TAT polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the anti-TAT antibody or TAT polypeptide. The presence of such epitope-tagged forms of the anti-TAT antibody or TAT polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the anti-TAT antibody or TAT polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].



In an alternative embodiment, the chimeric molecule may comprise a fusion of the anti-TAT antibody or TAT polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of an anti-TAT antibody or TAT polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH<sub>2</sub> and CH<sub>3</sub>, or the hinge, CH<sub>1</sub>, CH<sub>2</sub> and CH<sub>3</sub> regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

#### I. Preparation of Anti-TAT Antibodies and TAT Polypeptides

The description below relates primarily to production of anti-TAT antibodies and TAT polypeptides by culturing cells transformed or transfected with a vector containing anti-TAT antibody- and TAT polypeptide-encoding nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare anti-TAT antibodies and TAT polypeptides. For instance, the appropriate amino acid sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the anti-TAT antibody or TAT polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the desired anti-TAT antibody or TAT polypeptide.

##### 1. Isolation of DNA Encoding Anti-TAT Antibody or TAT Polypeptide

DNA encoding anti-TAT antibody or TAT polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the anti-TAT antibody or TAT polypeptide mRNA and to express it at a detectable level. Accordingly, human anti-TAT antibody or TAT polypeptide DNA can be conveniently obtained from a cDNA library prepared from human tissue. The anti-TAT antibody- or TAT polypeptide-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding anti-TAT antibody or TAT polypeptide is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

Techniques for screening a cDNA library are well known in the art. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for anti-TAT antibody or TAT polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example,  $\text{CaCl}_2$ ,  $\text{CaPO}_4$ , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as

*P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan'*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan'*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

Full length antibody, antibody fragments, and antibody fusion proteins can be produced in bacteria, in particular when glycosylation and Fc effector function are not needed, such as when the therapeutic antibody is conjugated to a cytotoxic agent (e.g., a toxin) and the immunoconjugate by itself shows effectiveness in tumor cell destruction. Full length antibodies have greater half life in circulation. Production in *E. coli* is faster and more cost efficient. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. 5,648,237 (Carter et al.), U.S. 5,789,199 (Joly et al.), and U.S. 5,840,523 (Simmons et al.) which describes translation initiation region (TIR) and signal sequences for optimizing expression and secretion, these patents incorporated herein by reference. After expression, the antibody is isolated from the *E. coli* cell paste in a soluble fraction and can be purified through, e.g., a protein A or G column depending on the isotype. Final purification can be carried out similar to the process for purifying antibody expressed e.g., in CHO cells.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-TAT antibody- or TAT polypeptide-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylophilic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts

may be found in C. Anthony, The Biochemistry of Methyloprophs, 269 (1982).

Suitable host cells for the expression of glycosylated anti-TAT antibody or TAT polypeptide are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells, such as cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression or cloning vectors for anti-TAT antibody or TAT polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding anti-TAT antibody or TAT polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The TAT may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the anti-TAT antibody- or TAT polypeptide-encoding DNA that is inserted into

the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the anti-TAT antibody- or TAT polypeptide-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the anti-TAT antibody- or TAT polypeptide-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the *tac* promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding anti-TAT antibody or TAT polypeptide.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase,

and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

Anti-TAT antibody or TAT polypeptide transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the anti-TAT antibody or TAT polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the anti-TAT antibody or TAT polypeptide coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding anti-TAT antibody or TAT polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of anti-TAT antibody or TAT polypeptide in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Culturing the Host Cells

The host cells used to produce the anti-TAT antibody or TAT polypeptide of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin,

or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

#### 5. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence TAT polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to TAT DNA and encoding a specific antibody epitope.

#### 6. Purification of Anti-TAT Antibody and TAT Polypeptide

Forms of anti-TAT antibody and TAT polypeptide may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of anti-TAT antibody and TAT polypeptide can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify anti-TAT antibody and TAT polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the anti-TAT antibody and TAT polypeptide. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular anti-TAT antibody or TAT polypeptide produced.

When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, are removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of *E. coli*. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.

The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human  $\gamma 1$ ,  $\gamma 2$  or  $\gamma 4$  heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human  $\gamma 3$  (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a  $C_H3$  domain, the Bakerbond ABX<sup>TM</sup> resin (J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE<sup>TM</sup> chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.

Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).

#### J. Pharmaceutical Formulations

Therapeutic formulations of the anti-TAT antibodies, TAT binding oligopeptides, TAT binding organic molecules and/or TAT polypeptides used in accordance with the present invention are prepared for storage by mixing the antibody, polypeptide, oligopeptide or organic molecule having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as acetate, Tris, phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than



about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; tonicifiers such as trehalose and sodium chloride; sugars such as sucrose, mannitol, trehalose or sorbitol; surfactant such as polysorbate; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN®, PLURONICS® or polyethylene glycol (PEG). The antibody preferably comprises the antibody at a concentration of between 5-200 mg/ml, preferably between 10-100 mg/ml.

The formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, in addition to an anti-TAT antibody, TAT binding oligopeptide, or TAT binding organic molecule, it may be desirable to include in the one formulation, an additional antibody, e.g., a second anti-TAT antibody which binds a different epitope on the TAT polypeptide, or an antibody to some other target such as a growth factor that affects the growth of the particular cancer. Alternatively, or additionally, the composition may further comprise a chemotherapeutic agent, cytotoxic agent, cytokine, growth inhibitory agent, anti-hormonal agent, and/or cardioprotectant. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRONDEPOT® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

K. Diagnosis and Treatment with Anti-TAT Antibodies, TAT Binding Oligopeptides and TAT Binding Organic Molecules

To determine TAT expression in the cancer, various diagnostic assays are available. In one embodiment, TAT polypeptide overexpression may be analyzed by immunohistochemistry (IHC). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a TAT protein staining intensity criteria as follows:

Score 0 - no staining is observed or membrane staining is observed in less than 10% of tumor cells.

Score 1+ - a faint/barely perceptible membrane staining is detected in more than 10% of the tumor cells.

The cells are only stained in part of their membrane.

Score 2+ - a weak to moderate complete membrane staining is observed in more than 10% of the tumor cells.

5           Score 3+ - a moderate to strong complete membrane staining is observed in more than 10% of the tumor cells.

Those tumors with 0 or 1+ scores for TAT polypeptide expression may be characterized as not overexpressing TAT, whereas those tumors with 2+ or 3+ scores may be characterized as overexpressing TAT.

10           Alternatively, or additionally, FISH assays such as the INFORM® (sold by Ventana, Arizona) or PATHVISION® (Vysis, Illinois) may be carried out on formalin-fixed, paraffin-embedded tumor tissue to determine the extent (if any) of TAT overexpression in the tumor.

15           TAT overexpression or amplification may be evaluated using an *in vivo* diagnostic assay, e.g., by administering a molecule (such as an antibody, oligopeptide or organic molecule) which binds the molecule to be detected and is tagged with a detectable label (e.g., a radioactive isotope or a fluorescent label) and externally scanning the patient for localization of the label.

20           As described above, the anti-TAT antibodies, oligopeptides and organic molecules of the invention have various non-therapeutic applications. The anti-TAT antibodies, oligopeptides and organic molecules of the present invention can be useful for diagnosis and staging of TAT polypeptide-expressing cancers (e.g., in radioimaging). The antibodies, oligopeptides and organic molecules are also useful for purification or immunoprecipitation of TAT polypeptide from cells, for detection and quantitation of TAT polypeptide *in vitro*, e.g., in an ELISA or a Western blot, to kill and eliminate TAT-expressing cells from a population of mixed cells as a step in the purification of other cells.

25           Currently, depending on the stage of the cancer, cancer treatment involves one or a combination of the following therapies: surgery to remove the cancerous tissue, radiation therapy, and chemotherapy. Anti-TAT antibody, oligopeptide or organic molecule therapy may be especially desirable in elderly patients who do not tolerate the toxicity and side effects of chemotherapy well and in metastatic disease where radiation therapy has limited usefulness. The tumor targeting anti-TAT antibodies, oligopeptides and organic molecules of the invention are useful to alleviate TAT-expressing cancers upon initial diagnosis of the disease or during relapse. For therapeutic applications, the anti-TAT antibody, oligopeptide or organic molecule can be used alone, or in  
30           combination therapy with, e.g., hormones, antiangiogens, or radiolabelled compounds, or with surgery, cryotherapy, and/or radiotherapy. Anti-TAT antibody, oligopeptide or organic molecule treatment can be administered in conjunction with other forms of conventional therapy, either consecutively with, pre- or post-conventional therapy. Chemotherapeutic drugs such as TAXOTERE® (docetaxel), TAXOL® (paclitaxel), estramustine and mitoxantrone are used in treating cancer, in particular, in good risk patients. In the present  
35           method of the invention for treating or alleviating cancer, the cancer patient can be administered anti-TAT antibody, oligopeptide or organic molecule in conjunction with treatment with the one or more of the preceding chemotherapeutic agents. In particular, combination therapy with paclitaxel and modified derivatives (see, e.g.,

EP0600517) is contemplated. The anti-TAT antibody, oligopeptide or organic molecule will be administered with a therapeutically effective dose of the chemotherapeutic agent. In another embodiment, the anti-TAT antibody, oligopeptide or organic molecule is administered in conjunction with chemotherapy to enhance the activity and efficacy of the chemotherapeutic agent, e.g., paclitaxel. The Physicians' Desk Reference (PDR) discloses dosages of these agents that have been used in treatment of various cancers. The dosing regimen and dosages of these  
5      aforementioned chemotherapeutic drugs that are therapeutically effective will depend on the particular cancer being treated, the extent of the disease and other factors familiar to the physician of skill in the art and can be determined by the physician.

In one particular embodiment, a conjugate comprising an anti-TAT antibody, oligopeptide or organic molecule conjugated with a cytotoxic agent is administered to the patient. Preferably, the immunoconjugate bound  
10     to the TAT protein is internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the cancer cell to which it binds. In a preferred embodiment, the cytotoxic agent targets or interferes with the nucleic acid in the cancer cell. Examples of such cytotoxic agents are described above and include maytansinoids, calicheamicins, ribonucleases and DNA endonucleases.

The anti-TAT antibodies, oligopeptides, organic molecules or toxin conjugates thereof are administered  
15     to a human patient, in accord with known methods, such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous or subcutaneous administration of the antibody, oligopeptide or organic molecule is preferred.

Other therapeutic regimens may be combined with the administration of the anti-TAT antibody, oligopeptide or organic molecule. The combined administration includes co-administration, using separate  
20     formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities. Preferably such combined therapy results in a synergistic therapeutic effect.

It may also be desirable to combine administration of the anti-TAT antibody or antibodies, oligopeptides  
25     or organic molecules, with administration of an antibody directed against another tumor antigen associated with the particular cancer.

In another embodiment, the therapeutic treatment methods of the present invention involves the combined administration of an anti-TAT antibody (or antibodies), oligopeptides or organic molecules and one or more chemotherapeutic agents or growth inhibitory agents, including co-administration of cocktails of different  
30     chemotherapeutic agents. Chemotherapeutic agents include estramustine phosphate, prednimustine, cisplatin, 5-fluorouracil, melphalan, cyclophosphamide, hydroxyurea and hydroxyureataxanes (such as paclitaxel and doxorubicin) and/or anthracycline antibiotics. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service Ed., M.C.  
35     Perry, Williams & Wilkins, Baltimore, MD (1992).

The antibody, oligopeptide or organic molecule may be combined with an anti-hormonal compound; e.g., an anti-estrogen compound such as tamoxifen; an anti-progesterone such as onapristone (see, EP 616 812); or an

anti-androgen such as flutamide, in dosages known for such molecules. Where the cancer to be treated is androgen independent cancer, the patient may previously have been subjected to anti-androgen therapy and, after the cancer becomes androgen independent, the anti-TAT antibody, oligopeptide or organic molecule (and optionally other agents as described herein) may be administered to the patient.

Sometimes, it may be beneficial to also co-administer a cardioprotectant (to prevent or reduce myocardial dysfunction associated with the therapy) or one or more cytokines to the patient. In addition to the above therapeutic regimes, the patient may be subjected to surgical removal of cancer cells and/or radiation therapy, before, simultaneously with, or post antibody, oligopeptide or organic molecule therapy. Suitable dosages for any of the above co-administered agents are those presently used and may be lowered due to the combined action (synergy) of the agent and anti-TAT antibody, oligopeptide or organic molecule.

For the prevention or treatment of disease, the dosage and mode of administration will be chosen by the physician according to known criteria. The appropriate dosage of antibody, oligopeptide or organic molecule will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody, oligopeptide or organic molecule is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, oligopeptide or organic molecule, and the discretion of the attending physician. The antibody, oligopeptide or organic molecule is suitably administered to the patient at one time or over a series of treatments. Preferably, the antibody, oligopeptide or organic molecule is administered by intravenous infusion or by subcutaneous injections. Depending on the type and severity of the disease, about 1 µg/kg to about 50 mg/kg body weight (e.g., about 0.1-15mg/kg/dose) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A dosing regimen can comprise administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the anti-TAT antibody. However, other dosage regimens may be useful. A typical daily dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. The progress of this therapy can be readily monitored by conventional methods and assays and based on criteria known to the physician or other persons of skill in the art.

Aside from administration of the antibody protein to the patient, the present application contemplates administration of the antibody by gene therapy. Such administration of nucleic acid encoding the antibody is encompassed by the expression "administering a therapeutically effective amount of an antibody". See, for example, WO96/07321 published March 14, 1996 concerning the use of gene therapy to generate intracellular antibodies.

There are two major approaches to getting the nucleic acid (optionally contained in a vector) into the patient's cells; *in vivo* and *ex vivo*. For *in vivo* delivery the nucleic acid is injected directly into the patient, usually at the site where the antibody is required. For *ex vivo* treatment, the patient's cells are removed, the nucleic acid is introduced into these isolated cells and the modified cells are administered to the patient either directly or, for example, encapsulated within porous membranes which are implanted into the patient (see, e.g., U.S. Patent Nos. 4,892,538 and 5,283,187). There are a variety of techniques available for introducing nucleic acids into viable cells.

The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. A commonly used vector for *ex vivo* delivery of the gene is a retroviral vector.

5 The currently preferred *in vivo* nucleic acid transfer techniques include transfection with viral vectors (such as adenovirus, Herpes simplex I virus, or adeno-associated virus) and lipid-based systems (useful lipids for lipid-mediated transfer of the gene are DOTMA, DOPE and DC-Chol, for example). For review of the currently known gene marking and gene therapy protocols see Anderson et al., Science 256:808-813 (1992). See also WO 93/25673 and the references cited therein.

10 The anti-TAT antibodies of the invention can be in the different forms encompassed by the definition of "antibody" herein. Thus, the antibodies include full length or intact antibody, antibody fragments, native sequence antibody or amino acid variants, humanized, chimeric or fusion antibodies, immunoconjugates, and functional fragments thereof. In fusion antibodies an antibody sequence is fused to a heterologous polypeptide sequence. The antibodies can be modified in the Fc region to provide desired effector functions. As discussed in more detail in the sections herein, with the appropriate Fc regions, the naked antibody bound on the cell surface  
15 can induce cytotoxicity, e.g., via antibody-dependent cellular cytotoxicity (ADCC) or by recruiting complement in complement dependent cytotoxicity, or some other mechanism. Alternatively, where it is desirable to eliminate or reduce effector function, so as to minimize side effects or therapeutic complications, certain other Fc regions may be used.

20 In one embodiment, the antibody competes for binding or bind substantially to, the same epitope as the antibodies of the invention. Antibodies having the biological characteristics of the present anti-TAT antibodies of the invention are also contemplated, specifically including the *in vivo* tumor targeting and any cell proliferation inhibition or cytotoxic characteristics.

Methods of producing the above antibodies are described in detail herein.

25 The present anti-TAT antibodies, oligopeptides and organic molecules are useful for treating a TAT-expressing cancer or alleviating one or more symptoms of the cancer in a mammal. Such a cancer includes prostate cancer, cancer of the urinary tract, lung cancer, breast cancer, colon cancer and ovarian cancer, more specifically, prostate adenocarcinoma, renal cell carcinomas, colorectal adenocarcinomas, lung adenocarcinomas, lung squamous cell carcinomas, and pleural mesothelioma. The cancers encompass metastatic cancers of any of the preceding. The antibody, oligopeptide or organic molecule is able to bind to at least a portion of the cancer cells  
30 that express TAT polypeptide in the mammal. In a preferred embodiment, the antibody, oligopeptide or organic molecule is effective to destroy or kill TAT-expressing tumor cells or inhibit the growth of such tumor cells, *in vitro* or *in vivo*, upon binding to TAT polypeptide on the cell. Such an antibody includes a naked anti-TAT antibody (not conjugated to any agent). Naked antibodies that have cytotoxic or cell growth inhibition properties can be further harnessed with a cytotoxic agent to render them even more potent in tumor cell destruction. Cytotoxic  
35 properties can be conferred to an anti-TAT antibody by, e.g., conjugating the antibody with a cytotoxic agent, to form an immunoconjugate as described herein. The cytotoxic agent or a growth inhibitory agent is preferably a small molecule. Toxins such as calicheamicin or a maytansinoid and analogs or derivatives thereof, are preferable.

The invention provides a composition comprising an anti-TAT antibody, oligopeptide or organic molecule of the invention, and a carrier. For the purposes of treating cancer, compositions can be administered to the patient in need of such treatment, wherein the composition can comprise one or more anti-TAT antibodies present as an immunoconjugate or as the naked antibody. In a further embodiment, the compositions can comprise these antibodies, oligopeptides or organic molecules in combination with other therapeutic agents such as cytotoxic or growth inhibitory agents, including chemotherapeutic agents. The invention also provides formulations comprising an anti-TAT antibody, oligopeptide or organic molecule of the invention, and a carrier. In one embodiment, the formulation is a therapeutic formulation comprising a pharmaceutically acceptable carrier.

Another aspect of the invention is isolated nucleic acids encoding the anti-TAT antibodies. Nucleic acids encoding both the H and L chains and especially the hypervariable region residues, chains which encode the native sequence antibody as well as variants, modifications and humanized versions of the antibody, are encompassed.

The invention also provides methods useful for treating a TAT polypeptide-expressing cancer or alleviating one or more symptoms of the cancer in a mammal, comprising administering a therapeutically effective amount of an anti-TAT antibody, oligopeptide or organic molecule to the mammal. The antibody, oligopeptide or organic molecule therapeutic compositions can be administered short term (acute) or chronic, or intermittent as directed by physician. Also provided are methods of inhibiting the growth of, and killing a TAT polypeptide-expressing cell.

The invention also provides kits and articles of manufacture comprising at least one anti-TAT antibody, oligopeptide or organic molecule. Kits containing anti-TAT antibodies, oligopeptides or organic molecules find use, e.g., for TAT cell killing assays, for purification or immunoprecipitation of TAT polypeptide from cells. For example, for isolation and purification of TAT, the kit can contain an anti-TAT antibody, oligopeptide or organic molecule coupled to beads (e.g., sepharose beads). Kits can be provided which contain the antibodies, oligopeptides or organic molecules for detection and quantitation of TAT *in vitro*, e.g., in an ELISA or a Western blot. Such antibody, oligopeptide or organic molecule useful for detection may be provided with a label such as a fluorescent or radiolabel.

#### L. Articles of Manufacture and Kits

Another embodiment of the invention is an article of manufacture containing materials useful for the treatment of anti-TAT expressing cancer. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the cancer condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an anti-TAT antibody, oligopeptide or organic molecule of the invention. The label or package insert indicates that the composition is used for treating cancer. The label or package insert will further comprise instructions for administering the antibody, oligopeptide or organic molecule composition to the cancer patient. Additionally, the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI),

phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Kits are also provided that are useful for various purposes, e.g., for TAT-expressing cell killing assays, for purification or immunoprecipitation of TAT polypeptide from cells. For isolation and purification of TAT polypeptide, the kit can contain an anti-TAT antibody, oligopeptide or organic molecule coupled to beads (e.g.,  
5   sepharose beads). Kits can be provided which contain the antibodies, oligopeptides or organic molecules for detection and quantitation of TAT polypeptide *in vitro*, e.g., in an ELISA or a Western blot. As with the article of manufacture, the kit comprises a container and a label or package insert on or associated with the container. The container holds a composition comprising at least one anti-TAT antibody, oligopeptide or organic molecule of the invention. Additional containers may be included that contain, e.g., diluents and buffers, control antibodies.  
10   The label or package insert may provide a description of the composition as well as instructions for the intended *in vitro* or diagnostic use.

M.     Uses for TAT Polypeptides and TAT-Polypeptide Encoding Nucleic Acids

Nucleotide sequences (or their complement) encoding TAT polypeptides have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the  
15   generation of anti-sense RNA and DNA probes. TAT-encoding nucleic acid will also be useful for the preparation of TAT polypeptides by the recombinant techniques described herein, wherein those TAT polypeptides may find use, for example, in the preparation of anti-TAT antibodies as described herein.

The full-length native sequence TAT gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length TAT cDNA or to isolate still other cDNAs (for instance, those encoding  
20   naturally-occurring variants of TAT or TAT from other species) which have a desired sequence identity to the native TAT sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence TAT. By way of example, a screening  
25   method will comprise isolating the coding region of the TAT gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as <sup>32</sup>P or <sup>35</sup>S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the TAT gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which  
30   members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below. Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.

Other useful fragments of the TAT-encoding nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target TAT mRNA  
35   (sense) or TAT DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of TAT DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense

oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechniques 6:958, 1988).

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. Such methods are encompassed by the present invention. The antisense oligonucleotides thus may be used to block expression of TAT proteins, wherein those TAT proteins may play a role in the induction of cancer in mammals. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

Preferred intragenic sites for antisense binding include the region incorporating the translation initiation/start codon (5'-AUG / 5'-ATG) or termination/stop codon (5'-UAA, 5'-UAG and 5'-UGA / 5'-TAA, 5'-TAG and 5'-TGA) of the open reading frame (ORF) of the gene. These regions refer to a portion of the mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation or termination codon. Other preferred regions for antisense binding include: introns; exons; intron-exon junctions; the open reading frame (ORF) or "coding region," which is the region between the translation initiation codon and the translation termination codon; the 5' cap of an mRNA which comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage and includes 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap; the 5' untranslated region (5'UTR), the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene; and the 3' untranslated region (3'UTR), the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene.

Specific examples of preferred antisense compounds useful for inhibiting expression of TAT proteins include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotri-esters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and borano-phosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5'



to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included. Representative United States patents that teach the preparation of phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative United States patents that teach the preparation of such oligonucleosides include, but are not limited to, U.S. Pat. Nos.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, each of which is herein incorporated by reference.

In other preferred antisense oligonucleotides, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.

Preferred antisense oligonucleotides incorporate phosphorothioate backbones and/or heteroatom backbones, and in particular -CH<sub>2</sub>-NH-O-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub>- [known as a methylene(methylimino) or MMI backbone], -CH<sub>2</sub>-O-N(CH<sub>3</sub>)-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-N(CH<sub>3</sub>)-CH<sub>2</sub>- and -O-N(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub>- [wherein the native phosphodiester backbone is represented as -O-P-O-CH<sub>2</sub>-] described in the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are antisense oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-alkyl, S-alkyl, or N-alkyl; O-alkenyl, S-alkynyl, or N-alkenyl; O-alkynyl, S-alkynyl or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Particularly preferred are O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other preferred antisense oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH<sub>2</sub>-)<sub>n</sub> group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 2'-allyl (2'-CH<sub>2</sub>-CH=CH<sub>2</sub>), 2'-O-allyl (2'-O-CH<sub>2</sub>-CH=CH<sub>2</sub>) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C≡C-CH<sub>3</sub> or -CH<sub>2</sub>-C≡CH) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl

and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine  
5 (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindele cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include  
10 those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, and those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine,  
15 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2.degree. C. (Sanghvi et al, Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications. Representative United States patents that teach the preparation of modified nucleobases include, but are not limited to: U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos.: 4,845,205;  
20 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; 5,681,941 and 5,750,692, each of which is herein incorporated by reference.

Another modification of antisense oligonucleotides chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide.  
25 The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterol, lipids, cation lipids, phospholipids, cationic phospholipids, biotin, phenazine, folate,  
30 phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Conjugate moieties include but are not limited to lipid moieties such  
35 as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol

(Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmitoyl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999) and United States patents Nos.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Preferred chimeric antisense oligonucleotides incorporate at least one 2' modified sugar (preferably 2'-O-(CH<sub>2</sub>)<sub>2</sub>-O-CH<sub>3</sub>) at the 3' terminal to confer nuclease resistance and a region with at least 4 contiguous 2'-H sugars to confer RNase H activity. Such compounds have also been referred to in the art as hybrids or gapmers. Preferred gapmers

have a region of 2' modified sugars (preferably 2'-O-(CH<sub>2</sub>)<sub>2</sub>-O-CH<sub>3</sub>) at the 3'-terminal and at the 5' terminal separated by at least one region having at least 4 contiguous 2'-H sugars and preferably incorporate phosphorothioate backbone linkages. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaPO<sub>4</sub>-mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either *in vivo* or *ex vivo*. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see WO 90/13641).

Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

Antisense or sense RNA or DNA molecules are generally at least about 5 nucleotides in length, alternatively at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related TAT coding sequences.

Nucleotide sequences encoding a TAT can also be used to construct hybridization probes for mapping the gene which encodes that TAT and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

When the coding sequences for TAT encode a protein which binds to another protein (example, where the TAT is a receptor), the TAT can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor TAT can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native TAT or a receptor for TAT. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

Nucleic acids which encode TAT or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding TAT can be used to clone genomic DNA encoding TAT in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding TAT. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009.

Typically, particular cells would be targeted for TAT transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding TAT introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding TAT. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of TAT can be used to construct a TAT "knock out" animal which has a defective or altered gene encoding TAT as a result of homologous recombination between the endogenous gene encoding TAT and altered genomic DNA encoding TAT introduced into an embryonic stem cell of the animal. For example, cDNA encoding TAT can be used to clone genomic DNA encoding TAT in accordance with established techniques. A portion of the genomic DNA encoding TAT can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the TAT polypeptide.

Nucleic acid encoding the TAT polypeptides may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik *et al.*, *Proc. Natl. Acad. Sci. USA* 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the

use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnology 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson et al., Science 256, 808-813 (1992).

The nucleic acid molecules encoding the TAT polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each TAT nucleic acid molecule of the present invention can be used as a chromosome marker.

The TAT polypeptides and nucleic acid molecules of the present invention may also be used diagnostically for tissue typing, wherein the TAT polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type. TAT nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.

This invention encompasses methods of screening compounds to identify those that mimic the TAT polypeptide (agonists) or prevent the effect of the TAT polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the TAT polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins, including e.g., inhibiting the expression of TAT polypeptide from cells. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

All assays for antagonists are common in that they call for contacting the drug candidate with a TAT polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the TAT polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the TAT polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the TAT



polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to a particular TAT polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER™) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a TAT polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

To assay for antagonists, the TAT polypeptide may be added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the TAT polypeptide indicates that the compound is an antagonist to the TAT polypeptide. Alternatively,

antagonists may be detected by combining the TAT polypeptide and a potential antagonist with membrane-bound TAT polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The TAT polypeptide can be labeled, such as by radioactivity, such that the number of TAT polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the TAT polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the TAT polypeptide. Transfected cells that are grown on glass slides are exposed to labeled TAT polypeptide. The TAT polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled TAT polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled TAT polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with TAT polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the TAT polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the TAT polypeptide.

Another potential TAT polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature TAT polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073

(1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the TAT polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the TAT polypeptide (antisense - Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the TAT polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the TAT polypeptide, thereby blocking the normal biological activity of the TAT polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Biology, 4:469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/33551, *supra*.

These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

Isolated TAT polypeptide-encoding nucleic acid can be used herein for recombinantly producing TAT polypeptide using techniques well known in the art and as described herein. In turn, the produced TAT polypeptides can be employed for generating anti-TAT antibodies using techniques well known in the art and as described herein.

Antibodies specifically binding a TAT polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders, including cancer, in the form of pharmaceutical compositions.

If the TAT polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco *et al.*, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

## EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

### EXAMPLE 1: Tissue Expression Profiling Using GeneExpress®

A proprietary database containing gene expression information (GeneExpress®, Gene Logic Inc., Gaithersburg, MD) was analyzed in an attempt to identify polypeptides (and their encoding nucleic acids) whose expression is significantly upregulated in a particular tumor tissue(s) of interest as compared to other tumor(s) and/or normal tissues. Specifically, analysis of the GeneExpress® database was conducted using either software available through Gene Logic Inc., Gaithersburg, MD, for use with the GeneExpress® database or with proprietary software written and developed at Genentech, Inc. for use with the GeneExpress® database. The rating of positive hits in the analysis is based upon several criteria including, for example, tissue specificity, tumor specificity and expression level in normal essential and/or normal proliferating tissues. The following is a list of molecules whose tissue expression profile as determined from an analysis of the GeneExpress® database evidences high tissue expression and significant upregulation of expression in a specific tumor or tumors as compared to other tumor(s) and/or normal tissues and optionally relatively low expression in normal essential and/or normal proliferating tissues. As such, the molecules listed below are excellent polypeptide targets for the diagnosis and therapy of cancer in mammals.

<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
DNA96792 (TAT239)	colon tumor	normal colon tissue
DNA96792 (TAT239)	rectum tumor	normal rectum tissue
DNA96792 (TAT239)	pancreas tumor	normal pancreas tissue
DNA96792 (TAT239)	lung tumor	normal lung tissue
DNA96792 (TAT239)	stomach tumor	normal stomach tissue
DNA96792 (TAT239)	esophagus tumor	normal esophagus tissue
DNA96792 (TAT239)	breast tumor	normal breast tissue
DNA96792 (TAT239)	uterus tumor	normal uterus tissue
DNA225793 (TAT223)	ovarian tumor	normal ovarian tissue
DNA225793 (TAT223)	kidney tumor	normal kidney tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA227611 (TAT175)	prostate tumor	normal prostate tissue
	DNA227611 (TAT175)	colon tumor	normal colon tissue
	DNA227611 (TAT175)	breast tumor	normal breast tissue
	DNA261021 (TAT208)	breast tumor	normal breast tissue
5	DNA260655 (TAT209)	lung tumor	normal lung tissue
	DNA260655 (TAT209)	colon tumor	normal colon tissue
	DNA260655 (TAT209)	breast tumor	normal breast tissue
	DNA260655 (TAT209)	liver tumor	normal liver tissue
	DNA260655 (TAT209)	ovarian tumor	normal ovarian tissue
10	DNA260655 (TAT209)	skin tumor	normal skin tissue
	DNA260655 (TAT209)	spleen tumor	normal spleen tissue
	DNA260655 (TAT209)	myeloid tumor	normal myeloid tissue
	DNA260655 (TAT209)	muscle tumor	normal muscle tissue
	DNA260655 (TAT209)	bone tumor	normal bone tissue
15	DNA261001 (TAT181)	bone tumor	normal bone tissue
	DNA261001 (TAT181)	lung tumor	normal lung tissue
	DNA266928 (TAT182)	bone tumor	normal bone tissue
	DNA266928 (TAT182)	lung tumor	normal lung tissue
	DNA268035 (TAT222)	breast tumor	normal breast tissue
20	DNA268035 (TAT222)	colon tumor	normal colon tissue
	DNA268035 (TAT222)	ovarian tumor	normal ovarian tissue
	DNA268035 (TAT222)	uterine tumor	normal uterine tissue
	DNA77509 (TAT177)	colon tumor	normal colon tissue
	DNA87993 (TAT235)	breast tumor	normal breast tissue
25	DNA87993 (TAT235)	pancreatic tumor	normal pancreatic tissue
	DNA87993 (TAT235)	lung tumor	normal lung tissue
	DNA87993 (TAT235)	colon tumor	normal colon tissue
	DNA87993 (TAT235)	rectum tumor	normal rectum tissue
	DNA87993 (TAT235)	gallbladder tumor	normal gallbladder tissue
30	DNA92980 (TAT234)	bone tumor	normal bone tissue
	DNA92980 (TAT234)	breast tumor	normal breast tissue
	DNA92980 (TAT234)	cervical tumor	normal cervical tissue
	DNA92980 (TAT234)	colon tumor	normal colon tissue
	DNA92980 (TAT234)	rectum tumor	normal rectum tissue
35	DNA92980 (TAT234)	endometrial tumor	normal endometrial tissue
	DNA92980 (TAT234)	liver tumor	normal liver tissue
	DNA92980 (TAT234)	lung tumor	normal lung tissue
	DNA92980 (TAT234)	ovarian tumor	normal ovarian tissue
	DNA92980 (TAT234)	pancreatic tumor	normal pancreatic tissue
40	DNA92980 (TAT234)	skin tumor	normal skin tissue
	DNA92980 (TAT234)	soft tissue tumor	normal soft tissue
	DNA92980 (TAT234)	stomach tumor	normal stomach tissue
	DNA92980 (TAT234)	bladder tumor	normal bladder tissue
	DNA92980 (TAT234)	thyroid tumor	normal thyroid tissue
45	DNA105792 (TAT233)	bone tumor	normal bone tissue
	DNA105792 (TAT233)	breast tumor	normal breast tissue
	DNA105792 (TAT233)	endometrial tumor	normal endometrial tissue
	DNA105792 (TAT233)	esophagus tumor	normal esophagus tissue
	DNA105792 (TAT233)	kidney tumor	normal kidney tissue
50	DNA105792 (TAT233)	lung tumor	normal lung tissue
	DNA105792 (TAT233)	ovarian tumor	normal ovarian tissue
	DNA105792 (TAT233)	pancreatic tumor	normal pancreatic tissue
	DNA105792 (TAT233)	prostate tumor	normal prostate tissue
	DNA105792 (TAT233)	soft tissue tumor	normal soft tissue
55	DNA105792 (TAT233)	stomach tumor	normal stomach tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
5	DNA105792 (TAT233)	thyroid tumor	normal thyroid tissue
	DNA105792 (TAT233)	bladder tumor	normal bladder tissue
	DNA105792 (TAT233)	brain tumor	normal brain tissue
	DNA105792 (TAT233)	Wilm's tumor	normal associated tissue
	DNA119474 (TAT228)	uterine tumor	normal uterine tissue
10	DNA119474 (TAT228)	ovarian tumor	normal ovarian tissue
	DNA280351 (TAT248)	squamous cell lung tumor	normal squamous cell lung tissue
	DNA280351 (TAT248)	colon tumor	normal colon tissue
	DNA150648 (TAT232)	liver tumor	normal liver tissue
	DNA150648 (TAT232)	breast tumor	normal breast tissue
15	DNA150648 (TAT232)	brain tumor	normal brain tissue
	DNA150648 (TAT232)	lung tumor	normal lung tissue
	DNA150648 (TAT232)	colon tumor	normal colon tissue
	DNA150648 (TAT232)	rectum tumor	normal rectum tissue
	DNA150648 (TAT232)	kidney tumor	normal kidney tissue
20	DNA150648 (TAT232)	bladder tumor	normal bladder tissue
	DNA179651 (TAT224)	breast tumor	normal breast tissue
	DNA179651 (TAT224)	cervical tumor	normal cervical tissue
	DNA179651 (TAT224)	colon tumor	normal colon tissue
	DNA179651 (TAT224)	rectum tumor	normal rectum tissue
25	DNA179651 (TAT224)	uterine tumor	normal uterine tissue
	DNA179651 (TAT224)	lung tumor	normal lung tissue
	DNA179651 (TAT224)	ovarian tumor	normal ovarian tissue
	DNA207698 (TAT237)	breast tumor	normal breast tissue
	DNA207698 (TAT237)	colon tumor	normal colon tissue
30	DNA207698 (TAT237)	ovarian tumor	normal ovarian tissue
	DNA207698 (TAT237)	pancreatic tumor	normal pancreatic tissue
	DNA207698 (TAT237)	stomach tumor	normal stomach tissue
	DNA225886 (TAT236)	breast tumor	normal breast tissue
	DNA225886 (TAT236)	colon tumor	normal colon tissue
35	DNA225886 (TAT236)	rectum tumor	normal rectum tissue
	DNA225886 (TAT236)	endometrial tumor	normal endometrial tissue
	DNA225886 (TAT236)	lung tumor	normal lung tissue
	DNA225886 (TAT236)	ovarian tumor	normal ovarian tissue
	DNA225886 (TAT236)	pancreas tumor	normal pancreas tissue
40	DNA225886 (TAT236)	prostate tumor	normal prostate tissue
	DNA225886 (TAT236)	bladder tumor	normal bladder tissue
	DNA226717 (TAT185)	glioma	normal glial tissue
	DNA226717 (TAT185)	brain tumor	normal brain tissue
	DNA227162 (TAT225)	breast tumor	normal breast tissue
45	DNA227162 (TAT225)	endometrial tumor	normal endometrial tissue
	DNA227162 (TAT225)	lung tumor	normal lung tissue
	DNA227162 (TAT225)	ovarian tumor	normal ovarian tissue
	DNA277804 (TAT247)	breast tumor	normal breast tissue
	DNA277804 (TAT247)	endometrial tumor	normal endometrial tissue
50	DNA277804 (TAT247)	lung tumor	normal lung tissue
	DNA277804 (TAT247)	ovarian tumor	normal ovarian tissue
	DNA233034 (TAT174)	glioma	normal glial tissue
	DNA233034 (TAT174)	brain tumor	normal brain tissue
	DNA266920 (TAT214)	glioma	normal glial tissue
55	DNA266920 (TAT214)	brain tumor	normal brain tissue
	DNA266921 (TAT220)	glioma	normal glial tissue
	DNA266921 (TAT220)	brain tumor	normal brain tissue
	DNA266922 (TAT221)	glioma	normal glial tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA266922 (TAT221)	brain tumor	normal brain tissue
	DNA234441 (TAT201)	colon tumor	normal colon tissue
	DNA234441 (TAT201)	rectum tumor	normal rectum tissue
	DNA234834 (TAT179)	breast tumor	normal breast tissue
5	DNA234834 (TAT179)	colon tumor	normal colon tissue
	DNA234834 (TAT179)	rectum tumor	normal rectum tissue
	DNA234834 (TAT179)	prostate tumor	normal prostate tissue
	DNA234834 (TAT179)	pancreatic tumor	normal pancreatic tissue
	DNA234834 (TAT179)	endometrial tumor	normal endometrial tissue
10	DNA234834 (TAT179)	lung tumor	normal lung tissue
	DNA234834 (TAT179)	ovarian tumor	normal ovarian tissue
	DNA247587 (TAT216)	breast tumor	normal breast tissue
	DNA247587 (TAT216)	lung tumor	normal lung tissue
	DNA247587 (TAT216)	ovarian tumor	normal ovarian tissue
15	DNA247587 (TAT216)	pancreatic tumor	normal pancreatic tissue
	DNA247587 (TAT216)	stomach tumor	normal stomach tissue
	DNA247587 (TAT216)	urinary tumor	normal urinary tissue
	DNA255987 (TAT218)	breast tumor	normal breast tissue
	DNA56041 (TAT206)	lymphoid tumor	normal lymphoid tissue
20	DNA257845 (TAT374)	lymphoid tumor	normal lymphoid tissue
	DNA247476 (TAT180)	bone tumor	normal bone tissue
	DNA247476 (TAT180)	breast tumor	normal breast tissue
	DNA247476 (TAT180)	colon tumor	normal colon tissue
	DNA247476 (TAT180)	rectum tumor	normal rectum tissue
25	DNA247476 (TAT180)	kidney tumor	normal kidney tissue
	DNA247476 (TAT180)	lung tumor	normal lung tissue
	DNA247476 (TAT180)	pancreatic tumor	normal pancreatic tissue
	DNA247476 (TAT180)	prostate tumor	normal prostate tissue
	DNA247476 (TAT180)	skin tumor	normal skin tissue
30	DNA247476 (TAT180)	soft tissue tumor	normal soft tissue
	DNA247476 (TAT180)	stomach tumor	normal stomach tissue
	DNA260990 (TAT375)	bone tumor	normal bone tissue
	DNA260990 (TAT375)	breast tumor	normal breast tissue
	DNA260990 (TAT375)	colon tumor	normal colon tissue
35	DNA260990 (TAT375)	rectum tumor	normal rectum tissue
	DNA260990 (TAT375)	kidney tumor	normal kidney tissue
	DNA260990 (TAT375)	lung tumor	normal lung tissue
	DNA260990 (TAT375)	pancreatic tumor	normal pancreatic tissue
	DNA260990 (TAT375)	prostate tumor	normal prostate tissue
40	DNA260990 (TAT375)	skin tumor	normal skin tissue
	DNA260990 (TAT375)	soft tissue tumor	normal soft tissue
	DNA260990 (TAT375)	stomach tumor	normal stomach tissue
	DNA261013 (TAT176)	breast tumor	normal breast tissue
	DNA261013 (TAT176)	colon tumor	normal colon tissue
45	DNA261013 (TAT176)	rectum tumor	normal rectum tissue
	DNA261013 (TAT176)	lung tumor	normal lung tissue
	DNA261013 (TAT176)	ovarian tumor	normal ovarian tissue
	DNA261013 (TAT176)	stomach tumor	normal stomach tissue
	DNA262144 (TAT184)	breast tumor	normal breast tissue
50	DNA262144 (TAT184)	colon tumor	normal colon tissue
	DNA262144 (TAT184)	rectum tumor	normal rectum tissue
	DNA262144 (TAT184)	endometrial tumor	normal endometrial tissue
	DNA262144 (TAT184)	kidney tumor	normal kidney tissue
	DNA262144 (TAT184)	lung tumor	normal lung tissue
55	DNA262144 (TAT184)	ovarian tumor	normal ovarian tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA267342 (TAT213))	stroma associated with the following tumors: bone, breast, colon, rectum, lung, ovarian, pancreas, soft tissue, bladder	normal associated tissues, respectively
5	DNA267626 (TAT217)	breast tumor	normal breast tissue
	DNA267626 (TAT217)	colon tumor	normal colon tissue
	DNA267626 (TAT217)	rectum tumor	normal rectum tissue
	DNA267626 (TAT217)	endometrial tumor	normal endometrial tissue
	DNA267626 (TAT217)	lung tumor	normal lung tissue
10	DNA267626 (TAT217)	pancreatic tumor	normal pancreatic tissue
	DNA268334 (TAT202)	kidney tumor	normal kidney tissue
	DNA269238 (TAT215)	kidney tumor	normal kidney tissue
	DNA272578 (TAT238)	liver tumor	normal liver tissue
	DNA272578 (TAT238)	lung tumor	normal lung tissue
15	DNA272578 (TAT238)	ovarian tumor	normal ovarian tissue
	DNA304853 (TAT376)	breast tumor	normal breast tissue
	DNA304853 (TAT376)	colon tumor	normal colon tissue
	DNA304853 (TAT376)	rectum tumor	normal rectum tissue
	DNA304853 (TAT376)	prostate tumor	normal prostate tissue
20	DNA304853 (TAT376)	pancreatic tumor	normal pancreatic tissue
	DNA304853 (TAT376)	endometrial tumor	normal endometrial tissue
	DNA304853 (TAT376)	lung tumor	normal lung tissue
	DNA304853 (TAT376)	ovarian tumor	normal ovarian tissue
	DNA304854 (TAT377)	breast tumor	normal breast tissue
25	DNA304854 (TAT377)	colon tumor	normal colon tissue
	DNA304854 (TAT377)	rectum tumor	normal rectum tissue
	DNA304854 (TAT377)	prostate tumor	normal prostate tissue
	DNA304854 (TAT377)	pancreatic tumor	normal pancreatic tissue
	DNA304854 (TAT377)	endometrial tumor	normal endometrial tissue
30	DNA304854 (TAT377)	lung tumor	normal lung tissue
	DNA304854 (TAT377)	ovarian tumor	normal ovarian tissue
	DNA304855 (TAT378)	breast tumor	normal breast tissue
	DNA304855 (TAT378)	colon tumor	normal colon tissue
	DNA304855 (TAT378)	rectum tumor	normal rectum tissue
35	DNA304855 (TAT378)	prostate tumor	normal prostate tissue
	DNA304855 (TAT378)	pancreatic tumor	normal pancreatic tissue
	DNA304855 (TAT378)	endometrial tumor	normal endometrial tissue
	DNA304855 (TAT378)	lung tumor	normal lung tissue
	DNA304855 (TAT378)	ovarian tumor	normal ovarian tissue
40	DNA287971 (TAT379)	bone tumor	normal bone tissue
	DNA287971 (TAT379)	breast tumor	normal breast tissue
	DNA287971 (TAT379)	colon tumor	normal colon tissue
	DNA287971 (TAT379)	rectum tumor	normal rectum tissue
	DNA287971 (TAT379)	kidney tumor	normal kidney tissue
45	DNA287971 (TAT379)	lung tumor	normal lung tissue
	DNA287971 (TAT379)	pancreatic tumor	normal pancreatic tissue
	DNA287971 (TAT379)	prostate tumor	normal prostate tissue
	DNA287971 (TAT379)	skin tumor	normal skin tissue
	DNA287971 (TAT379)	soft tissue tumor	normal soft tissue
50	DNA287971 (TAT379)	stomach tumor	normal stomach tissue

#### EXAMPLE 2: Microarray Analysis to Detect Upregulation of TAT Polypeptides in Cancerous Tumors

Nucleic acid microarrays, often containing thousands of gene sequences, are useful for identifying differentially expressed genes in diseased tissues as compared to their normal counterparts. Using nucleic acid



microarrays, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The cDNA probes are then hybridized to an array of nucleic acids immobilized on a solid support. The array is configured such that the sequence and position of each member of the array is known. For example, a selection of genes known to be expressed in certain disease states may be arrayed on a solid support. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene. If the hybridization signal of a probe from a test (disease tissue) sample is greater than hybridization signal of a probe from a control (normal tissue) sample, the gene or genes overexpressed in the disease tissue are identified. The implication of this result is that an overexpressed protein in a diseased tissue is useful not only as a diagnostic marker for the presence of the disease condition, but also as a therapeutic target for treatment of the disease condition.

The methodology of hybridization of nucleic acids and microarray technology is well known in the art. In one example, the specific preparation of nucleic acids for hybridization and probes, slides, and hybridization conditions are all detailed in PCT Patent Application Serial No. PCT/US01/10482, filed on March 30, 2001 and which is herein incorporated by reference.

In the present example, cancerous tumors derived from various human tissues were studied for upregulated gene expression relative to cancerous tumors from different tissue types and/or non-cancerous human tissues in an attempt to identify those polypeptides which are overexpressed in a particular cancerous tumor(s). In certain experiments, cancerous human tumor tissue and non-cancerous human tumor tissue of the same tissue type (often from the same patient) were obtained and analyzed for TAT polypeptide expression. Additionally, cancerous human tumor tissue from any of a variety of different human tumors was obtained and compared to a "universal" epithelial control sample which was prepared by pooling non-cancerous human tissues of epithelial origin, including liver, kidney, and lung. mRNA isolated from the pooled tissues represents a mixture of expressed gene products from these different tissues. Microarray hybridization experiments using the pooled control samples generated a linear plot in a 2-color analysis. The slope of the line generated in a 2-color analysis was then used to normalize the ratios of (test:control detection) within each experiment. The normalized ratios from various experiments were then compared and used to identify clustering of gene expression. Thus, the pooled "universal control" sample not only allowed effective relative gene expression determinations in a simple 2-sample comparison, it also allowed multi-sample comparisons across several experiments.

In the present experiments, nucleic acid probes derived from the herein described TAT polypeptide-encoding nucleic acid sequences were used in the creation of the microarray and RNA from various tumor tissues were used for the hybridization thereto. Below is shown the results of these experiments, demonstrating that various TAT polypeptides of the present invention are significantly overexpressed in various human tumor tissues as compared to their normal counterpart tissue(s). Moreover, all of the molecules shown below are significantly overexpressed in their specific tumor tissue(s) as compared to in the "universal" epithelial control. As described above, these data demonstrate that the TAT polypeptides of the present invention are useful not only as diagnostic markers for the presence of one or more cancerous tumors, but also serve as therapeutic targets for the treatment of those tumors.

<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
DNA172500 (TAT219)	renal cell carcinoma	normal kidney (renal cell) tissue

### EXAMPLE 3: Quantitative Analysis of TAT mRNA Expression

In this assay, a 5' nuclease assay (for example, TaqMan®) and real-time quantitative PCR (for example, ABIPrizm 7700 Sequence Detection System® (Perkin Elmer, Applied Biosystems Division, Foster City, CA)), were used to find genes that are significantly overexpressed in a cancerous tumor or tumors as compared to other cancerous tumors or normal non-cancerous tissue. The 5' nuclease assay reaction is a fluorescent PCR-based technique which makes use of the 5' exonuclease activity of Taq DNA polymerase enzyme to monitor gene expression in real time. Two oligonucleotide primers (whose sequences are based upon the gene or EST sequence of interest) are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the PCR amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

The 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI Prism 7700™ Sequence Detection. The system consists of a thermocycler, laser, charge-coupled device (CCD) camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

The starting material for the screen was mRNA isolated from a variety of different cancerous tissues. The mRNA is quantitated precisely, e.g., fluorometrically. As a negative control, RNA was isolated from various normal tissues of the same tissue type as the cancerous tissues being tested.

5' nuclease assay data are initially expressed as Ct, or the threshold cycle. This is defined as the cycle at which the reporter signal accumulates above the background level of fluorescence. The  $\Delta C_t$  values are used as quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer mRNA results to normal human mRNA results. As one Ct unit corresponds to 1 PCR cycle or approximately a 2-fold relative increase relative to normal, two units corresponds to a 4-fold relative increase, 3 units corresponds to an 8-fold relative increase and so on, one can quantitatively measure the relative fold increase in mRNA expression between two or more different tissues. Using this technique, the molecules listed below have been identified as being significantly overexpressed in a particular tumor(s) as compared to their normal non-cancerous counterpart tissue(s) (from both the same and different tissue donors) and thus, represent excellent polypeptide targets for the diagnosis and therapy of cancer in mammals.

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA261021 (TAT208)	lung tumor	normal lung tissue
	DNA77509 (TAT177)	colon tumor	normal colon tissue
	DNA119474 (TAT226)	ovarian tumor	normal ovarian tissue
5	DNA179651 (TAT224)	ovarian tumor	normal ovarian tissue
	DNA226717 (TAT185)	glioma	normal glial/brain tissue
	DNA227162 (TAT225)	ovarian tumor	normal ovarian tissue
	DNA277804 (TAT247)	ovarian tumor	normal ovarian tissue
	DNA233034 (TAT174)	glioma	normal glial/brain tissue
	DNA266920 (TAT214)	glioma	normal glial/brain tissue
10	DNA266921 (TAT220)	glioma	normal glial/brain tissue
	DNA266922 (TAT221)	glioma	normal glial/brain tissue
	DNA234441 (TAT201)	colon tumor	normal colon tissue
	DNA234834 (TAT179)	colon tumor	normal colon tissue
15	DNA247587 (TAT216)	squamous cell lung tumor	normal squamous cell lung tissue
	DNA255987 (TAT218)	breast tumor	normal breast tissue
	DNA247476 (TAT180)	colon tumor	normal colon tissue
	DNA260990 (TAT375)	colon tumor	normal colon tissue
	DNA261013 (TAT176)	breast tumor	normal breast tissue
20	DNA262144 (TAT184)	kidney tumor	normal kidney tissue
	DNA267342 (TAT213)	breast tumor	normal breast tissue
	DNA267626 (TAT217)	breast tumor	normal breast tissue
	DNA268334 (TAT202)	kidney tumor	normal kidney tissue
	DNA269238 (TAT215)	kidney tumor	normal kidney tissue
25	DNA87993 (TAT235)	lung tumor	normal lung tissue
	DNA92980 (TAT234)	ovarian tumor	normal ovarian tissue
	DNA105792 (TAT233)	lung tumor	normal lung tissue
	DNA207698 (TAT237)	colon tumor	normal colon tissue
	DNA225886 (TAT236)	colon tumor	normal colon tissue
30	DNA272578 (TAT238)	ovarian tumor	normal ovarian tissue
	DNA304853 (TAT376)	colon tumor	normal colon tissue
	DNA304854 (TAT377)	colon tumor	normal colon tissue
	DNA304855 (TAT378)	colon tumor	normal colon tissue
35	DNA287971 (TAT379)	colon tumor	normal colon tissue

#### EXAMPLE 4: *In situ* Hybridization

*In situ* hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis and aid in chromosome mapping.

*In situ* hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1:169-176 (1994), using PCR-generated <sup>33</sup>P-labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinized in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, *supra*. A [<sup>33</sup>-P] UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in Kodak NTB2 nuclear track emulsion and exposed for 4 weeks.

<sup>33</sup>P-Riboprobe synthesis

6.0 µl (125 mCi) of <sup>33</sup>P-UTP (Amersham BF 1002, SA<2000 Ci/mmol) were speed vac dried. To each tube containing dried <sup>33</sup>P-UTP, the following ingredients were added:

2.0 µl 5x transcription buffer

1.0 µl DTT (100 mM)

5 2.0 µl NTP mix (2.5 mM : 10 µ; each of 10 mM GTP, CTP & ATP + 10 µl H<sub>2</sub>O)

1.0 µl UTP (50 µM)

1.0 µl Rnasin

1.0 µl DNA template (1µg)

1.0 µl H<sub>2</sub>O

10 1.0 µl RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

The tubes were incubated at 37°C for one hour. 1.0 µl RQ1 DNase were added, followed by incubation at 37°C for 15 minutes. 90 µl TE (10 mM Tris pH 7.6/1mMEDTA pH 8.0) were added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a Microcon-50 ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After  
15 the final recovery spin, 100 µl TE were added. 1 µl of the final product was pipetted on DE81 paper and counted in 6 ml of Biofluor II.

The probe was run on a TBE/urea gel. 1-3 µl of the probe or 5 µl of RNA Mrk III were added to 3 µl of loading buffer. After heating on a 95°C heat block for three minutes, the probe was immediately placed on ice. The wells of gel were flushed, the sample loaded, and run at 180-250 volts for 45 minutes. The gel was wrapped  
20 in saran wrap and exposed to XAR film with an intensifying screen in -70°C freezer one hour to overnight.

<sup>33</sup>P-HybridizationA. Pretreatment of frozen sections

The slides were removed from the freezer, placed on aluminium trays and thawed at room temperature for 5 minutes. The trays were placed in 55°C incubator for five minutes to reduce condensation. The slides were fixed  
25 for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml SQ H<sub>2</sub>O). After deproteinization in 0.5 µg/ml proteinase K for 10 minutes at 37°C (12.5 µl of 10 mg/ml stock in 250 ml prewarmed RNase-free RNase buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, 100% ethanol, 2 minutes each.

B. Pretreatment of paraffin-embedded sections

The slides were deparaffinized, placed in SQ H<sub>2</sub>O, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinized in 20 µg/ml proteinase K (500 µl of 10 mg/ml in 250 ml RNase-free RNase buffer; 37°C, 15 minutes) - human embryo, or 8 x proteinase K (100 µl in 250 ml RNase buffer, 37°C, 30 minutes) - formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

C. Prehybridization

The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) - saturated filter paper.

D. Hybridization

1.0 x 10<sup>6</sup> cpm probe and 1.0 µl tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48 µl hybridization buffer were added per slide. After vortexing, 50 µl <sup>33</sup>P mix were added to 50 µl prehybridization on slide. The slides were incubated overnight at 55°C.

E. Washes

5 Washing was done 2 x 10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25M EDTA, V<sub>f</sub>=4L), followed by RNaseA treatment at 37°C for 30 minutes (500 µl of 10 mg/ml in 250 ml Rnase buffer = 20 µg/ml). The slides were washed 2 x 10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA, V<sub>f</sub>=4L).

F. Oligonucleotides

10 *In situ* analysis was performed on a variety of DNA sequences disclosed herein. The oligonucleotides employed for these analyses were obtained so as to be complementary to the nucleic acids (or the complements thereof) as shown in the accompanying figures.

G. Results

15 *In situ* analysis was performed on a variety of DNA sequences disclosed herein. The results from these analyses are as follows.

(1) DNA119474 (TAT226)

20 Positive expression is observed in 2 of 3 non-small cell lung carcinomas, 2 of 3 pancreatic adenocarcinomas, 1 of 2 hepatocellular carcinomas and 2 of 3 endometrial adenocarcinomas. In a separate analysis, 10 of 16 ovarian adenocarcinomas are positive and 3 of 9 endometrial adenocarcinomas are positive. All normal tissues examined are negative for expression.

(2) DNA179651 (TAT224)

In one analysis, expression is seen in 5 of 7 uterine adenocarcinomas and in 7 of 16 ovarian adenocarcinomas. Two cases of dysgerminoma are positive as is one case of a Brenner's tumor.

25 In another analysis, 33 of 68 ovarian adenocarcinomas (serous, mucinous, endometrioid, clear cell) are positive for expression. Moderate to strong expression is seen in normal endometrium (no other normal tissues) and normal ovarian stroma is negative.

In yet another analysis, positive expression is seen in 3/3 endometrial, 2/2 colorectal, 1/3 transitional cell, 3/3 lung and 1/2 ovarian cancers.

(3) DNA227162 (TAT225)

30 Expression is seen in the following tumors: 1 of 3 lung cancers, 1 of 2 colon cancers, 1 of 1 pancreatic cancer, 2 of 3 transitional cell carcinomas, 3 of 3 endometrial carcinomas, 2 of 2 ovarian carcinomas and 2 of 3 malignant melanomas.

In a separate analysis, positive expression is seen in 6 of 9 uterine adenocarcinomas and 6 of 14 ovarian tumors.

35 With regard to expression in normal tissues, weak expression is seen in one core of urothelium (superficial cell layer positive) and one core of gall bladder mucosa. All other normal tissues are negative for expression.

(4) DNA277804 (TAT247)

Expression is seen in the following tumors: 1 of 3 lung cancers, 1 of 2 colon cancers, 1 of 1 pancreatic cancer, 2 of 3 transitional cell carcinomas, 3 of 3 endometrial carcinomas, 2 of 2 ovarian carcinomas and 2 of 3 malignant melanomas.

In a separate analysis, positive expression is seen in 6 of 9 uterine adenocarcinomas and 6 of 14 ovarian tumors.

With regard to expression in normal tissues, weak expression is seen in one core of urothelium (superficial cell layer positive) and one core of gall bladder mucosa. All other normal tissues are negative for expression.

(5) DNA234441 (TAT201)

Weak (and inconsistent) expression is seen in normal kidney, normal colon mucosa and normal gallbladder. Weak to moderate, though somewhat inconsistent expression is seen in normal gastrointestinal mucosa (esophagus, stomach, small intestine, colon, anus). Significant expression in tumors is seen as follows: 11 of 12 colorectal adenocarcinomas, 4 of 4 gastric adenocarcinomas, 6 of 8 metastatic adenocarcinomas, 4 of 4 esophageal cancers and 1 of 2 pancreatic adenocarcinomas.

(6) DNA234834 (TAT179)

With regard to normal tissues, it appears that there is a weak signal in colon mucosa and breast epithelium. With regard to tumor tissues, expression is seen in 1 of 2 non-small cell lung carcinomas, 2 of 2 colon cancers, 1 of 2 pancreatic cancers, 1 of 2 hepatocellular carcinomas, 3 of 3 endometrial carcinomas, 1 of 2 ovarian carcinomas and 2 of 3 malignant melanomas.

In a separate analysis, 12 of 16 colorectal carcinomas are positive for expression; 2 of 8 gastric adenocarcinoma are positive for expression, 2 of 4 esophageal carcinomas are positive for expression; 7 of 10 metastatic adenocarcinoma are positive for expression and 1 of 2 cholangiocarcinomas are positive for expression. Expression level in tumor tissues is consistently higher than in normal tissues.

(7) DNA247587 (TAT216)

Expression is seen in 13 of 16 non-small cell lung carcinomas. Expression is also seen in benign bronchial mucosa and occasional activated pneumocytes. Moreover, 65 of 89 cases of invasive breast cancer are positive for expression. Strong expression is seen in normal skin and normal urothelium. Moderate expression is seen in normal mammary epithelium and trophoblasts of the placenta, weak expression in normal prostate and normal gall bladder epithelium and distal renal tubules.

(8) DNA56041 (TAT206)

In non-malignant lymphoid tissue expression is seen in occasional larger lymphoid cells within germinal centers and in interfollicular regions. Positive cells account for less than 5% of all lymphoid cells. In section of spleen scattered positive cells are seen within the periarteriolar lymphoid sheath and in the marginal zone.

In four cases of Hodgkin's disease Reed-Sternberg cells are negative, positive signal is observed in scattered lymphocytes. Three of four cases of follicular lymphoma are positive (weak to moderate), four of six cases of diffuse large cell lymphoma are positive (weak to moderate). Two cases of small lymphocytic lymphoma show a weak signal in variable proportion of cells.

(9) DNA257845 (TAT374)

In non-malignant lymphoid tissue expression is seen in occasional larger lymphoid cells within germinal centers and in interfollicular regions. Positive cells account for less than 5% of all lymphoid cells. In section of spleen scattered positive cells are seen within the periarteriolar lymphoid sheath and in the marginal zone.

In four cases of Hodgkin's disease Reed-Sternberg cells are negative, positive signal is observed in scattered lymphocytes. Three of four cases of follicular lymphoma are positive (weak to moderate), four of six cases of diffuse large cell lymphoma are positive (weak to moderate). Two cases of small lymphocytic lymphoma show a weak signal in variable proportion of cells.

(10) DNA247476 (TAT180)

With regard to normal tissues, strong expression is seen in prostatic epithelium and in a section of peripheral nerve. Moderate expression is seen in renal glomeruli. Weak expression is seen in bile duct epithelium and mammary epithelium. Two sections of stomach show weak expression in a subset of gastric glands. Sections of colon and small intestine show a signal in lamina propria and/or submucosa, most likely in small autonomic nerve fibers. Another independent ISH study fails to show expression in peripheral nerves of prostatectomy sections, despite adequate signal in prostatic epithelium.

In a separate analysis, 42 of 77 breast tumors are positive (55%) for expression.

In yet another analysis, 8 of 11 breast cancers are positive for expression.

In yet another analysis, expression is seen in 1/2 non-small cell lung carcinomas, 1/3 colorectal adenocarcinomas, 2/3 pancreatic adenocarcinomas, 1/1 prostate cancers, 1/3 transitional cell carcinomas, 3/3 renal cell carcinomas, 3/3 endometrial adenocarcinomas, 1/2 ovarian adenocarcinomas and 1/3 malignant melanomas.

In yet another analysis, expression is seen in 42 of 45 (93%) prostate cancers.

In yet another analysis, expression is seen in all of 23 primary and in 12 of 15 (80%) metastatic prostate cancers analyzed.

In yet another analysis, expression is observed in the following carcinomas as follows: pancreatic adenocarcinoma - 2 of 2 cases are positive; colorectal adenocarcinoma - 12 of 14 cases are positive; gastric adenocarcinoma - 6 of 8 cases are positive; esophageal carcinoma - 2 of 3 cases are positive; cholangiocarcinoma - 1 of 1 case is positive; metastatic adenocarcinoma (ovary, liver, lymph node, diaphragm) - 8 of 12 cases are positive.

(11) DNA260990 (TAT375)

With regard to normal tissues, strong expression is seen in prostatic epithelium and in a section of peripheral nerve. Moderate expression is seen in renal glomeruli. Weak expression is seen in bile duct epithelium and mammary epithelium. Two sections of stomach show weak expression in a subset of gastric glands. Sections of colon and small intestine show a signal in lamina propria and/or submucosa, most likely in small autonomic nerve fibers. Another independent ISH study fails to show expression in peripheral nerves of prostatectomy sections, despite adequate signal in prostatic epithelium.

In a separate analysis, 42 of 77 breast tumors are positive (55%) for expression.

In yet another analysis, 8 of 11 breast cancers are positive for expression.

In yet another analysis, expression is seen in 1/2 non-small cell lung carcinomas, 1/3 colorectal adenocarcinomas, 2/3 pancreatic adenocarcinomas, 1/1 prostate cancers, 1/3 transitional cell carcinomas, 3/3 renal cell carcinomas, 3/3 endometrial adenocarcinomas, 1/2 ovarian adenocarcinomas and 1/3 malignant melanomas.

In yet another analysis, expression is seen in 42 of 45 (93%) prostate cancers.

In yet another analysis, expression is seen in all of 23 primary and in 12 of 15 (80%) metastatic prostate cancers analyzed.

In yet another analysis, expression is observed in the following carcinomas as follows: pancreatic adenocarcinoma - 2 of 2 cases are positive; colorectal adenocarcinoma - 12 of 14 cases are positive; gastric adenocarcinoma - 6 of 8 cases are positive; esophageal carcinoma - 2 of 3 cases are positive; cholangiocarcinoma - 1 of 1 case is positive; metastatic adenocarcinoma (ovary, liver, lymph node, diaphragm) - 8 of 12 cases are positive.

(12) DNA261013 (TAT176)

With regard to normal tissues, prostate epithelium shows a weak positive signal. Also, one core of colonic mucosa shows a weak signal in mucosal epithelium. Two cores of a testicular neoplasm are positive.

In another analysis, 87 cases of infiltrating ductal breast cancer are available for review. 40 cases are positive for expression. Additionally, all tested cell lines (A549, SK-MES, SKBR3, MDA231, MDA453, MDA175, MCF7) are positive for expression.

In another analysis, there is no consistent expression in benign colon, small intestinal, liver, pancreatic, gastric or esophageal tissue. In malignant tumors expression is observed as follows: colorectal adenocarcinoma: 10 of 14 cases are positive, gastric adenocarcinoma: 4 of 8 cases are positive, esophageal carcinoma: 3 of 4 cases are positive and metastatic adenocarcinoma: 8 of 11 cases are positive.

(13) DNA262144 (TAT184)

Two of 4 cases of non-small cell lung carcinoma are positive for expression while no signal is observed in non-neoplastic lung. In a separate analysis, three cases of non-small cell lung carcinoma are positive

(14) DNA267342 (TAT213)

Expression is not observed in any of the normal adult tissues tested. Seventy four cases of breast cancer are available for review and 30 cases give a positive signal. Expression localizes to tumor-associated stroma.

In a separate analysis, expression is seen in a minority of sarcomas; moderate and occasionally strong expression is seen in a case of a synovial sarcoma, angiosarcoma, fibrosarcoma, gliosarcoma and malignant fibrohistiocytoma. In most cases expression appears to localize to the malignant cell population.

(15) DNA267626 (TAT217)

Expression is seen in 6 of 9 invasive breast cancers. Expression is in most cases of moderate intensity, expression is also seen in benign mammary epithelium and fibroadenoma. The large sections included in this study show expression in 1 of 1 endometrial adenocarcinomas, in 2 of 3 invasive ductal breast cancers, in benign renal tubules, in normal breast epithelium and in epidermis. Sections of lung, brain, myometrium and eye are negative.

(16) DNA268334 (TAT202)

No expression is seen in any of the adult, normal tissues tested while expression is observed in 3 of 3 renal cell carcinomas.



(17) DNA269238 (TAT215)

Tumor-associated vasculature was strongly positive in all renal cell carcinomas tested (n=6), in all hepatocellular carcinomas tested (n=3), in all gastric adenocarcinomas tested (n=5), in all endometrial adenocarcinomas tested (n=3), in all malignant melanomas tested (n=3), in all malignant lymphomas tested (n=3), in all pancreatic adenocarcinomas tested (n=1), in all esophageal carcinomas tested (n=4), in all cholangiocarcinomas tested (n=2), in 93% of all non-small cell lung cancers tested (n=15), in 86% of all invasive ductal breast cancers tested (n=88), in 83% of all colorectal adenocarcinomas tested (n=12), in 67% of all metastatic adenocarcinomas tested (n=6), in 75% of all transitional cell carcinomas tested (n=4). While TAT215 expression is also observed in endothelial components of various normal non-cancerous tissues, the expression level is significantly lower in these non-cancerous tissues as compared to their cancerous counterparts and the expression pattern in the tumor tissues was distinct from that in the normal tissues, thereby providing a means for both therapy and diagnosis of the cancerous condition.

(18) DNA304853 (TAT376)

With regard to normal tissues, it appears that there is a weak signal in colon mucosa and breast epithelium. With regard to tumor tissues, expression is seen in 1 of 2 non-small cell lung carcinomas, 2 of 2 colon cancers, 1 of 2 pancreatic cancers, 1 of 2 hepatocellular carcinomas, 3 of 3 endometrial carcinomas, 1 of 2 ovarian carcinomas and 2 of 3 malignant melanomas.

In a separate analysis, 12 of 16 colorectal carcinomas are positive for expression; 2 of 8 gastric adenocarcinoma are positive for expression, 2 of 4 esophageal carcinomas are positive for expression; 7 of 10 metastatic adenocarcinoma are positive for expression and 1 of 2 cholangiocarcinomas are positive for expression. Expression level in tumor tissues is consistently higher than in normal tissues.

(19) DNA304854 (TAT377)

With regard to normal tissues, it appears that there is a weak signal in colon mucosa and breast epithelium. With regard to tumor tissues, expression is seen in 1 of 2 non-small cell lung carcinomas, 2 of 2 colon cancers, 1 of 2 pancreatic cancers, 1 of 2 hepatocellular carcinomas, 3 of 3 endometrial carcinomas, 1 of 2 ovarian carcinomas and 2 of 3 malignant melanomas.

In a separate analysis, 12 of 16 colorectal carcinomas are positive for expression; 2 of 8 gastric adenocarcinoma are positive for expression, 2 of 4 esophageal carcinomas are positive for expression; 7 of 10 metastatic adenocarcinoma are positive for expression and 1 of 2 cholangiocarcinomas are positive for expression. Expression level in tumor tissues is consistently higher than in normal tissues.

(20) DNA304855 (TAT378)

With regard to normal tissues, it appears that there is a weak signal in colon mucosa and breast epithelium. With regard to tumor tissues, expression is seen in 1 of 2 non-small cell lung carcinomas, 2 of 2 colon cancers, 1 of 2 pancreatic cancers, 1 of 2 hepatocellular carcinomas, 3 of 3 endometrial carcinomas, 1 of 2 ovarian carcinomas and 2 of 3 malignant melanomas.

In a separate analysis, 12 of 16 colorectal carcinomas are positive for expression; 2 of 8 gastric adenocarcinoma are positive for expression, 2 of 4 esophageal carcinomas are positive for expression; 7 of 10 metastatic adenocarcinoma are positive for expression and 1 of 2 cholangiocarcinomas are positive for expression.

Expression level in tumor tissues is consistently higher than in normal tissues.

(21) DNA287971 (TAT379)

With regard to normal tissues, strong expression is seen in prostatic epithelium and in a section of peripheral nerve. Moderate expression is seen in renal glomeruli. Weak expression is seen in bile duct epithelium and mammary epithelium. Two sections of stomach show weak expression in a subset of gastric glands. Sections of colon and small intestine show a signal in lamina propria and/or submucosa, most likely in small autonomic nerve fibers. Another independent ISH study fails to show expression in peripheral nerves of prostatectomy sections, despite adequate signal in prostatic epithelium.

In a separate analysis, 42 of 77 breast tumors are positive (55%) for expression.

In yet another analysis, 8 of 11 breast cancers are positive for expression.

In yet another analysis, expression is seen in 1/2 non-small cell lung carcinomas, 1/3 colorectal adenocarcinomas, 2/3 pancreatic adenocarcinomas, 1/1 prostate cancers, 1/3 transitional cell carcinomas, 3/3 renal cell carcinomas, 3/3 endometrial adenocarcinomas, 1/2 ovarian adenocarcinomas and 1/3 malignant melanomas.

In yet another analysis, expression is seen in 42 of 45 (93%) prostate cancers.

In yet another analysis, expression is seen in all of 23 primary and in 12 of 15 (80%) metastatic prostate cancers analyzed.

In yet another analysis, expression is observed in the following carcinomas as follows: pancreatic adenocarcinoma - 2 of 2 cases are positive; colorectal adenocarcinoma - 12 of 14 cases are positive; gastric adenocarcinoma - 6 of 8 cases are positive; esophageal carcinoma - 2 of 3 cases are positive; cholangiocarcinoma - 1 of 1 case is positive; metastatic adenocarcinoma (ovary, liver, lymph node, diaphragm) - 8 of 12 cases are positive.

#### EXAMPLE 5: Verification and Analysis of Differential TAT Polypeptide Expression by GEPIS

TAT polypeptides which may have been identified as a tumor antigen as described in one or more of the above Examples were analyzed and verified as follows. An expressed sequence tag (EST) DNA database (LIFESEQ®, Incyte Pharmaceuticals, Palo Alto, CA) was searched and interesting EST sequences were identified by GEPIS. Gene expression profiling *in silico* (GEPIS) is a bioinformatics tool developed at Genentech, Inc. that characterizes genes of interest for new cancer therapeutic targets. GEPIS takes advantage of large amounts of EST sequence and library information to determine gene expression profiles. GEPIS is capable of determining the expression profile of a gene based upon its proportional correlation with the number of its occurrences in EST databases, and it works by integrating the LIFESEQ® EST relational database and Genentech proprietary information in a stringent and statistically meaningful way. In this example, GEPIS is used to identify and cross-validate novel tumor antigens, although GEPIS can be configured to perform either very specific analyses or broad screening tasks. For the initial screen, GEPIS is used to identify EST sequences from the LIFESEQ® database that correlate to expression in a particular tissue or tissues of interest (often a tumor tissue of interest). The EST sequences identified in this initial screen (or consensus sequences obtained from aligning multiple related and overlapping EST sequences obtained from the initial screen) were then subjected to a screen intended to identify the presence of at least one transmembrane domain in the encoded protein. Finally, GEPIS was employed

to generate a complete tissue expression profile for the various sequences of interest. Using this type of screening bioinformatics, various TAT polypeptides (and their encoding nucleic acid molecules) were identified as being significantly overexpressed in a particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. The rating of GEPIS hits is based upon several criteria including, for example, tissue specificity, tumor specificity and expression level in normal essential and/or normal proliferating tissues. The following is a list of molecules whose tissue expression profile as determined by GEPIS evidences high tissue expression and significant upregulation of expression in a specific tumor or tumors as compared to other tumor(s) and/or normal tissues and optionally relatively low expression in normal essential and/or normal proliferating tissues. As such, the molecules listed below are excellent polypeptide targets for the diagnosis and therapy of cancer in mammals.

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
10	DNA67962 (TAT207)	colon tumor	normal colon tissue
	DNA67962 (TAT207)	uterus tumor	normal uterus tissue
	DNA67962 (TAT207)	lung tumor	normal lung tissue
	DNA67962 (TAT207)	prostate tumor	normal prostate tissue
15	DNA67962 (TAT207)	breast tumor	normal breast tissue
	DNA96792 (TAT239)	colon tumor	normal colon tissue
	DNA96792 (TAT239)	rectum tumor	normal rectum tissue
	DNA96792 (TAT239)	pancreas tumor	normal pancreas tissue
	DNA96792 (TAT239)	lung tumor	normal lung tissue
20	DNA96792 (TAT239)	stomach tumor	normal stomach tissue
	DNA96792 (TAT239)	esophagus tumor	normal esophagus tissue
	DNA96792 (TAT239)	breast tumor	normal breast tissue
	DNA96792 (TAT239)	uterus tumor	normal uterus tissue
	DNA96964 (TAT193)	breast tumor	normal breast tissue
25	DNA96964 (TAT193)	brain tumor	normal brain tissue
	DNA142915 (TAT199)	breast tumor	normal breast tissue
	DNA142915 (TAT199)	ovary tumor	normal ovary tissue
	DNA142915 (TAT199)	brain tumor	normal brain tissue
	DNA208551 (TAT178)	prostate tumor	normal prostate tissue
30	DNA208551 (TAT178)	colon tumor	normal colon tissue
	DNA210159 (TAT198)	prostate tumor	normal prostate tissue
	DNA210159 (TAT198)	uterus tumor	normal uterus tissue
	DNA210159 (TAT198)	breast tumor	normal breast tissue
	DNA210159 (TAT198)	ovarian tumor	normal ovarian tissue
35	DNA225706 (TAT194)	adrenal tumor	normal adrenal tissue
	DNA225706 (TAT194)	prostate tumor	normal prostate tissue
	DNA225706 (TAT194)	breast tumor	normal breast tissue
	DNA225706 (TAT194)	connective tissue tumor	normal connective tissue
	DNA225793 (TAT223)	ovarian tumor	normal ovarian tissue
40	DNA225793 (TAT223)	fallopian tube tumor	normal fallopian tube tissue
	DNA225793 (TAT223)	kidney tumor	normal kidney tissue
	DNA225796 (TAT196)	breast tumor	normal breast tissue
	DNA225943 (TAT195)	liver tumor	normal liver tissue
	DNA225943 (TAT195)	lung tumor	normal lung tissue
45	DNA225943 (TAT195)	breast tumor	normal breast tissue
	DNA226283 (TAT203)	uterine tumor	normal uterine tissue
	DNA226283 (TAT203)	breast tumor	normal breast tissue
	DNA226283 (TAT203)	squamous cell lung tumor	normal squamous cell lung tissue
50	DNA226283 (TAT203)	colon tumor	normal colon tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
5	DNA226283 (TAT203)	ovarian tumor	normal ovarian tissue
	DNA226589 (TAT200)	brain tumor	normal brain tissue
	DNA226589 (TAT200)	colon tumor	normal colon tissue
	DNA226589 (TAT200)	breast tumor	normal breast tissue
	DNA226589 (TAT200)	prostate tumor	normal prostate tissue
	DNA226622 (TAT205)	squamous cell lung tumor	normal squamous cell lung tissue
10	DNA226622 (TAT205)	kidney tumor	normal kidney tissue
	DNA226622 (TAT205)	uterine tumor	normal uterine tissue
	DNA226622 (TAT205)	breast tumor	normal breast tissue
	DNA226622 (TAT205)	colon tumor	normal colon tissue
	DNA227545 (TAT197)	breast tumor	normal breast tissue
15	DNA227611 (TAT175)	prostate tumor	normal prostate tissue
	DNA227611 (TAT175)	colon tumor	normal colon tissue
	DNA227611 (TAT175)	breast tumor	normal breast tissue
	DNA227611 (TAT175)	uterine tumor	normal uterine tissue
	DNA261021 (TAT208)	prostate tumor	normal prostate tissue
20	DNA261021 (TAT208)	colon tumor	normal colon tissue
	DNA261021 (TAT208)	breast tumor	normal breast tissue
	DNA261021 (TAT208)	uterine tumor	normal uterine tissue
	DNA260655 (TAT209)	lung tumor	normal lung tissue
	DNA260655 (TAT209)	colon tumor	normal colon tissue
25	DNA260655 (TAT209)	breast tumor	normal breast tissue
	DNA260655 (TAT209)	liver tumor	normal liver tissue
	DNA260655 (TAT209)	ovarian tumor	normal ovarian tissue
	DNA260655 (TAT209)	skin tumor	normal skin tissue
	DNA260655 (TAT209)	spleen tumor	normal spleen tissue
30	DNA260655 (TAT209)	myeloid tumor	normal myeloid tissue
	DNA260655 (TAT209)	muscle tumor	normal muscle tissue
	DNA260655 (TAT209)	bone tumor	normal bone tissue
	DNA260945 (TAT192)	brain tumor	normal brain tissue
	DNA260945 (TAT192)	breast tumor	normal breast tissue
35	DNA260945 (TAT192)	colon tumor	normal colon tissue
	DNA260945 (TAT192)	ovarian tumor	normal ovarian tissue
	DNA260945 (TAT192)	pancreatic tumor	normal pancreatic tissue
	DNA261001 (TAT181)	bone tumor	normal bone tissue
	DNA261001 (TAT181)	lung tumor	normal lung tissue
40	DNA266928 (TAT182)	bone tumor	normal bone tissue
	DNA266928 (TAT182)	lung tumor	normal lung tissue
	DNA268035 (TAT222)	ovarian tumor	normal ovarian tissue
	DNA277797 (TAT212)	breast tumor	normal breast tissue
	DNA277797 (TAT212)	pancreatic tumor	normal pancreatic tissue
45	DNA77509 (TAT177)	colon tumor	normal colon tissue
	DNA77509 (TAT177)	testis tumor	normal testis tissue
	DNA87993 (TAT235)	breast tumor	normal breast tissue
	DNA87993 (TAT235)	prostate tumor	normal prostate tissue
	DNA87993 (TAT235)	colon tumor	normal colon tissue
50	DNA87993 (TAT235)	ovarian tumor	normal ovarian tissue
	DNA92980 (TAT234)	bone tumor	normal bone tissue
	DNA92980 (TAT234)	breast tumor	normal breast tissue
	DNA92980 (TAT234)	cervical tumor	normal cervical tissue
	DNA92980 (TAT234)	colon tumor	normal colon tissue
55	DNA92980 (TAT234)	rectum tumor	normal rectum tissue
	DNA92980 (TAT234)	endometrial tumor	normal endometrial tissue
	DNA92980 (TAT234)	liver tumor	normal liver tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA92980 (TAT234)	lung tumor	normal lung tissue
	DNA92980 (TAT234)	ovarian tumor	normal ovarian tissue
	DNA92980 (TAT234)	pancreatic tumor	normal pancreatic tissue
	DNA92980 (TAT234)	skin tumor	normal skin tissue
5	DNA92980 (TAT234)	soft tissue tumor	normal soft tissue
	DNA92980 (TAT234)	stomach tumor	normal stomach tissue
	DNA92980 (TAT234)	bladder tumor	normal bladder tissue
	DNA92980 (TAT234)	thyroid tumor	normal thyroid tissue
	DNA92980 (TAT234)	esophagus tumor	normal esophagus tissue
10	DNA92980 (TAT234)	testis tumor	normal testis tissue
	DNA105792 (TAT233)	adrenal tumor	normal adrenal tissue
	DNA105792 (TAT233)	breast tumor	normal breast tissue
	DNA105792 (TAT233)	endometrial tumor	normal endometrial tissue
	DNA105792 (TAT233)	esophagus tumor	normal esophagus tissue
15	DNA105792 (TAT233)	kidney tumor	normal kidney tissue
	DNA105792 (TAT233)	lung tumor	normal lung tissue
	DNA105792 (TAT233)	ovarian tumor	normal ovarian tissue
	DNA105792 (TAT233)	pancreatic tumor	normal pancreatic tissue
	DNA105792 (TAT233)	prostate tumor	normal prostate tissue
20	DNA105792 (TAT233)	soft tissue tumor	normal soft tissue
	DNA105792 (TAT233)	myeloid tumor	normal myeloid tissue
	DNA105792 (TAT233)	thyroid tumor	normal thyroid tissue
	DNA105792 (TAT233)	bladder tumor	normal bladder tissue
	DNA105792 (TAT233)	brain tumor	normal brain tissue
25	DNA105792 (TAT233)	testis tumor	normal testis tissue
	DNA119474 (TAT226)	kidney tumor	normal kidney tissue
	DNA119474 (TAT226)	adrenal tumor	normal adrenal tissue
	DNA119474 (TAT226)	uterine tumor	normal uterine tissue
	DNA119474 (TAT226)	ovarian tumor	normal ovarian tissue
30	DNA150491 (TAT204)	squamous cell lung tumor	normal squamous cell lung tissue
	DNA150491 (TAT204)	colon tumor	normal colon tissue
	DNA280351 (TAT248)	squamous cell lung tumor	normal squamous cell lung tissue
35	DNA280351 (TAT248)	colon tumor	normal colon tissue
	DNA150648 (TAT232)	liver tumor	normal liver tissue
	DNA150648 (TAT232)	breast tumor	normal breast tissue
	DNA150648 (TAT232)	brain tumor	normal brain tissue
	DNA150648 (TAT232)	lung tumor	normal lung tissue
40	DNA150648 (TAT232)	colon tumor	normal colon tissue
	DNA150648 (TAT232)	rectum tumor	normal rectum tissue
	DNA150648 (TAT232)	kidney tumor	normal kidney tissue
	DNA150648 (TAT232)	bladder tumor	normal bladder tissue
	DNA179651 (TAT224)	colon tumor	normal colon tissue
45	DNA179651 (TAT224)	uterine tumor	normal uterine tissue
	DNA179651 (TAT224)	lung tumor	normal lung tissue
	DNA179651 (TAT224)	kidney tumor	normal kidney tissue
	DNA225886 (TAT236)	breast tumor	normal breast tissue
	DNA225886 (TAT236)	colon tumor	normal colon tissue
50	DNA225886 (TAT236)	rectum tumor	normal rectum tissue
	DNA225886 (TAT236)	ovarian tumor	normal ovarian tissue
	DNA225886 (TAT236)	pancreas tumor	normal pancreas tissue
	DNA225886 (TAT236)	prostate tumor	normal prostate tissue
	DNA225886 (TAT236)	bladder tumor	normal bladder tissue
55	DNA225886 (TAT236)	testis tumor	normal testis tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA226717 (TAT185)	glioma	normal glial tissue
	DNA226717 (TAT185)	brain tumor	normal brain tissue
	DNA227162 (TAT225)	myeloid tumor	normal myeloid tissue
5	DNA227162 (TAT225)	uterine tumor	normal uterine tissue
	DNA227162 (TAT225)	prostate tumor	normal prostate tissue
	DNA277804 (TAT247)	myeloid tumor	normal myeloid tissue
	DNA277804 (TAT247)	uterine tumor	normal uterine tissue
	DNA277804 (TAT247)	prostate tumor	normal prostate tissue
10	DNA233034 (TAT174)	glioma	normal glial tissue
	DNA233034 (TAT174)	brain tumor	normal brain tissue
	DNA233034 (TAT174)	kidney tumor	normal kidney tissue
	DNA233034 (TAT174)	adrenal tumor	normal adrenal tissue
	DNA266920 (TAT214)	glioma	normal glial tissue
	DNA266920 (TAT214)	brain tumor	normal brain tissue
15	DNA266920 (TAT214)	kidney tumor	normal kidney tissue
	DNA266920 (TAT214)	adrenal tumor	normal adrenal tissue
	DNA266921 (TAT220)	glioma	normal glial tissue
	DNA266921 (TAT220)	brain tumor	normal brain tissue
	DNA266921 (TAT220)	kidney tumor	normal kidney tissue
20	DNA266921 (TAT220)	adrenal tumor	normal adrenal tissue
	DNA266922 (TAT221)	glioma	normal glial tissue
	DNA266922 (TAT221)	brain tumor	normal brain tissue
	DNA266922 (TAT221)	kidney tumor	normal kidney tissue
	DNA266922 (TAT221)	adrenal tumor	normal adrenal tissue
25	DNA234834 (TAT179)	colon tumor	normal colon tissue
	DNA234834 (TAT179)	uterine tumor	normal uterine tissue
	DNA234834 (TAT179)	breast tumor	normal breast tissue
	DNA234834 (TAT179)	prostate tumor	normal prostate tissue
	DNA247587 (TAT216)	breast tumor	normal breast tissue
30	DNA247587 (TAT216)	prostate tumor	normal prostate tissue
	DNA247587 (TAT216)	bladder tumor	normal bladder tissue
	DNA247587 (TAT216)	lymphoid tumor	normal lymphoid tissue
	DNA255987 (TAT218)	brain tumor	normal brain tissue
	DNA255987 (TAT218)	breast tumor	normal breast tissue
35	DNA247476 (TAT180)	prostate tumor	normal prostate tissue
	DNA247476 (TAT180)	pancreas tumor	normal pancreas tissue
	DNA247476 (TAT180)	brain tumor	normal brain tissue
	DNA247476 (TAT180)	stomach tumor	normal stomach tissue
	DNA247476 (TAT180)	bladder tumor	normal bladder tissue
40	DNA247476 (TAT180)	soft tissue tumor	normal soft tissue
	DNA247476 (TAT180)	skin tumor	normal skin tissue
	DNA247476 (TAT180)	kidney tumor	normal kidney tissue
	DNA260990 (TAT375)	prostate tumor	normal prostate tissue
	DNA260990 (TAT375)	pancreas tumor	normal pancreas tissue
45	DNA260990 (TAT375)	brain tumor	normal brain tissue
	DNA260990 (TAT375)	stomach tumor	normal stomach tissue
	DNA260990 (TAT375)	bladder tumor	normal bladder tissue
	DNA260990 (TAT375)	soft tissue tumor	normal soft tissue
	DNA260990 (TAT375)	skin tumor	normal skin tissue
50	DNA260990 (TAT375)	kidney tumor	normal kidney tissue
	DNA261013 (TAT176)	prostate tumor	normal prostate tissue
	DNA261013 (TAT176)	colon tumor	normal colon tissue
	DNA261013 (TAT176)	small intestine tumor	normal small intestine tissue
	DNA261013 (TAT176)	pancreatic tumor	normal pancreatic tissue
55	DNA261013 (TAT176)	uterine tumor	normal uterine tissue

	<u>Molecule</u>	<u>upregulation of expression in:</u>	<u>as compared to:</u>
	DNA261013 (TAT176)	ovarian tumor	normal ovarian tissue
	DNA261013 (TAT176)	bladder tumor	normal bladder tissue
	DNA261013 (TAT176)	stomach tumor	normal stomach tissue
5	DNA267342 (TAT213)	breast tumor	normal breast tissue
	DNA267342 (TAT213)	uterine tumor	normal uterine tissue
	DNA267342 (TAT213)	colon tumor	normal colon tissue
	DNA267342 (TAT213)	kidney tumor	normal kidney tissue
	DNA267342 (TAT213)	bladder tumor	normal bladder tissue
	DNA267342 (TAT213)	bone tumor	normal bone tissue
10	DNA267342 (TAT213)	ovarian tumor	normal ovarian tissue
	DNA267342 (TAT213)	pancreatic tumor	normal pancreatic tissue
	DNA267626 (TAT217)	breast tumor	normal breast tissue
	DNA267626 (TAT217)	colon tumor	normal colon tissue
	DNA267626 (TAT217)	pancreatic tumor	normal pancreatic tissue
15	DNA267626 (TAT217)	ovarian tumor	normal ovarian tissue
	DNA268334 (TAT202)	kidney tumor	normal kidney tissue
	DNA269238 (TAT215)	colon tumor	normal colon tissue
	DNA269238 (TAT215)	kidney tumor	normal kidney tissue
	DNA269238 (TAT215)	adrenal tumor	normal adrenal tissue
20	DNA269238 (TAT215)	bladder tumor	normal bladder tissue
	DNA272578 (TAT238)	adrenal tumor	normal adrenal tissue
	DNA272578 (TAT238)	lung tumor	normal lung tissue
	DNA272578 (TAT238)	ovarian tumor	normal ovarian tissue
	DNA272578 (TAT238)	uterine tumor	normal uterine tissue
25	DNA304853 (TAT376)	colon tumor	normal colon tissue
	DNA304853 (TAT376)	uterine tumor	normal uterine tissue
	DNA304853 (TAT376)	breast tumor	normal breast tissue
	DNA304853 (TAT376)	prostate tumor	normal prostate tissue
	DNA304854 (TAT377)	colon tumor	normal colon tissue
30	DNA304854 (TAT377)	uterine tumor	normal uterine tissue
	DNA304854 (TAT377)	breast tumor	normal breast tissue
	DNA304854 (TAT377)	prostate tumor	normal prostate tissue
	DNA304855 (TAT378)	colon tumor	normal colon tissue
	DNA304855 (TAT378)	uterine tumor	normal uterine tissue
35	DNA304855 (TAT378)	breast tumor	normal breast tissue
	DNA304855 (TAT378)	prostate tumor	normal prostate tissue
	DNA287971 (TAT379)	prostate tumor	normal prostate tissue
	DNA287971 (TAT379)	pancreas tumor	normal pancreas tissue
	DNA287971 (TAT379)	brain tumor	normal brain tissue
40	DNA287971 (TAT379)	stomach tumor	normal stomach tissue
	DNA287971 (TAT379)	bladder tumor	normal bladder tissue
	DNA287971 (TAT379)	soft tissue tumor	normal soft tissue
	DNA287971 (TAT379)	skin tumor	normal skin tissue
45	DNA287971 (TAT379)	kidney tumor	normal kidney tissue

#### EXAMPLE 6: Use of TAT as a hybridization probe

The following method describes use of a nucleotide sequence encoding TAT as a hybridization probe for, i.e., diagnosis of the presence of a tumor in a mammal.

DNA comprising the coding sequence of full-length or mature TAT as disclosed herein can also be employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of TAT) in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled TAT-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

5 DNAs having a desired sequence identity with the DNA encoding full-length native sequence TAT can then be identified using standard techniques known in the art.

#### EXAMPLE 7: Expression of TAT in *E. coli*

10 This example illustrates preparation of an unglycosylated form of TAT by recombinant expression in *E. coli*.

The DNA sequence encoding TAT is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the TAT coding region, lambda transcriptional terminator, and an argU gene.

15 The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

20 Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

25 After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized TAT protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

30 TAT may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding TAT is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by



mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium citrate•2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

*E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded TAT polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Certain of the TAT polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

#### EXAMPLE 8: Expression of TAT in mammalian cells

This example illustrates preparation of a potentially glycosylated form of TAT by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the TAT DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the TAT DNA using ligation methods such as described in Sambrook et al., supra. The resulting vector is called pRK5-TAT.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-TAT DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya et al., Cell, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of TAT polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, TAT may be introduced into 293 cells transiently using the dextran sulfate method described by Sompanyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5-TAT DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin and 0.1 µg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed TAT can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, TAT can be expressed in CHO cells. The pRK5-TAT can be transfected into CHO cells using known reagents such as CaPO<sub>4</sub> or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as <sup>35</sup>S-methionine. After determining the presence of TAT polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed TAT can then be concentrated and purified by any selected method.

Epitope-tagged TAT may also be expressed in host CHO cells. The TAT may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged TAT insert can then be subcloned into a SV40

driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged TAT can then be concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

TAT may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect® (Quiagen), Dosper® or Fugene® (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately  $3 \times 10^7$  cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2  $\mu\text{m}$  filtered PS20 with 5% 0.2  $\mu\text{m}$  diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with  $3 \times 10^5$  cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at  $1.2 \times 10^6$  cells/mL. On day 0, the cell number pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22  $\mu\text{m}$  filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is

pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Certain of the TAT polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

#### EXAMPLE 9: Expression of TAT in Yeast

The following method describes recombinant expression of TAT in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of TAT from the ADH2/GAPDH promoter. DNA encoding TAT and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of TAT. For secretion, DNA encoding TAT can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native TAT signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of TAT.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant TAT can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing TAT may further be purified using selected column chromatography resins.

Certain of the TAT polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

#### EXAMPLE 10: Expression of TAT in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of TAT in Baculovirus-infected insect cells.

The sequence coding for TAT is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as

pVL1393 (Novagen). Briefly, the sequence encoding TAT or the desired portion of the coding sequence of TAT such as the sequence encoding an extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

5 Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (Pharmlingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

10 Expressed poly-his tagged TAT can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 15 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 μm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which 20 elutes nonspecifically bound protein. After reaching A<sub>280</sub> baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged TAT are pooled and dialyzed against loading buffer.

25 Alternatively, purification of the IgG tagged (or Fc tagged) TAT can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Certain of the TAT polypeptides disclosed herein have been successfully expressed and purified using this technique(s).

#### EXAMPLE 11: Preparation of Antibodies that Bind TAT

30 This example illustrates preparation of monoclonal antibodies which can specifically bind TAT.

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, supra. Immunogens that may be employed include purified TAT, fusion proteins containing TAT, and cells expressing recombinant TAT on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

35 Mice, such as Balb/c, are immunized with the TAT immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into

the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-TAT antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of TAT. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against TAT. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against TAT is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-TAT monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

#### EXAMPLE 12: Purification of TAT Polypeptides Using Specific Antibodies

Native or recombinant TAT polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-TAT polypeptide, mature TAT polypeptide, or pre-TAT polypeptide is purified by immunoaffinity chromatography using antibodies specific for the TAT polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-TAT polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of TAT polypeptide by preparing a fraction from cells containing TAT polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble TAT polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble TAT polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of TAT polypeptide (e.g., high ionic

strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/TAT polypeptide binding (e.g., a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and TAT polypeptide is collected.

EXAMPLE 13: *In Vitro* Tumor Cell Killing Assay

5 Mammalian cells expressing the TAT polypeptide of interest may be obtained using standard expression vector and cloning techniques. Alternatively, many tumor cell lines expressing TAT polypeptides of interest are publicly available, for example, through the ATCC and can be routinely identified using standard ELISA or FACS analysis. Anti-TAT polypeptide monoclonal antibodies (and toxin conjugated derivatives thereof) may then be employed in assays to determine the ability of the antibody to kill TAT polypeptide expressing cells *in vitro*.

10 For example, cells expressing the TAT polypeptide of interest are obtained as described above and plated into 96 well dishes. In one analysis, the antibody/toxin conjugate (or naked antibody) is included throughout the cell incubation for a period of 4 days. In a second independent analysis, the cells are incubated for 1 hour with the antibody/toxin conjugate (or naked antibody) and then washed and incubated in the absence of antibody/toxin conjugate for a period of 4 days. Cell viability is then measured using the CellTiter-Glo Luminescent Cell Viability  
15 Assay from Promega (Cat# G7571). Untreated cells serve as a negative control.

EXAMPLE 14: *In Vivo* Tumor Cell Killing Assay

To test the efficacy of conjugated or unconjugated anti-TAT polypeptide monoclonal antibodies, anti-TAT antibody is injected intraperitoneally into nude mice 24 hours prior to receiving tumor promoting cells  
20 subcutaneously in the flank. Antibody injections continue twice per week for the remainder of the study. Tumor volume is then measured twice per week.

The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to  
25 practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs  
30 that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description  
35 and fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated antibody that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

2. An isolated antibody that binds to a polypeptide having:

(a) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120);

(b) the amino acid sequence shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 57-112, 114, 116, 118 or 120 (SEQ ID NOS:57-112, 114, 116, 118 or 120), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-56, 113, 115, 117 or 119 (SEQ ID NOS:1-56, 113, 115, 117 or 119).

3. The antibody of Claim 1 which is a monoclonal antibody.

4. The antibody of Claim 1 which is an antibody fragment.

5. The antibody of Claim 1 which is a chimeric or a humanized antibody.

6. The antibody of Claim 1 which is conjugated to a growth inhibitory agent.



7. The antibody of Claim 1 which is conjugated to a cytotoxic agent.
8. The antibody of Claim 7, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
- 5 9. The antibody of Claim 7, wherein the cytotoxic agent is a toxin.
- 10 10. The antibody of Claim 9, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.
- 10 11. The antibody of Claim 9, wherein the toxin is a maytansinoid.
12. The antibody of Claim 1 which is produced in bacteria.
13. The antibody of Claim 1 which is produced in CHO cells.
- 15 14. The antibody of Claim 1 which induces death of a cell to which it binds.
15. The antibody of Claim 1 which is detectably labeled.

1/136

**FIGURE 1**

CTCCGGGTCCCCAGGGGCTGCGCCGGGCGGCCTGGCAAGGGGGACGAGTCAGTGGACACTCCAGGAAGAGCGG  
CCCCGCGGGGGGCGATGACCGTGCGCTGACCCTGACTCACTCCAGGTCCGGAGGCGGGGGCCCCCGGGGCGACT  
CGGGGGCGGACCGCGGGGCGGAGCTGCCGCCCGTGAGTCCGGCCGAGCCACCTGAGCCCCGAGCCGCGGGACACC  
GTCGCTCCTGCTCTCCGAATGCTGCGCACCGCGATGGGCCTGAGGAGCTGGCTCGCCGCCCATGGGGCGCGCT  
GCCGCCTCGGCCACCGCTGCTGCTGCTCCTGCTGCTGCTGCTCCTGCTGCAGCCGCCGCCTCCGACCTGGGCGC  
TCAGCCCCCGGATCAGCCTGCCTCTGGGCTCTGAAGAGCGGCCATTCTCAGATTGCAAGCTGAACACATCTCC  
AACTACACAGCCCTTCTGCTGAGCAGGGATGGCAGGACCCTGTACGTGGGTGCTCGAGAGGCCCTCTTTGCACT  
CAGTAGCAACCTCAGCTTCCTGCCAGGCGGGGAGTACCAGGAGCTGCTTTGGGGTGCAGACGCAGAGAAGAAAC  
AGCAGTGCAGCTTCAAGGGCAAGGACCCACAGCGCGACTGTCAAACTACATCAAGATCCTCCTGCCGCTCAGC  
GGCAGTCACCTGTTACCTGTGGCACAGCAGCCTTCAGCCCCATGTGTACCTACATCAACATGGGAACTTCAC  
CCTGGCAAGGGACGAGAAGGGGAATGTCTCCTGGAAGATGGCAAGGGCCGTTGTCCCTTCGACCCGAATTTCA  
AGTCCACTGCCCTGGTGGTTGATGGCGAGCTCTACACTGGAACAGTCAGCAGCTTCCAAGGGAATGACCCGGCC  
ATCTCGCGGAGCCAAAGCCTTCGCCCCACCAAGACCGAGAGCTCCCTCAACTGGCTGCAAGACCCAGCTTTTGT  
GGCCTCAGCCTACATTCCTGAGAGCCTGGGCAGCTTGCAAGGCGATGATGACAAGATCTACTTTTCTTCAGCG  
AGACTGGCCAGGAATTTGAGTTCTTTGAGAACACCAATTTGTCTCCGCATTGCCCGCATCTGCAAGGGCGATGAG  
GGTGGAGAGCGGGTGCTACAGCAGCGCTGGACCTCCTTCAAGGCCAGCTGCTGTGCTCAGGCCCCGACGA  
TGGCTTCCCCTTCAACGTGCTGCAGGATGTCTTCACGCTGAGCCCCAGCCCCAGGACTGGCGTGACACCCCTTT  
TCTATGGGGTCTTCACTTCCCAGTGGCACAGGGGAACTACAGAAGGCTCTGCCGCTGTGTCTTCAATGAAG  
GATGTGCAGAGAGTCTTCAGCGGCCTCTACAAGGAGGTGAACCGTGAGACACAGCAGTGGTACACCGTGACCCA  
CCCQGTGCCACACCCCGGCCTGGAGCGTGATCACCAACAGTGCCCGGGAAAGGAAGATCAACTCATCCCTGC  
AGCTCCCAGACCGCGTGCTGAACTTCTCAAGGACCACTTCTGATGGACGGGCAGGTCCGAAGCCGCATGCTG  
CTGCTGCAGCCCCAGGCTCGCTACCAGCGCGTGGCTGTACACCGCGTCCCTGGCCTGCACCACACCTACGATGT  
CCTCTTCTGGGCACTGGTGACGGCCGGCTCCACAAGGCAGTGAGCGTGGGCCCCCGGGTGACATCATTGAGG  
AGCTGCAGATCTTCTCATCGGGACAGCCCGTGAGAATCTGCTCCTGGACACCCACAGGGGGCTGCTGTATGCG  
GCCTCACACTCGGGCGTAGTCCAGGTGCCCATGGCCAACTGCAGCCTGTACCGGAGCTGTGGGGACTGCCTCCT  
CGCCCCGGGACCCCTACTGTGCTTGGAGCGGCTCCAGCTGCAAGCACGTACAGCCTTACCAGCCTCAGCTGGCCA  
CCAGGCGGTGGATCCAGGACATCGAGGGAGCCAGCGCCAAGGACCTTTCAGCGCGTCTTCGGTTGTGTCCCCG  
TCTTTTGTACCAACAGGGGAGAAGCCATGTGAGCAAGTCCAGTTCCAGCCCAACACAGTGAACACTTTGGCCTG  
CCCGCTCCTCTCCAACCTGGCGACCCGACTCTGGCTACGCAACGGGGCCCCCGTCAATGCCTCGGCCCTCCTGAC  
ACGTGCTACCACTGGGGACCTGCTGCTGGTGGGCACCAACAGTGGGGGAGTTCCAGTGGTCACTGAGAG  
GAGGGCTTCCAGCAGCTGGTAGCCAGCTACTGCCAGAGGTGGTGGAGGACGGGGTGGCAGACCAACAGATGA  
GGGTGGCAGGTGATACCCGTCATTATCAGCAGCTACGCGTGTGAGTGCACCAGCTGGTGGCAAGGCCAGCTGGGGTG  
CAGACAGGTCTTACTGGAAGGAGTTCTGGTGATGTGCACGCTCTTTGTGCTGGCCGTGCTGCTCCAGTTTTTA  
TTCTTGCTCTACCGGCACCGGAACAGCATGAAAGTCTTCTGAAGCAGGGGGAATGTGCCAGCGTGACCCCCAA  
GACCTGCCCTGTGGTGCTGCCCCCTGAGACCCGCCCCACTCAACGGCCTAGGGCCCCCTAGCACCCCGCTCGATC  
ACCGAGGGTACCAGTCCCTGTGAGACAGCCCCCGGGGGCCCCGAGTCTTCACTGAGTCAGAGAAGAGGCCACTC  
AGCATCCAAGACAGCTTCGTGGAGGTATCCCCAGTGTGCCCCCGGCCCGGGTCCGCCTTGGCTCGGAGATCCG  
TGACTCTGTGGTGTGAGAGCTGACTTCCAGAGGACGCTGCCCTGGCTTCAGGGGCTGTGAATGCTCGGAGAGGG  
TCAACTGGACCTCCCCTCCGCTCTGCTCTTCGTGGAACACGACCGTGGTGGCCGGCCCTTGGGAGCCTTGGAGC  
CAGCTGGCCTGCTGCTCTCCAGTCAAGTAGCGAAGCTCCTACACCCAGACACCCAAACAGCCGTGGCCCCAGA  
GGTCTGGCCAAATATGGGGGCCTGCCTAGGTTGGTGGAAACAGTGCTCCTTATGTAAACTGAGCCCTTTGTTTA  
AAAAACAATTCCAAATGTGAAACTAGAAATGAGAGGGAAAGAGATAGCATGGCATGCAGCACACAGGCTGCTCCA  
GTTTCATGGCCTCCCAGGGGTGCTGGGGATGCATCCAAAGTGGTTGTCTGAGACAGAGTTGGAAACCCCTCACCAA  
CTGGCCTCTTACCTTCCACATTATCCCGCTGCCACCGGCTGCCCTGTCTCACTGCAGATTCAGGACCAGCTTG  
GGCTGCGTGCGTTCTGCCTTGCCAGTCAGCCGAGGATGTAGTTGTTGCTGCCGTGCTCCACCACCTCAGGGAC  
CAGAGGGCTAGGTTGGCACTGCGGCCCTCACAGGTCCTGGGCTCGGACCCAACTCCTGGACCTTTCCAGCCTG  
TATCAGGCTGTGGCCACACGAGAGGACAGCGCGAGCTCAGGAGAGATTTCGTGACAATGACGCTTTCCCTCA  
GAATTCAGGGAAGAGAATGTGCGCTGCCTTCCCTGCTTGTGCGTGAGAACCCGTGTGCCCTTCCACCATAT  
CCACCTCGCTCCATCTTTGAACTCAAACACGAGGAATACTGCACCCTGGTCTCTCCCGAGTCCCGAGTTT  
ACCTCCATCCCTACCTTCCCTCACTCTAAGGGATATCAACACTGCCAGCACAGGGGGCCCTGAATTTATGTG  
GTTTTTATACATTTTTTTAATAAGATGCACCTTTATGTATTTTTTTAATAAAGTCTGAAGAATTACTGTTTTAAAA  
AAAAAA

2/136

**FIGURE 2**

GGAAAGGCTGAGTCTCCAGCTCAAGGTCAAACGTCCAAGGCCGAAAGCCCTCCAGTTTCCCCTGGACGCCTTG  
CTCCTGCTTCTGCTACGACCTTCTGGGGAAAACGAATTTCTCATTTTCTTCTTAAATTGCCATTTTCGCTTTAG  
GAGATGAATGTTTTCTTTGGCTGTTTTGGCAATGACTCTGAATTAAAGCGATGCTAACGCCTCTTTTCCCCCT  
AATTGTTAAAAGCTATGGACTGCAGGAAGATGGCCCGCTTCTCTTACAGTGTGATTTGGATCATGGCCATTTCT  
AAAGTCTTTGAACTGGGATTAGTTGCCGGGCTGGGCCATCAGGAATTTGCTCGTCCATCTCGGGGATACCTGGC  
CTTCAGAGATGACAGCATTTGGCCCCAGGAGGAGCCTGCAATTCGGCCCTCGGTCTTCCCAGCGTGTGCCGCCCA  
TGGGGATACAGCACAGTAAGGAGCTAAACAGAACCTGCTGCCTGAATGGGGGAACCTGCATGCTGGGGTCCTTT  
TGTGCCTGCCCTCCCTCCTTCTACGGACGGAAGTGTGAGCACGATGTGCGCAAAGAGAACTGTGGGTCTGTGCC  
CCATGACACCTGGCTGCCCAAGAAGTGTTCCTGTGTAAATGCTGGCACGGTCAGCTCCGCTGCTTTCCTCAGG  
CATTTCTACCCGGCTGTGATGGCCTTGTGATGGATGAGCACCTCGTGGCTTCCAGGACTCCAGAACTACCACCG  
TCTGCACGTACTACCACTTTTTATGCTAGTTGGCATCTGCCCTTCTATACAAAGCTACTATTAATCGACATTGAC  
CTATTTCCAGAAATACAATTTTAGATATCATGCAAATTTTCATGACCAGTAAAGGCTGCTGCTACAATGTCCTAA  
CTGAAAGATGATCATTTGTAGTTGCCTTAAAATAATGAATACATTTCCAAAATGGTCTCTAACATTTCTTACA  
GAACTACTTCTTACTTCTTTGCCCTGCCCTCTCCCAAAAACTACTTCTTTTTTCAAAGAAAGTCAGCCATAT  
CTCCATTGTGCCTAAGTCCAGTGTTCTTTTTTTTTTTTTTTTGGAGACGGAGTCTCACTCTGTACCCAGGCTG  
GACTGCAATGACGCGATCTTGGTTCAGTGCACCTCCGCATCCGGGGTTCAAGCCATTCTCCTGCCTCAGCCTC  
CCAAGTAACTGGGATTACAGGCATGTGTACCATGCCAGCTAATTTTTTTGTATTTTGTAGTAGAGATGGGGGT  
TTCACCATATTGGCCAGTCTGGTCTCGAACTCCTGACCTTGTGATCCACTCGCCTCAGCCTCTCGAAGTGCTGA  
GATTACACACGTGAGCAACTGTGCAAGGCCTGGTGTCTTGTGATACATGTAATTCTACCAAGGTCTTCTTAATA  
TGTTCTTTTAAATGATTGAATTATATGTTTCTGAGATTATTGGAGACTAATTCTAATGTGGACCTTAGAATACAGTT  
TTGAGTAGAGTTGATCAAAATCAATTAAAATAGTCTCTTTAAAAGGAAAGAAAACATCTTTAAGGGGAGGAACC  
AGAGTGCTGAAGGAATGGAAGTCCATCTGCGTGTGTGCAGGGAGACTGGGTAGGAAAGAGGAAGCAAATAGAAG  
AGAGAGGTTGAAAAACAAAATGGGTTACTTGATTGGTGATTAGGTGGTGGTAGAGAAGCAAGTAAAAAGGCTAA  
ATGGAAGGGCAAGTTTCCATCATCTATAGAAAGCTATATAAGACAAGAACTCCCCTTTTTTTTCCCAAAGGCATT  
ATAAAAAGAATGAAGCCTCCTTAGAAAAAAATTATACCTCAATGTCCCCAACAAGATTGCTTAATAAAATTGTG  
TTTCTCCAAGCTATTCAATTCTTTTAACTGTTGTAGAAGACAAAATGTTTACAATATATTTAGTTGTAAACCA  
AGTGATCAAACCTACATATTGTAAAGCCATTTTTTAAAATACATTGTATATATGTGTATGCACAGTAAAAATGGA  
AACTATATTGAA

3/136

**FIGURE 3**

GCCAGGAGGGAGAGCCTTCCCCAAGCAAACAATCCAGAGCAGCTGTGCAAACAACGGTGCATAAATGAGGCCTC  
CTGGACCATGAAGCGAGTCCTGAGCTGCGTCCCGGAGCCCACGGTGGTCATGGCTGCCAGAGCGCTCTGCATGC  
TGGGGCTGGTCCTGGCCTTGCTGTCCTCCAGCTCTGCTGAGGAGTACGTGGGCCTGTCTGCAAACCAGTGTGCC  
GTGCCAGCCAAGGACAGGGTGGACTGCGGCTACCCCCATGTCACCCCCAAGGAGTGCAACAACCGGGGCTGCTG  
CTTTGACTCCAGGATCCCTGGAGTGCCTTGGTGTTTCAAGCCCCTGCAGGAAGCAGAATGCACCTTCTTGAGGCA  
CCTCCAGCTGCCCCCGGCCGGGGGATGCGAGGCTCGGAGCACCCCTTGCCCGGCTGTGATTGCTGCCAGGCACTG  
TTCATCTCAGCTTTTCTGTCCCTTTGCTCCCGGCAAGCGCTTCTGCTGAAAGTTCATATCTGGAGCCTGATGTC  
TTAACGAATAAAGGTCCCATGCTCCACCCGA

4/136

**FIGURE 4**

GACCAGACTCGTCTCAGGCCAGTTGCAGCCTTCTCAGCCAAACGCCGACCAAGGAAAACTCACTACCATGGAGAA  
TTGCAGTGATTTGCTTTTGCCTCCTAGGCATCACCTGTGCCATACCAGTTAAACAGGCTGATTCTGGAAGTTCT  
GAGGAAAAGCAGCTTTACAACAAATACCCAGATGCTGTGGCCACATGGCTAAACCCTGACCCATCTCAGAAGCA  
GAATCTCCTAGCCCCACAGAATGCTGTGTCTCTGAAGAAACCAATGACTTTAAACAAGAGACCCTTCCAAGTA  
AGTCCAACGAAAGCCATGACCACATGGATGATATGGATGATGAAGATGATGATGACCATGTGGACAGCCAGGAC  
TCCATTGACTCGAACGACTCTGATGATGTAGATGACACTGATGATTCTCACCAGTCTGATGAGTCTCACCATTCT  
TGATGAATCTGATGAACTGGTCACTGATTTTCCCACGGACCTGCCAGCAACCGAAGTTTTCACTCCAGTTGTCC  
CCACAGTAGACACATATGATGGCCGAGGTGATAGTGTGGTTTATGGACTGAGGTCAAAATCTAAGAAGTTTTCGC  
AGACCTGACATCCAGTACCCTGATGCTACAGACGAGGACATCACCTCACACATGGAAAGCGAGGAGTTGAATGG  
TGCATACAAGGCCATCCCCGTTGCCAGGACCTGAACGCGCCTTCTGATTGGGACAGCCGTGGGAAGGACAGTT  
ATGAAACGAGTCAGCTGGATGACCAGAGTGCTGAAACCCACAGCCACAAGCAGTCCAGATTATATAAGCGGAAA  
GCCAATGATGAGAGCAATGAGCATTCCGATGTGATTGATAGTCAGGAACCTTTCCAAAGTCAGCCGTGAATTCCA  
CAGCCATGAATTTACAGCCATGAAGATATGCTGGTTGTAGACCCCCAAAAGTAAGGAAGAAGATAAACACCTGA  
AATTCGTATTTCTCATGAATTAGATAGTGCATCTTCTGAGGTCAATTAAAAGGAGAAAAAATACAATTTCTCA  
CTTTGCATTTAGTCAAAAGAAAAAATGCTTTATAGCAAAATGAAAGAGAACATGAAATGCTTCTTTCTCAGTTT  
ATTGGTTGAATGTGTATCTATTTGAGTCTGGAATAACTAATGTGTTTGATAATTAGTTTGTGGCTTCA  
TGGAAACTCCCTGTAAACTAAAAGCTTCAGGGTTATGTCTATGTTCAATCTATAGAAGAAATGCAAACTATCAC  
TGTATTTTAATATTTGTTATTCTCTCATGAATAGAAATTTATGTAGAAGCAAACAAAATACTTTTACCCACTTA  
AAAAGAGAATATAACATTTTATGTCACTATAATCTTTTGTTTTTTAAGTTAGTGTATATTTTGTGTGATTATC  
TTTTTGTGGTGTGAATAA

5/136

**FIGURE 5**

CGGACGCGTGGGCGGAGGGAAGAGGACCGCAAACCAACCCAGGACCCGCTCAGTTCCACGCGCGGCAGCCCTCC  
GTGCGCGCAGGCTCGGTATGAGCCGCACAGCCTACACGGTGGGAGCCCTGCTTCTCCTCTTGGGGACCCTGCTG  
CCGGCTGCTGAAGGGAAGAAAGGGTCCCAAGGTGCCATCCCCCGCCAGACAAGGCCCAGCACAATGACTC  
AGAGCAGACTCAGTCGCCCCAGCAGCCTGGCTCCAGGAACCGGGGGCGGGCCAAGGGCGGGGCACTGCCATGC  
CCGGGGAGGAGGTGCTGGAGTCCAGCCAAGAGGCCCTGCATGTGACGGAGCGCAAATACCTGAAGCGAGACTGG  
TGCAAAACCCAGCCGCTTAAGCAGACCATCCACGAGGAAGGCTGCAACAGTCGCACCATCATCAACCGCTTCTG  
TTACGGCCAGTGCAACTCTTTCTACATCCCCAGGCACATCCGGAAGGAGGAAGGTTCTTTTCAGTCCTGCTCCT  
TCTGCAAGCCCAAGAAATTCACTACCATGATGGTCACACTCAACTGCCCTGAACTACAGCCACCTACCAAGAAG  
AAGAGAGTCACACGTGTGAAGCAGTGTGCTTGCATATCCATCGATTTGGATTAAGCCAAATCCAGGTGCACCCA  
GCATGTCCTAGGAATGCAGCCCCAGGAAGTCCCAGACCTAAAACAACCAGATTXXXXXXXXXXXXXXXXXXXXX  
XXXXXXXXXXXXXXXXXXXXXAGACTTACGATGCATGTATACAAACGAATAGCAGATAATGATGACTAGTTCAC  
ACATAAAGTCCTTTTAAGGAGAAAACTAAAATGAAAAGTGGATAAACAGAACATTTATAAGTGATCAGTTAAT  
GCCTAAGAGTGAAAGTAGTTCTATTGACATTCCTCAAGATATTTAATATCAACTGCATTATGTATTATGTCTGC  
TTAAATCATTTAAAAACGGCAAAGAATTATATAGACTATGAGGTACCTTGCTGTGTAGGAGGATGAAAGGGGAG  
TTGATAGTCTCATAAACTAATTTGGCTTCAAGTTTCATGAATCTGTAAGTAGAATTTAATTTTCACCCAATA  
ATGTTCTATATAGCCTTTGCTAAAGAGCAACTAATAAATTAAACCTATTCTTTCAA

6/136

**FIGURE 6**

CGGACCTGAACCCCTAAAAGCGGAACCGCCTCCCGCCCTCGCCATCGCGGAGCTGAGTCGCCGGCGGGCGGTGGC  
TGCTGCCAGACCCGGAGTTTCCTCTTTCACTGGATGGAGCTGAACTTTGGGCGGCCAGAGCAGCACAGCTGTCC  
GGGGATCGCTGCATGCTGAGCTCCCTCGGCAAGACCCAGCGGCGGCTCGGGATTTTTTTGGGGGGCGGGGACC  
AGCCCCGCGCCGGCACCATGTTCTGGCGACCTGTACTTCGCGCTGCCGCTCTTGGACTTGCTCCTGTCGGCC  
GAAGTGAGCGGCGGAGACCGCCTGGATTGCGTGAAAGCCAGTGATCAGTGCCTGAAGGAGCAGAGCTGCAGCAC  
CAAGTACCGCACGCTAAGGCAGTGCGTGGCGGGCAAGGAGACCAACTTCAGCCTGGCATCCGGCCTGGAGGCCA  
AGGATGAGTGCCGCAGCGCCATGGAGGCCCTGAAGCAGAAGTCGCTCTACAACCTGCCGCTGCAAGCGGGGTATG  
AAGAAGGAGAAGAAGTGCCTGCGCATTTACTGGAGCATGTACCAGAGCCTGCAGGGAAATGATCTGCTGGAGGA  
TTCCCCATATGAACCAGTTAACAGCAGATTGTCAGATATATTCCGGGTGGTCCCATTTCATATCAGTGGAGCACA  
TTCCCAAAGGGAACAAGTGCCTGGATGCAGCGAAGGCCTGCAACCTCGACGACATTTGCAAGAAGTACAGGTGC  
GCGTACATCACCCCGTGCACCACCAGCGTGTCCAATGATGTCTGCAACCGCCGCAAGTGCCACAAGGCCCTCCG  
GCAGTTCTTTGACAAGGTCCCGGCCAAGCACAGCTACGGAATGCTCTTCTGCTCCTGCCGGGACATCGCCTGCA  
CAGAGCGGAGGCGACAGACCATCGTGCCTGTGTGCTCCTATGAAGAGAGGGAGAAGCCCAACTGTTTGAATTTG  
CAGGACTCCTGCAAGACGAATTACATCTGCAGATCTCGCCTTGCGGATTTTTTTTACCAACTGCCAGCCAGAGTC  
AAGGTCTGTGTCAGCAGCTGTCTAAAGGAAAACCTACGCTGACTGCCTCCTCGCCTACTCGGGGCTTATTGGCACAG  
TCATGACCCCCAACTACATAGACTCCAGTAGCCTCAGTGTGGCCCCATGGTGTGACTGCAGCAACAGTGGGAAC  
GACCTAGAAGAGTGCTTGAAATTTTTGAATTTCTTCAAGGACAATACATGTCTTAAAAATGCAATTCAAGCCTT  
TGGCAATGGCTCCGATGTGACCGTGTGGCAGCCAGCCTTCCCAGTACAGACCACCCTGCCACTACCACCCTG  
CCCTCCGGGTAAAGAACAAGCCCCCTGGGGCCAGCAGGGTCTGAGAATGAAATTCCCACTCATGTTTTGCCACCG  
TGTGCAAATTTACAGGCACAGAAGCTGAAATCCAATGTGTGCGGCAATACACACCTCTGTATTTCCAATGGTAA  
TTATGAAAAAGAAGGTCTCGGTGCTTCCAGCCACATAACCACAAAATCAATGGCTGCTCCTCCAAGCTGTGGTC  
TGAGCCCACTGCTGGTCTGGTGGTAACCGCTCTGTCCACCCTATTATCTTTAACAGAAACATCATAGCTGCAT  
TAAAAAATACAATATGGACATGTAAAAAGACAAAACCAAGTTATCTGTTTCCTGTTCTCTTGTATAGCTGAA  
ATTCCAGTTTAGGAGCTCAGTTGAGAAACAGTTCCATTCAACTGGAACATTTTTTTTTTTCTTTTAAGAAAG  
CTTCTTGTGATCCTTCGGGGCTTCTGTGAAAACCTGATGCAGTGCTCCATCCAACTCAGAAGGCTTTGGGAT  
ATGCTGTATTTTAAAGGGACAGTTTGTAACCTGGGCTGTAAAGCAAACCTGGGGCTGTGTTTTCGATGATGATGA  
TGATCATGATGATGATCATCATGATCATGATGATGATCATCATGATCATGATGATGATTTTAAAGTTTTACTT  
CTGGCCTTTCTAGCTAGAGAAGGAGTTAATATTTCTAAGGTAACCTCCCATATCTCCTTTAATGACATTGATTT  
CTAATGATATAAATTTTACGCTACATTGATGCCAAGCTTTTTTGCCACAAAGAAGATTCTTACCAAGAGTGGGC  
TTTGTGGAAACAGCTGGTACTGATGTTTACCTTTATATATGTACTAGCATTTTCCACGCTGATGTTTATGTACT  
GTAAACAGTTCTGCACTCTTGTACAAAAGAAAAACACCTGTCACATCCAAATATAAAA

7/136

**FIGURE 7**

ATGCAGCACCGAGGCTTCCTCCTCCTCACCTCCTCGCCCTGCTGGCGCTCACCTCCGCGGTGCCCCAAAAGAA  
AGATAAGGTGAAGAAGGGCGGCCCGGGGAGCGAGTGCGCTGAGTGGGCCTGGGGGCCCTGCACCCCAGCAGCA  
AGGATTGCGGCGTGGGTTTCCGCGAGGGCACCTGCGGGGCCAGACCCAGCGCATCCGGTGCAGGGTGCCCTGC  
AACTGGAAGAAGGAGTTTGGAGCCGACTGCAAGTACAAGTTTGAGAACTGGGGTGCGTGTGATGGGGGCACAGG  
CACCAAAGTCCGCCAAGGCACCCTGAAGAAGGCGCGCTACAATGCTCAGTGCCAGGAGACCATCCGCGTCACCA  
AGCCCTGCACCCCCAAGACCAAAGCAAAGGCCAAAGCCAAGAAAGGGAAGGGAAAGGACTTAGACGCCAAGCCTG  
GATGCCAAGGAGCCCCTGGTGTACATGGGGCCTGGCCCACGCCCTCCCTCTCCCAGGCCCCGAGATGTGACCCA  
CCAGTGCCTTCTGTCTGCTCGTTAGCTTTAATCAATCATGCCCC



8/136

**FIGURE 8**

GCGGCAGCAGCGCGGGCCCCAGCAGCCTCGGCAGCCACAGCCGCTGCAGCCGGGGCAGCCTCCGCTGCTGTGCGC  
CTCCTCTGATGCGCTTGCCCTCTCCCGGCCCCGGGACTCCGGGAGAAATGTGGGTCCCTAGGCATCGCGGCAACTT  
TTTGCGGATTGTTCTTGCTTCCAGGCTTTGCGCTGCAAATCCAGTGCTACCAGTGTGAAGAATTCCAGCTGAAC  
AACGACTGCTCCTCCCCGAGTTCATTGTGAATTGCACGGTGAACGTTCAAGACATGTGTCAGAAAGAAGTGAT  
GGAGCAAAGTGCCGGGATCATGTACCGCAAGTCCTGTGCATCATCAGCGGCCTGTCTCATCGCCTCTGCCGGGT  
ACCAGTCCTTCTGCTCCCCAGGGAAACTGAACTCAGTTTGCATCAGCTGCTGCAACACCCCTCTTTGTAACGGG  
CCAAGGCCCAAGAAAAGGGGAAGTTCTGCCTCGGCCCTCAGGCCAGGGCTCCGCACCACCATCCTGTTCCCTCAA  
ATTAGCCCTCTTCTCGGCACACTGCTTGAAGCTGAAGGAGATGCCACCCCTCCTGCATTGTTCTTCCAGCCCTC  
GCCCCCAACCCCCACCTCCCTGAGTGAGTTTCTTCTGGGTGTCCTTTTATTCTGGGTAGGGAGCGGGAGTCCG  
TGTTCTCTTTTGTTCCTGTGCAAATAATGAAAGAGCTCGGTAAAGCATTCTGAATAAATTACAGCCTGACTGAAT  
TTTCAGTATGTACTTGAAGGAAGGAGGTGGAGTGAAAGTTCACCCCATGTCTGTGTAACCGGAGTCAAGGCCA  
GGCTGGCAGAGTCAGTCCTTAGAAGTCACTGAGGTGGGCATCTGCCTTTTGTAAGCCTCCAGTGTCATTCCTCA  
TCCCTGATGGGGGCATAGTTTGAGACTGCAGAGTGAGAGTGACGTTTCTTAGGGCTGGAGGGCCAGTCCCAC  
TCAAGGCTCCCTCGCTTGACATTCAAAC TTCATGCTCCTGAAAACCATTCCTCTGCAGCAGAATTGGCTGGTTTC  
GCGCCTGAGTTGGGCTCTAGTGACTCGAGACTCAATGACTGGGACTTAGACTGGGGCTCGGCCTCGCTCTGAAA  
AGTGCTTAAGAAAATCTTCTCAGTTCTCCTTGCAAGGACTGGCGCCGGGACGCGAAGAGCAACGGGCGCTGCA  
CAAAGCGGGCGCTGTGCGGTGGTGGAGTGCGCATGTACGCGCAGGCGCTTCTCGTGGTTGGCGTGCTGCAGCGAC  
AGGCGGCAGCACAGCACCTGCACGAACACCCGCCGAAACTGCTGCGAGGACACCGTGTACAGGAGCGGGTTGAT  
GACCGAGCTGAGGTAGAAAAACGTCTCCGAGAAGGGGAGGAGGATCATGTACGCCCGGAAGTAGGACCTCGTCC  
AGTCGTGCTTGGGTTTGGCCGCAGCCATGATCCTCCGAATCTGGTTGGGCATCCAGCATACGGCCAATGTCACA  
ACAATCAGCCCTGGGCAGACACGAGCAGGAGGGAGAGACAGAGA

9/136

**FIGURE 9**

CACCCTCCGTGGCAAGGCGAGGCCCGGGGGCGGGGCCGGGGTCACCACGCCTGCCCCAGGGAACCGCACAGACG  
GTACTCACCCTTCTTGCGATGATGTGAGATGATAAAATGCCTACATGATGAGATGAAGTGAGATGAAAAACATA  
GGCCTTGATGGAATGGGAAATTCCAGAGATAATTTGCACGTGCGCTAAGCTGCGGCTACCCCCGCAAGCAAC  
CTTCCAAGTCCTTCGTGGCAATGGTGCTTCCGTGGGGACCGTGCTCATGTTCCGCTGCCCCCTCCAACCACCAGA  
TGGTGGGGTCTGGGCTCCTCACCTGCACCTGGAAGGGGAGCATCGCTGAGTGGTCTTCAGGGTCCCCAGTGTGC  
AAACTGGTGCCACCACACGAGACCTTTGGCTTCAAGGTGGCCGTGATCGCCTCCATTGTGAGCTGTGCCATCAT  
CCTGCTCATGTCCATGGCCTTCCTCACCTGCTGCCTCCTCAAGTGCGTGAAGAAGAGCAAGCGGCGGCGCTCCA  
ACAGGTCAGCCCAGCTGTGGTCCCAGCTGAAAGATGAGGACTTGGAGACGGTGCAGGCCGCATACCTTGGCCTC  
AAGCACTTCAACAAACCCGTGAGCGGGCCCAGCCAGGCGCACGACAACCACAGCTTCACCACAGACCATGGTGA  
GAGCACCAGCAAGCTGGCCAGTGTGACCCGCAGCGTGGACAAGGACCCTGGGATCCCCAGAGCTCTAAGCCTCA  
GTGGCTCCTCCAGCTCACCCCAAGCCCAGGTGATGGTGCACATGGCAAACCCAGACAGCCCCTGCCTGCCTCT  
GGGCTGGCCACAGGAATGCCACAACAGCCCGCAGCATATGCCCTAGGGTCAACCACGCAGTGAGGCTGGTGCCCA  
TGCTCCACACTGGGAGGCCAGGCTGACCCCAACAGCCAGTCAGCTACAACCTCCACATCAACTCCACATGCGCCC  
AGCTCGAGACTGATGAGTGGAATCAGCTTCCAGGTGTAGGGACCCCTTGAGGGGCCGAGCTGACATCCAAGGCT  
GAGGACCCCAAGTGGGGAGTGTCTGTTCGGCATATCCTGGCCGTAACGATTTTTATAGTTATGGACTACTTGA  
AACCCTACTGAGGGTAATTTACTAGCTGTGGCCTCCCACTAACTAGCATTCCTTTAAAGAGACTGGGAAATGT  
TTAAGCAAATCTAGTTTTGTATAATAAAATAAGAAAATAGCAATAAACTTCTTTTCAGCAACTACAAA

10/136

**FIGURE 10A**

CTGACTGCACTGGTGTGGTCCCTGGCAATCCAACCTGGCACCATCGCAGTTGGAGTACTATGCATCTTCACCA  
GATGAAAAGGCTCTAGTAGAAGCTGCTGCAAGGATTGGTATTGTGTTTATTGGCAATTCTGAAGAACTATGGA  
GGTTAAACTCTTGGAAACTGGAACGGTACAACTGCTTCATATTCTGGAATTTGATTTCAGATCGTAGGAGAA  
TGAGTGTAATTGTTTCAGGCACCTTCAGGTGAGAAGTTATTATTTGCTAAAGGAGCTGAGTCATCAATTCTCCCT  
AAATGTATAGGTGGAGAAATAGAAAAACCAGAATTCATGTAGATGAATTTGCTTTGAAAGGGCTAAGAACTCT  
GTGTATAGCATATAGAAAATTTACATCAAAAGAGTATGAGGAAATAGATAAACGCATATTTGAAGCCAGGACTG  
CCTTGACAGCAGCGGGAAGAGAAATTGGCAGCTGTTTTCCAGTTCATAGAGAAAGACCTGATATTACTTGGAGCC  
ACAGCAGTAGAAGACAGACTACAAGATAAAGTTTCAGAAACTATTGAAGCATTGAGAATGGCTGGTATCAAAGT  
ATGGGTACTTACTGGGGATAAACATGAAACAGCTGTTAGTGTGAGTTTATCATGTGGCCATTTTCATAGAACCA  
TGAACATCCTTGAACCTTATAAACAGAAATCAGACAGCGAGTGTGCTGAACAATTGAGGCAGCTTGCCAGAAGA  
ATTACAGAGGATCATGTGATTCAGCATGGGCTGGTAGTGGATGGGACCAGCCTATCTCTTGCACCTCAGGGAGCA  
TGAAAACTATTTATGGAAGTTTGCAGAAATGTTTCAGCTGTATTATGCTGTCTGATGGCTCCACTGCAGAAAG  
CAAAAGTAATAAGACTAATAAAAAATATCCCTGAGAAACCTATAACATTGGCTGTTGGTGTATGGTGTAAATGAC  
GTAAGCATGATACAAGAAGCCCATGTTGGCATGGAATCATGGGTAAAGAAGGAAGACAGGCTGCAAGAAACAG  
TGACTATGCAATGACAGATTTAAGTTCCTCTCCAAATTGCTTTTTTGTTCATGGTCATTTTTATTATATTAGAA  
TAGCTACCCCTGTACAGTATTTTTTTTATAAGAATGTGTGCTTTATCACACCCAGTTTTTATATCAGTTCTAC  
TGTTTGTCTCTCAGCAAAACATTGTATGACAGCGTGACCTGACTTTATAACAATATTTGTTTTACTTCCCTACC  
TATTCTGATATATAGTCTTTTGGAAACAGCATGTAGACCCTCATGTGTACAAAATAAGCCCACCCCTTTATCGAG  
ACATTAGTAAAAACCGCCTCTTAAGTATTAACATTTCTTTATTGGACCATCCTGGGCTTCAGTCATGCCCTTT  
ATTTTCTTTTTTGGATCCTATTTACTAATAGGGAAAGATACATCTCTGCTTGGAAATGGCCAGATGTTTGGAAA  
CTGGACATTTGGCACTTTGGTCTTCACAGTCATGGTTATTACAGTCACAGTAAAGATGGCTCTGGAACTCATT  
TTTGGACTTGGATCAACCATCTCGTTACCTGGGGATCTATTATATTTTTATTTTGTATTTTCTTGTTTTATGGA  
GGGATTCTCTGGCCATTTTTTGGGCTCCAGAAATATGTATTTTGTGTTTATTCAGCTCCTGTCAAGTGGTCTGC  
TTGGTTTGCCATAATCCTCATGGTTGTTACATGTCTATTTCTTGATATCATAAAGAAGGTCTTTGACCGACACC  
TCCACCCTACAAGTACTGAAAAGGCACAGCTTACTGAAACAAATGCAGGTATCAAGTGCTTGGACTCCATGTGC  
TGTTTCCCGGAAGGAGAAGCAGCGTGTGCATCTGTTGGAAGAATGCTGGAACGAGTTATAGGAAGATGTAGTCC  
AACCACATCAGCAGATCATGGAGTGCATCGGATCCTTTCTATACCAACGACAGGACATCTTGACTCTCTCCA  
CAATGGACTCATCTACTTGTTAAAGGGGCGAGTAGTACTTTGTGGGAGCCAGTTCACCTCTTCTAAAAATTC  
GTGTGATCACCCCTGTTAATGGCCACACTAGCTCTGAAATTAATTTCCAAAATCTTTGTAGTAGTTCATACCCAC  
TCAGATTATAATGGCAAACAAACAGAAAGCATTAGTACAAAGCCCTCCCAACACCCCTTAATTTGAATCTGAAC  
ATGTTAAAAATTTGAGAATAAAGAGACATTTTTTCATCTCTTTGTCTGGTTTGTCCCTTGTGCTTATGGGACTCCT  
AATGGCATTTCAGTCTGTTGCTGAGGCCATTATATTTTAATATAAATGTAGAAAAAGAGAGAAATCTTAGTAA  
AGAGTATTTTTTAGTATTAGCTTGATTATTGACTCTTCTATTTAAATCTGCTTCTGTAAATTATGCTGAAAGTT  
TGCCTTGAGAACTCTATTTTTTTATTAGAGTTATATTTAAAGCTTTTCATGGGAAAAGTTAATGTGAATACTGA  
GGAATTTTGGTCCCTCAGTGACCTGTGTTGTTAATTCATTAATGCATTCTGAGTTCACAGAGCAAATTAGGAGA  
ATCATTTCACCAACCATTTATTACTGCAGTATGGGGAGTAAATTTATACCAATTCCTCTAACTGTACTGTAACACA  
GCCTGTAAAGTTAGCCATATAAATGCAAGGGTATATCATATATACAAATCAGGAATCAGGTCCGTTCCACCGAAC  
TTCAAATTGATGTTTACTAATATTTTTGTGACAGAGTATAAAGACCCTATAGTGGGTAAATTAGATACTATTAG  
CATATTATTAATTTAATGTCTTTATCATTGGATCTTTTGCATGCTTTAATCTGGTTAACATATTTAAATTTGCT  
TTTTTTCTCTTTACCTGAAGGCTCTGTGTATAGTATTTTCATGACATCGTTGTACAGTTTAACTATCAATAAAAA  
GTTTGGACAGTATTTAAATATTGCAAATATGTTTAATTATACAAATCAGAATAGTATGGGTAATTAATGAATA  
CAAAAAGAAGAGCCTCTTTCTGCAGCCGACTTAGACATGCTCTTCCCTTTCTATAAGCTAGATTTTAGAATAAA  
GGGTTTCAGTTAATAATCTTATTTTCAGGTTATGTCATCTAACTTATAGCAAACCTACCACAATCAGTGAGTTT  
TGCCAGTGTCCAGTACAAGGCATATTTTCAGGTGTGGCTGTGGAATGTAAAAATGCTCAACTTGATTCAGGTAA  
TGTTAGCAATAAATTAATGCTAAGAATGATTAATCGGGTACATGTTACTGTAATTAACCTATTGCACCTTCAAA  
ACCTAACTTCCATCCTGAATTTATCAAGTAGTTAGTATGTCATTTGTTTTGTTTTTATTGAAAAGTAATGTT  
GTCTTAAGATTTAGAAGTGATTATTAGCTTGAGAACTATTACCCAGCTCTAAGCAAATAATGATTGTATACATA  
TTAAGATAATGGTTAAATGCGGTTTTACCAAGTTTTCCCTTGAAAATGTAATTCCTTTATGGAGATTTATTGTG  
CAGCCCTAAGCTTCCCTCCCATTTTCATGAATATAAGGCTTCTAGAATTGGACTGGCAGGGGAAAGAAATGGTAGA  
GACAGAAATTAAGACTTTATCCTTGTGTTGCTTGTAACTATTATTTTCTTGCTAATGTAACATTTGTCTGTTCC  
AGTGATGTAAGGATATTAAGTTATTAAGCTAAATATTAATTTTCAAAAATAGTCTTCTTAACTTAGATATTT  
CATAGCTGGATTTAGGAAGATCTGTTATTCTGGAAGTACTAAAAAGAATAATACAACGTACAATGTCTGCATTC  
ACTAATTCATGTTCCAGAAGAGGAAATAATGAAGATATACTCAGTAGAGTACTAGGTGGGAGGATATGGAAATT  
TGCTCATAAAATCTCTTATAAAACGTGCATATAACAAAATGACACCCAGTAGGCCTGCATTACATTTACATGAC

11/136

**FIGURE 10B**

CGTGTTTATTTGCCATCAAATAAACTGAGTACTGACACCAGACAAAGACTCCAAAGTCATAAAATAGCCTATGA  
CCAAGTGCAGCAAGACAGGAGGTCAGCTCGCCTATAATGGTGCTTAAAGTGTGATTGATGTAATTTTCTGTACT  
CACCATTTGAAGTTAGTTAAGGAGAAGTTTATTTTTTTTAAAAAAGTAAATGGCAACCACTAGTGTGCTCATCC  
TGAAGTGTACTCCAAATCCACTCCGTTTTTAAAGCAAATTTATCTTGTGATTTTAAAGAAAAGAGTTTTCTATT  
TATTTAAGAAAAGTAACAATGCAGTCTGCAAGCTTTCAGTAGTTTTCTAGTGCTATATTCATCCTGTAAAACCTCT  
TACTACGTAACCAAGTAATCACAAGGAAAGTGTCCCTTTGCATATTTCTTTAAAATTCCTTCTTTGGAAAGTAT  
GATGTTGATAATTAACCTACCCTTATCTGCCAAAACCAAGAGCAAAATGCTAAATACGTTATTGCTAATCAGTGG  
TCTCAAATCGATTTGCCTCCCTTTGCCTCGTCTGAGGGCTGTAAGCCTGAAGATAGTGGCAAGCACCAAGTCAG  
TTTCCAAAATTGCCCCCTCAGCTGCTTTAAGTGACTCAGCACCTGCCTCAGCTTCAGCAGGCGTAGGCTCACCC  
TGGGCGGAGCAAAGTATGGGCCAGGGAGAACTACAGCTACGAAGACCTGCTGTCGAGTTGAGAAAAGGGGAGAA  
TTTATGGTCTGAATTTTCTAACTGTCTCTTCTTGGGTCTAAAGCTCATAATACACAAAGGCTTCCAGACCTG  
AGCCACACCCAGGCCCTATCCTGAACAGGAGACTAAACAGAGGCAAATCAACCTAGGAAATACTTGCATTCTG  
CCCTACGGTTAGTACCAGGACTGAGGTCATTTCTACTGGAAAAGATTGTGAGATTGAACTTATCTGATCGCTTG  
AGACTCCTAATAGGCAGGAGTCAAGGCCACTAGAAAATTGACAGTTAAGAGCCAAAAGTTTTTAAATATGCTA  
CTCTGAAAAATCTCGTGAAGGCTGTAGGAAAAGGGAGAACTTCCATGTTGGTGTTTTTCTGTAAAGATCAGT  
TTGGGGTATGATATAAGCAGGTATTAATAAAAAATAACACACCAAAGAGTTACGTAAAACATGTTTTATTAATTT  
TGGTCCCCACGTACAGACATTTTATTTCTATTTTGAAATGAGTTATCTATTTTCATAAAAGTAAAACACTATTA  
AAGTGCTGTTTTATGTGAAATAACTTGAATGTTGTTCCCTATAAAAAATAGATCATAACTCATGATATGTTTGTA  
ATCATGGTAATTTAGATTTTTATGAGGAATGAGTATCTGGAAATATTGTAGCAATACTGGTTTTAAATTTTGG  
ACCTGAGACACTGTGGCTGTCTAATGTAATCCTTTAAAAATTCTCTGCATTGTCAGTAAATGTAGTATATTATT  
GTACAGCTACTCATAATTTTTTAAAGTTTATGAAGTTATATTTATCAAATAAAAACCTTTCCTATAT

12/136

**FIGURE 11A**

ATGTGGGAAGAAGAAGACATTGCTATTCTGTTCAATAAAGAACCAGGAAAAACAGAGAATATTGAAAATAATCT  
AAGTTCCAACCATAGAAGAAGCTGCAGAAGAAGTGAAGAAAGTGATGATGATTTGGATTTTGATATTGGTTTAG  
AAAACACAGGAGGAGACCCTCAAATTTCTGAGATTTATTTTCAGACTTCCTTGCTTTTTTGGTTCTCTACAATTTT  
ATCATTCCAATTTTATTATATGTGACAGTCGAAATGCAGAAATTTCTTGATCATTTTTTATTGGCTGGGATCT  
TGATCTGTATCATGAAGAATCAGATCAGAAAGCTCAAGTCAATACTTCCGATCTGAATGAAGAGCTTGGACAGG  
TAGAGTACGTGTTTACAGATAAACTGGTACACTGCAGAAAAATGAGATGCAGTTTCGGGAATGTTCAATTAAT  
GGCATGAAATACCAAGAAATTAATGGTAGACTTGTACCCGAAGGACCAACACCAGACTCTTCAGAAGGAACTT  
ATCTTATCTTAGTAGTTTATCCCATCTTAACAACCTATCCCATCTTACAACCAGTTCCTCTTCAGAACCAGTC  
CTGAAAATGAACTGAACTAATTAAGAACATGATCTCTTCTTTAAAGCAGTCAGTCTCTGTACACTGTACAG  
ATTAGCAATGTTCAAACCTGACTGCACTGGTGATGGTCCCTGGCAATCCAACCTGGCACCATCGCAGTTGGAGTA  
CTATGCATCTTCACCAGATGAAAAGGCTCTAGTAGAAGCTGCTGCAAGGTACAACTGCTTCATATTCTGGAAT  
TTGATTCAGATCGTAGGAGAATGAGTGTAATTGTTTCAGGCACCTTCAGGTGAGAAGTTATTATTTGTAAAGGA  
GCTGAGTCATCAATTTCTCCCTAAATGTATAGGTGGAGAAATAGAAAAACCAGAATTCATGTAGATGAATTTGC  
TTTGAAAGGGCTAAGAACTCTGTGTATAGCATATAGAAAATTTACATCAAAAGAGTATGAGGAAATAGATAAAC  
GCATATTTGAAGCCAGGACTGCCTTGCAGCAGCGGGAAGAGAAATTTGGCAGCTGTTTTCCAGTTCATAGAGAAA  
GACCTGATATTACTTGGAGCCACAGCAGTAGAAGACAGACTACAAGATAAAAGTTCGAGAACTATTGAAGCATT  
GAGAATGGCTGGTATCAAAGTATGGGTACTTACTGGGGATAAACATGAAACAGCTGTTAGTGTGAGTTTATCAT  
GTGGCCATTTTCATAGAACCATGAACATCCTTGAACCTATAAACAGAAATCAGACAGCGAGTGTGCTGAACAA  
TTGAGGCAGCTTGCCAGAAGAATTACAGAGGATCATGTGATTCAGCATGGGCTGGTAGTGGATGGGACCAGCCT  
ATCTCTTGCACTCAGGGAGCATGAAAACTATTTATGGAAGTTTGCAGAAATTTGTTTCAGCTGTATTATGCTGTC  
GTATGGCTCCACTGCAGAAAGCAAAAGTAATAAGACTAATAAAAATATCACCTGAGAAACCTATAACATTGGCT  
GTTGGTGATGGTGCTAATGACGTAAGCATGATACAAGAAGCCCATGTTGGCATAGGAATCATGGGTAAAGAAGG  
AAGACAGGCTGCAAGAAACAGTGACTATGCAATAGCCAGATTTAAGTTCCTCTCCAAATTGCTTTTTTGTTCATG  
GTCATTTTTTATTATATTAGAATAGCTACCCTTGTACAGTATTTTTTTTTATAAGAATGTGTGCTTTATCACACCC  
CAGTTTTTATATCAGTTCTACTGTTTTGTTTTCTCAGCAACATTTGTATGACAGCGTGACCTGACTTTATACAA  
TATTTGTTTTACTTCCCTACCTATTCTGATATATAGTCTTTTGGAACAGCATGTAGACCCTCATGTGTTACAAA  
ATAAGCCCACCCTTTATCGAGACATTAGTAAAAACCGCCTCTTAAGTATTAACAATTTCTTTATTGGACCATC  
CTGGGCTTCAGTCATGCCTTTATTTTCTTTTTTGGATCCTATTTACTAATAGGGAAGATACATCTCTGCTTGG  
AAATGGCCAGATGTTTGGAACTGGACATTTGGCACTTTGGTCTTCACAGTCATGGTTATTACAGTCACAGTAA  
AGATGGCTCTGGAACTCATTTTGGACTTTGGACTCAACCATCTCGTTACCTGGGGATCTATTATATTTTTATTTT  
GTATTTCTCTGTTTTATGGAGGGATTCTCTGGCCATTTTGGGCTCCCAGAATATGTATTTTGTGTTTTATTCA  
GCTCCTGTCAAGTGGTTCTGCTTGGTTTGGCATAATCCTCATGGTTGTTACATGTCTATTTCTTGATATCATAA  
AGAAGGTCTTTGACCGACACCTCCACCCTACAAGTACTGAAAAGGCACAGCTTACTGAAACAAATGCAGGTATC  
AAGTGCTTGGACTCCATGTGCTGTTTCCCGGAAGGAGAAGCAGCGTGTGCATCTGTTGGAAGAATGCTGGAACG  
AGTTATAGGAAGATGTAGTCCAACCCACATCAGCAGATCATGGAGTGCATCGGATCCTTTCTATACCAACGACA  
GGAGCATCTTGACTCTCTCCACAATGGACTCATCTACTTGTTAAAGGGGCAGTAGTACTTTGTGGGAGCCAGTT  
CACCTCCTTTCTTAAATTCAGTGTGATCACCTGTAAATGGCCACACTAGCTCTGAAATTAATTTCCAAAATC  
TTTGTAGTAGTTTCATACCCACTCAGAGTTATAATGGCAAACAAACAGAAAGCATTAGTACAAGCCCCCTCCCAAC  
ACCCTTAATTTGAATCTGAACATGTTAAATTTGAGAATAAAGAGACATTTTTTCATCTCTTTGTCTGGTTTGTG  
CCTTGTGCTTATGGGACTCCTAATGGCATTTCAGTCTGTTGCTGAGGCCATTATATTTTAATATAAATGTAGAA  
AAAAGAGAGAAATCTTAGTAAAGAGTATTTTTTAGTATTAGCTTGATATTGACTCTTCTATTTAAATCTGCTT  
CTGTAAATTATGCTGAAAGTTTGCCTTGAGAACTCTATTTTTTTATTAGAGTTATATTTAAAGCTTTTCATGGG  
AAAAGTTAATGTGAATACTGAGGAATTTTGGTCCCTCAGTGACCTGTGTTGTTAATTCATTAATGCATTCTGAG  
TTCACAGAGCAAATAGGAGAATCATTTCCAACCATTTTACTGCAGTATGGGGAGTAAATTTATACCAATTC  
CTCTAACTGTACTGTAACACAGCCTGTAAAGTTAGCCATATAAATGCAAGGGTATATATACAAATCAGG  
AATCAGGTCCGTTACCGAACTTCAAATTGATGTTTACTAATATTTTGTGACAGAGTATAAAGACCCCTATAGT  
GGGTAAATTAGATACTATTAGCATATTATTAATTTAATGTCTTTATCATTGGATCTTTTGCATGCTTTAATCTG  
GTTAACATATTAAATTTGCTTTTTTTCTCTTACCTGAAGGCTCTGTGTATAGTATTTTCATGACATCGTTGTA  
CAGTTTAACATATCAATAAAAAAGTTTGGACAGTATTTAAATATTGCAAATATGTTTAATTATACAAATCAGAATA  
GTATGGGTAAATTAATGAATACAAAAGAAGAGCCTCTTTCTGCAGCCGACTTAGACATGCTCTTCCCTTTCTA  
TAAGCTAGATTTTAGAATAAAGGGTTTCAGTTAATAATCTTATTTTCAGGTTATGTCATCTAACTTATAGCAAA  
CTACCACAATACAGTGAGTTCTGCCAGTGTCCAGTACAAGGCATATTTTCAGGTGTGGCTGTGGAATGTAAAAA  
TGCTCAACTTGATCAGGTAATGTTAGCAATAAATTAATGCTAAGAATGATTAATCGGGTACATGTTACTGTA  
ATTAACCTCATTGCACTTCAAAACCTAACTCCATCCTGAATTTATCAAGTAGTTCAGTATTGTCATTTGTTTTT

13/136

**FIGURE 11B**

GTGTTTATTGAAAAGTAATGTTGTCTTAAGATTTAGAAAGTGATTATTAGCTTGAGAACTATTACCCAGCTCTAAG  
CAAATAATGATTGTATACATATTAAGATAATGGTTAAATGCGGTTTTACCAAGTTTTCCCTTGAAAAATGTAATT  
CCTTTATGGAGATTTATTGTGCAGCCCTAAGCTTCCTTCCCATTTTCATGAATATAAGGCTTCTAGAATTGGACT  
GGCAGGGGAAAGAATGGTAGAGACAGAAATTAAGACTTTATCCTTGTTTGCTTGTAACCTATTATTTTCTTGCT  
AATGTAACATTTGTCTGTTCCAGTGATGTAAGGATATTAAGTTATTAAGCTAAATATTAATTTTCAAAAATAGT  
CCTTCTTTAACTTAGATATTTTCATAGCTGGATTTAGGAAGATCTGTTATTCTGGAAGTACTAAAAAGAATAATA  
CAACGTACAATGTCTGCATTCACTAATTCATGTTCCAGAAGAGGAAATAATGAAGATATACTCAGTAGAGTACT  
AGGTGGGAGGATATGGAAATTTGCTCATAAAATCTCTTATAAAACGTGCATATAACAAAATGACACCCAGTAGG  
CCTGCATTACATTTACATGACCGTGTTTATTTGCCATCAAATAAACTGAGTACTGACACCAGACAAAGACTCCA  
AAGTCATAAAATAGCCTATGACCAACTGCAGCAAGACAGGAGGTCAGCTCGCCTATAATGGTGCTTAAAGTGTTG  
ATTGATGTAATTTTCTGTACTCACCATTTGAAGTTAGTTAAGGAGAACTTTATTTTTTTAAAAAAGTAAATGG  
CAACCACTAGTGTGCTCATCCTGAAGTGTACTCCAAATCCACTCCGTTTTTAAAGCAAAATATCTTGTGATT  
TTAAGAAAAGAGTTTTCTATTTATTTAAGAAAGTAACAATGCAGTCTGCAAGCTTTCAGTAGTTTTCTAGTGCT  
ATATTCATCCTGTAAAACCTTTACTACGTAACCAGTAATCACAAGGAAAGTGTCCTTTTGCATATTTCTTTAA  
AATTCCTTCTTTGGAAAGTATGATGTTGATAATTAACCTTACCCTTATCTGCCAAAACAGAGCAAAATGCTAAA  
TACGTTATTGCTAATCAGTGGTCTCAAATCGATTTGCCTCCCTTTGCCTCGTCTGAGGGCTGTAAGCCTGAAGA  
TAGTGGCAAGCACCAGTCAGTTTCCAAAATTGCCCCCTCAGCTGCTTTAAGTGACTCAGCACCCCTGCCTCAGCT  
TCAGCAGGCGTAGGCTCACCCCTGGGCGGAGCAAAGTATGGGCCAGGGAGAACTACAGCTACGAAGACCTGCTGT  
CGAGTTGAGAAAAGGGGAGAATTTATGGTCTGAATTTTCTAACTGTCTCTTTCTTGGGTCTAAAGCTCATAAT  
ACACAAAGGCTTCCAGACCTGAGCCACACCCAGGCCCTATCCTGAACAGGAGACTAAACAGAGGCAAATCAACC  
CTAGGAAATACTTGCATTCTGCCCTACGGTTAGTACCAGGACTGAGGTCATTTCTACTGGAAAAGATTGTGAGA  
TTGAACTTATCTGATCGCTTGAGACTCCTAATAGGCAGGAGTCAAGGCCACTAGAAAATTGACAGTTAAGAGCC  
AAAAGTTTTTAAAATATGCTACTCTGAAAAATCTCGTGAAGGCTGTAGGAAAAGGGAGAATCTTCCATGTTGGT  
GTTTTTCCTGTAAAGATCAGTTTGGGGTATGATATAAGCAGGTATTAATAAAAAATAACACACCAAAGAGTTACG  
TAAAACATGTTTTATTAATTTTGGTCCCCACGTACAGACATTTTATTTCTATTTTGAAATGAGTTATCTATTTT  
CATAAAAGTAAAACACTATTAAAGTGCTGTTTTATGTGAAATAACTTGAATGTTGTTCCATAAAAAATAGATC  
ATAACTCATGATATGTTTGTAATCATGGTAATTTAGATTTTTATGAGGAATGAGTATCTGGAAATATTGTAGCA  
ATACTTGGTTTAAATTTTGGACCTGAGACACTGTGGCTGTCTAATGTAATCCTTTAAAATTCTCTGCATTGT  
CAGTAAATGTAGTATATTATTGTACAGCTACTCATAATTTTTTAAAGTTTATGAAGTTATATTTATCAAATAAA  
AACTTCCTATAT

14/136

**FIGURE 12**

GCACGAGGGCGCTTTTGTCTCCGGTGAGTTTTGTGGCGGGAAGCTTCTGCGCTGGTGCTTAGTAACCGACTTTC  
CTCCGGACTCCTGCACGACCTGCTCCTACAGCCGGCGATCCACTCCCGGCTGTTCCCCGGAGGGTCCAGAGGC  
CTTTCAGAAGGAGAAGGCAGCTCTGTTTCTCTGCAGAGGAGTAGGGTCCTTTCAGCCATGAAGCATGTGTTGAA  
CCTCTACCTGTTAGGTGTGGTACTGACCCTACTCTCCATCTTCGTTAGAGTGATGGAGTCCCTAGAAGGCTTAC  
TAGAGAGCCCATCGCCTGGGACCTCCTGGACCACCAGAAGCCAACCTAGCCAACACAGAGCCCACCAAGGGCCTT  
CCAGACCATCCATCCAGAAGCATGTTGATAAGACCTCCTTCCATACTGGCCATATTTTGGAACTGACCTAGAC  
ATGTCCAGATGGGAGTCCCATTCTAGCAGACAAGCTGAGCACCGTTGTAACCAGAGAACTATTACTAGGCCTT  
GAAGAACCTGTCTAACTGGATGCTCATTGCCTGGGCAAGGCCTGTTTAGGCCGGTTGCGGTGGCTCATGCCTGT  
AATCCTAGCACTTTGGGAGGCTGAGGTGGGTGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTCGCCAACAT  
GGCGAAACCCCATCTCTACTAAAAATACAAAAGTTAGCTGGGTGTGGTGGCAGAGGCCTGTAATCCCAGTTCCT  
TGGGAGGCTGAGGCGGGAGAATTGCTTGAACCCGGGGACGGAGGTTGCAGTGAACCGAGATCGCACTGCTGTAC  
CCAGCCTGGGCCACAGTGCAAGACTCCATCTCAAAAAAAAAAAGAAAAGAAAAGCCTGTTTAATGCACAGGTG  
TGAGTGGATTGCTTATGGCTATGAGATAGGTTGATCTCGCCCTTACCCCGGGGTCTGGTGTATGCTGTGCTTTC  
CTCAGCAGTATGGCTCTGACATCTCTTAGATGTCCCAACTTCAGCTGTTGGGAGATGGTGATATTTTCAACCCCT  
ACTTCCTAAACATCTGTCTGGGGTTCCTTTAGTCTTGAATGTCTTATGCTCAATTATTTGGTGTGAGCCTCTC  
TTCCACAAGAGCTCCTCCATGTTTGGATAGCAGTTGAAGAGGTTGTGTGGGTGGGCTGTTGGGAGTGAGGATGG  
AGTGTTCAGTGCCCATTTCTCATTTTACATTTTAAAGTCGTTCCCTCCAACATAGTGTGTATTGGTCTGAAGGGG  
GTGGTGGGATGCCAAAGCCTGCTCAAGTTATGGACATTGTGGCCACCATGTGGCTTAAATGATTTTTTCTAACT  
AATAAAGTGGAAATATATATTTCAAAAAAAAAAAAAAAAAA

15/136

**FIGURE 13**

ATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCTCGNGTCGACGGTATCGATAAGCTTGATATCGA  
ATTTCGGCCACACTGGCCGGATCCTCTAGAGATCCCTCGACCTCGACCCACGCGTCCGCCCACGCGTCCGATGTG  
CCTCTGGGCAAAGAAGCAGAGCTAACGAGGAAAGGGATTTAAAGAGTTTTTCTTGGGTGTTTGTCAAACTTTAA  
TTCCCTGTCTGTGTGCAGAGGGGATTCAACTTCAATTTTTCTGCAGTGGCTCTGAGTCCAGCCCCTTACTTAAA  
GATCTGGAAAGCATGAAAGACTGGGCTTTTTTTCCTATGTCTCTTGGGAAGTGCAGCTGCAATCCCGACAAATGC  
AAGATTATTATCTGATCATTCCAAACCAACTGCTGAAACGGTAGCACCCGACAACACTGCAATCCCCAGTTTAA  
GGGCTGAAGATGAAGAAAATGAAAAAGAAACAGCAGTATCCACAGAAGACGATTCCCACCATAAGGCTGAAAAA  
TCATCAGTACTAAAGTCAAAGAGGAAAGCCATGAACAGTCAGCAGAACAGGGCAAGAGTTCTAGCCAAGAGCT  
GGGATTGAAGGATCAAGANGACAGTGATGGTGACTTAAGTGTGAATTTGGAGTATGCACCAACTGAAGGTACAT  
TGGACATAAAAGAAGATATGAGTGAGCCTCAGGAGAAAACTCTCAGANACACTGATTTTTTGGGCTCCTGGGGT  
AGTTCCTTCCAGATTCTACCACAGAAGTTT



16/136

**FIGURE 14**

CGCGGGCCATGGCTCCCTGGGCGGAGGCCGAGCACTCGGCGCTGAACCCGCTGCGCGCGGTGTGGCTCACGCTG  
ACCGCCGCCTTCCTGCTGACCCTACTGCTGCAGCTCCTGCCGCCCCGGCCTGCTCCCGGGCTGCGCGATCTTCCA  
GGACCTGATCCGCTATGGGAAAACCAAGTGTGGGGAGCCGTCGCGCCCCGCCGCTGCCGAGCCTTTGATGTCC  
CCAAGAGATATTTTTCCCACTTTTATATCATCTCAGTGCTGTGGAATGGCTTCCTGCTTTGGTGCCTTACTCAA  
TCTCTGTTCCCTGGGAGCACCTTTTCCAAGCTGGCTTCATGGTTTGCTCAGAATTCTCGGGGCGGCACAGTTCCA  
GGGAGGGGAGCTGGCACTGTCTGCATTCTTAGTGCTAGTATTTCTGTGGCTGCACAGCTTACGAAGACTCTTCG  
AGTGCCCTCTACGTCAGTGTCTTCTCCAATGTCATGATTCACGTCGTGCAGTACTGTTTTGGACTTGTCTATTAT  
GTCCCTTGTTGGCCTAACTGTGCTGAGCCAAGTGCCAATGGATGGCAGGAATGCCTACATAACAGGGAAAAATCT  
ATTGATGCAAGCACGGTGGTTCCATATTCTTGGGATGATGATGTTTCATCTGGTCATCTGCCCATCAGTATAAGT  
GCCATGTTATTCTCGGCAATCTCAGGAAAAATAAAGCAGGAGTGGTCATTCACTGTAACCACAGGATCCCATTT  
GGAGACTGGTTTGAATATGTTTCTTCCCCTAACTACTTAGCAGAGCTGATGATCTACGTTTCCATGGCCGTCAC  
CTTTGGGTTCCACAACCTTAACTTGGTGGCTAGTGGTGACAAATGTCTTCTTTAATCAGGCCCTGTCTGCCTTTC  
TCAGCCACCAATTCTACAAAAGCAAATTTGTCTCTTACCCGAAGCATAGGAAAGCTTTCCTACCATTTTTGTTT  
TAAGTTAACCTCAGTCATGAAGAATGCAAACCAGGTGATGGTTTCAATGCCTAAGGACAGTGAAGTCTGGAGCC  
CAAAGTACAGTTTTCAGCAAAGCTGTTTGAACTCTCCATTCCATTTCTATACCCCAAGTTTTCACTGAATGA  
GCATGGCAGTGCCACTCAATAAAATGAATCTCCAAAGTATCTTCAAAGAATAAATACTAATGGCAAAAAAAAAAAAA

17/136

**FIGURE 15**

TCCACACACACAAAAAACCTGCGCGTGAGGGGGGAGGAAAAGCAGGGCCTTTAAAAAGGCAATCACAACTT  
TTGCTGCCAGGAATGCCCTTGCTTTGGCTGAGAGGATTTCTGTTGGCAAGTTGCTGGATTATAGTGAGGAGTTCC  
CCCACCCAGGATCCGAGGGGCACAGCGCGGCCCCGACTGTCCGTCTGTGCGCTGGCCGCCCTCCCAAAGGA  
TGTACCCAACTCTCAGCCAGAGATGGTGGAGGCCGTCAAGAAGCACATTTTAAACATGCTGCACCTGAAGAAGA  
GACCCGATGTCACCCAGCCGGTACCCAAGGCGGCGCTTCTGAACGCGATCAGAAAGCTTCATGTGGGCAAAGTC  
GGGGAGAACGGGTATGTGGAGATAGAGGATGACATTGGAAGGAGGGCAGAAATGAATGAACCTTATGGAGCAGAC  
CTCGGAGATCATCACGTTTGCCGAGTCAGGAACAGCCAGGAAGACGCTGCACTTCGAGATTTCCAAGGAAGGCA  
GTGACCTGTCAGTGGTGGAGCGTGCAGAACTCTGGCTCTTCCTAAAAGTCCCCAAGGCCAACAGGACCAGGACC  
AAAGTCACCATCCGCCTCTTCCAGCAGCAGAAGCACCCGCAGGGCAGCTTGGACACAGGGGAAGAGGCCGAGGA  
AGTGGGCTTAAAGGGGGAGAGGAGTGAACGTGTGCTCTCTGAAAAAGTAGTAGACGCTCGGAAGAGCACCTGGC  
ATGTCTTCCCTGTCTCCAGCAGCATCCAGCGGTTGCTGGACCAGGGCAAGAGCTCCCTGGACGTTCCGATTGCC  
TGTGAGCAGTGCCAGGAGAGTGGCGCCAGCTTGGTTCTCTGGGCAAGAAGAAGAAGAAGAGGAGGGGGGA  
AGGGAAAAAGAAGGGCGGAGGTGAAGGTGGGGCAGGAGCAGATGAGGAAAAGGAGCAGTCGCACAGACCTTTCC  
TCATGCTGCAGGCCCCGGCAGTCTGAAGACCACCCTCATCGCCGGCGTCGGCGGGGCTTGGAGTGTGATGGCAAG  
GTCAACATCTGCTGTAAGAAACAGTTCTTTGTCAAGGACATCGGCTGGAATGACTGGATCATTGCTCC  
CTCTGGCTATCATGCCAACTACTGCGAGGGTGAGTGCCCGAGCCATATAGCAGGCACGTCCGGGTCTCACTGT  
CCTTCCACTCAACAGTCATCAACCACTACCGCATGCGGGGCCATAGCCCCCTTTGCCAACCTCAAATCGTGCTGT  
GTGCCCACCAAGCTGAGACCCATGTCCATGTTGTACTATGATGATGGTCAAAACATCATCAAAAAGGACATTCA  
GAACATGATCGTGGAGGAGTGTGGGTGCTCATAGAGTTGCCCAGCCCAGGGGGAAGGGAGCAAGAGTTGTCCA  
GAGAAGACAGTGGCAAAATGAAGAAATTTTTAAGGTTTCTGAGTTAACCAGAAAAATAGAAATTAAAAACAAAA  
CAAAACAAAAAACAACAAAAAACAAGTAAATTAACAAACCTGATGAAACAGATGAAACAGATGA  
AGGAAGATGTGGAAATCTTAGCCTGCCTTAGCCAGGGCTCAGAGATGAAGCAGTGAAGAGACAGATTGGGAGGG  
AAAGGGAGAATGGTGTACCCTTTATTTCTTCTGAAATCACACTGATGACATCAGTTGTTTAAACGGGGTATTGT  
CCTTTCCCCCTTGAGGTTCCCTTGTGAGCTTGAATCAACCAATCTGATCTGCAGTAGTGTGGACTAGAACAAC  
CCAAATAGCATCTAGAAAGCCATGAGTTTGAAGGGGCCATCACAGGCACTTTCCTAGCCTAAT

18/136

FIGURE 16

[illegible]

19/136

**FIGURE 17A**

CGCTCGCCATGGGCCACTCCCCACCTGTCCTGCCTTTGTGTGCCTCTGTGTCTTTGCTGGGTGGCCTGACCTTT  
GGTTATGAACTGGCAGTCATATCAGGTGCCCTGCTGCCACTGCAGCTTGACTTTGGGCTAAGCTGCTTGAGACA  
GGAGTTCTGGTGGGCAGCCTGCTCCTGGGGGCTCTCCTCGCCTCCCTGGTTGGTGGCTTCCTCATTGACTGCT  
ATGGCAGGAAGCAAGCCATCCTCGGGAGCAACTTGGTGTGCTGGCAGGCAGCCTGACCCTGGGCCTGGCTGGT  
TCCCTGGCCTGGCTGGTCTGGGGCCGCGCTGTGGTTGGCTTCGCCATTCCCTCTCCTCCATGGCTTGCTGTAT  
CTACGTGTCAGAGCTGGTGGGGCCACGGCAGCGGGGAGTGCTGGTGTCCCTCTATGAGGCAGGCATCACCGTGG  
GCATCCTGCTCTCCTATGCCCTCAACTATGCACTGGCTGGTACCCCTGGGGATGGAGGCACATGTTGCGCTGG  
GCCACTGCACCTGCTGTCTGCAATCCCTCAGCCTCCTCTTCCCTCCCTGCTGGTACAGATGAGACTGCAACACA  
CAAGGACCTCATCCCCTCCAGGGAGGTGAGGCCCCCAAGCTGGGCCCGGGAGGCCACGGTACTCCTTTCTGG  
ACCTCTTCAGGGCACGCGATAACATGCGAGGGCCGACCACAGTGGGCCTGGGGCTGGTGTCTTCCAGCAACTA  
ACAGGGCAGCCCAACGTGCTGTGCTATGCCTCCACCATCTTCAGCTCCGTTGGTTTCCATGGGGGATCCTCAGC  
CGTGCTGGCCTCTGTGGGGCTTGGCGCAGTGAAGGTGGCAGCTACCCTGACCGCCATGGGGCTGGTGGACCGTG  
CAGGCCGAGGGCTCTGTTGCTAGCTGGCTGTGCCCTCATGGCCCTGTCCGTAGTGGCATAGGCATAGGCCTCGTCAGC  
TTTGCCGTGCCCATGGACTCAGGCCCAAGCTGTCTGGCTGTGCCAATGCCACCGGGCAGACAGGCCTCGTCAGC  
AGACTCTGGCCTGCTGCAGGACTCCTCTCTACCTCCCATTTCCAAGGACCAATGAGGACCAAAGGGAGCCAATCT  
TGTCCTACTGCTAAGAAAAACCAAGCCCCATCCAGATCTGGAGACCCCTCAGCCCTCCTCGGCTGGCCCTGAGC  
TCTGCCCTCCCTGGGGCCCCCTCTGCCGCTCGGGGGCATGCACTGCTGCGCTGGACCGCACTGCTGTGCCTGAT  
GGTCTTTGTGAGTGCCTTCTCCTTTGGGTTTGGGGCAGTGACCTGGCTTGTCTCAGCGAGATCTACCTGTGG  
AGATACGAGGAAGAGCCTTCGCCCTTCTGCAACAGCTTCAACTGGGCGGCCAACCTCTTCATCAGCCTCTCCTTC  
CTCGATCTCATTGGCACCATCGGCTTGTCTGGACCTTCCTGCTCTACGGAAGTACCGCTGTCTCGGCCTGGG  
CTTCATCTATTTATTTGTTCTGAAACAAAAGGCCAGTCGTTGGCAGAGATAGACCAGCAGTTCCAGAAGAGAC  
GGTTCACCCTGAGCTTTGGCCACAGGCAGAACTCCACTGGCATCCCGTACAGCCGCATCGAGATCTCTGCGGCC  
TCCTGAGGAATCCGTCTGCCTGGAAATCTGGAAGTGTGGCTTTGGCAGACCATCTCCAGCATCCTGCTTCCTA  
GGCCCCAGAGCACAAGTTCCAGCTGGTCTTTTGGGAGTGGCCCCCTGCCCCAAAGGTGGTCTGCTTTTGTGGG  
GTAAAAAGGATGAAAGTCTGAGAATGCCCAACTCTTCATTTTGAGTCTCAGGCCCTGAAGGTTCTGAGGATCT  
AGCTTCATGCCTCAGTTTCCCCATTGACTTGCACATCTCTGCAGTATTTATAAGAAGAATATTCTATGAAGTCT  
TTGTTGCACCATGGACTTTTCTCAAAGAATCTCAAGGTACCAATCCTGGCAGGAAGTCTCTCCCGATATCACC  
CCTAAATCCAAATGAGGATATCATCTTTTCTAATCTCTTTTTTCAACTGGCTGGGACATTTTCCGAAGGGGGAA  
GTCTCTTTTTTTTACTCTTATCATTTTTTTTTTTTGGAGGTGGAGTCTCATTCTGTGTTGCCCAGGCTGGCTGATCT  
TGGCTCACTGCAACCTCCACCTCCTGAGTTCAAGCGATTCTTGTGCCTCAGCCTCCTAAGCAGCTGGGACTACA  
GGCGCATGCAACCATACCCAGCTAATTTATTTTTTAGCAGAGATGGGGTTTCACTGTGTTGGCCAGGCTGGTCTGT  
GAACTCCTGAGCTCAAGTGATCCACCCACCTCAGCCTCCCAGAGTGCTAGGATTACAGGCCTTTTGACTCTTTT  
ATCTGAGTTTTATTGACCCCTCTAATTCTCTTACCCAGAATATTTATCCTTCACCAGCAACTCTGACTCTTTGA  
CGGGAGGCCTCAGTTCTAGTCTTGGTCTGCTGGTGTCTGCTGTAGGAATGACCACGGGCTCAGTTTCCCC  
ATTTGTATAATGGGAAGCCTGTACCAGGTATTCTTAAGATTTCTCCTGACTCCAGTGAGCTGGAATTTCTAAAT  
GCTGGTCTAGGAGCTGTCTCCAGGATGGTGCAGGATGGCTTTGCGGAAAGGAGATGGGTTTGGAGGCCAACAAA  
CCTGCTTGTCAATATTGCCTTTGCCTCTTGGCAGCCCTTGAAGTTGAGTAAATAACAACCTCCCTGAACCTCAGT  
TTCCTCATCTGCAGAATGGGGATAATTATGTCCCAGGGGTATATTTAGACCCTGTTTCCTTTTCCAGGAGGGTCCC  
CAGCTGGTCCAGGGCCTGGGAAATTTCTACTTATCCTCATACCCAGGTCCCTCCTTTGGACCCCTGTAAAGGGT  
CAGGGTGAATCAGATGGGGGACTGAGCAAGTAGCTATGACTGCAGATCATGTAAGGAAGGGACTGACAAGAAGC  
TCCCAGATGCTGGGGAGAAATGAAGAGCTAAAATAGATCCTAGGTGCTGGATGCTTTGTATCCATGCGTGCACA  
TATGGGTGCTGGCAGAGCCCCCAAGGACTCTGGCCTCTCGAGTTCTCCTATCTTCTCCATTCTAGATGCTTCCC  
TTGTATCCAGTGATGTGCTGGAGCTGGCTTTGCCAAGCTTGTGAGAGCTGGTTGCTACATTTTCAGGATTTTTTA  
CAAGTTGGTAAACACAGCCATTATAAAAAATTAATGATTTAAATTTATAATTAAGTAAATTACATTTAAACAA  
AAAAATTATACTCAAAATTCATTACTTAATTTTACTACCTGTTACTATTATCTGTGCTTTTGGAGGCTATTTCTA  
CATAGTAACTCTTATGGAGACCTAGGGGAGACACCGCGCATCTCTTCCGTATTCCCCCATCAATGACATCATGT  
TAGTCTTTGGTTGCTTAACTGGCTGTGGGGAGTGTTTTTGTATCACAAAGATTAGAGAGGACTACACATCAGGG  
CTTGATTTATGTTTGTGATTTTTCTAGACTGTGAGACATGCTGGATAAAATGTGAGTAATGCAAATTAAGCTT  
TAAAGTATGTCTTGTGTTGTAGCCAATACATGGTGTATAGCACCAAAAAATGGAGGGATTATTCTTCCAGTAGTT  
GAACACTGTCTCCGTTTTCAGCTGACAGCTGCTCAAATCATTTAAGAAGGAGTTCTGACATTCATTTTTCATTGT  
TTTACTTTTGTCTTCCCTCACTAGTGTAACAAAAATTTCAACCAGCATTCATGCCGAACCTATACCCATTCTTC  
AGTGCCTAGCTGTACAGTTATCAGGGATTTTTATTTGTAGTCTAATTTTGTCAAATCATGGCCAAATCGCAGTG  
ATAGTTGACTTTGGATACAAGGTTTGGCAAAAAAATAATTAACAAAATATTCTGTAAGAATCAATTGTCTA  
TATGGAATTTAGGATAAAGAATATTTACAATAAAGAATATTTACAATAAAGAGTTTATTATTATTTGTAAGTTG

20/136

**FIGURE 17B**

TGTGCAACAAACATACCCTTTATCTCTGTAAAATTTATACACACAAAAATTAACAAAAGATTCTGTAAGAATTA  
ATTGGCTATATGGAATTTAGGATAGAATATTTACAATAAAGAGTATTTACAATAAA

21/136

**FIGURE 18A**

GCTTCAGTCCCGCGACCGAAGCAGGGCGCGCAGCAGCGCTGAGTGCCCCGGAACGTGCGTCGCGCCCCCAGTGT  
CCGTCGCGTCCGCCGCGCCCCGGGCGGGGATGGGGCGGCCAGACTGAGCGCCGCACCCGCCATCCAGACCCGCC  
GGCCCTAGCCGCAGTCCCTCCAGCCGTGGCCCCAGCGCGCACGGGCGATGCGGAAGGCGACGTCCGGTGCCGCG  
GGGCTGCGTCTGCTGTTGCTGCTGCTGCTGCCGCTGCTAGGCAAAGTGGCATTGGGCCTCTACTTCTCGAGGGA  
TGCTTACTGGGAGAAGCTGTATGTGGACCAGGCGGCCGGCAGCCCTTGCTGTACGTCCATGCCCTGCGGGACG  
CCCCTGAGGAGGTGCCAGCTTCCGCCCTGGGCCAGCATCTCTACGGCACGTACCGCACXCGGCTGCATGAGAAC  
AACTGGATCTGCATCCAGGAGGACACCGGCCCTCCTCTACCTTAACCGGAGCCTGGACCATAGCTCCTGGGAGAA  
GCTCAGTGTCCGCAACCGCGGCTTTCCCTGCTCACCGTCTACCTCAAGGTCTTCTGTCCACCCACATCCCTTC  
GTGAGGGCGAGTGCCAGTGGCCAGGCTGTGCCCGCGTATACTTCTCCTTCTTCAACACCTCCTTTCCAGCCTGC  
AGCTCCCTCAAGCCCCGGGAGCTCTGCTTCCAGAGACAAGGCCCTCCTTCCGCATTCCGGGAGAACCAGCCCC  
AGGCACCTTCCACCAGTTCCGCCCTGCTGCCTGTGCAGTTCTTGTGCCCAACATCAGCGTGGCCTACAGGCTCC  
TGGAGGGTGAGGGTCTGCCCTTCCGCTGCGCCCCGGACAGCCTGGAGGTGAGCACGCGCTGGGCCCTGGACCGC  
GAGCAGCGGGAGAAGTACGAGCTGGTGGCCGTGTGCACCGTGCACGCCGCGCGCGCAGGAGGTGGTGTATGGT  
GCCCTTCCCGGTGACCGTGTACGACGAGGACGACTCGGCCGCCACCTTCCCGCGGGCGTGCACACCGCCAGCG  
CCGTGGTGGAGTTCAAGCGGAAGGAGGACACCGTGGTGGCCACGCTGCGTGTCTTCGATGCAGACGTGGTACCT  
GCATCAGGGGAGCTGGTGAGGCGGTACACAAGCACGCTGCTCCCCGGGGACACCTGGGCCAGCAGACCTTCCG  
GGTGAACACTGGCCCAACGAGACCTCGGTCCAGGCCAACGGCAGCTTCGTGCGGGCGACCGTACATGACTATA  
GGCTGGTTCTCAACCGGAACCTCTCCATCTCGGAGAACCGCACCATGCAGCTGGCGGTGCTGGTCAATGACTCA  
GACTTCCAGGGCCAGGAGCGGGCGTCCCTTGTCTCCACTTCAACGTGTGGTGTGCGGGTGCAGCTGCACCT  
GCCCAGTACCTACTCCCTCTCCGTGAGCAGGAGGGCTCGCCGATTTGCCAGATCGGGAAAGTCTGTGTGGAAA  
ACTGCCAGGCGTTCACTGGCATCAACGTCCAGTACAAGCTGCATTCTCTGGTGCCAACTGCAGCACGCTAGGG  
GTGGTCACCTCAGCCGAGGACACCTCGGGGATCCTGTTTGTGAATGACACCAAGGCCCTGCGGCGGCCCAAGTG  
TGCCGAACCTTCACTACATGGTGGTGGCCACCGACCAGCAGACCTCTAGGCAGGCCAGGCCAGCTGCTTGTA  
CAGTGGAGGGGTATATGTGGCCGAGGAGGCGGGCTGCCCCCTGTCTGTGCAGTCAGCAAGAGACGGCTGGAG  
TGTGAGGAGTGTGGCGGCCCTGGGCTCCCCAACAGGCAGGTGTGAGTGGAGGCAAGGAGATGGCAAAGGGATCAC  
CAGGAACCTTCTCCACCTGCTCTCCCAGCACCAAGACCTGCCCCGACGGCCACTGCGATGTTGTGGAGACCCAAG  
ACATCAACATTTGCCCTCAGGACTGCCTCCGGGGCAGCATTGTTGGGGGACACGAGCCTGGGGAGCCCCGGGGG  
ATTAAAGCTGGCTATGGCACCTGCAACTGCTTCCCTGAGGAGGAGAAGTGCTTCTGCGAGCCCCGAAGACATCCA  
GGATCCACTGTGCGACGAGCTGTGCCGCACGGTGATCGCAGCCGCTGTCTCTTCTCCTTCACTCGTCTCGGTGC  
TGCTGTCTGCCCTTCTGCATCCACTGCTACCACAAGTTTGCCCAAGCCACCCATCTCCTCAGCTGAGATGACC  
TTCCGGAGGCCCGCCAGGCCCTTCCCGGTGCTGCTTCCCTGCTTCCGGTGCCCGCGGGCCCTCGCTGGACTCCAT  
GGAGAACCAGGTCTCCGTGGATGCCTTCAAGATCCTGGAGGATCCAAAGTGGGAATTCCTCGGAAGAAGTGG  
TTCTTGGAAGAACTCTAGGAGAAGGCCAATTTGGAAGAGTGGTCAAGGCAACGGCCTTCCATCTGAAAGGCAGA  
GCAGGGTACACCACGGTGGCCGTGAAGATGCTGAAAGAGAAGCCCTCCCCGAGTGAGCTTCGAGACCTGCTGTC  
AGAGTTCAACGTCTGAAGCAGGTCAACCACCCACATGTATCAAAATGTATGGGGCCTGCAGCCAGGATGGCC  
CGCTCCTCCTCATCGTGGAGTACGCCAAATACGGCTCCCTGCGGGGCTTCTCCGCGAGAGCCGCAAAGTGGG  
CCTGGCTACCTGGGCAGTGGAGGACGCCGCAACTCCAGCTCCCTGGACCACCCGATGAGCGGGCCCTCACCAT  
GGGCGACCTCATCTCATTTGCCTGGCAGATCTCACAGGGGATGCAGTATCTGGCCGAGATGAAGCTCGTTTCATC  
GGGACTTGGCAGCCAGAAACATCCTGGTAGCTGAGGGGCGGAAGATGAAGATTTCCGATTTCCGGCTTGTCCCGA  
GATGTTTATGAAGAGGATTCTACGTGAAGAGGAGCCAGGGTCCGATTCCAGTTAAATGGATGGCAATTGAATC  
CCTTTTGTATCATATCTACACCACGCAAAGTGATGTATGGTCTTTTGGTGTCTGTGCTGTGGGAGATCGTGACCC  
TAGGGGGAAACCCCTATCCTGGGATTCCTCCTGAGCGGCTCTTCAACCTTCTGAAGACCGGCCACCGGATGGAG  
AGGCCAGACAACCTGCAGCGAGGAGATGTACCGCCTGATGCTGCAATGCTGGAAGCAGGAGCCGGACAAAAGGCC  
GGTGTGTTGCGGACATCAGCAAAGACCTGGAGAAGATGATGGTTAAGAGGAGAGACTACTTGGACCTTGC GGCGT  
CCACTCCATCTGACTCCCTGATTTATGACGACGGCCTCTCAGAGGAGGAGACACCGCTGGTGGACTGTAATAAT  
GCCCCCTCCCTCGAGCCCTCCCTTCCACATGGATTGAAAACAACTCTATGGCATGTGCAGACCCGAACTGGCC  
TGGAGAGAGTCTGTACCACTACGAGAGCTATGGCACTAACACTGGGTTCCTCAAGATATCCAAATGATAGTG  
TATATGCTAATCTGATGCTTTTCAACCTCAGCGGCAAAATTAATGGACACGTTTGATAGTTAAACATTTCTTTGTG  
AAAGGTAATGGACTCACAAAGGGGAAGAAACATGCTGAGAATGGAAAGTCTACCGGCCCTTTCTTTGTGAACGTC  
ACATTGGCCGAGCCGTGTTCACTTCCAGGTGGCAGACTCGTTTTTGGTAGTTTTGTTTTAACTTCCAAGGTGGT  
TTTACTTCTGATAGCCGGTGATTTTCCCTCCTAGCAGACATGCCACACCGGGTAAGAGCTCTGAGTCTTAGTGG  
TTAAGCATTCCTTTCTTCTCAGTGCCAGCAGCACCAGTGTGGTCTGTGTCCATCAGTGACCACCAACATTC  
TGTGTTACATGTGTGGGTCCAACACTTACTACCTGGTGTATGAAATGGACCTGAAGTGTGGATTTTTCTAG  
TTGCCGCCAAACAAGGCAAAAAAATTTAAACATGAAGCACACACAAAAAAGGCAGTAGGAAAAATGCTGGCC

22/136

**FIGURE 18B**

CTGATGACCTGTCCTTATTTCAGAATGAGAGACTGCGGGGGGGGCCTGGGGGTAGTGTC AATGCCCCCTCCAGGGC  
TGGAGGGGAAGAGGGGCCCCGAGGATGGGCCTGGGCTCAGCATTTCGAGATCTTGAGAATGATTTTTTTTAAATC  
ATGCAACCTTTCTTAGGAAGACATTTGGTTTTTCATCATGATTAAGATGATTCCTAGATTTAGCACAATGGAGA  
GATTCCATGCCATCTTTACTATGTGGATGGTGGTATCAGGGAAGAGGGCTCACAAGACACATTTGTCCCCCGGG  
CCCACCACATCATCTCACGTGTTTCGGTACTGAGCAGCCACTACCCCTGATGAGAACAGTATGAAGAAAGGGGG  
CTGTTGGAGTCCCAGAATTGCTGACAGCAGAGGCTTTGCTGCTGTGAATCCACCTGCCACCAGCCTGCAGCAC  
ACCCACAGCCAAGTAGAGGCGAAACGAGTGGCTCATCTACCTGTTAGGAGCAGGTAGGGCTTGTA CTCACTT  
TAATTTGAATCTTATCAACTTACTCATAAAGGGACAGGCTAGCTAGCTGTGTCAGAAGTAGCAATGACAATGAC  
CAAGGACTGCTACACCTCTGATTACAATTCTGATGTGAAAAAGATGGTGTGTTGGCTCTTATAGAGCCTGTGTGA  
AAGGCCCATGGATCAGCTCTTCTGTGTTTGTAATTTAATGCTGCTACAAGATGTTTCTGTTTCTTAGATTCTG  
ACCATGACTCATAAGCTTCTTGTCAATTCTTCATTGCTTGTGTTGTGGTCACAGATGCACAACACTCCTCCAGTCT  
TGTGGGGGCAGCTTTTGGAAGTCTCAGCAGCTCTTCTGGCTGTGTTGTCAGCACTGTAACCTTCGCAGAAAAGA  
GTCGGATTACCAAAACACTGCCTGCTCTTCAGACTTAAAGCACTGATAGGACTTAAAATAGTCTCATTCAAATA  
CTGTATTTTATATAGGCATTTCAAAAAACAGCAAAATTGTGGCATTTTGTGAGGCCAAGGCTTGGATGCGTGT  
GTAATAGAGCCTTATGGTGTGTGCGCACACCCCAGAGGAGATTTGAAAAATGCTTATTGGACACGTAACTTG  
GCTCTAATTTGGGCTGTTTTTCAGATACACTGTGATAAGTTCTTTTACAAATATCTATAGACATGGTAACTTT  
TGGTTTTTCAGATATGCTTAATGATAGTCTTACTAAATGCAGAAATAAGAATAAACTTTCTCAAATTATTAAAAA  
TGCCTACACAGTAAGTGTGAATTGCTGCAACAGGTTTGTTCCTCAGGAGGGTAAGAACTCCAGGTCTAAACAGCT  
GACCCAGTGATGGGGAATTTATCCTTGACCAATTTATCCTTGACCAATAACCTAATTGTCTATTCTGAGTTAT  
AAAGGTCCCCATCCTTATTAGCTCTACTGGAATTTTCATACACGTAAATGCAGAAGTTACTAAGTATTAAGTAT  
TACTGAGTATTAAGTAGTAATCTGTCAGTTATTAAAATTTGTAAATCTATTTATGAAAGGTCATTAAACCAGA  
TCATGTTCTTTTTTTGTAATCAAGGTGACTAAGAAAATCAGTTGTGTAAATAAAATCATGTATC

23/136

**FIGURE 19A**

TGAGAGCCAAGCAAAGAACATTAAGGAAGGAAGGAGGAATGAGGGCTGGATACGGTGCAGTGAAAAAGGCACTTC  
CAAGAGTGGGGCACTCACTACGCACAGACTCGACGGTGCCATCAGCATGAGAACTTACCCTACTTCTTGCTGC  
TCTTTTGGGTGGGCCAGCCCTACCCAACCTCTCTCAACTCCACTATCAAAGAGGACTAGTGGTTTCCCAGCAAAG  
AAAAGGGCCCTGGAGCTCTCTGGAAACAGCAAAAATGAGCTGAACCGTTCAAAAAGGAGCTGGATGTGGAATCA  
GTTCTTTCTCCTGGAGGAATACACAGGATCCGATTATCAGTATGTGGGCAAGTTACATTTCAGACCAGGATAGAG  
GAGATGGATCACTTAAATATATCCTTTTCAGGAGATGGAGCAGGAGATCTCTTCATTATTAATGAAAAACAGGC  
GACATACAGGCCACCAAGAGGCTGGACAGGGAAGAAAAACCCGTTTACATCCTTCGAGCTCAAGCTATAAACAG  
AAGGACAGGGAGACCCGCTGGAGCCCGAGTCTGAATTCATCATCAAGATCCATGACATCAATGACAATGAACCAA  
TATTCACCAAGGAGGTTTACACAGCCACTGTCCTGAAATGTCTGATGTCTGGTACATTTGTTGTCCAAAGTCAT  
GCGACGGATGCAGATGATCCAACATATGGGAACAGTGCTAAAGTTGTCTACAGTATTCTACAGGGACAGCCCTA  
TTTTTCAGTTGAATCAGAAACAGGTATTATCAAGACAGCTTTGCTCAACATGGATCGAGAAAAACAGGGAGCAGT  
ACCAAGTGGTGATTCAAGCCAAGGATATGGGCGGCCAGATGGGAGGATTATCTGGGACCACCACCGTGAACATC  
ACACTGACTGATGTCAACGACAACCCCTCCCCGATTCCCCCAGAGTACATACCAGTTTAAACTCCTGAATCTTC  
TCCACCGGGGACACCAATTGGCAGAATCAAAGCCAGCGACGCTGATGTGGGAGAAAATGCTGAAATTGAGTACA  
GCATCACAGACGGTGAGGGGCTGGATATGTTTGATGTCTACCCGACCAGGAAACCCAGGAAGGGATTATAACT  
GTCAAAAAGCTCTTGGACTTTGAAAAGAAGAAAGTGTATACCCTTAAAGTGGAAGCCTCCAATCCTTATGTTGA  
GCCACGATTTCTCTACTTGGGGCCTTTCAAAGATTACGCCACGGTTAGAATTGTGGTGGAGGATGTAGATGAGC  
CACCTGTCTTCAGCAAACCTGGCCTACATCTTACAAATAAGAGAAGATGCTCAGATAAACACCACAATAGGCTCC  
GTCACAGCCCAAGATCCAGATGCTGCCAGGAATCCTGTCAAGTACTCTGTAGATCGACACACAGATATGGACAG  
AATATTCAACATTGATTCTGGAAATGGTTTCGATTTTTACATCGAAACTTCTTGACCGAGAAACACTGCTATGGC  
ACAACATTACAGTGATAGCAACAGAGATCAATAATCCAAAGCAAAGTAGTCGAGTACCTCTATATATTAAAGTT  
CTAGATGTCAATGACAACGCCCCAGAATTTGCTGAGTTCTATGAAACTTTTGTCTGTGAAAAAGCAAAGGCAGA  
TCAGTTGATTTCAGACCCTGCATGCTGTTGACAAGGATGACCCCTTATAGTGGACACCAATTTTCGTTTTCTTGG  
CCCCTGAAGCAGCCAGTGGCTCAAACCTTTACCATTCAAGACAACAAAGACAACACGGCGGGGAATCTTAACTCGG  
AAAAATGGCTATAATAGACACGAGATGAGCACCTATCTCTTGCCCTGTGGTCATTTTCAGACAACGACTACCCAGT  
TCAAAGCAGCACTGGGACAGTGAATGTCCGGGTCTGTGCATGTGACCACCACGGGAACATGCAATCCTGCCATG  
CGGAGGCGCTCATCCACCCACGGGACTGAGCACGGGGGCTCTGGTTGCCATCCTTCTGTGCATCTGTGATCCTTA  
CTAGTGACAGTGGTGCTGTTTGACGCTCTGAGGCGGCAGCGAAAAAAGAGCCTTTGATCATTTCCAAAGAGGA  
CATCAGAGATAACATTGTCTAGTTACAACGACGAAGGTGGTGGAGAGGAGGACACCCAGGCTTTTGATATCGGCA  
CCCTGAGGAATCCTGAAGCCATAGAGGACAACAAATTACGAAGGGACATTGTGCCCCGAAGCCCTTTTCTTACCC  
CGACGGACTCCAACAGCTCGCGACAACACCGATGTGAGAGATTTTCAATTAACCAAAGGTTAAAGGAAAATGACAC  
GGACCCCACTGCCCCGCCATACGACTCCTTGGCCACTTACGCCTATGAAGGCACTGGCTCCGTGGCGGATTCCC  
TGAGCTCGCTGGAGTCAGTGACCACGGATGCAGATCAAGACTATGATTACCTTAGTGACTGGGGACCTCGATTTC  
AAAAAGCTTGAGATATGTATGGAGGAGTGGACAGTGACAAAGACTCCTAACTCTGTTGCCTTTTTTCATTTTCCA  
ATACGACACTGAAATATGTGAAGTGGCTATTTCTTTATATTTTACACTACTCCGTGAAGGCTTCTCTGTTCTA  
CCCGTTCCAAAAGCCAATGGCTGCAGTCCGTGTGGATCCAATGTTAGAGACTTTTTTCTAGTACACTTTTATGA  
GCTTCCAAGGGGCAAAATTTTTATTTTTTAGTGATCCAGTTAAACCAAGTCAGCCCAACAGGCAGGTGCCGGAGG  
GGAGGACAGGGAACAGTATTTCCACTTGTCTCAGGGCAGCGTGCCCGCTTCCGCTGTCTGTTGTTTACTAC  
ACTCCTATGTCAGGTCAGCCAACCTGCCCTAACTGTACATTTACAGGCTAATGGGATAAAGGACTGTGCTTTAAA  
GATAAAAAATATCATCATAGTAAAAGAAATGAGGGCATATCGGCTCACAAGAGATAAACTACATAGGGGTGTTT  
ATTTGTGTACAAAGAATTTAAAATAACACTTGGCCATGCTATTTGTTCTTCAAGAACTTTCTCTGCCATCAAC  
TACTATTCAAACCTCAAATCCACCCATATGTTAAAATTTCTCATTACTCTTAAGGAATAGAAGCAAATTAACG  
GTAACATCCAAAAGCAACCACAAACCTAGTACGACTTCATTCCTTCCACTAACTCATAGTTTGTATATCCTAG  
ACTAGACATGCGAAAGTTTGCCCTTTGTACCATATAAAGGGGGAGGAAATAGCTAATAATGTTAACCAGGAA  
TATATTTTACCATAACATTTAAAGTTTTGGCCACCACATGTATCACGGGTCACCTGAAATTTTTCAGTATCAG  
TAGGCTAATGTCAAATTTGTTTAAAAATCTTGAAAGAATTTTCTGAGACAAATTTAACTTCTTGCTATAG  
TTGTCAGTATTATTTCTACTATACTGTACATGAAAGTAGCAGTGTGAAGTACAATAATTCATATTTCTCATATCC  
TTCTTACACGACTAAGTTGAATTAGTAAAGTTAGATTAAATAAACTTAAATCTCACTCTAGGAGTTCAAGTGA  
GAGGTTAGAGCCAGCCACACTTGAACCTAATACCCCTGCCCTTGACATCTGGAAACCTCTACATATTTATATAAC  
GTGATACATTTGGATAAACAACATTGAGATTATGATGAAAACCTACATATTCATGTTTGGAAAGACCCCTGGAA  
GAGGAAAAATGGATTCCCTTAAACAAAAGTGTTTAAGATTGTAATTAATAATGATAGTTGATTTTCAAAGCATT  
AATTTTTTTTCATTGTTTTTAACTTTGCTTTTCATGACCATCCTGCCATCCTTGACTTTGAACTAATGATAAAGT  
AATGATCTCAAACATATGACAGAAAAGTAATGTAAAATCCATCCAATCTATTATTTCTCTAATTATGCAATTAGC  
CTCATAGTTATTATCCAGAGGACCCAACCTGAACCTGAACCTAATCCTTCTGGCAGATTCAAATCGTTTTATTTACA



24/136

**FIGURE 19B**

CGCTGTTCTAATGGCACTTATCATTAGAATCTTACCTTGTGCAGTCATCAGAAATTCCAGCGTACTATAATGAA  
AACATCCTTGTTTTGAAAACCTAAAAGACAGGCTCTGTATATATATATACTTAAGAATATGCTGACTTCACTTA  
TTAGTCTTAGGGATTTATTTTCAATTAATATTAATTTTCTACAAATAATTTTAGTGTCATTTCCATTTGGGGAT  
ATTGTCATATCAGCACATATTTTCTGTTTGAAACACACTGTTGTTTAGTTAAGTTTAAATAGGTGTATTACC  
CAAGAAGTAAAGATGGAAACGTT

25/136

**FIGURE 20**

CGGTGGAGGCCACAGACACCTCAAACCTGGATTCCACAATTCTACGTTAAGTGTGGAGTTTTTATTACTCTGC  
TG TAGGAAAGCCTTTGCCAATGCTTACAAGGAAGTGT TATCCCTGCTTCTCTGGGTTCTGTTTGATGGAGGTC  
TCCTAACACCACTACAACCACAGCCACAGCAGACTTTAGCCACAGAGCCAAGAGAAAATGTTATCCATCTGCCA  
GGACAACGGTCACATTTCCAACGTGTTAAACGTGGCTGGGTATGGAATCAATTTTTTGTGCTGGAAGAATACGT  
GGGCTCCGAGCCTCAGTATGTGGGAAAGCTCCATTCCGACTTAGACAAGGGAGAGGGCACTGTGAAATACACCC  
TCTCAGGAGATGGCGCTGGCACCGTTTTTACCATTGATGAAACCACAGGGACATTCATGCAATAAGGAGCCTA  
GATAGAGAAGAGAAACCTTTCTACACTCTTCGTGCTCAGGCTGTGGACATAGAAACCAGAAAGCCCCCTGGAGCC  
TGAATCAGAATTCATCATCAAAGTGCAGGATATTAATGATAATGAGCCAAAGTTTTTGGATGGACCTTATGTTG  
CTACTGTTCCAGAAATGTCTCCTGTGGGTGCATATGTACTCCAGGTCAAGGCCACAGATGCAGATGACCCGACC  
TATGGAAACAGTGCCAGAGTCGTTTACAGCATTCTTCAGGGACAACCTTATTTCTCTATTGATCCCAAGACAGG  
TGTTATTAGAACAGCTTTGCCAAACATGGACAGAGAAGTCAAAGAACAATATCAAGTACTCATCCAAGCCAAGG  
ATATGGGAGGACAGCTTGGAGGATTAGCCGGAACAACAATAGTCAACATCACTCTCACCGATGTCAATGACAAT  
CCACCTCGATTCCCCAAAAGCATCTTCCACTTGAAAGTTCTGAGTCTTCCCCTATTGGTTTCAGCTATTGGAAG  
AATAAGAGCTGTGGATCCTGATTTTGGACAAAATGCAGAAATTGAATACAATATTGTTCCAGGAGATGGGGGAA  
ATTTGTTTGACATCGTCACAGATGAGGATACACAAGAGGGAGTCATCAAATTGAAAAAGCCTTTAGATTTTGAA  
ACAAAGAAGGCATACACTTTCAAAGTTGAGGCTTCCAACCTTCACCTTGACCACCGGTTTCACTCGGCGGGCCC  
TTTCAAAGACACAGCTACGGTGAAGATCAGCGTGCTGGACGTAGATGAGCCACCGGTTTTTCAGCAAGCCGCTCT  
ACACCATGGAGGTTTATGAAGACACTCCGGTAGGGACCATCATTTGGCGCTGTCACTGCTCAAGACCTGGATGTA  
GGCAGCGGTGCTGTTAGGTACTTCATAGATTGGAAGAGTGATGGGGACAGCTACTTTACAATAGATGGAAATGA  
AGGAACCATCGCCACTAATGAATTACTAGACAGAGAAAGCACTGCGCAGTATAATTTCTCCATAATTGCGAGTA  
AAGTTAGTAACCCTTTATTGACCAGCAAAGTCAATATACTGATTAATGTCTTAGATGTAAATGAATTTCTCTCCA  
GAAATATCTGTGCCATATGAGACAGCCGTGTGTGAAAATGCCAAGCCAGGACAGATAATTCAGATAGTCAGTGC  
TGCAGACCGAGATCTTTCACCTGCTGGGCAACAATTCTCCTTTAGATTATCACCTGAGGCTGCTATCAAACCAA  
ATTTTACAGTTCGTGACTTCAGAAACAACACAGCGGGGATTGAAACCCGAAGAAATGGATACAGCCGCAGGCAG  
CAAGAGTTGTATTTCTCCCTGTTGTAATAGAAGACAGCAGCTACCTGTCCAGAGCAGCACAAACACAATGAC  
TATTCGAGTCTGTAGATGTGACTCTGATGGCACCATCCTGTCTTGTAATGTGGAAGCAATTTTTCTACCTGTAG  
GACTTAGCACTGGGGCGTTGATTGCAATTCTACTATGCATTGTTATACTCTTAGCCATAGTTGTACTGTATGTA  
GCACTGCGAAGGCAGAAGAAAAAGCACACCCTGATGACCTCTAAAGAAGACATCAGAGACAACGTCATCCATTA  
CGATGATGAAGGAGGTGGGGAGGAAGATACCCAGGCTTTTCGACATCGGGGCTCTGAGAAACCCAAAAGTGATTG  
AGGAGAACAAAATTTCGAGGGATATAAAACCAGACTCTCTCTGTTTACCTCGTCAGAGACCACCCATGGAAGAT  
AACACAGACATAAGGGATTTCAATTCATCAAAGGCTACAGGAAAATGATGTAGATCCAAGTCCCCACCAATCGA  
TTCACTGGCCACATATGCCTACGAAGGGAGTGGGTCCGTGGCAGAGTCCCTCAGCTCTATAGACTCTCTCACCA  
CAGAAGCCGACCAGGACTATGACTATCTGACAGACTGGGGACCCCGCTTTAAAGTCTTGGCAGACATGTTTGGC  
GAAGAAGAGAGTTATAACCCTGATAAAGTCACTTAAGGGAGTCGTGGAGGCTAAAATACAACCGAGAGGGGAGA  
TTTTT

26/136

**FIGURE 21**

GGCTCTCACCCCTCCTCTCCTGCAGCTCCAGCTCTGTGCTCTGCCTCTGAGGAGACCATGGGCCCGGCCTCTGTGT  
ACCCTGCTACTCCTGATGGCTACCCTGGCTGGGGCTCTGGCCTCGAGCTCCAAGGAGGAGAATAGGATAATCCC  
AGGTGGCATCTATGATGCAGACCTCAATGATGAGTGGGTACAGCGTGCCCTTCACTTCGCCATCAGCGAGTACA  
ACAAGGCCACCGAAGATGAGTACTACAGACGCCCGCTGCAGGTGCTGCGAGCCAGGGAGCAGACCTTTGGGGGG  
GTGAATTACTTCTTCGACGTAGAGGTGGGCCGCACCATATGTACCAAGTCCCAGCCCAACTTGGACACCTGTGC  
CTTCCATGAACAGCCAGAACTGCAGAAGAAACAGTTATGCTCTTTCGAGATCTACGAAGTTCCTGGGAGGACA  
GAATGTCCCTGGTGAATTCCAGGTGTCAAGAAGCCTAGGGGTCTGTGCCAGGCCAGTCACACCGACCACCACCC  
ACTCCACCCCCCTGTAGTGCTCCACCCCTGGACTGGTGGCCCCCACCCTGCGGGAGGCCTCCCCATGTGCCTG  
TGCCAAGAGACAGACAGAGAAGGCTGCAGGAGTCCTTTGTTGCTCAGCAGGGCGCTCTGCCCTCCCTCCTTCCT  
TCTTGCTTCTAATAGACCTGGTACATGGTACACACACCCCCACCTCCTGCAATTAAACAGTAGCATCGCC

27/136

**FIGURE 22**

GGCAGCGGTGGCAGGGGCTGCAGGAGCAAGTGACCAGGAGCAGGACTGGGGACAGGCCTGATCGCCCCTGCACG  
AACCAGACCCCTTCGCCGCCCTCACGATGACTACCTCTCCGATCCTGCAGCTGCTGCTGCGGCTCTCACTGTGCG  
GGCTGCTGCTCCAGAGGGCGGAGACAGGCTCTAAGGGGCAGACGGCGGGGGAGCTGTACCAGCGCTGGGAACGG  
TACCGCAGGGAGTGCCAGGAGACCTTGGCAGCCGCGGAACCGCCTTCAGGCCTCGCCTGTAACGGGTCTTCGA  
TATGTACGTCTGCTGGGACTATGCTGCACCCAATGCCACTGCCCGTGCGTCCTGCCCTGGTACCTGCCCTGGC  
ACCACCATGTGGCTGCAGGTTTCGTCTCCGCCAGTGTGGCAGTGATGGCCAATGGGGACTTTGGAGAGACCAT  
ACACAATGTGAGAACCCAGAGAAGAATGAGGCCCTTCTGGACCAAAGGCTCATCTTGGAGCGGTTGCAGGTCAT  
GTACACTGTGCGCTACTCCCTGTCTCTCGCCACACTGCTGCTAGCCCTGCTCATCTTGAGTTTGTTTCAGGCGGC  
TACATTGCACTAGAACTATATCCACATCAACCTGTTACGTCTTTTCATGCTGCGAGCTGCGGCCATTCTCAGC  
CGAGACCGTCTGCTACCTCGACCTGGCCCCCTACCTTGGGGACAGGCCCTTGCGCTGTGGAACCAGGCCCTCGC  
TGCCTGCCGCACGGCCCAGATCGTGACCCAGTACTGCGTGCGTGCCAACTACACGTGGCTGCTGGTGGAGGGCG  
TCTACCTGCACAGTCTCCTGGTGCTCGTGGGAGGCTCCGAGGAGGGCCACTTCCGCTACTACCTGCTCCTCGGC  
TGGGGGGCCCCCGCGCTTTTCGTCAATCCCTGGGTGATCGTCAGGTACCTGTACGAGAACACGCAGTGCTGGGA  
GCGCAACGAAGTCAAGGCCATTTGGTGGATTATACGGACCCCCATCCTCATGACCATCTTGATTAATTTCTCTCA  
TTTTTATCCGCATTCTTGGCATTCTCCTGTCCAAGCTGAGGACACGGCAAATGCGCTGCCGGGATTACCGGCTG  
AGGCTGGCTCGCTCCACGCTGACGCTGGTGCCCTGCTGGGTGTCCACGAGGTGGTGTGTTGCTCCCGTGACAGA  
GGAACAGGCCCCGGGGCGCCCTGCGCTTCGCCAAGCTCGGCTTTGAGATCTTCCTCAGCTCCTTCCAGGGCTTCC  
TGGTCAGCGTCCTCTACTGCTTCATCAACAAGGAGGTGCAGTCGGAGATCCGCCGTGGCTGGCACCCTGCGC  
CTGCGCCGCAGCCTGGGCGAGGAGCAACGCCAGCTCCCGAGCGCGCCTTCCGGGCCCTGCCCTCCGGCTCCGG  
CCCCGGCGAGGTCCCCACCAGCCGCGGCTTGTCTCGGGACCTTCCAGGGCCTGGGAATGAGGCCAGCCGGG  
AGTTGGAAAGTTACTGCTAGGGGGCGGGATCCCCGTGTCTGTTAGTTAGCATGGATTTATTGAGTGCCAACTG  
CGTGCCAGGCCCAGTACGGAGGACGCTGGGGAAAATGGTGAAGGAAACAGAAAAAAGGTCCCTGCCCTTCTGGAG  
ATGACAACTGAGTGGGGAAAACAGACCGTGAACACAAAACATCAAGTTCCACACACGCTATGGAATGGTTATGA  
AGGGAAGCGAGAAGGGGGCCTAGGGTGGTCTGGGAGGCGTCTCCAAGGAGGTGACACTTAAGCCATCCCCGAAA  
GAGGTGAAAGAGATCACTTTGGGGAGAGCTGGAGAACAGGATTCTAGGCGGAAGCGATAGCATAGGCAAAGGCC  
CTTGGGCAGGAAGGCGCTCAGCCTTGGCTGGAGTAGAATTAAGTCAGAGCCAACAGGTTGGGGAGAGACAGAGA  
AGTGGGCAGGGGCACCCAAGTTGGGATTTTCAATTTAGGTGCATTGGAGATTCTTAGGAGTGTCTCTTGGGGGTA  
ATATTTTATTTTTTAAAAAATGAGGAT

28/136

**FIGURE 23**

GCCAGAGCGTGAGCCGCGACCTCCGCGCAGGTGGTTCGCGCCGGTCTCCGCGGAAATGTTGTCCAAAGTTCTTCC  
AGTCCTCCTAGGCATCTTATTGATCCTCCAGTCGAGGGTCGAGGGACCTCAGACTGAATCAAAGAATGAAGCCT  
CTTCCCGTGATGTTGTCTATGGCCCCCAGCCCCAGCCTCTGGAAAAATCAGCTCCTCTCTGAGGAAACAAAGTCA  
ACTGAGACTGAGACTGGGAGCAGAGTTGGCAAACCTGCCAGAAGCCTCTCGCATCCTGAACACTATCCTGAGTAA  
TTATGACCACAAACTGCGCCCTGGCATTGGAGAGAAGCCCACTGTGGTCACTGTTGAGATCGCCGTCAACAGCC  
TTGGTCCTCTCTCTATCCTAGACATGGAATACACCATTGACATCATCTTCTCCAGACCTGGTACGACGAACGC  
CTCTGTTACAACGACACCTTTGAGTCTCTTGTCTGAATGGCAATGTGGTGAGCCAGCTATGGATCCCGGACAC  
CTTTTTTAGGAATTCTAAGAGGACCCACGAGCATGAGATCACCATGCCCAACCAGATGGTCCGCATCTACAAGG  
ATGGCAAGGTGTTGTACACAATTAGGATGACCATTGATGCCGGATGCTCACTCCACATGCTCAGATTTCCAATG  
GATTCTCACTCTTGCCCTCTATCTTTCTCTAGCTTTTCTCTATCCTGAGAATGAGATGATCTACAAGTGGGAAAA  
TTTCAAGCTTGAAATCAATGAGAAGAACTCCTGGAAGCTCTTCCAGTTTGATTTTACAGGAGTGAGCAACAAAA  
CTGAAATAATCACAACCCCAAGTTGGTGACTTCATGGTCATGACGATTTTCTTCAATGTGAGCAGGCGGTTTGGC  
TATGTTGCCCTTTCAAACCTATGTCCCTTCTTCCGTGACCACGATGCTCTCCTGGGTTTCTTTGGATCAAGAC  
AGAGTCGCTCCAGCCCGGACCTCTCTAGGGATCACCTCTGTTCTGACCATGACCAGTTGGGCACCTTTTCTC  
GTAAGAATTTCCGCGTGTCTCTATATCACAGCCTTGGATTTCATATATCGCCATCTGCTTCGTCTTCTGCTTC  
TGCGCTCTGTTGGAGTTTGTCTGTGCTCAACTTCTCTGATCTACAACCAGACAAAAGCCCATGCTTCTCTAACT  
CCGCCATCCTCGTATCAATAGCCGTGCCCATGCCCGTACCCGTGCACGTTCCCGAGCCTGTGCCCGCCAACATC  
AGGAAGCTTTTGTGTGCCAGATTGTCAACCTGAGGGGAAGTGATGGAGAGGAGCGCCCGTCTTGCTCAGCCAG  
CAGCCCCCTAGCCAGGTAGCCCTGAGGGTCCCCGCAGCCTCTGCTCCAAGCTGGCCTGCTGTGAGTGGTGCAA  
GCGTTTTTAAGAAGTACTTCTGCATGGTCCCCGATTGTGAGGGCAGTACCTGGCAGCAGGGCCGCTCTGCATCC  
ATGTCTACCGCCTGGATAACTACTCGAGAGTTGTTTTCCCACTGACTTTCTTCTTCTTCAATGTGCTCTACTGG  
CTTGTTTGCCTTAACTTGTAGGTACCAGCTGGTACCCTGTGGGGCAACCTCTCCAGTTCCCCAGGAGGTCCAAG  
CCCCTTGCCAAGGGAGTTGGGGGAAAGCAGCAGCAGCAGCAGGAGCGACTAGAGTTTTTCTGCCCCATTCCCC  
AAACAGAAGCTTGCAAGAGGGTTTGTCTTTGCTGCCCTCTCCCCTACCTGGCCCCATTCACTGAGTCTTCTCAGC  
AGACCATTTCAAATTATTAATAAATGGGCCACCTCCCTCTTCTTCAAGGAGCATCCGTGATGCTCAGTGTTCAA  
AACCACAGCCACTTAGTGATCAGCTCCCTAAAACCATGCCTAAGTACAGGCGGATTAGCTATCTTCCAACAATG  
CTGACCACCAGACAATTACTGCATTTTTCCAGAAGCCCACTATTGCCTTTGTAGTGCTTTCGGCCAGTTCTGG  
CCTCAGCCTCAAAGTGCACCGACTAGTTGCTTGCCTATACCTGGCACCTCATTAAAGATGCTGGGCAGCAGTATA  
ACAGGAGGAAGAGATCCCTCTCCTTTGGTCAGATTATTATGTTCTCAGTTCTCTCTCCCTGCTACCCCTTTCTC  
TGCAGATAGATAGACACTGGCATTATCCCTTTAGGAAGAGGGGGGGCAGCAAGAGAGCCTATTTGGGACAGCA  
TTCTCTCTCTCTGCTGCTGTGACATCTCCCTCTCCTTGCTGGCTCCATCTTTCGTCTGCACTACCAATTCAAT  
GCCCTTCATCCAATGGGTATCTATTTTTGTGTGTGATTATAGTAACTACTCCCTGCTTTATATGCCACCTCTT  
CCTTCTCTTTGACCCCTGTGACTCTTCTGTAACTTTCCCACTGACTTCCCCTAGCCCTGACCCAGGCACTAGG  
CCTTGGTGACTTCTTGGGGCCAAGAACTAAGGAAACTCGGCTTTGCAACAGGCATTACTCGCCATTGATTGGT  
GCCCACCCAGGGCACACTGTGCGAGTTCTATCACTTGCTTGACCCCTGGACCATAAACCAGTCCACTGTTATA  
CCCGGGGCACCTCTAACCATCACAATCAATCAATCAAATTCCTTAAATTTGTATGGCACTGGAACCTTTGGCAAA  
GCACTTTTGACAAGTTGTGTCTGATTGGAGCTTCATGATAGCCTTGTTGACATCTTTAGGGCAGGATTCTTATCC  
CCATTTTGCAGATGAAAACCTGAGTCACAGATTTCTGTGGGACTGTGGATCTCACTGGAAGCTATCCAAGAGC  
CCACTGTACCTTCTAGACCACATGATAGGGCTAGACAGCTCAGTTACCATGATTCTCTTCTGTACCTCTGC  
TGGCACACCAAGTGGCAAGGCCAGAAATGGCGACCTCTCTTTAGCTCAATTTCTGGGCCTGAGGTGCTCAGACTG  
CCCCAAGATCAAATCTCTCCTGGCTGTAGTAACCCAGTGGAATGAATTTGGACATGCCCCAATGCTTCTATAT  
GCTAAGTGAAATCTGTGTCTGTAATTTGTTGGGGGTGGATAGGGTGGGGTCTCCATCTACTTTTTGTACCAT  
CATCTGAAATGGGGAAATATGTAAATAAATATATCAGCAAAGCAAAAAGAAAAAAAAA

29/136

**FIGURE 24A**

GGTGGCCTCTGTGGCCGTCCAGGCTAGCGGCGGCCCGCAGGCGGGCGGGGAGAAAGACTCTCTCACCTGGTCTTG  
CGGCTGTGGCCACCGCCGGCCAGGGGTGTGGAGGGCGTGCTGCCGAGACGTCCGCCGGGCTCTGCAGTTCCGC  
CGGGGGTTCGGGCAGCTATCGAGCCGCGGCCACGGCGCCCTCCTCCGGCGCCCCGGGACTGGCCGGGGTTCGGGG  
AGACGCCGTGAGCCGTGCGCTGGCCGAGCCAGGGTGGAACTGCCCGGCACGGCTGTGCCCTCGGTGCCGGAG  
GATGCTGCGCCCGCAGCCGGGACGGCGGCGGGGTCCGCGATGAGGGCCCCGCGCGGCCGGGACGGGGCTGGG  
CAGACCCTTGGGGCCACCCCGAGCCAGAGCCGTTTCCAGGTGGACCTGGTTTCCGAGAACGCCGGGCGGGCCG  
CTGCTGCGGCGGCGGCGGCGGCGGCGGCGGCGGCTGGTGCTGGGGCGGGGGCCAAAGCAGACCCCCGCG  
GACGGGGAAGCCAGCGGCGAGAGCGAGCCAGCTAAAGGCAGCGAGGAAGCCAAGGGCCGCTTCCGCGTGAACCTT  
CGTGAGCCAGCTGCCTCCTCGTTCGGCTGAAGACAGCCTGTGAGATGCTGCCGGGGTTCGGAGTCGACGGGCCCA  
ACGTGAGCTTCCAGAACGGCGGGGACACGGTGTGAGCGAGGGCAGCAGCCTGCACTCCGGCGGCGGCGGCGGC  
AGTGGGCACCACCAGCACTACTATTATGATACCCACACCAACACCTACTACCTGCGCACCTTCGGCCACAACAC  
CATGGACGCTGTGCCCAGGATCGATCACTACCGGCACACAGCCGCGCAGCTGGGCGAGAAGCTGCTCCGGCCTA  
GCCTGGCGGAGCTCCACGACGAGCTGGAAAAGGAACCTTTTGGAGGATGGCTTTGCAAAATGGGGAAGAAAGTACT  
CCAACCAGAGATGCTGTGGTCACGTATACATGCAGAAAGTAAAGGAGTCTGTAAGTTTGGCTGGATCAAGGGTGT  
ATTAGTACGTTGTATGTTAAACATTTGGGGGTGTGATGCTTTTTCATTAGATTGTCATGGATTGTGGGTCAAGCTG  
GAATAGGCTATCAGTCCTTGTAATAATGATGGCCACTGTTGTGACAACATATCACAGGATTGTCTACTTCAGCA  
ATAGCAACTAATGGATTTGTAAGAGGAGGAGGAGCATATTATTTAATATCTAGAAGTCTAGGGCCAGAATTTGG  
TGGTGCAATTGGTCTAATCTTCGCCTTTGCCAACGCTGTTGCAGTTGCTATGTATGTGGTTGGATTTGCAGAAA  
CCGTGGTGGAGTTGCTTAAGGAACATTCCATACTTATGATAGATGAAATCAATGATATCCGAATTATTGGAGCC  
ATTACAGTCGTGATTCTTTTAGGTATCTCAGTAGCTGGAATGGAGTGGGAAGCAAAAGCTCAGATTGTTCTTTT  
GGTGATCCTACTTCTTGCTATTGGTGATTTTCGTCATAGGAACATTTATCCCACTGGAGAGCAAGAAGCCAAAAG  
GGTTTTTTGGTTATAAATCTGAAATATTTAATGAGAACTTTGGGCCGATTTTCGAGAGGAAGAGACTTTCTTT  
TCTGTATTTGCCATCTTTTTTCTGCTGCAACTGGTATTCTGGCTGGAGCAAATATCTCAGGTGATCTTGCAGA  
TCCTCAGTCAGCCATACCCAAAGGAACACTCCTAGCCATTTTAATTACTACATTGGTTTACGTAGGAATTGCAG  
TATCTGTAGGTTCTTGTGTTGTTTCGAGATGCCACTGGAAACGTTAATGACACTATCGTAACAGAGCTAACAAAC  
TGTAATCTGTCAGCCTGCAAATTAACCTTTGATTTTTTCATCTTGTGAAAGCAGTCCTTGTTCCTATGGCCTAAT  
GAACAACCTTCCAGGTAATGAGTATGGTGTGAGGATTTACACCACTAATTTCTGCAGGTATATTTTCAGCCACTC  
TTTCTTCAGCATTAGCATCCCTAGTGAGTGTCTCCAAAATATTTTCAGGCTCTATGTAAGGACAACATCTACCCA  
GCTTTCAGATGTTTGTCTAAAGGTTATGGGAAAAAATGAACCTCTTCGTGGCTACATCTTAACATCTTAAAT  
TGCATTGGATTATCTTAATTGCTGAACCTGAATGTTATTGCAACCAATTATCTCAAACCTCTTCTTGCATCAT  
ATGCATTGATCAATTTTTTCAGTATTCCATGCACTATCACTTGCAAAATCTCCAGGATGGCGTCTCTGCATTCAAATAC  
TACAACATGTGGATATCACTTCTTGGAGCAATTCTTTGTTGCATAGTAATGTTTCGTCAATTAACCTGGTGGGCTGC  
ATTGCTAACATATGTGATAGTCCTTGGGCTGTATATTTATGTTACCTACAAAAAACAGATGTGAATTGGGGAT  
CCTCTACACAAGCCCTGACTTACCTGAATGCACTGCAGCATTCATTCGTCTTTCTGGAGTGGGAAGACCACGTG  
AAAAACTTTAGGCCACAGTGTCTTGTATGACAGGTGCTCCAAACTCACGTCCAGCTTTACTTCATCTTGTTC  
TGATTTTCAAAAAATGTTGGTTGATGATCTGTGGCCATGTACATATGGGTCTCAGAGACAAGCCATGAAAG  
AGATGTCCATCGATCAAGCCAAATATCAGCGATGGCTTATTAAGAACAAAATGAAGGCATTTTATGCTCCAGTA  
CATGCAGATGACTTGAGAGAAGGTGCACAGTATTTGATGCAGGCTGCTGGTCTTGGTCGTATGAAGCCAAACAC  
ACTTGTCTTGGATTTAAGAAAGATTGGTTGCAAGCAGATATGAGGGATGTGGATATGTATATAAACTTATTTT  
ATGATGCTTTTGCATACAATATGGAGTAGTGGTTATTTCGCCTAAAAGAAGGTCTGGATATATCTCATCTTCAA  
GGACAAGAAGAAATTATTGTCATCACAAGAGAAATCTCCTGGCACCAAGGATGTGGTAGTAAGTGTGGAATATAG  
TAAAAAGTCCGATTTAGATACTTCCAAACCACTCAGTGAAAAACCAATTACACACAAAGTTGAGGAAGAGGATG  
GCAAGACTGCAACTCAACCACTGTTGAAAAAGAATCCAAAGGCCCTATTGTGCCTTTAAATGTAGCTGACCAA  
AAGCTTCTTGAAGCTAGTACACAGTTTCAGAAAAACAAGGAAAGAATACTATTGATGTCTGGTGGCTTTTGA  
TGATGGAGGTTTGACCTTATTGATACCTTACCTTCTGACGACCAAGAAAAAATGGAAGAGCTGAAGATCAGAG  
TATTCATTGGTGGAAAGATAAACAGAATAGACCATGACCGGAGCGATGGCTACTTTGCTTAGCAAGTTCGGG  
ATAGACTTTTCTGATATCATGGTTCTAGGAGATATCAATACCAAAACCAAGAAAGAAATATTATAGCTTTTGA  
GAAATCATTGAGCCATACAGACTTTCATGAAGATGATAAAGAGCAAGATATTGCAGATAAAATGAAAGAGATG  
AACCATGGCGAATAACAGATAATGAGCTTGAACCTTTATAAGACCAAGACATACCGGCAGATCAGGTTAAATGAG  
TTATTAAAGGAACATTCAAGCACAGCTAATATTATTGTGATGAGTCTCCCAAGTTGCACGAAAAGGTGCTGTGTC  
TAGTGCTCTCTACATGGCATGGTTAGAAGCTCTATCTAAGGACCTACCACCAATCCTCCTAGTTTCGTGGGAATC  
ATCAGAGTGTCTTACCTTCTATTCATAAATGTTCTATACAGTGGACAGCCCTCCAGAATGGTACTTCAGTGCC  
TAGTGTAGTAACCTGAAATCTTCAATGACACATTAACATCACAATGGCGAATGGTGACTTTTCTTTCACGATTT  
CATTAATTTGAAAGCACACAGGAAAGCTTGCTCCATTGATAACGTGTATGGAGACTTCGGTTTTAGTCAATTC

30/136

**FIGURE 24B**

ATATCTCAATCTTAATGGTGATTCTTCTCTGTTGAACTGAAGTTTGTGAGAGTAGTTTTCCTTTGCTACTTGAA  
TAGCAATAAAAAGCGTGTTAACTTTTTGG

31/136

**FIGURE 25A**

GAGCTTGTCAGACGAAGCCTCGCAGGGATGGGTTGGAGCCTGGGCCGTGCTTCGCTCAGGCAGCGTTTGAGGC  
AGACCCAGCAGGGTCCTCCTGGGGCCTTCCTGCCTTTGAACTGCGGTGGCGGGCGGGCGCACGGTCTCCTGTAC  
GCCCTAGACTAGGGGCGCCATCTCCATGGCCACGGCCGTGAGCCGGCCCTGCGCCGGCAGGTGCGGGGACATA  
CTGTGGCGCGTTTTGGGCTGGAGGATAGTTGCAAGTATTGTTTGGTCAGTGCTATTTCTACCCATCTGCACCAC  
AGTATTTATAATTTTCAGCAGGATTGATTTGTTTCATCCTATACAGTGGCTGTCTGATTCTTTTCAGTGACCTGT  
ATAGTTCCTATGTAATCTTTTACTTCCTGCTGCTGTGTCAGTGGTAATAATAATAAAGTATTTTCAATGTGGAG  
TTCTATGCAGTTGTGCCTTCTATTCCCTTGCTCCAGACTAGCTCTGATAGGGAAGATCATTCATCCTCAGCAACT  
CATGCACTCATTTATTCATGCTGCAATGGGAATGGTGATGGCCTGGTGTGCTGCAGTGATAACCCAGGGCCAGT  
ACAGCTTTCTTGTGGTTCCTGCACTGGTACTAACAGCTTTGGTAGCCCTGCTGCGCAAACCTGCTTAAATGAA  
TATCATCTTTTTTTCCTACTGACTGGAGCATTATGCGCTATAGCTATAGCCTCCTGTATTTTGTTAACAACAT  
GAACTATCTTCCATTTCCCATCATACAGCAATACAAGTTCTTGCGTTTTAGGAGATCTCTGCTCTTATTAGTTA  
AACACAGTTGTGTGGAATCACTGTTCTGGTTAGAAATTTCTGCATTTTATATTATTTTCTTGGCTATATTCCC  
AAAGCTTGGATTAGCACTGCTATGAACCTTCACATAGATGAGCAGGTTTCATAGGCCACTTGACACAGTGAGTGG  
CCTCTTAAATCTCTCGTTACTCTACCATGTCTGGCTGTGTGGTGTCTTTCTCCTGACGACTTGGTATGTCTCAT  
GGTACTCTTCAAATCTATGCCACAGAGGCTCATGTGTTTTCTGTTCAACCACCATTTGCAGAAGGGTCAGAT  
GAGTGCCTTCCAAAAGTGTTAAATAGCAATCCTCCCCCATCATAAAGTATTTAGCCTTGCAGGACCTGATGTT  
GCTTCTCAATATTCTCCTTCACGAAGACAAGAAGTTTTCAGCCTCAGCCAACCAGGTGGACATCCCCACAATT  
GGACAGCCATTTCAAGGGAGTGTTTGAATCTTTTAAATGGTATGACTCAGAACTGATTCTCTATCAAGAAGCT  
GCTGCTACGAATGGGAGAGTGTTTTCATCTTACCCAGTGGAACCTAAGAAATTAATTTCTCCAGAAGAACTGC  
TTTTCAGACACCAAATCTAGCCAGATGCCTCGGCCCTTCAGTGCCACCATTAGTTAAACATCACTGTTTTCTT  
CAAATTTATCTACACCTGATGTTGTGAGCCCATTTGGGACCCCATTTGGCTCTAGTGTAATGAATCGGATGGCT  
GGAATTTTTGATGTAAACACCTGCTATGGGTCAACGCAAAGTCTCAGCTAATAAGAAGGGGGCCAAGATTGTG  
GACATCAGCTTCTGATCAGCAAATGACTGAATTTTCTAATCCTTCTCCATCTACCTCTATTAGTGCTGAGGGTA  
AGACAATGAGACAACCCAGTGATTTATTCATGGATTTCAGAATAAACGTGAACAGATTAAAGATTTCTTGTC  
AAACGGGTGCTGATAATGTATTTTTTTCAGTAAGCACCCAGAGGCCTCCATTCAGGCTGTTTTTTCAGATGCCCA  
AATGCATATTTGGGCATTAGAAGGTCTGTGCGACTTAGTAGCAGCATCATTTACAGAGGATAGATTTGGAGTTG  
TCCAGACGACACTACCAGCTATCCTTAATACTTTGTTGACACTGCAAGAGGCAGTCGACAAGTACTTTAAGCTT  
CCTCATGCTTCCAGTAAACACCCCGGATTTTCAGGAAGCCTTGTGGACACTTCATATAAAACATTAAAGATTTGC  
ATTCAGAGCATCACTGAAAACCTGCCATCTATACTAAGTACTACATTTGGTGAACATCTGAATGCTGTGCAAG  
CATCTGCAGAACATCAGAAAAGACTTCAACAGTTCTTGGAGTTTCAAAGAATAGTTAAGTAATATAAACTGTGTT  
CATTACACTCTGATACAACTACAGATGGGACAGTAAATGTTTCAGCATTTCTGGATCAGAAGAAAACGGACTAA  
TTAGATGCTTCTTTGTGCGTGGTGGTTGCTTTGAAAACATACTTTAATGGGAGAAATCATGGAAAGAAATCT  
CAACAGAATAAATGAAAACCTGCCCTTTCTGTACCGATTGCTTTTTGTGTGTGTGGTATAATAAAATCTTTATTC  
AATTTTACAGAAGCATTGATGGCAGTCGAAATGTCTCTAGCTCATATAACTTAATAGTAATAACTAAAAACTT  
TTAGAATTTACTTTTTGAAAGGAGGGAAGCCAGTTCTGAAATGAGTATAGGTTGATTTTCATAGTCTTCTTAATTA  
AGAGTTTAGCTCTTTGTAACTCAAATACATAAACTTTTTAAGTGTAGTTTCATTTACTGAAGGATAAAAAATG  
GTAACAGTGCAGCAATATTCACAAAAAATATTGTCTAACGGACATATTTTGTTAATCTGTTAGGTTGGGTTTTT  
GTTTCCAGGGACAAATTAATTTGTATGATTACCCAAAAAAGGGTCTCAGTTTACAGATGCTAACTCTATATAA  
AGGAATGTGGAAAAACTCAGTTCTTAAGTTACAAGATTAATAAATTCACATTTGGTCTTTAAGAAACAATTGACT  
GACATCTATGAATTTATTTTGTATCATGCTAGTAAACACGAAGTATTAATGTATGGGTATTTTCCAGCTAGTT  
TTGCTTTCTTTTTCTGGAGCAAAACATTAAGTGATTGCAGAGTTTTTCAAGCAAGAGAAAAAGGTTTGCAAAAA  
AACCCAGGAAATGTTCCCTTTTTTCCCCACCATTCTCTTATAGATCAAATCTGTGAACTTGTCTGGTCT  
CTCAAAGGGAGCAGCCTCTGTAGTGTTAAATGGCTAATTAATAAGGAAGATCTTTATAGCCAGAAACAACCTA  
GTCATCAAATAGCAAGTGAAACCAAAACGTCAGAGGGATTACTGTACTTGGAAAGTATGTTGTGTGTCCCAAATG  
TGAACGAAGTATTGTTAGAATTTATTAGATCAGCTTCTTTGGAGATCAAAGATTGGAATCCTAGTCATAGATA  
TTCACTGGACTGGCTTTGGACTGAAATGCTCCTTTGTAATCTTTTCCCTATTGCTTTTCCCTTCTAGTGTCCCA  
AAATATTTTCTTTAAAGTCAGCACAGTACTGTATGAATCTTTAATGTGGTATCATATATGTCTACTTTTGTCT  
TGATTTCATCGATGATTATATCTTTATAATTTGAATATTTTAGCTCCGGGTCCTGTTGCCCTTCAAGCAGTACA  
TGCCAAATTATAAATAGGTGCTACTGGCCTTGAGCATATCACTGTGGGACAGTTCCCCAATTGTCAAGTGTTTA  
GATATGTAGACTATTGCCATTTGTTTTTTTTGTTTTGGTTTTGCTTTGTGTCTGAAGCTGAATTGATTTCTTTTT  
TTTGAATGTGAAAGTTGAATTTCAAACGTAGTCATTTCTTACAGATGGCCAAGACAGAAATTTGTGGCTAGGTT  
GACTGAGAAGTGTGTCTTCCATGTATTAACACAATTAAGCTTTTTATATTCCACTCTCTGTGCTGACCCTGGC  
TGAGGCATTTTGGGAGACAAGGACTCTGAATCTTCTGCTTCCATTAAAGAAGAACTGTGATATTCAACATTGGA  
TTTCTGAGAATAAAGATAGGATGATTCCTTTGAACTTTGACTTACTTGTATAAAATGTCCAGCTAGGTTAGGTT



32/136

**FIGURE 25B**

TTTGCCATTTCTATATACTTTGGGTAAAGCTACATTTGATGAGCAATGTGAATGTTTCTGAGAATGTTTCATTC  
CTGTTTTCTCTTAAGAGAATGTGCTGTGTACTAAATACAGGCCACATAGTGTCTGCCTGTTGAAGATCTGGAAA  
CTGCCTCCCCAGATCTGTATTGTATTTGGTAGGTAAGGGGGTCAGTTTCTTTTCTCATTGTGTGTTGATAATC  
TACACACCATCTGTTGGAACCAGGGTGTATTATGGGGAACCTCCTGTGTACTAGGAGGAGGACCTTAGGGA  
GACCAAGAGGAGAGAAGCATTTCTTTGATGAAGTCACATCCTGTCTATGAGCCCACTAATGCTGTAACATTGG  
CCTGAAAGAGAGTGTTCTTTAAAAGCCTTTCTCGGCTGTTAGTATAAAAACATGATGGTATCAGCTCTTAGCAT  
GTTTGCTTGACCTTATGGAAGGTATAAATCCACAGAACTTCCTTCCCAGAGAACTGGGAAATTGTCCTAGAAA  
TAAACCTTGACAGTTGAGTGGACATGGATAAGCAACAATTTGTTACTTTGCAGGATTTGTTCCCTTGGTAATTG  
TTTGGTGTGTCATCCTGTAAATATTCATGATAGTCTGTTTATATCCTTTTGTATATCGTTGATACTGGATTGGG  
TAGAAAAATAAATTGGCAATTTAAAAAATGGAACAGTTAATTGAAA

33/136

**FIGURE 26A**

GATGGGGGCCCCGTTTGTCTGGGCCTTGGGCCTTTTGATGCTGCAGATGCTGCTCTTTGTGGCTGGGGAACAGG  
GCACACAGGATATCACCGATGCCAGCGAAAGGGGGCTCCACATGCAGAAGCTGGGGTCTGGGTGAGTGCAGGCT  
GCGCTGGCGGAGCTGGTGGCCCTGCCCTGTCTTTACCCTGCAGCCACGGCCAAGCGCAGCCCGAGATGCCCC  
TCGGATAAAGTGGAACCAAGGTGCGGACTGCGTCGGGCCAGCGACAGGACTTGCCCATCCTGGTGGCCAAGGACA  
ATGTCTGTAGGGTGGCCAAAAGCTGGCAGGGACGAGTGTCACTGCCTTCCTACCCCCGGCGCCGAGCCAACGCC  
ACGCTACTTCTGGGGCCACTGAGGGCCAGTGACTCTGGGCTGTACCGCTGCCAGGTGGTGGGGGCATCGAGGA  
TGAGCAGGACCTGGTGCCCTTGAGGTTGACAGGTGTTGTGTTCCACTACCGATCAGCCCCGGACCGCTATGCAC  
TGACCTTCGCTGAGGCCCAGGAGGCCTGCCGTCTCAGCTCAGCCATCATTGCAGCCCCCTCGGCATCTACAGGCT  
GCCTTTGAGGATGGCTTTGACAACCTGTGATGCTGGCTGGCTCTCTGACCGCACTGTTGCGGTATCCTATACCCA  
GTCCCGTCTCGTTGCTATGGCGACCGTAGCAGCCTTCCAGGGGTTTCGAGCTATGGGAGGCGCAACCCACAGG  
AACTCTACGATGTGTATTGCTTTGCCCGGGAGCTGGGGGGCGAGGTCTTCTACGTGGGCCCCGGCCGCGCCTG  
ACACTGGCCGGCGCGCGTGCACAGTGCCGCGCCAGGGTGCCGCGCTGGCCTCGGTGGGACAGCTGCACCTGGC  
CTGGCATGAGGGCTGGACCAAGTGCGACCCGGGCTGGCTGGCCGACGGCAGCGTGCGCTACCCGATCCAGACGC  
CGCGCCGGCGCTGCGGGGGCCAGCCCCGGGCGTGCGCACCGCTCTACCGCTTCGCTAACCGGACCGGCTTCCCC  
TCACCCGCGAGCGCTTCGACGCCTACTGCTTCCGAGCTCATACCCACGTCACAACATGGAGACCTAGAGAC  
CCCATCCTCTGGGGATGAGGGGGAGATTCTGTGCAGAGGGGGCCCCCAGTTAGAGAACTGGAGCCCACCTTGG  
AGGAGGAAGAGTGGTACCCCTGACTTCCAGGAGCCTCTGGTGTCCAGTGGGGAAGAAGAAACCTGATTTTG  
GAGGAGAAGCAGGAGTCTCAACAGACCCTCAGCCCTACCCCTGGGGACCCATGCTGGCCTCATGGCCCACTGG  
GGAAGTGTGGCTAAGCACGGTGGCCCCCAGCCCTAGCGACATGGGGGCAGGCACTGCAGCAAGTTCACACACGG  
AGGTGGCCCCAACTGACCCTATGCCTAGGAGAAGGGGGCGCTTCAAAGGGTTGAATGGGCGCTACTTCCAGCAG  
CAGGAACCGGAGCCGGGGCTGCAAGGGGGGATGGAGGCCAGCGCCAGCCCCCAGCTCAGAGGCTGCAGTGAA  
CCAAATGGAGCCTCCGTTGGCCATGGCAGTCACAGAGATGTTGGGCAGTGGCCAGAGCCGGAGCCCTGGGCTG  
ATCTGACCAATGAGGTGGATATGCCCTGGAGCTGGTTCGTCTGGTGGCAAGAGCTCCCCAGAGCCCTGGCTGTGG  
CCCCCTACCATGGTCCCACCCAGCATCTCAGGCCACAGCAGGGCCCCCTGTCTCTGGAGCTAGAGAAAGCCGAGGG  
CCCCAGTGCCAGGCCAGCCACCCAGACCTGTTTTGGTCCCCCTTGGAGGCCACTGTCTCAGCTCCCAGCCCTG  
CCCCCTGGGAGGCATTCCCTGTGGCCACCTCCCCAGATCTCCCTATGATGGCCATGCTGCGTGGTCCCAAAGAG  
TGGATGCTACCACACCCACCCCATCTCCACCGAGGCCAATAGAGTTGAGGCACATGGTGAGGCCACCGCCAC  
GGCTCCACCCCTCCCTGTCTGCAGAGACCAAGGTGTATTCCCTGCCTCTCTCTTTGACCCCAACAGGACAGGGTG  
GAGAGGCCATGCCCACAACACCTGAGTCCCCCAGGGCAGACTCAGAGAACTGGGGAGACCAGCCCTGCTCAG  
GTCAACAAAGCTGAGCACTCCAGCTCCAGCCCATGGCCTTCTGTAAACAGGAATGTGGCTGTAGGTTTTGTCCC  
CACTGAGACTGCCACTGAGCCAACGGGCCTCAGGGGTATCCCGGGTCTGAGTCTGGGGTCTTCGACACAGCAG  
AAAGCCCCACTTCTGGCTTGAGGCCACTGTAGATGAGGTGCAGGACCCCTGGCCCTCAGTGTACAGCAAAGGG  
CTGGATGCAAGTTCCCATCTGCCCCCTGGGGAGCCCTGGAGTCTTCTTGGTACCCAAAGTCACCCCAAATTT  
GGAGCCTTGGGTGTCTACAGATGAAGGACCCACTGTGAATCCCATGGATTCCACAGTCACGCCGGCCCCAGTG  
ATGCTAGTGGAATTTGGGAACCTGGATCCAGGTGTTTGAAGAAGCCGAAAGCACCACTTGAGCCCTCAGGTG  
GCCCTGGATACAAGCATTGTGACGCCCCCTCAGCACCCTGGAGCAGGGGGACAAGGTGGAGTTCCAGCCATGTC  
TACACTGGGCTCCTCAAGCTCCCAACCCACCCAGAGCCAGAGGATCAGGTGGAGACCCAGGGAACATCAGGAG  
CTTCAGTGCCTCCGCATCAGAGCAGTCCCTAGGGAAACCGGCTGTTCTCTCTGGGACACCGACTGCAGCCAGT  
GTGGGCGAGTCTGCCTCAGTTTCTCAGGGGAGCCTACGGTACCGTGGGACCCCTCCAGCACCTGCTGCCTGT  
CACCTTGGGCATAGAGGACTTCGAACCTGGAGGTCTGGCAGGGAGCCCGGTGTAGAGAGCTTCTGGGAGGAGG  
TGGCAAGTGGAGAGGAGCCAGCCCTGCCAGGGACCCCTATGAATGCAGGTGCGGAGGAGGTGCACTCAGATCCC  
TGTGAGAACAACCTTGTCTTCATGGAGGGACATGTAATGCCAATGGCACCATGTATGGCTGTAGCTGTGATCA  
GGGCTTCGCCGGGGAGAACTGTGAGATTGACATTGATGACTGCCTCTGCAGCCCTGTGAGAATGGAGGCACCT  
GTATTGATGAGGTCAATGGCTTTGTCTGCCTTTGCCCTCCCCAGCTATGGGGGCAGCTTTTGTGAGAAAGACACC  
GAGGGCTGTGACCGCGGGCTGGCATAAGTTCCAGGGCCACTGTTACCGCTATTTTGGCCACCGGAGGGCATGGGA  
AGATGCCGAGAAGGACTGCCGCGCGCGCTCCGGCCACCTGACCAGCGTCCACTACCCGAGGAACACAGCTTCA  
TTAATAGCTTTGGGCATGAAAACAGTGGATCGGCCTGAACAGCAGGATCGTGGAGAGAGATTTCAGTGGACG  
GACAACACGGGCTGCAATTTGAGAAGTGGCGAGAGAACCAGCCGACAATTTCTTCGCGGGTGGCGAGGACTG  
TGTGGTGTGATGGTGGCGCATGAAAAGCGGGCGCTGGAACGATGTCCCTGCAACTACAACCTACCCTATGTCTGCA  
AGAAGGGGCAGTGTCTGTGGTCCCCCTCCGGCAGTGGAGAATGCCTCACTCATCGGTGCCGCAAGGGCCAAG  
AACAATGTCCATGCCACTGTAAGGTACAGTGCAATGAAGGATTTGCCAGCACCATGTGGTCAACCATTCGATG  
CCGGAGCAATGGCAAGTGGGACAGGCCCCAAATTTGTCTGCACCAAACCCAGACGTTTACATCGGATGCGGGGAC  
ACCACCACCACCACCAACACCACCACCAGCATCACCACCACAAATCCCGCAAGGAGCGCAGAAAACACAAGAAA  
CACCCAACGGAGGACTGGGAGAAGGACGAAGGGAATTTTTGCTGAAGAACCAGAAAAAAGAAAGCACACACCT

34/136

**FIGURE 26B**

TTCCCATGCCTCCTCTGGAGCCTTCGCCTGGGGAGACAGAACCCAGAGAGAAACAAGAGAGTCCAGAAGTCCCT  
GAACCCCAAAGTGTCTCGCAAAAAAATATTCCTTTGAACAAAGGTCTTCTTTTCCTTTTTTTACATACACAA  
GATCTTCTTGGCAGGTGGAGCCAGGTGTCTGAAAAGTTCATTCTCGTCTGGCTGAAGTCTGGGAGTGTGTCCCA  
GCTGAGGGGAAGCACAAGTAGCAAAGCTCATTGGTCTGGTCTCTTGTTTGCCAGGCTGATTGAAGCAGGCCTTGA  
TGAGGGTGCATGAGTGTATGTTTGCATTACATGAAGGAATTGCTTTTCACACCAGAAATTCAGACTTAGTCAA  
TGTTGGCTGAATTCCTAAATCCAGGAAGAAGCCTGGACGTAGGGTCATTAGCTTTGGGAATAGAAGGCTACACA  
GAAGCACACTGTTTTTGAAGTTGACAACAGCTCTCCCTTTACCCTGGACTTCAGCCCAAGTCCGTCTTTGGTC  
TTGGTGGATAAACACACAGTGTGGAGATCCACGTACTGCATTTTAGGGATGTTTTTAGGACAACCTCCCTCCA  
TGCTTCAGAGTTAGGAGTGAGAATGATCAAAGCAATATGTAGGTGATGGAGGGAGAGTGTATTGCTAACCTT  
CCAGGTCTAGTCCAGCGCTGAGATTTGGTGGTCTGCATGTGTGATGAATCTCTTTCACACAAATAGACGAGAG  
GATATTTAGGGCTAGATGAGCCCAGATTTCTTCCCCCTCCATCTCTCAGGGAGACAAAGAACCTCCTTCCTGGA  
CCAAGGAGGTGCTGCCAAGTTTTCTAGCCCAGTGCACATACCCAGTCTTAAGCAGACATTGGTAGTGCCCCTG  
CCCTGGGTCCCCTCCTGCCCCACCCACCTTGTCCCTGGCCATTGCCTGGTGGTCTAGAAACACTTAAAGT  
TGAAGTAGTGACACCTACCTGCGGTCAATTTGTAGAGAGATGCTCAGTGTAAAGTGAACACACAAACACAC  
ACACACACACATTTTTCTCTTGTAGATTTAATTTTTTAAGTGGGAAAGAACTCACCTTGCTTCCCTCCCCAA  
ATGTGCAACCTGTAAAGGTCTCTCCACACCAGGGGCCAGGATCCAGTTCCTCATCTCTGGCAGGAAAGATCC  
ACAGCTTTTCCCTCCATGTCTGTACTCACTTTCAGCAGTCCGGGTAAATCTGTGGATCAGGGTTAAAAAGCA  
CCGTGGAGAATGGCCCTCTTCAGGAAAGAAAAATAAGCAAATGAATGGTCCACCTAGGGGTTACAGTAAAGAAAG  
AAATGTGTTAACTGAGCCTGAATCCCTTCTGGGAAGTAATAATGACCATTGACAACCTAAGAAGTAGACACCATG  
CTAAAGACTTACATACAATCTCCTTGAATCTTCTCAATAGCCCATTGACTTAGAACTGTTACTTTCCCATTTT  
ACACACAGTGAAACTGAGGCTCAGATATAAAGGAAAGGTACTGGCTTGAAGTCACAACCACGACAGGAGTAAGG  
ATTTGGAATAAGGATTTGGTCCTGTTTTCTGGACCAATCCTTACTCTGGCTCTGCTTACACTTTCTCTCCATC  
ACCAAATCCTTACTCCAAATCCAGAAGTCAGAGCCAACCTCCCATCTTGGTCTGACCCAAATCCTGCTCTGGAC  
TCTGGAGAGGAGATTGAAATATAATTGCACCTCATAACATTTAGGAAATGGTTAAGAAGTGAAACTGAACC  
CTTATCCTTGTCTTCAATCTTCCCTCCCTGTAGACATCTATCTTATATGGTTATTATTACAGAAAACCCAGGGAT  
ACAGGTTTGTCTTCTTACTTTGATAACTCTTCTTAGTTTAAAAATAATAATAACACATCTTTGGTCATCTAT  
GTCACACAAAAATTTTCTTTGTTTGGGGGGGCTGGGGATGCAGTGTTTTTTGGGGGGTCTTGGTTTATGCTC  
CCTGCCCTTGAGCCCCCTCAGCCGTTTGCCTGCCCCACCTCGGCTCCATGGTGGGAGGGGGCTCTGGTCTTTT  
CTAAAGTGGGCGGTTTGTCTTTTGATCTTTCCCTTTTGGATGTGCGTGTGTCTGCGTGTGCCATGTGCGTGG  
CACGCATATGAGTGTGTGTGCGTGTGAACGGCTTTGGGTCTGCTGGTTTTGCTGTGAGCTGCAGTGTCTGTG  
GGTCTGTGGTATCTGACACTGTGGACATTAATGTACTTCTTGGACATTTTAAATAAATTTTTTAACAGTTCAAAA  
AAAAAAAAAAAAAAAAAAAAA

35/136

**FIGURE 27A**

ACTAGAGATGGCGGGCGGGCTGCTCTGAAGAGACCTCGGCGGGCGGCGGAGGAGGAGAGAAGCGCAGCGCCGCGC  
CGCGCCGGGGGCCCATGTGGGGAGGAGTCGGAGTCGCTGTTGCCGCCGCCGCTGTAGCTGCTGGACCCGAGTGG  
GAGTGAGGGGGAAACGGCAGGATCAAGTTTCGCCGAGCACCTCTCCGCGCACATCACTCCCGAGTGAGGAAAGCA  
ATACATCCAGTATGAGGCTTCAAGGATATGCTGTATTTCAGCTCAGGACCAGGCACCTTCTGTGGAAGTTACAG  
ATGAGGACACAGTAAAGAGGTATTTTGGCAAGTTTGAAGAGAAGTTTTTCCAAACCTGTGAAAAAGAACTTGCC  
AAAATCAACACATTTTATTTCAGAGAAGCTCGCAGAGGCTCAGCGCAGGTTTGTCTACACTTCAGAATGAGCTTCA  
GTCATCACTGGATGCACAGAAAGAAAGCACTGGTGTTACTACGCTGCGACAACGCAGAAAGCCAGTCTTCCACT  
TGTCCCATGAGGAACGTGTCCAACATAGAAATATTTAAAGACCTTAAACTGGCCTTCAGTGAGTTCTACCTCAGT  
CTAATCCTGCTGCAGAACTATCAGAATCTGAATTTTACAGGGTTTCGAAAAATCCTGAAAAAGCATGACAAGAT  
CCTGGAACATCTCGTGGAGCAGATTGGCGAGTGGCTCACGTAGAGGTGGCCCCATTTTATACATGCAAGAAAA  
TCAACCAGCTTATCTCTGAACTGAGGCTGTAGTGACCAATGAAGTTGAAGATGGTGACAGACAAAAGGCTATG  
AAGCGTTTACGTGTCCCCCTTTGGGAGCTGCTCAGCCTGCACCAGCATGGACTACTTTTAGAGTTGGCCTATT  
TTGTGGAATATTTCATTGTACTGAATATTACCCTTGTGCTTGCCGCTGTATTTAACTTGAACAGATAGAAGTA  
TATGGCCCTTGATAAGAATCTATCGGGGTGGCTTCTCTGTGAATTTCCTTTTCTACTGGGCATCAACACG  
TATGGTTGGAGACAGGCTGGAGTAAACCATGACTCATCTTTGAACCTTAATCCGAGAAGCAATTTGTCTCATCA  
ACATCTCTTTGAGATTGCTGGATTCTCGGGATATTGTGGTGCTGAGCCTTCTGGCATGCTTCTTTGCTCCAA  
TTAGTGTCTATCCCCACATATGTGTATCCACTTGCCCTTTATGGATTTATGGTTTTCTTCTTATCAACCCACC  
AAACTTTTCTACTATAAATCCCGGTTTTGGCTGCTTAACTGCTGTTTCGAGTATTTACAGCCCCCTTCATAA  
GGTAGGCTTTGCTGATTTCTGGCTGGCGGATCAGCTGAACAGCCTGTCAGTGATACTGATGGACCTGGAATATA  
TGATCTGCTTCTACAGTTTGGAGCTCAAATGGGATGAAAGTAAGGGCCTGTTGCCAAATAATTCAGAAGATCA  
GGAATTTGCCACAAATATACATATGGTGTGCGGGCCATTGTTCACTGCATTCCTGCTTGGCTTCGCTTCATCCA  
GTGCTGCGCCGATATCGAGACACAAAAGGGCCTTTCCTCATTAGTTAATGCTGGCAAGTACTCCACAACCTT  
TCTTCATGGTGGCGTTTGCAGCCCTTTACAGCACTCACAAAGAACGAGGTCACTCGGACACTATGGTGTTCTTT  
TACCTGTGGATTGTCTTTTATATCATCAGTTCCTGCTATACCCCTCATCTGGGATCTCAAGATGGACTGGGGTCT  
CTTCGATAAGAAATGCTGGAGAGAACACTTTCTCCGGGAAGAGATTGTATACCCCCAAAAGCCTACTACTACT  
GTGCCATAATAGAGGATGTGATTCTGCGCTTTGCTTGGACTATCCAAATCTCGATTACCTCTACAACCTTTGTTG  
CCTCATTCTGGGGACATCATTTGCTACTGTCTTTGCCCACTTGAGGTTTTCCGGCGATTTGTGTGGAACCTCTT  
CCGCTGGAGAATGAACATCTGAATAACTGTGGTGAATCCGTGCTGTGCGGACATCTCTGTGGCCCCCTGA  
ACGCAGATGATCAGACTCTCCTAGAACAGATGATGGACCGGATGATGGGGTACGAAACCCGAGAAGAACTCG  
TCATGGAAGTACAACAGCATATCCCTGCGCCGGCCTCGCTCGCTTCTCAATCCAAGGCTCGTGACACTAA  
GGTATTGATAGAAGACACAGATGATGAAGCTAACACTTGAATTTTTCTGAAGTCTAGCTTAACATCTTTGGTTTT  
CCTACTCTACAATCCTTTCTCGACCAACGCAACCTCTAGTACCTTTCCAGCCGAAAACAGGAGAAAACACATA  
ACACATTTTCCGAGCTCTTCCGGATCGGATCCTATGGACTCCAAACAAGCTCACTGTGTTTCTTTCTTTCTT  
CTGGTTTAATTTTAATTTTCTATTTTCAAAACAAGTATTTACTTCATTGCCAATCAGAGGATGTTTTAAGAAA  
CAAAACATAGTATCTTATGGATTGTTTACAATCACAAGGACATAGATACCTATCAGGATGAAGAACAGGCATTG  
CAAGGACCTCTGATGGGACGGTACTGAGATATCTCGGCTCCGCTCAGCCCGGTTTTGAATGGTTGAAACCGG  
ACATTGGTTTTTAAATTTTTTGTGAGTTTATGTGGAGAATTTTTTTCTTTCTTCATACCCAGCGCAAAGGCAC  
TGGCCGCACTTGCAGGAAAAGTGCAACTTAAAGCAGTACCTTCATTTCATGAAGCTACTTTTTAATTTGATGTAA  
CTTTTCTTATTTTGGGAAGGGTTGCTGGGTGGGTGGGAAAATATGATGTATTTGTTACACATAGTTTTCTCATTA  
TTTATGAACTTAACCATAACAGATGATATAACTCCTGTGCAATGAAGGTGATAACAGTAAAAGTGATATAACT  
CCTGTGCAATGAAGGTGATAACAGTAAAAGAAGGCAGGGGAAACTTACGTTGGATGACATTTATGAGGGTCAGT  
CCCACATACCTCTTTCAGGAGACAACCTTGACCCAGTTTGACCTTTCTTTTCTTTGTTTTATTTTAAGCCAAA  
GTTTCATTGCTAACTTCTTAAGTTGCTGCTGCTTTAGAGTCCTGAGCATATCTCTCATAACAAGGAATCCCACA  
CTTCACACCACCGGCTGAATTTTCATGGAAGAGGTTCTGATAATTTTTTTAACTTTTTAAGGAACAGATGTGGAA  
TACACTGGCCCATATTTCAACCTTAACAGCTGAAGCTATGCCCTATTATGCATCCACATGTATGGTCCCTGTAG  
CGTAGCTTTACTAGCTCTGAATCAGAAGACAGCTATTTTCAGAGGCTCTGTGTGGCCCTACTAGATAGTTTTT  
TCTTCTGGGTTCAACCACTTTAGCCAGAATTTGATCAAATTAAGAGTCTGTGATGGGGAACCTATATTTTGGAG  
CACATGGAACAAATTATACCTTCTCATTCATATATGTTGATACAAAAGACCTTGGCAGCCATTTCTCCAGCA  
GTTTTAAAGGATGAACATTGGATTTTCATGCCATCCCATAGAAAACCTGTTTTAAATTTTAGGGATCTTTACTT  
GGTCATACATGAAAAGTACACTGCTTAGAAATTATAGACTATTATGATCTGTCCACAGTGCCCATTTGTCACCTC  
TTTGTCTCATTTCTTCCCTTTGTTCTTAGTCATCCAAATAAGCCTGAAAACCATAAGAGATATTACTTTATTG  
AATATGGTTGGCATTAATTTAGCATTTTCATTATCTAACAAAATTAATATAAATTCAGGACATGGTAAAATGT  
GTTTTAATAACCCCAAGACCCAAATGAAAATTTCAAAGTCAATACCAGCAGATTTCATGAAAGTAAATTTAGTCC  
TATAATTTTTCAGCTTAATTATAAACAAAGGAACAAATAAGTGGAAGGCAGCTATTACCATTTCGCTTAGTCAA

36/136

**FIGURE 27B**

ACATTCGGTTACTGCCCTTTAATACACTCCTATCATCAGCACTTCCACCATGTATTACAAGTCTTGACCCATCC  
CTGTCGTAAGTCCAGTAAAAGTTACTGTTACTAGAAAATTTTTATCAATTAAGTACAAATAGTTTCTTTTAA  
AGTAGTTTCTTCCATCTTTATTCTGACTAGCTTCCAAAATGTGTTCCCTTTTTGAATCGAGGTTTTTTGTTTT  
GTTTTGTTTTCTGAAAAATCATACAACTTTGTGCTTCTATTGCTTTTTTGTGTTTGTGAAGCATGTCCCTTG  
GCCCCAATGGAAGAGGAAATGTTTAATTAATGCTTTTTAGTTTAAATAAATTGAATCATTATAATAATCAGTG  
TTAACAATTTAGTGACCCTTGGTAGGTAAAGGTTGCATTATTTATACTTGAGATTTTTTTCCCTAACTATTC  
TGTTTTTTGTACTTTAAACTATGGGGGAAATATCACTGGTCTGTCAAGAAACAGCAGTAATTATTACTGAGTT  
AAATTGAAAAGTCCAGTGGACCAGGCATTTCTTATATAAATAAAATTGGTGGTACTAATGTGT

37/136

**FIGURE 28**

CCCTTGCTGGACCCGAGTGGGAGTGAGGGGAAACGGCAGGATGAAGTTCGCCGAGCACCTCTCCGCGCACATC  
ACTCCCGAGTGGAGGAAGCAATACATCCAGTATGAGGCTTTCAAGGATATGCTGTATTACAGCTCAGGACCAGGC  
ACCTTCTGTGGAAGTTACAGATGAGGACACAGTAAAGAGGTATTTTGCCAAGTTTGAAGAGAAGTTTTTCCAAA  
CCTGTGAAAAAGAACTTGCCAAAATCAACACATTTTATTTCAGAGAAGCTCGCAGAGGCTCAGCGCAGGTTTGCT  
ACACTTCAGAATGAGCTTCAGTCATCACTGGATGCACAGAAAGAAAGCACTGGTGTACTACGCTGCGACAACG  
CAGAAAGCCAGTCTTCCACTTGTCCCATGAGGAACGTGTCCAACATAGAAATATTAAAGACCTTAAACTGGCCT  
TCAGTGAGTTCTACCTCAGTCTAATCCTGCTGCAGAACTATCAGAATCTGAATTTTACAGGGTTTCGAAAAATC  
CTGAAAAAGCATGACAAGATCCTGGAAACATCTCGTGGAGCAGATTGGCGAGTGGCTCACGTAGAGGTGGCCCC  
ATTTTATACATGCAAGAAAATCAACCAGCTTATCTCTGAACTGAGGCTGTAGTGACCAATGAACTTGAAGATG  
GTGACAGACAAAAGGCTATGAAGCGTTTACGTGTCCCCCTTTGGGAGCTGCTCAGCCTGCACCAGCATGGACT  
ACTTTTAGAGTTGGCCTATTTTGTGGAATATTCATTGTACTGAATATTACCCTTGTGCTTGCCGCTGTATTTAA  
ACTTGAAACAGATAGAAGTATATGGCCCTTGATAAGAATCTATCGGGGTGGCTTCTTCTGATTGAATTCCTTT  
TTCTACTGGGCATCAACACGTATGGTTGGAGACAGGCTGGAGTAAACCATGTACTCATCTTTGAACTTAATCCG  
AGAAGCAATTTGTCTCATCAACATCTCTTTGAGATTGCTGGATTCTCGGGATATTGTGGTGCCTGAGCCTTCT  
GGCATGCTTCTTTGCTCCAATTAGTGTATCCCCACATATGTGTATCCACTTGCCCTTTATGGATTTATGGTTT  
TCTTCCTTATCAACCCACCAAACTTTCTACTATAAATCCCGGTTTTGGCTGCTTAACTGCTGTTTCGAGTA  
TTTACAGCCCCCTTCCATAAGGTAGGCTTTGCTGATTTCTGGCTGGCGGATCAGCTGAACAGCCTGTCTAGTGT  
ACTGATGGACCTGGAATATATGATCTGCTTCTACAGTTTGGAGCTCAAATGGGATGAAAGTAAGGGCCTGTTGC  
CAAATAATTGAGAAGATCAGGAATTTGCCACAAATATACATATGGTGTGCGGGCCATTGTTTCAGTGCATTCCT  
GCTTGGCTTCGCTTCATCCAGTGCCTGCGCCGATATCGAGACACAAAAGGGCCTTTCCTCATTTAGTTAATGC  
TGGCAAATACTCCACAACCTTTCTTCATGGTGACGTTTGCAGCCCTTTACAGCACTCACAAAGAACGAGGTCCT  
CGGACACTATGGTGTCTTTTACCTGTGGATTGTCTTTTATATCATCAGTTCCTGCTATACCCTCATCTGGGAT  
CTCAAGATGGACTGGGGTCTCTTCGATAAGAATGCTGGAGAGAACACTTTCCTCCGGGAAGAGATTGTATACCC  
CCAAAAGCCTACTACTACTGTGCCATAATAGAGGATGTGATTCTGCGCTTTGCTTGGACTATCCAAATCTCGA  
TTACCTCTACAACCTTTGTTGCCCTCATTCTGGGGACATCATTGCTACTGTCTTTGCCCCACTTGAGGTTTTCCGG  
CGATTTGTGTGGAACCTTCTCCGCCTGGAGAATGAACATCTGAATAACTGTGGTGAATTCCGTGCTGTGCGGGA  
CATCTCTGTGGCCCCCTGAACGCAGATGATCAGACTCTCCTAGAACAGATGATGGACCAGGATGATGGGGTAC  
GAAACCGCCAGAAGAATCGGTCATGGAAGTACAACCAGAGCATATCCCTGCGCCGGCCTCGCCTCGCTTCTCAA  
TCCAAGGCTCGTGACACTAAGGTATTGATAGAAGACACAGATGATGAAGCTAACACTTGAATTTTCTGAAGTCT  
AGCTTAACATCTTTGGTTTTCTACTCTACAATCCTTTCTCGACCAACGCAAGGGC

38/136

**FIGURE 29**

GCGCCCTAGCCCTCTTTTCGGGGATACTGGCCGACCCCTCTTCCTTTTCCCCTTTAGTGAAGGCCTCCCCGTC  
GCCGCGCGGCTTCCCGGAGCCGACTGCAGACTCCCTCAGCCCGGTGTTCCCCGCGTCCGGACGCCGAGGTGCGG  
GCTTCGCAGAACTCGGGCCCCCTCCATCCGCCCTCAGAAAAGGGAGCGATGTTGATCTCAGGAAGCACAAAGGG  
ACCTTCCTAGCTCTGACTGAACCACGGAGCTCACCCCTGGACAGTATCACTCCGTGGAGGAAGACTGTGAGACTG  
TGGCTGGAAGCCAGATTGTAGCCACACATCCGCCCTGCCCTACCCAGAGCCCTGGAGCAGCAACTGGCTGCA  
GATCACAGACACAGTGAGGATATGAGTGTAGGGGTGAGCACCTCAGCCCTCTTTCCCAACCTCGGGCACAAG  
CGTGGGCATGTCTACCTTCTCCATCATGGACTATGTGGTGTTCGTCTGCTGCTGGTTCTCTCTTTGCCATTG  
GGCTCTACCATGCTTGTCTGTGGCTGGGGCCGGCATACTGTTGGTGAGCTGCTGATGGCGGACCGCAAAATGGGC  
TGCCTTCCGGTGGCACTGTCCCTGCTGGCCACCTTCCAGTCAGCCGTGGCCATCCTGGGTGTGCCGTGAGAGAT  
CTACCGATTTGGGACCCAATATTGGTTCCCTGGGCTGCTGCTACTTTCTGGGGCTGCTGATACCTGCACACATCT  
TCATCCCCGTTTTCTACCGCCTGCATCTCACCAGTGCCATGAGTACCTGGAGCTTCGATTCAATAAAACTGTG  
CGAGTGTGTGGAAGTGTGACCTTCATCTTTCCAGATGGTGATCTACATGGGAGTTGTGCTCTATGCTCCGTCAAT  
GGCTCTCAATGCAGTGACTGGCTTTGATCTGTGGCTGTCCGTGCTGGCCCTGGGCATTGTCTGTACCGTCTATA  
CAGCTCTGGGTGGGCTGAAGGCCGTATCTGGACAGATGTGTTCCAGACACTGGTCTGATGTTCCCTCGGGCAGCTG  
GCAGTTATCATCTGTGGGTGAGCTGGATCCAGACCCCTTTGTGCGGCACACCTTCTGGACCTTGGCCTTCGGGGGTGTCT  
TCATGATGCTCTCCTTATACGGGGTGAACCAGGCTCAGGTGCAGCGGTACCTCAGTTCGCCGACGGAGAAGGCT  
GCTGTGCTCTCCTGTTATGCAGTGTTCCCTTCCAGCAGGTGTCCCTCTGCGTGGGCTGCCTCATTTGGCCTGGT  
CATGTTTCGCGTATTACCAGGAGTATCCCATGAGCATTACAGCAGGCTCAGGCAGCCCCAGACCAGTTTCGTCTGT  
ACTTTGTGATGGATCTCCTGAAGGGCCTGCCAGGCTGCCAGGGCTCTTCATTGCCTGCCTCTTCAGCGGCTCT  
CTCAGCACTATATCCTCTGCTTTTAATTCATTGGCAACTGTTACGATGGAAGACCTGATTGACCTTGGTTCCC  
TGAGTTCTCTGAAGCCCGGGCCATCATGCTTTCCAGAGGCTTGCCTTTGGCTATGGGCTGCTTTGTCTAGGAA  
TGGCCTATATTTCCCTCCAGATGGGACCTGTGCTGCAGGCAGCAATCAGCATCTTTGGCATGGTTGGGGGACCG  
CTGCTGGGACTCTTCTGCCTTGGAAATGTTCTTTCCATGTGCTAACCTCCTGGTGCTGTTGTGGGGCTGTTGGC  
TGGGCTCGTCATGGCCTTCTGGATTGGCATCGGGAGCATCGTGACCAGCATGGGCTTCAGCATGCCACCCCTCTC  
CCTCTAATGGGTCCAGCTTCTCCCTGCCCACCAATCTAACCGTTGCCACTGTGACCACACTGATGCCCTTGACT  
ACCTTCTCCAAGCCACAGGGCTGCAGCGGTTCTATTCCCTGTCTTACTTATGGTACAGTGCTCACAACCTCCAC  
CACAGTGATTGTGGTGGGCCTGATTGTGAGTCTACTCACTGGGAGAATGCGAGGCCGGTCCCTGAACCTGCAA  
CCATTTACCCAGTGTTGCCAAAGCTCCTGTCCCTCCTTCCGTTGTCTGTGAGAAGCGGCTCCACTGCAGGAGC  
TACGGCCAGGACCACCTCGACACTGGCCTGTTTCTGAGAAGCCGAGGAATGGTGTGCTGGGGGACAGCAGAGA  
CAAGGAGGCCATGGCCCTGGATGGCACAGCCTATCAGGGGAGCAGCTCCACCTGCATCCTCCAGGAGACCTCCC  
TGTTGATGTTGACTCAGGACCCCGCCTCTGTCTCACTGTGCCAGGCCATAGCCAGAGGCCACCTGTAGTACAG  
GGATGAGTCTTGGTGTGTTCTGCAGGGACAGGCCTGGATGATCTAGCTCATACCAAGGACCTTGTCTGAGAG  
GTTCTTGCCTGCAGGAGAAGCTGTACATCTCAAGCATGTGAGGCACCGTTTTTCTCGTCGCTTGCCAATCTGT  
TTTTTAAAGGATCAGGCTCGTAGGGAGCAGGATCATGCCAGAAATAGGGATGGAAGTGCATCCTCTGGGAAAAA  
GATAATGGCTTCTGATTCAACATAGCCATAGTCTTTGAAGTAAGTGGCTAGAAACAGCACTCTGGTTATAATT  
GCCCCAGGGCCTGATTGAGGACTGACTCTCCACCATAAACTGGAAGCTGCTTCCCTGTAGTCCCCATTTTCTCAG  
TACCAGTTCTGCCAGCCACAGTGAGCCCTATTATTACTTTTCTGATTTGTCTGTGACACTCAAGCCCCCTCTCATT  
TTTATCTGTCTACCTCCATTCTGAAGAGGGAGGTTTTTGGTGTCCCTGGTCTCTGGGAATAGAAGATCCATTTG  
TCTTTGTGTAGAGCAAGCACGTTTTTCCACCTCACTGTCTCCATCCTCCACCTCTGAGATGGACACTTAAGAGAC  
GGGGCAAATGTGGATCCAAGAAACCAGGGCCATGACCAGGTCCACTGTGGAGCAGCCATCTATCTACCTGACTC  
CTGAGCCAGGCTGCCGTGGTGTCAATTTCTGTGATCCGTGCTCTGTTTCTTTTGGAGTTTCTTCTCCACATTAT  
CTTTGTTCTTGGGGAATAAAAACTACCATTGGACCTAAAAAAAAAAAAAAAAAAAA

39/136

**FIGURE 30**

GCGGGCGCCAGTGCACCGGAGGAGGTGAGCGCCAGGTCGCCTTCGCGGCCCCGGGGACACAGGCAGGGACGCGG  
GAGCTGATGCGGCTGGACCGGCCGGGGAAACAGTATTTTCTGGAAGGGGGCCCCCTCTGAAGCGGTCCAGGATCC  
TGCACATGGCGCTGACCGGGGCCTCAGACCCCTCTGCAGAGGCAGAGGCCAACGGGGAGAAGCCCTTTCTGCTG  
CGGGCATTGCAGATCGCGCTGGTGGTCTCCCTCTACTGGGTCACCTCCATCTCCATGGTGTTCCTTAATAAGTA  
CCTGCTGGACAGCCCCCTCCCTGCGGCTGGACACCCCCATCTTCGTACCTTCTACCAGTGCCTGGTGACCACGC  
TGCTGTGCAAAGGCCTCAGCGCTCTGGCCGCTGCTGCCCTGGTGCCGTGGACTTCCCCAGCTTGCGCCTGGAC  
CTCAGGGTGGCCCGCAGCGTCCTGCCCCCTGTCGGTGGTCTTCATCGGCATGATCACCTTCAATAACCTCTGCCT  
CAAGTACGTCGGTGTGGCCTTCTACAATGTGGGCCGCTCACTCACCACCGTCTTCAACGTGCTGCTCTCCTACC  
TGCTGCTCAAGCAGACCACCTCCTTCTATGCCCTGCTCACCTGCGGTATCATCATCGGGGGCTTCTGGCTTGGT  
GTGGACCAGGAGGGGGCAGAAGGCACCCTGTCGTGGCTGGGCACCGTCTTCGGCGTGCTGGCTAGCCTCTGTGT  
CTCGCTCAACGCCATCTACACCACGAAGGTGCTCCCGGCGGTGGACGGCAGCATCTGGCGCCTGACTTTCTACA  
ACAACGTCAACGCCTGCATCCTCTTCCTGCCCCCTGCTCCTGCTGCTCGGGGAGCTTCAGGCCCTGCGTGACCTT  
GCCCAGCTGGGCAGTGCCCACTTCTGGGGGATGATGACGCTGGGCGGCCTGTTTGGCTTTGCCATCGGCTACGT  
GACAGGACTGCAGATCAAGTTCACCAGTCCGCTGACCCACAATGTGTGCGGCACGGCCAAGGCCTGTGCCCAGA  
CAGTGCTGGCCGTGCTCTACTACGAGGAGACCAAGAGCTTCCTCTGGTGGACGAGCAACATGATGGTGCTGGGC  
GGCTCCTCCGCCTACACCTGGGTGAGGGGCTGGGAGATGAAGAAGACTCCGGAGGAGCCCAGCCCCAAAGACAG  
CGAGAAGAGCGCCATGGGGGTGTGAGACACACAGGCACCCTGGATGGCCCGGCCCCGGGGCCCGTACACAGGCG  
GGGCCAGCACAGTAGTGAAGGCGGTCTCCTGGACCCCAGAAGCGTGCTGTGGTGTGGACTGGGTGCTACTTATA  
GACCCAATCAGAATACGGTGGTTGAGAAGGAACCAGTGTTTACAAGTAATATCAGAAAGTTGAAGGAACCAGTG  
TTTACAAGTAATACCAGAAAGTTGCC



40/136

**FIGURE 31**

GCCCTTATCCTGCACATGGCGCTGACCGGGGCCCTCAGACCCCTCTGCAGAGGCAGAGGCCAACGGGGAGAAGCC  
CTTTCTGCTGCGGGCATTGCAGATCGCGCTGGTGGTCTCCCTCTACTGGGTACCTCCATCTCCATGGTGTTCC  
TTAATAAGTACCTGCTGGACAGCCCCCTCCCTGCGGCTGGACACCCCCATCTTCGTCACCTTCTACCAGTGCCTG  
GTGACCACGCTGCTGTGCAAGGCCTCAGCGCTCTGGCCGCCTGCTGCCCTGGTGCCGTGGACTTCCCCAGCTT  
GCGCCTGGACCTCAGGGTGGCCCGCAGCGTCCTGCCCCCTGTCGGTGGTCTTCATCGGCATGATCACCTTCAATA  
ACCTCTGCCTCAAGTACGTGCGGTGTGGCCTTCTACAATGTGGGCCGCTCACTCACCACCGTCTTCAACGTGCTG  
CTCTCCTACCTGCTGCTCAAGCAGACCACCTCCTTCTATGCCCTGCTCACCTGCGGTATCATCATCGGGGGCTT  
CTGGCTTGGTGTGGACCAGGAGGGGGCAGAAGGCACCCTGTCGTGGCTGGGCACCGTCTTCGGCGTGCTGGCTA  
GCCTCTGTGTCTCGCTCAACGCCATCTACACCACGAAGGTGCTCCCGGCGGTGGACGGCAGCATCTGGCGCCTG  
ACTTTCTACAACAACGTCAACGCCTGCATCCTCTTCCTGCCCCTGCTCCTGCTGCTCGGGGAGCTTCAGGCCCT  
GCGTGACTTTGCCCAGCTGGGCAGTGCCCACTTCTGGGGGATGATGACGCTGGGCGGCCTGTTTGGCTTTGCCA  
TCGGCTACGTGACAGGACTGCAGATCAAGTTCACCAGTCCGCTGACCCACAATGTGTGCGGGCACGGCCAAGGCC  
TGTGCCCAGACAGTGCTGGCCGTGCTCTACTACGAGGAGACCAAGAGCTTCCTCTGGTGGACGAGCAACATGAT  
GGTGCTGGGCGGCTCCTCCGCCTACACCTGGGTGAGGGGCTGGGAGATGAAGAAGACTCCGGAGGAGCCCAGCC  
CCAAAGACAGCGAGAAGAGCGCCATGGGGGTGTGAGCACCACAGGCACCCTGAAGGGC

41/136

**FIGURE 32**

CCGAGCGCGGGGCACCGGGGGCCTCCTGTATAGGCGGGCACCATGGGCTCCTGCTCCGGCCGCTGCGCGCTCGT  
CGTCCTCTGCGCTTTTCAGCTGGTCGCCGCCCTGGAGAGGCAGGTGTTTGACTTCCTGGGCTACCAGTGGGCGC  
CCATCCTGGCCAACTTTGTCCACATCATCATCGTCATCCTGGGACTCTTCGGCACCATCCAGTACCGGCTGCGC  
TACGTCATGGTGTACACGCTGTGGGCAGCCGTCTGGGTACCTGGAACGTCTTCATCATCTGCTTCTACCTGGA  
AGTCGGTGGCCTCTTACAGGACAGCGAGCTACTGACCTTCAGCCTCTCCCGGCATCGCTCCTGGTGGCGTGAGC  
GCTGGCCAGGCTGTCTGCATGAGGAGGTGCCAGCAGTGGGCCTCGGGGCCCCCATGGCCAGGCCCTGGTGTCA  
GGTGTCTGGCTGTGCCCTGGAGCCCAGCTATGTGGAGGCCCTACACAGTGGCCTGCAGATCCTGATCGCGCTTCT  
GGGCTTTGTCTGTGGCTGCCAGGTGGTCAGCGTGTTTACGGAGGAAGAGGACAGCTTTGATTTTCATTGGTGGAT  
TTGATCCATTTTCTCTCTACCATGTCAATGAAAAGCCATCCAGTCTCTTGTCCAAGCAGGTGTACTTGCCTGCG  
TAAGTGAGGAAACAGCTGATCCTGCTCCTGTGGCCTCCAGCCTCAGCGACCGACCAGTGACAATGACAGGAGCT  
CCCAGGCCTTGGGACGCGCCCCCAGCAGCCCCCAGGCGGCCGCGCAGCACCTGCCCTGGGTTCCTAAGTACT  
GGACACCAGCCAGGGCGGCAGGGCAGTGCCACGGCTGGCTGCAGCGTCAAGAGAGTTTGTAATTCCTTTCTCT  
TAAAAAAAAA

42/136

**FIGURE 33**

CTCCTGTATAGGCGGGCACCATGGGCTCCTGCTCCGGCCGCTGCGCGCTCGTCGTCCTCTGCGCTTTTCAGCTG  
GTCGCCGCCCTGGAGAGGCAGGTGTTTGACTTCCTGGGCTACCAAGTGGGCGCCATCCTGGCCAACTTTGTCCA  
CATCATCATCGTCATCCTGGGACTCTTCGGCACCATCCAGTACCGGCTGCGCTATGTCATGGTGTACACGCTGT  
GGGCAGCCGTCTGGGTACCTGGAACGTCTTCATCATCTGCTTCTACCTGGAAGTCGGTGGCCTCTTAAAGGAC  
AGCGAGCTACTGACCTTCAGCCTCTCCCGGCATCGCTCCTGGTGGCGTGAGCGCTGGCCAGGCTGTCTGCATGA  
GGAGGTGCCAGCAGTGGGCCTCGGGGCCCCCATGGCCAGGCCCTGGTGTGAGGTGCTGGCTGTGCCCTGGAGC  
CCAGCTATGTGGAGGCCCTACACAGTTGCCTGCAGATCCTGATCGCGCTTCTGGGCTTTGTCTGTGGCTGCCAG  
GTGGTCAGCGTGTTTACGGAGGAAGAGGACAGCTTTGATTTTATTGGTGGATTTGATCCATTTCTCTCTACCA  
TGTC AATGAAAAGCCATCCAGTCTCTTGTCCAAGCAGGTGTACTTGCCTGCGTTAAGTGAGGAAACAGCTGATCC

43/136

**FIGURE 34**

CTCCTGTATAGGCGGGCACCATGGGCTCCTGCTCCGGCCGCTGCGCGCTCGTCGTCCTCTGCGCTTTTCAGCTG  
GTCGCCGCCCTGGAGAGGCAGGTGTTTGACTTCCTGGGCTACCAGTGGGCGCCCATCCTGGCCAACTTTGTCCA  
CATCATCATCGTCATCCTGGGACTCTTCGGCACCATCCAGTACCGGCTGCGCTATGTCATGGTGTACACGCTGT  
GGGCAGCCGTCTGGGTACCTGGAACGTCTTCATCATCTGCTTCTACCTGGAAGTCGGTGGCCTCTTAAAGGAC  
AGCGAGCTACTGACCTTCAGCCTCTCCCGGCATCGCTCCTGGTGGCGTGAGCGCTGGCCAGGCTGTCTGCATGA  
GGAGGTGCCAGCAGTGGGCCTCGGGGCCCCCATGGCCAGGCCCTGGTGTGAGGTGCTGGCTGTGCCCTGGAGC  
CCAGCTATGTGGAGGCCCTACACAGTTGCCTGCAGATCCTGATCGCGCTTCTGGGCTTTGTCTGTGGCTGCCAG  
GTGGTCAGCGTGTTTACGGAGGAAGAGGACAGCTGCCTGCGTAAGTGAAGGAAACAGCTGATCCA

44/136

**FIGURE 35**

CTCCTGTATAGGCGGGCACCATGGGCTCCTGCTCCGGCCGCTGCGCGCTCGTCGTCCCTCTGCGCTTTTCAGCTG  
GTCGCCGCCCTGGAGAGGCAGGTGTTTGA~~CT~~TCCCTGGGCTACCAGTGGGCGCCCATCCTGGCCAACTTTGTCCA  
CATCATCATCGTCATCCTGGGACTCTTCGGCACCATCCAGTACCGGCTGCGCTACGTCATGGTGTACACGCTGT  
GGGCAGCCGTCTGGGTACCTGGAACGTCTTCATCATCTGCTTCTACCTGGAAGTCGGTGGCCTCTTACAGGAC  
AGCGAGCTACTGACCTTCAGCCTCTCCCGGCATCGCTCCTGGTGGCGTGAGCGCTGGCCAGGCTGTCTGCATGA  
GGAGGTGCCAGCAGTGGGCCTCGGGGCCCCCATGGCCAGGCCCTGGTGTGTCAGGTGCTGGCTGTGCCCTGGAGC  
CCAGCTATGTGGAGGCCCTACACAGTGGCCTGCAGATCCTGATCGCGCTTCTGGGCTTTGTCTGTGGCTGCCAG  
GTGGTCAGCGTGTTTACGGAGGAAGAGGACAGCTGCCTGCGTAAGTGAAGGAAACAGCTGATCCA

45/136

**FIGURE 36**

GCATGGAAAGTCTTTATTTGAGCCCCTTAGCTGATGTGGAATCAGAAGAGCAAAAAGGTCATCTTCAGAGTGGC  
CTGGGCTGGGTCTTTTCTCTCCAGGATAGAAAAGTGGTGGTCACTTTATCCCTAGTAGACATGCTGCTGGGCT  
TTATCGCCCCAGCATTCCCATCCCCTCCAGAGCCCCTTGTCACCTCCAGACCAGCGAGTGTGGGCCTTTATCTGG  
ACTCTGCTTCCTCCCTGGGGACACCAGGTCTTGAGCAAGAGAACTTGGCAGGCTCTCCCCATGGCACTCTTAT  
TCCTCCTCCTGTTCTTATGTGGAACCTCCCAGGCTGCAGACAACATGCAGGCCATCTATGTGGCCTTGCGGGAG  
GCAGTAGAGCTGCCATGTCCCTCACCACCTACTCTACATGGGGACGAACACCTGTCATGGTTCTGCAGCCCTGC  
AGCAGGCTCCTTCACCACCCTGGTAGCCCAAGTCCAAGTGGGCAGGCCAGCCCCAGACCCTGGAAAACCAGGAA  
GGGAATCCAGGCTCAGACTGCTGGGGAACCTATTCTTTGTGGTTGGAGGGATCCAAAGAGGAAGATGCCGGGCGG  
TACTGGTGCGCTGTGCTAGGTCAGCACCACAACCTACCAGAACTGGAGGGTGTACGACGTCTTGGTGCTCAAAGG  
ATCCCAGTTATCTGCAAGGGCTGCAGATGGATCCCCCTGCAATGTCTCCTGTGCTCTGTGGTCCCCAGCAGAC  
GCATGGACTCTGTGACCTGGCAGGAAGGGAAGGGTCCCGTGAGGGGCCGTGTTCACTCCTTCTGGGGCAGTGAG  
GCTGCCCTGCTCTTGGTGTGTCCTGGGGAGGGGCTTTCTGAGCCCAGGAGCCGAAGACCAAGAATCATCCGCTG  
CCTCATGACTCACAACAAAGGGGTGAGCTTTAGCCTGGCAGCCTCCATCGATGCTTCTCCTGCCCTCTGTGCCC  
CTTCCACGGGCTGGGACATGCCTTGGAATTCTGATGCTGCTGCTCACAATGGGCCAGGGAGTTGTCATCCTGGCC  
CTCAGCATCGTGCTCTGGAGGCAGAGGGTCCGTGGGGCTCCAGGCAGAGGAAACCGAATGCGGTGCTACAACCTG  
TGGTGGAAGCCCCAGCAGTTCTTGCAAAGAGGCCGTGACCACCTGTGGCGAGGGCAGACCCCAGCCAGGCCTGG  
AACAGATCAAGCTACCTGGAAACCCCCCAGTGACCTTGATTACCAACATCCAGCCTGCGTCGCAGCCCATCAT  
TGCAATCAAGTGGAGACAGAGTCGGTGGGAGACGTGACTTATCCAGCCCACAGGGACTGCTACCTGGGAGACCT  
GTGCAACAGCGCCGTGGCAAGCCATGTGGCCCCCTGCAGGCATTTTGGCTGCAGCAGCTACCGCCCTGACCTGTC  
TCTTGCCAGGACTGTGGAGCGGATAGGGGGAGTAGGAGTAGAGAAGGGAACAAGGGAGCAAGGGAACAAGGGAC  
ATCTGAACATCTAATGTGAGAAGAGAAACATCCTTCTGTGAGTCATTAAAATCTATGAACCACTCT

46/136

**FIGURE 37A**

CTTTAGAGAAAGGAAGGGCCAAACTACGACTTGGCTTTCTGAAACGGAAGCATAAAATGTTCTTTTCTCCATT  
TGTCTGGATCTGAGAACCTGCATTTGGTATTAGCTAGTGGAAGCAGTATGTATGGTTGAAGTGCATTGCTGCAG  
CTGGTAGCATGAGTGGTGGCCACCAGCTGCAGCTGGCTGCCCTCTGGCCCTGGCTGCTGATGGCTACCCTGCAG  
GCAGGCTTTGGACGCACAGGACTGGTACTGGCAGCAGCGGTGGAGTCTGAAAGATCAGCAGAACAGAAAGCTGT  
TATCAGAGTGATCCCCCTTGAAAATGGACCCACAGGAAAATTAATGCAGTCCCACCCACTGTACCTGTGCAATGCCAGTGATGAC  
TTGCTGAAATAACTCCAGCAGAAGGAAAATTAATGCAGTCCCACCCACTGTACCTGTGCAATGCCAGTGATGAC  
GACAATCTGGAGCCTGGATTTCATCAGCATCGTCAAGCTGGAGAGTCCCTCGACGGGCCCCCGCCCCCTGCCTGTC  
ACTGGCTAGCAAGGCTCGGATGGCGGGTGAGCGAGGAGCCAGTGCTGTCTCTTTGACATCACTGAGGATCGAG  
CTGCTGCTGAGCAGCTGCAGCAGCCGCTGGGGCTGACCTGGCCAGTGGTGTGATCTGGGGTAATGACGCTGAG  
AAGCTGATGGAGTTTGTGTACAAGAACCAAAGGCCCATGTGAGGATTGAGCTGAAGGAGCCCCCGGCCTGGCC  
AGATTATGATGTGTGGATCCTAATGACAGTGGTGGGCACCATCTTTGTGATCATCCTGGCTTCGGTGCTGCGCA  
TCCGGTGCCGCCCGCCACAGCAGGCCGGATCCGCTTCAGCAGAGAACAGCCTGGGCCATCAGCCAGCTGGCC  
ACCAGGAGGTACCAGGCCAGCTGCAGGCAGGCCGGGTGAGTGGCCAGACTCAGGGAGCAGCTGCAGCTCAGC  
CCCTGTGTGTGCCATCTGTCTGGAGGAGTCTCTGAGGGGCAGGAGCTACGGGTCAATTCCTGCCCTCCATGAGT  
TCCATCGTAACTGTGTGGACCCCTGGTTACATCAGCATCGGACTTGCCCCCTCTGCGTGTTCACATCACAGAG  
GGAGATTCAATTTCCAGTCCCTGGGACCCCTCTCGATCTTACCAAGAACCAGGTCTGAAGACTCCACCTCATTCG  
CCAGCATCCCGGCCATGCCACTACCACCTCCCTGCTGCCTACCTGTTGGGCCCTTCCCGGAGTGCAGTGGCTC  
GGCCCCACGACCTGGTCCCTTCTGCCATCCAGGAGCCAGGCATGGGCCCTCGGCATCACCGCTTCCCCAGA  
GCTGCACATCCCCGGGCTCCAGGAGAGCAGCAGCGCTGGCAGGAGCCAGCACCCCTATGCACAAGGCTGGGG  
AATGAGCCACCTCCAATCCACCTCACAGCACCTGCTGCTTGGCCAGTGCCCCACGCCGGGCCAGGCCCTTG  
ACAGCAGTGGATCTGGAGAAAGCTATTGCACAGAACGCAGTGGGTACCTGGCAGATGGGCCAGCCAGTGACTCC  
AGCTCAGGGCCCTGTCTATGGCTCTTCCAGTGACTCTGTGGTCAACTGCACGGACATCAGCCTACAGGGGGTCCA  
TGGCAGCAGTTCTACTTTCTGCAGCTCCCTAAGCAGTGACTTTGACCCCTAGTGTACTGCAGCCCTAAAGGGG  
ATCCCCAGCGAGTGGACATGCAGCCTAGTGTGACCTCTCGGCCCTCGTTCCCTGGACTCGGTGGTGCCACAGGG  
GAAACCCAGGTTTCCAGCCATGTCCACTACCACCGCCACCGGCACCACCTACAAAAAGCGGTTCCAGTGGCA  
TGGCAGGAAGCCTGGCCAGAAACCGGAGTCCCCAGTCCAGGCCTCCTATTCTCGGACACAGCCCCAGCCAG  
AGCCACCTTCTCCTGATCAGCAAGTACCAGGATCCAACTCAGCAGCCCCCTCGGGGCGGCTCTCTAACCCACAG  
TGCCCCAGGGCCCTCCCTGAGCCAGCCCCCTGGCCAGTTGACGCCTCCAGCATCTGCCCCAGTACCAGCAGTCT  
GTTCAACTTGCAAAAATCCAGCCTCTCTGCCCCGACCCACAGAGGAAAGCGGGGGGCTCCCTCCGAGCCCA  
CCCCTGGCTCTCGGCCCCAGGATGCAACTGTGCACCCAGCTTGCAGATTTTTTCCCATTACACCCCCAGTGTG  
GCATATCCTTGGTCCCCAGAGGCACACCCCTTGATCTGTGGACCTCAGGCCTGGACAAGAGGCTGTCTACCAGA  
AACCCAGGCCCTGTACTCAAATTCACAGCCAGTGTGGTTGTGCCTGACTCCTCGCCAGCCCCCTGGAACCAC  
ATCCACCTGGGGAGGGGGCTTCTGAATGGAGTTCTGACACCGCAGAGGGCAGGCCATGCCCTTATCCGCACCTGC  
CAGGTGCTGTGGGCCAGCCTGGCTCAGAGGAGGAACTCAGAGGAGCTGTGTGAACAGGCTGTGTGAATGTTCA  
GGCCTAGCTCCAACCAAGAGTGTGCTCCAGATGTGTTTGGGCCCTACCTGGCACAGAGTCTGCTCCTGGGAAA  
GGAAAGGACCACAGCAAACACCATTCTTTTTTGGCGTACTTCTTAGAAGCACTGGAAGAGGAGTGGTGATGGTGG  
AGGGTGAGAGGGTGCCGTTTTCTGCTCCAGCTCCAGACCTTGTCTGCAGAAAACATCTGCAGTGCAGCAAATCC  
ATGTCCAGCCAGGCAACCAGCTGCTGCCTGTGGCGTGTGTGGGCTGGATCCCTTGAAGGCTGAGTTTTTGGGG  
CAGAAAGCTAGCTATGGGTAGCCAGGTGTTACAAAGGTGCTGCTCCTTCTCCAACCCCTACTTGGTTTTCCCTCA  
CCCCAAGCCTCATGTTTCATACCAGCCAGTGGGTTTCAGCAGAACGCATGACACCTTATCACCTCCCTCCTTGGGT  
GAGCTCTGAACACCAGCTTTGGCCCCCTCCACAGTAAGGCTGCTACATCAGGGGCAACCCTGGCTCTATCATTTT  
CCTTTTTTGGCAAAAGGACCAGTAGCATAGGTGAGCCCTGAGCACTAAAAGGAGGGGTCCCTGAAGCTTTCCCA  
CTATAGTGTGGAGTTCTGTCCCTGAGGTGGGTACAGCAGCCTTGGTTCTCTGAGGGGTGAGAATAAGAATAGT  
GGGGAGGGAATACTCCTCCTGAAGATTTCTGTCTCAGAGTCCCAGAGAGGTAGAAAGGAGGAATTTCTGCT  
GGACTTCATCTGGCAGAGGAAGGATGGAATGAAGGTAGAAAAGGCAGAAATTACAGCTGAGCGGGGACAACAAA  
GAGTTCTCTCTGGGAAAAGTTTTGTCTTAGAGCAAGGATGGAATAAGGGGACAACAAAGGAAAAGCAAAGTGT  
GACCCCTTGGGTTTTGGACAGCCAGAGGCCAGCTCCCAAGTAAAGCCATACAGGCCAGGACCCACAGGAGAG  
TGGATTAGAGCACAAAGTCTGGCCTCACTGAGTGGACAAGAGTGTATGGGCCTCATCAGGGGTGACATTACCCCA  
GGGCAGCCTGACCACTCTTGGCCCCCTCAGGCATTATCCCATTTGGAATGTGAATGTGGTGGCAAAGTGGGCAGA  
GGACCCACCTGGGAACCTTTTTCCCTCAGTTAGTGGGGAGACTAGCACCTAGGTACCCACATGGGTATTTATA  
TCTGAACCAGACAGACGCTTGAATCAGGCACATATGTTAAGAAATATATTTATTTGCTAATATATTTATCCACAA  
ATGTGGTCTGGTCTTGTGGTTTTGTCTGTCTGCTGACTGTCACTCAGGGTAACAACGTCTCTTTCTACATCA  
AGAGAAGTAAATTATTTATGTTATCAGAGGCTAGGCTCCGATTCATGAAAGGATAGGGTAGAGTAGAGGGCTTG  
GCAATAAGAACTGGTTTTGTAAGCCCCTAAAAGTGTGGCTTAGTGAGATCAGGGAAGGAGAAAGCATGACTGGAT

47/136

**FIGURE 37B**

TCTTACTGTGCTTCAGTCATTATTATTATACTGTTCACTTCACACATTATCATACTTCAGTGACTYAGACCTTG  
GGCAAATACTCTGTGCCTCGCTTTTTTCAGTCCATAAAATGGGCCTACTTAATAGTTGTTGCAGGACTTACATGA  
GATAATAGAGTGTAGAAAATATGTTCCAAAGTGGAAGTTTTATTTCAGTGATAGAAAACATCCAAACCTGTCAC  
AGAGCCCATCTGAACACAGCATGGGACCGCCAACAAGAAGAAAGCCCGCCCGGAAGCAGCTCAATCAGGAGGCT  
GGGCTGGAATGACAGCGCAGCGGGGCCTGAAACTATTTATATCCCAAAGCTCCTCTCAGATAAACACAAATGAC  
TGC GTTCTGCCTGCACTCGGGCTATTGCGAGGACAGAGAGCTGGTGCTCCATTGGCGTGAAGTCTCCAGGGCCA  
GAAGGGGCCTTTGTCGCTTCCTCACAAGGCACAAGTTCCCCTTCTGCTTCCCCGAGAAAGGTTTGGTAGGGGTG  
GTGGTTTAGTGCTATAGAACAAGGCATTTGCTTCCTAGACGGTGAAATGAAAGGGAAAAAAGGACACCTAA  
TCTCCTACAAATGGTCTTTAGTAAAGGAACC



**FIGURE 38**

CAGACTCTGGGGGAGCTCGGAGCTCCCGATCACGGCTTCTTGGGGGTAGCTACGGCTGGGTGTGTAGAACAGGGG  
 CCGGGGCTGGGGCTGGGTCCCCTAGTGGAGACCCAAGTGCAGAGGGCAAGAACTCTGCAGCTTCCTGCCTTCTG  
 GGTCACTTCCTTATTCAAGTCTGCAGCCGGCTCCCAGGGAGATCTCGGTGGAACCTCAGAAAACGCTGGGCAGTC  
 TGCCTTTCAACCATGCCCCCTGTCCCTGGGAGCCGAGATGTGGGGGCCTGAGGCCTGGCTGCTGCTGCTGCTACT  
 GCTGGCATCATTTACAGGCCGGTGCCCCGCGGGGTGAGCTGGAGACCTCAGACGTGGTAACTGTGGTGCTGGGCC  
 AGGACGCAAAACTGCCCTGCTTCTACCGAGGGGACTCCGGCGAGCAAGTGGGGCAAGTGGCATGGGCTCGGGTG  
 GACGCGGGCGAAGGCGCCCAGGAACTAGCGCTACTGCACTCCAAATACGGGCTTCATGTGAGCCCCGGCTTACGA  
 GGGCCGCGTGGAGCAGCCGCCGCCCCACGCAACCCCCTGGACGGCTCAGTGCTCCTGCGCAACGCAGTGCAGG  
 CGGATGAGGGCGAGTACGAGTGCCGGGTGAGCACCTTCCCCGCCGGCAGCTTCCAGGCGCGGCTGCGGCTCCGA  
 GTGCTGGTGCTCCCCCTGCCCTCACTGAATCCTGGTCCAGCACTAGAAGAGGGCCAGGGCCTGACCCTGGCAGC  
 CTCCTGCACAGCTGAGGCGAGCCAGCCAGCCCCAGCGTGACCTGGGACACGAGGTCAAAGGCACAACGTCCAGCC  
 GTTCCCTTCAAGCACTCCCGCTCTGCTGCCGTGACCTCAGAGTTCACACTTGGTGCCCTAGCCGCAGCTGAATGGG  
 CAGCCACTGACTTGTGTGGTGTCCTATCCCTGACCTGCTCCAGGACCAAAGGATCACCCACATCCTCCACGTGTC  
 CTCCTTGCTGAGGCCTCTGTGAGGGGCCTTGAAGACCAAAATCTGTGGCACATTGGCAGAGAAGGAGCTATGC  
 TCAAGTGCTGAGTGAAGGGCAGCCCCCTCCCTCATACAACCTGGACACGGCTGGATGGGCCTCTGCCAGTGGG  
 GTACGAGTGGATGGGGACACTTTGGGCTTTCCCCCACTGACCACTGAGCACAGCGGCATCTACGTCTGCCATGT  
 CAGCAATGAGTTCTCCTCAAGGGATTCTCAGGTCACTGTGGATGTTCTTGACCCCCAGGAAGACTCTGGGAAGC  
 AGGTGGACCTAGTGTCAGCCTCGGTGGTGGTGGTGGGTGTGATCGCCGCACTCTTGTTCTGCCTTCTGGTGGTG  
 GTGGTGGTGCTCATGTCCCGATACCATCGGCGCAAGGCCAGCAGATGACCCAGAAATATGAGGAGGAGCTGAC  
 CCTGACCAGGGAGAACTCCATCCGAGGCTGCATTCCCATCACACGGACCCCAGGAGCCAGCCGGAGGAGAGTG  
 TAGGGCTGAGAGCCGAGGGCCACCGTGATAGTCTCAAGGACAACAGTAGCTGCTCTGTGATGAGTGAAGAGCCC  
 GAGGGCCGCAGTTACTCCACGCTGACCACGGTGAGGGAGATAGAAACACAGACTGAACTGCTGTCTCCAGGCTC  
 TGGGCGGGGCCGAGGAGGAGGAAGATCAGGATGAAGGCATCAAACAGGCCATGAACCATTTTGTTCAGGAGAATG  
 GGACCCCTACGGGCCAAGCCCACGGGCAATGGCATCTACATCAATGGGCGGGGACACCTGGTCTGACCCAGGCCT  
 GCCTCCCTTCCCTAGGCCTGGCTCCTTCTGTTGACATGGGAGATTTTAGCTCATCTTGGGGGCCCTCCTTAAACA  
 CCCCCATTTCTTGCGGAAGATGCTCCCCATCCCCTGACTGCTTGACCTTTACCTCCAACCCCTTCTGTTTCATCG  
 GGAGGGCTCCACCAATTGAGTCTCTCCCACCATGCATGCAGGTCACTGTGTGTGTGCATGTGTGCTCTGTGTGAG  
 TGTGACTGACTGTGTGTGTGTGAGGGGTGACTGTCCGTGGAGGGGTGACTGTGTCCGTGGTGTGTATTATGCT  
 TGTCATATCAGAGTCAAGTGAACGTGGGTGATGTGCCACGGGATTTGAGTGGTTGCGTGGGCAACACTGTGAG  
 GTTTTGGCGTGTGTGTGTGTGTGACCTCTGCCTGAAAAGCAGGTATTTTCTCAGACCCCAGAGC  
 AGTATTAATGATGCAGAGGTTGGAGGAGAGAGGTGGAGACTGTGGCTCAGACCCAGGTGTGCGGGCATAGCTGG  
 AGCTGGAATCTGCCTCCGGTGTGAGGGAACCTGTCTCCTACCACTTCGGAGCCATGGGGGCAAGTGTGAAGCAG  
 CCAGTCCCTGGGTGAGCCAGAGGCTTGAACCTGTTACAGAAGCCCTCTGCCCTCTGGTGCCCTCTGGGCCTGCTG  
 CATGTACATATTTTCTGTAAATATACATGCGCCGGGAGCTTCTTGCAAGGAATACTGCTCCGAATCACTTTTAAT  
 TTTTTTCTTTTTTTTTTTCTTGCCCTTTCCATTAGTTGTATTTTTTATTTATTTTATTTTTATTTTTTTTTTAGA  
 GATGGAGTCTCACTATGTTGCTCAGGCTGGCCTTGAACCTCTGGGCTCAAGCAATCCTCCTGCCTCAGCCTCCC  
 TAGTAGCTGGGACTTTAAGTGACACCACTGTGCCTGCTTTGAATCCTTTACGAAGAGAAAAAAAAAATTAAG  
 AAAGCCTTTAGATTTATCCAATGTTTACTACTGGGATTGCTTAAAGTGAGGCCCTCCAACACCAGGGGGTTAA  
 TTCTGTGATTGTGAAAGGGGGCTACTTCCAAGGCATCTTCATGCAGGCAGCCCCCTTGGGAGGGCACCTGAGAGC  
 TGGTAGAGTCTGAAATTAGGGATGTGAGCCTCGTGGTTACTGAGTAAGGTAAATTTGCATCCACCATTGTTTGT  
 GATACCTTAGGGAATTGCTTGGACCTGGTGACAAGGGCTCCTGTTCAATAGTGGTGTGTTGGGAGAGAGAGAGCA  
 GTGATTATAGACCGAGAGAGTAGGAGTTGAGGTGAGGTGAAGGAGGTGCTGGGGGTGAGAATGTCGCCTTTCCC  
 CCTGGGTTTTTGATCACTAATTCAAGGCTCTTCTGGATGTTTCTCTGGGTGGGGCTGGAGTTCAATGAGGTTT  
 ATTTTTAGCTGGCCCACCCAGATACACTCAGCCAGAATACCTAGATTTAGTACCCAAACTCTTCTAGTCTGAA  
 ATCTGCTGGATTCTGGCCTAAGGAGAGGCTCCCATCCTTGGTCCCCAGCCAGCCTAGGACTTCGAATGTGG  
 AGCCTGAAGATCTAAGATCCTAACATGATGACTTTTTATGTAAATATGTGCATATTTGTACATAAAATGATATTCT  
 GTTTTTAAATAAACAGACAAAAACTTGAAAAA  
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

49/136

**FIGURE 39**

TTGGGGGTTTATTCTCTTCCCTTCTAACTTGACAGGGTCTTGCTCTGTCATTTCAGGCAAGAGTGCAGTAGTGTG  
ATCACTTCTTACTGCCGCCTCAAGCTTCCAGCCTCAACTCAAGCAATCCTCCCACCTCAGCCACCCAAGTGGCT  
GGGACTACAGATTAAGAATGACCCAAAATAAATTAAAGCTTTGTTCCAAAGCCAATGTGTATACTGAAGTGCCT  
GATGGAGGATGGGGCTGGGCGGTAGCTGTTTCATTTTTCTTCGTTGAAGTCTTCACCTACGGCATCATCAAGAC  
ATTTGGTGTCTTCTTTAATGACTTAATGGACAGTTTTAATGAATCCAATAGCAGGATCTCATGGATAATCTCAA  
TCTGTGTGTTTGTCTTAACATTTTCAGCTCCCCTCGCCACAGTCCTGAGCAATCGTTTCGGACACCGTCTGGTA  
GTGATGTTGGGGGGGCTACTTGTGACACCGGGATGGTGGCCGCCTCCTTCTCACAAGAGGTTTCTCATATGTA  
CGTCGCCATCGGCATCATCTCTGGTCTGGGATACTGCTTTAGTTTTCTCCCAACTGTAACCATCCTATCACAAT  
ATTTTGGCAAAAGACGTTCCATAGTCACTGCAGTTGCTTCCACAGGAGAATGTTTCGCTGTGTTTGCTTTCGCA  
CCAGCAATCATGGCTCTGAAGGAGCGCATTGGCTGGAGATACAGCCTCCTCTTCGTGGGCCTACTACAGTTAAA  
CATTGTGTCATCTTCGGAGCACTGCTCAGACCCATCATTATCAGAGGACCAGCGTCACCGAAAATAGTCATCCAGG  
AAAATCGGAAAAGAAGCGCAGTATATGCTTGAAAAATGAGAAAACACGAACCTCAATAGACTCCATTGACTCAGGA  
GTAGAACTAACTACCTCACCTAAAAATGTGCCTACTCACACTAACCTGGAAGTGGAGCCGAAGGCCGACATGCA  
GCAGGTCTGGTGAAGACCAGCCCCAGGCCAAGCGAAAAGAAAGCCCCGCTATTAGACTTCTCCATTTTGAAAG  
AGAAAAGTTTTATTTGTTATGCATTATTTGGTCTCTTTGCAACACTGGGATTCTTTGCACCTTCCTTGTACATC  
ATTCTCTGGGCATTAGTCTGGGCATTGACCAGGACCGCGCTGCTTTTTTATTATCTACGATGGCCATTGCAGA  
AGTTTTTCGGAAGGATCGGAGCTGGTTTTTGTCTCAACAGGGAGCCCATTCGTAAGATTTACATTGAGCTCATCT  
GCGTCATCTTATTGACTGTGTCTCTGTTTGCCTTTACTTTTGCTACTGAATTCTGGGGTCTAATGTCATGCAGC  
ATATTTTTTGGGTTTATGGTTGGAACAATAGGAGGACTCACATTCCACTGCTTGCTGAAGATGATGTCGTGGGC  
ATTGCAGAAGATGTCCTTCTGCAGCTGGGGTCTACATCTTCATTTCAGAGCATAGCAGGACTGGCTGGACCGCCCC  
TTGCAGGTTTGTGGTGGACCAAAGTAAGATCTACAGCAGGGCCTTCTACTCCTGCGCAGCTGGCATGGCCCTG  
GCTGCTGTGTGCCTCGCCCTGGTGAGACCGTGTAAGATGGGACTGTGCCAGCGTCATCACTCAGGTGAAACAAA  
GGTAGTGAGCCATCGTGGGAAGACTTTACAGGACATACCTGAAGACTTTCTGGAAATGGATCTTGCAAAAAATG  
AGCACAGAGTTCACGTGCAAATGGAGCCGGTATGACACACTTTCTTACAACAACAGCCACTGTGTTGGCTGGAG  
AGGGATGGGGTGGGCCCCAACGGGGACACAAGGAGGCAGAGGAGCTAACCCCTCTACTCCACTTTCAAACTACA  
TTTTAAAGGGAATGTGTATGTGAAGAGCACTACCAACATCGCTTTTGTGTTTGTGTTTGTGTTTAAAGCTTTT  
TTTTTTTGCTTGTTTTTAAAGCCAAAACAAAAACAACCAAGCACTCTTCCATATATAAATCTGGCTGTATTCA  
GTAGCAATACAAGAGATATGTAGAAAGACTCTTTGGTTCACATTCCGATATTAAAAATAGTGACATGAACTGGCA  
AAGTGGTTTTAAAGCTTTCACGTGGGATAAAATGATTTTCTTTTTTCTTTTCTTCTTCTCCTATGGTCTTGTCT  
GAATAAACTACTCTCCTGAATAAAACAACATCCAACCCAGGTCATTGAAATGAAATGGCCAGTC

50/136

**FIGURE 40**

GATGTGCTCCTTGGAGCTGGTGTGCAGTGTCTGACTGTAAGATCAAGTCCAAACCTGTTTTGGAATTGAGGAA  
ACTTCTCTTTTGATCTCAGCCCTTGGTGGTCCAGGTCTTCATGCTGCTGTGGGTGATATTACTGGTCCTGGCTC  
CTGTCAGTGGACAGTTTGCAAGGACACCCAGGCCCATTATTTTCCTCCAGCCTCCATGGACCACAGTCTTCCAA  
GGAGAGAGAGTGACCCTCACTTGCAAGGGATTTTCGCTTCTACTCACCACAGAAAACAAAATGGTACCATCGGTA  
CCTTGGGAAAGAAATACTAAGAGAAACCCAGACAATATCCTTGAGGTTTCAGGAATCTGGAGAGTACAGATGCC  
AGGCCCAGGGCTCCCCCTCTCAGTAGCCCTGTGCACCTTGGATTTTTCTTCAGAGATGGGATTTCCCTCATGCTGCC  
CAGGCTAATGTTGAACTCCTGGGCTCAAGTGATCTGCTCACCTTAGGCCTCTCAAAGCGCTGGGATTACAGCTTC  
GCTGATCCTGCAAGCTCCACTTTCTGTGTTTGAAGGAGACTCTGTGGTTCTGAGGTGCCGGGCAAAGGCGGAAG  
TAACACTGAATAATACTATTTACAAGAATGATAATGTCCTGGCATTCCTTAATAAAAGAACTGACTTCCAAAAA  
AAAAAAAAAAAAAAAAAAAA

51/136

**FIGURE 41A**

AATTCACTAATGCATTCTGCTCTTTTTGAGAGCACAGCTTCTCAGATGTGCTCCTTGGAGCTGGTGTGCAGTGT  
CCTGACTGTAAGATCAAGTCCAAACCTGTTTTGGAATTGAGGAACTTCTCTTTTGATCTCAGCCCTTGGTGGT  
CCAGGTCTTCA~~ATC~~CTGCTGTGGGTGATATTACTGGTCCTGGCTCCTGTGAGTGACAGTTTGCAAGGACACCCA  
GGCCCATTATTTTCTCCAGCCTCCATGGACCACAGTCTTCCAAGGAGAGAGAGTGACCCTCACTTGCAAGGGA  
TTTCGCTTCTACTCACCACAGAAAACAAAATGGTACCATCGGTACCTCGGGAAAGAAATACTAAGAGAAACCCC  
AGACAATATCCTTGAGGTTTCAAGGAATCTGGAGAGTACAGATGCCAGGCCCAGGGCTCCCCTCTCAGTAGCCCTG  
TGCACTTGGATTTTTCTTCAGCTTCGCTGATCCTGCAAGCTCCACTTTCTGTGTTTGAAGGAGACTCTGTGGTT  
CTGAGGTGCCGGGCAAAGGCGGAAGTAACACTGAATAATACTATTTACAAGAATGATAATGTCTTGGCATTTCCT  
TAATAAAAGAACTGACTTCCATATTCTCATGCATGTCTCAAGGACAATGGTGCATATCGCTGTACTGGATATA  
AGGAAAGTTGTTGCCCTGTTTCTTCCAATACAGTCAAAATCCAAGTCCAAGAGCCATTTACACGTCCAGTGCTG  
AGAGCCAGCTCCTTCCAGCCCATCAGCGGGAACCCAGTGACCCTGACCTGTGAGACCCAGCTCTCTCTAGAGAG  
GTCAGATGTCCCGCTCCGGTTCGGCTTCTTCAGAGATGACCAGACCCTGGGATTAGGCTGGAGTCTCTCCCCGA  
ATTTCCAGATTACTGCCATGTGGAGTAAAGATTCAAGGGTCTACTGGTGTAAAGGCAGCAACAATGCCTCACAGC  
GTCATATCTGACAGCCCGAGATCCTGGATACAGGTGCAGATCCCTGCATCTCATCCTGTCTCACTCTCAGCCC  
TGAAAAGGCTCTGAATTTTGAGGGAACCAAGGTGACACTTCACTGTGAAACCCAGGAAGATTCTCTGCGCACTT  
TGTACAGGTTTTATCATGAGGGTGTCCCCCTGAGGCACAAGTCAGTCCGCTGTGAAAGGGGAGCATCCATCAGC  
TTCTCACTGACTACAGAGAATTCAAGGAACTACTACTGCACAGCTGACAATGGCCTTGGCGCCAAGCCCAGTAA  
GGCTGTGAGCCTCTCAGTCACTGTTCCCGTGTCTCATCCTGTCTCAACCTCAGCTCTCCTGAGGACCTGATTT  
TTGAGGGAGCCAAGGTGACACTTCACTGTGAAGCCCAGAGAGGTTCACTCCCCATCCTGTACCAGTTTCATCAT  
GAGGATGCTGCCCTGGAGCGTAGGTGGGCCAACTCTGCAGGAGGAGTGGCCATCAGCTTCTCTCTGACTGCAGA  
GCATTCAAGGAACTACTACTGCACAGCTGACAATGGCTTTGGCCCCCAGCGCAGTAAGGCGGTGAGCCTCTCCA  
TCACTGTCCCTGTGTCTCATCCTGTCTCAACCTCAGCTCTGCTGAGGCCCTGACTTTTGAAGGAGCCACTGTG  
ACACTTCACTGTGAAGTCCAGAGAGGTTCCCCACAAATCCTATACCAGTTTTATCATGAGGACATGCCCTGTG  
GAGCAGCTCAACACCCCTCTGTGGGAAGAGTGTCTTCAGCTTCTCTCTGACTGAAGGACATTCAGGGAATTACT  
ACTGCACAGCTGACAATGGCTTTGGTCCCCAGCGCAGTGAAGTGGTGAGCCTTTTTGTCACTGTTCCAGTGTCT  
CGCCCCATCCTCAACCTCAGGGTTCAGGGGCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCACTGTGAGGC  
CCCGAGAGGCTCTCCCCCAATCCTGTACTGGTTTTATCATGAGGATGTACCCCTGGGGAGCAGCTCAGCCCCCT  
CTGGAGGAGAAGCTTCTTTCAACCTCTCTCTGACTGCAGAACATTCTGGAACTACTCATGTGAGGCCAACAAAT  
GGCCTAGTGGCCCAGCACAGTGACACAATATCACTCAGTGTTATAGTTCCAGTATCTCGTCCCATCCTCACCTT  
CAGGGCTCCCAGGGGCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCACTGTGAGGCCCTGAGAGGCTCCTCCC  
CAATCCTGTACTGTTTTATCATGAAGATGTCAACCTTGGGTAAAGATCTCAGCCCCCTTGAGAGGAGGGGCTCC  
TTCAACCTCTCTCTGACTACAGAACATTTGGAATCTACTCCTGTGAGGCAGACAATGTTCCGGAGGGCCAGCG  
CAGTGAGATGGTGACACTGAAAGTTGCAGTTCCGGTGTCTCGCCCGGTCTCACCCCTCAGGGCTCCCGGGACCC  
ATGCTGCGGTGGGGGACCTGCTGGAGCTTCACTGTGAGGCCCTGAGAGGCTCTCCCCTGATCCTGTACCGGTTT  
TTTCATGAGGATGTACCCCTAGGAAATAGGTGCTCCCCCTCTGGAGGAGCGTCCTTAAACCTCTCTCTGACTGC  
AGAGCACTCTGGAACTACTCCTGTGAGGCCGACAATGGCCTCGGGGCCAGCGCAGTGAGACAGTGACACTTT  
ATATCACAGGGCTGACCGGAACAGAAGTGGCCCTTTTGCCACAGGAGTCGCCGGGGGCTGCTCAGCATAGCA  
GGCCTTGCTGCGGGGGCACTGCTGCTCTACTGCTGGCTCTCGAGAAAAGCAGGGAGAAAGCCTGCCTCTGACCC  
CGCCAGGAGCCCTCCAGACTCGGACTCCCAAGAGCCACCTATCACAATGTACCAGCCTGGGAAGAGCTGCAAC  
CAGTGTAACATAATGCAAATCCTAGAGGAGAAAATGTGGTTTACTCAGAAGTACGGATCATCCAAGAGAAAAAG  
AAACATGCAGTGGCCTCTGACCCCAGGCATCTCAGGAACAAGGGTCCCCTATCATCTACTCTGAAGTTAAGGT  
GGCGTCAACCCCGGTTTTCCGGATCCCTGTTCTTGGCTTCCTCAGCTCCTCACAGAT~~GA~~GTCCACACGTCTCTCC  
AACTGCTGTTTTCAGCCTCTGCACCCCAAAGTTCCCCTTGGGGGAGAAGCAGCATTGAAGTGGGAAGATTTAGGC  
TGCCCCAGACCATATCTACTGGCCTTTGTTTACATGTCTCATTCTCAGTCTGACCAGAATGCAGGGCCCTGC  
TGGACTGTACCTGTTTTCCAGTTAAAGCCCTGACTGGCAGGTTTTTTAATCCAGTGGCAAGGTGCTCCCCTC  
CAGGGCCCAGCACATCTCCTGGATTCTTAGTGGGCTTCAGCTGTGATTGCTGTTCTGAGTACTGCTCTCATCA  
CAGCCCCACAGAGGGGCTTACCACACAAGGGAGAGTGGGCTTCAGGAGATGCCGGGCTGGCCTAACAGCT  
CAGGCTCTCCTAACTCCGACACAGAGTCTCTGCTTTGGGTGGATGCAATTTCTCAATGTATCATCAGCTGGTGG  
GGCTACTGCAGTGTGCTGCCAAATGGGACAGCACACAGCCTGTGCACATGGGACATGTGATGGTCTCCCCACG  
GGGGCTGCATTTACACTCCTCCACCTGTCTCAAACCTCTAAGGTCGGCACCTTGACACCAAGGTAACCTTCTCTCC  
TGCTCATGTGTGAGTGTCTACCTGCCCAAGTAAGTGGCTTTTATACACCAAGTCCCAAGTTCTTCCCATCCTAA  
CAGAAGTAACCCAGCAAGTCAAGGCCAGGAGGACCAGGGGTGCAGACAGAACACATACTGGAACACAGGAGGTG  
CTCAATTACTATTTGACTGACTGACTGAATGAATGAATGAATGAGGAAGAAAACGTGTGGGTAATCAAACCTGGCA  
TAAATCCAGTGCCTCCTAGGAAATCCGGGAGGTATTCTGGCTTCCCTAAGAAACAACGGAAGAGAAGGAGC

52/136

**FIGURE 41B**

TTGGATGAGGAAACTGTTTCAGCAAGAGGAAGGGCTTCTCACACTTTTCATGTGCTTGTGGATCACCTGAGGATCC  
TGTGAAAATACAGATACTGATTCAGTGGGTCTGTGTAGAGCCTGAGACTGCCATTCTAACATGTTCCCAGGGGA  
TGCTGATGCTGCTGGCCCTGGGACTGCACTGCATGCATGTGAAGCCCTATAGGTCTCAGCAGAGGCCCATGGAG  
AGGGAATGTGTGGCTCTGGCTGCCCAGGGCCCCAACTCGGTTTCACACGGATCGTGCTGCTCCCTGGCCAGCCTTT  
GGCCACAGCACCACCAGCTGCTGTTGCTGAGAGAGCTTCTTCTCTGTGACATGTTGGCTTTCATCAGCCACCCT  
GGGAAGCGGAAAGTAGCTGCCACTATCTTTGTTTCCCCACCTCAGGCCTCACACTTTCCCATGAAAAGGGTGAA  
TGTATATAACCTGAGCCCTCTCCATTCAGAGTTGTTCTCCCATCTCTGAGCAATGGGATGTTCTGTTCCGCTTT  
TATGATATCCATCACATCTTATCTTGATCTTTGCTCCCAGTGGATTGTACAGTGATGACTTTTAAGCCCCACGG  
CCCTGAAATAAAATCCTTCCAAGGGCATTGGAAGCTCTCTCCACCTGAACCATGGCTTTTCATGCTTCCAAGTG  
TCAGGGCCTTGCCCAGATAGACAGGGCTGACTCTGCTGCCCCAACCTTTCAAGGAGGAAACCAGACACCTGAGA  
CAGGAGCCTGTATGCAGCCCAGTGCAGCCTTGCAGAGGACAAGGCTGGAGGCATTTGTCATCACTACAGATATG  
CACTAAAATAGACGTGGAGCAAGAGAAATGCATTCCCACCGAGGCCGCTTTTTTAGGCCTAGTTGAAAGTCAA  
GAAGGACAGCAGCAAGCATAGGCTCAGGATTAAAGAAAAAAATCTGCTCACAGTTTGTTCTGGAGGTCACATCA  
CCAACAAAGCTCACGCCCTATGCAGTTCTGAGAAGGTGGAGGCACCAGGCTCAAAAGAGGAAATTTAGAATTTT  
TCATTGGGAGAGTAAGGTACCCCCATCCAGAATGATAACTGCACAGTGGCAGAACAACTCCACCCTAATGTG  
GGTGGACCCCATCCAGTCTGTTGAAGGCCTGAGTGTAAACAAAAGGGCTTATTCTTCCTCAAGTAAGGGGGAAC  
CCTGCTTTGGGCTGGGACATAAGTTTTTCTGCTTTTCAGACGCAAACTGAAAAATGGCTCTTCTTGGGTCTTGAG  
CTTGCTGGCATATGGACTGAAAGAACTATGCTATTGGATCTCCTGGATCTCCAGCTTGCTGACTGCAGATCTT  
GAGATATGTCAGCCTCTACAGTCACAAGAGCTAATTCATTCTAATAAACCAATCTTTCTGTAAA

53/136

**FIGURE 42**

GGACCTGGGAAGGAGCATAGGACAGGGCAAGGCGGGATAAGGAGGGGCACCACAGCCCTTAAGGCACGAGGGAA  
CCTCACTGCGCATGCTCCTTTGGTGCCACCTCAGTGCGCATGTTCACTGGGCGTCTTCCCATCGGCCCCCTTCG  
CCAGTGTGGGAACGCGGCGGAGCTGTGAGCCGGCGACTCGGGTCCCTGAGGTCTGGATTCTTCTCCGCTACT  
GAGACACGGCGGACACACACAAACACAGAACCACACAGCCAGTCCCAGGAGCCCAGTAATGGAGAGCCCCAAAA  
AGAAGAACCAGCAGCTGAAAGTCGGGATCCTACACCTGGGCAGCAGACAGAAGAAGATCAGGATACAGCTGAGA  
TCCCAGTGCGCGACATGGAAGGTGATCTGCAAGAGCTGCATCAGTCAAACACCGGGGATAAATCTGGATTTGGG  
TTCCGGCGTCAAGGTGAAGATAATACCTAAAGAGGAACACTGTAAAATGCCAGAAGCAGGTGAAGAGCAACCAC  
AAGTTTTAAATGAAGACAAGCTGAAACAACGCAAGCTGGTTTTATATTAGATATTTGACTTAAACTATCTCAATA  
AAGTTTTGCAGCTTTCACCAAAAAAAAAAAAAAAAAA

54/136

**FIGURE 43**

AGCGGCTGGCGAGCCGGCGCCGGCCGAGCTGCGGGAGCCGCGGAGAGCACCAGCTGTGCGCCGCGGGAGCTGCTC  
CGGCCGCACCAATGCGGGAGCTGGCCATTGAGATCGGGGTGCGAGCCCTGCTCTTCGGAGTCTTCGTTTTTACAG  
AGTTTTTGGATCCGTTCCAGAGAGTCATCCAGCCAGAAGAGATCTGGCTCTATAAAAATCCTTTGGTGCAATCA  
GATAACATACCTACCCGCCTCATGTTTGCAATTTCTTTCTCACACCCCTGGCTGTTATTTGTGTGGTGAAAAT  
TATCCGGCGAACAGACAAGACTGAAATTAAGGAAGCCTTCTTAGCGGTGTCCTTGGCTCTTGCTTTGAATGGAG  
TCTGCACAAACACTATTAAATTAATAGTGGGAAGACCTCGCGCCGATTTCCTTTACCGCTGCTTTCCAGATGGA  
GTGATGAACTCGGAAATGCATTGCACAGGTGACCCCGATCTGGTGTCCGAGGGCCGAAAAGCTTCCCCAGCAT  
CCATTCTCTCTTTGCCTTTTCGGGCCTTGGCTTCACGACGTTCTACTTGGCGGGCAAGCTGCACTGCTTCACCG  
AGAGTGGGCGGGGAAAGAGCTGGCGGCTCTGTGCTGCCATCCTGCCCTTGTACTGCGCCATGATGATTGCCCTG  
TCCCGCATGTGCGACTACAAGCATCACTGGCAAGATTCTTTGTGGGTGGAGTCATCGCGCTCATTTTTTGCATA  
CATTTGCTACAGACAGCACTATCCTCCTCTGGGCCAACACAGCTTGCCATAAACCCTACGTTAGTCTGCGAGTT  
TGCCATAAACCCCTACGTTAGTCTGCGAGTCCCAGCCTCACTGAAGAAAGAGGAGAGGCCACAGCTGACAGCGC  
ACCCAGCTTGCTCTGGAGGGGATCACCGAAGGCCCGGTATGACCAGTGTCTGGGAGGATGGACACTAAGCCC  
TGGGCACATCTGCCACCCTGACATCATAACACAATAGAAATGGTTTTCTGTAGTGTATTTTTTCATCAGTTGTTT  
CTCAAAGTCATCGTACTTCTGCTTCTGTTTCACTGATGGTGTTCCTGCTACTTTAAATGTCTACTTCCAACATC  
CTTGAATTTGCAAGTGAAGGACAACAATCTCTGAGAGACGTGTGGAAGAGGCTGCGAAGGTGGGGTTTGGGGAG  
CTTCGCCGATTCTGCTATCTGAAATGTTTGCTGTAACAGCCACCTTCCTATGTTTTTCATGGTTAGTAAACATAA  
TAAACCTCCCATCGGGAAAAAATACAAAATTCATTGATTTAGGAATATATATATAATATTCACATGTGTAATT  
CCCCCCTCCCTTTAGTGAGGGTAATTCAAGATCCTTCTCAACTGCTTTGTGCGACTTAGACTTTATGTTGCAG  
CAGACTTTTTTATTTTACTTATAGCGCGGAATCCGTGTTTCCTCAGAATCAGGGAATCCGCCCCGAAAATCTGTT  
ACAAAGGCCGCCAAGTGACATAACT

55/136

**FIGURE 44**

TCCTTGGGTTTCGGGTGAAAGCGCCTGGGGGTTTCGTGGCCATGATCCCCGAGCTGCTGGAGAACTGAAGGCGGAC  
AGTCTCCTGCGAAACCAGGCAATGGCGGAGCTGGAGTTTGTTTCAGATCATCATCATCGTGGTGGTGATGATGGT  
GATGGTGGTGGTGATCACGTGCCTGCTGAGCCACTACAAGCTGTCTGCACGGTCCTTCATCAGCCGGCACAGCC  
AGGGGCGGAGGAGAGAAGATGCCCTGTCCTCAGAAGGATGCCTGTGGCCCTCGGAGAGCACAGTGTCAGGCAAC  
GGAATCCCAGAGCCGCAGGTCTACGCCCCGCTCGGCCCCACCGACCGCCTGGCCGTGCCGCCCTTCGCCACGCG  
GGAGCGCTTCCACCGCTTCCAGCCACCTATCCGTACCTGCAGCACGAGATCGACCTGCCACCCACCATCTCGC  
TGTGAGACGGGGAGGAGCCCCCACCCTACCAGGGCCCCTGCACCCTCCAGCTTCGGGACCCCGAGCAGCAGCTG  
GAACTGAACCGGGAGTCGGTGCGCGCACCCCCAAACAGAACCATCTTCGACAGTGACCTGATGGATAGTGCCAG  
GCTGGGCGGCCCCCTGCCCCCCCAGCAGTAACTCGGGCATCAGCGCCACGTGCTACGGCAGCGGCGGGCGCATGG  
AGGGGCCGCGCCACCTACAGCGAGGTCATCGGCCACTACCCGGGGTCCTCCTTCCAGCACCCAGCAGAGCAGT  
GGGCCGCCCTCCTTGCTGGAGGGGACCCGGCTCCACCACACACACATCGCGCCCTAGAGAGCGCAGCCATCTG  
GAGCAAAGAGAAGGATAAACAGAAAGGACACCCTCTCTAGGGTCCCCAGGGGGCGGGGCTGGGGCTGCGTAGG  
TGAAAAGGCAGAACACTCCGCGCTTCTTAGAAGAGGAGTGAGAGGAAGGCGGGGGCGCAGCAACGCATCGTGT  
GGCCCTCCCCTCCCACCTCCCTGTGTATAAATATTTACATGTGATGTCTGGTCTGAATGCACAAGCTAAGAGAG  
CTTGCAAAAAAAAAAAGAAAAAGAAAAAAAAAAACCACGTTTCTTTGTTGAGCTGTGTCTTGAAGGCAAAAGA  
AAAAAATTTCTACAGTAGTCTTTCTTGTTTCTAGTTGAGCTGCGTGCGTGAATGCTTATTTTCTTTGTTTAT  
GATAATTTCACTTAACTTTAAAGACATATTTGCACAAAACCTTTGTTTAAAGATCTGCAATATTATATATATAA  
ATATATATAAGATAAGAGAACTGTATGTGCGAGGGCAGGAGTATTTTGTATTAGAAGAGGCCTATTAAAAAA  
AAAAGTTGTTTTCTGAACTAGAAGAGGAAAAAAATGGCAATTTTTGAGTGCCAAGTCAGAAAGTGTGTATTACC  
TTGTAAAGAAAAAAATTACAAAGCAGGGGTTTAGAGTTATTTATATAAATGTTGAGATTTTGCACATTTTTTTA  
ATATAAATATGTCAGTGCTTGCTTGATGGAACTTCTCTTGTTGTCTGTTGAGACTTTAAGGGAGAAATGTCGGA  
ATTTCAGAGTCGCCTGACGGCAGAGGGTGAGCCCCCGTGGAGTCTGCAGAGAGGCCTTGCCAGGAGCGGCGGG  
CTTTCCCGAGGGGCCACTGTCCCTGCAGAGTGGATGCTTCTGCCTAGTGACAGGTTATCACCACGTTATATATT  
CCCTACCGAAGGAGACACCTTTTCCCCCTGACCCAGAACAGCCTTTAAATCACAAGCAAAATAGGAAAGTTAA  
CCACGGAGGCACCGAGTTCCAGGTAGTGGTTTTGCCTTTCCCAAAAATGAAAATAAACTGTTACCGAAGGAATT



56/136

**FIGURE 45**

GCCCTTCGGACAGTCTCCTGCGAAACCAGGCAATGGCGGAGCTGGAGTTTGTTTCAGATCATCATCATCGTGGTG  
GTGATGATGGTGATGGTGGTGGTGATCACGTGCCTGCTGAGCCACTACAAGCTGTCTGCACGGTCCTTCATCAG  
CCGGCACAGCCAGGGGCGGAGGAGAGAAGATGCCCTGTCTCAGAAAGGATGCCTGTGGCCCTCGGAGAGCACAG  
TGTCAGGCAACGGAATCCCAGAGCCGCAGGTCTACGCCCCGCCTCGGCCCACCGACCGCCTGGCCGTGCCGCCC  
TTCGCCCAGCGGGAGCGCTTCCACCGCTTCCAGCCCACCTATCCGTACCTGCAGCACGAGATCGACCTGCCGCC  
CACCATCTCGCTGTCAGACGGGGAGGAGCCCCACCCCTACCAGGGCCCCCTGCACCCTCCAGCTTCGGGACCCCG  
AGCAGCAGCTGGAACTGAACCGGGAGTCGGTGCGCGCACCCCCAAACAGAACCATCTTCGACAGTGACCTGATG  
GATAGTGCCAGGCTGGGCGGGCCCTGCCCCCCCAGCAGTAACTCGGGCATCAGCGCCACGTGCTACGGCAGCGG  
CGGGCGCATGGAGGGGCGCCGCCCCACCTACAGCGAGGTCATCGGCCACTACCCGGGGTCCTCCTTCCAGCACC  
AGCAGAGCAGTGGGCCGCCCTCCTTGCTGGAGGGGACCCGGCTCCACCACACACACATCGCGCCCCTAGAGAGC  
GCAGCCATCTGGAGCAAAGAGAAGGATAAACAGAAAGGACACCCTCTCTAGGGTCCCCAGAAGGGC

57/136

**FIGURE 46**

GGCGAGAGGCGGGCTGAGGCGGCCAGCGGCGGCAGGTGAGGCGGAACCAACCCTCCTGGCCATGGGAGGGGCC  
GTGGTGGACGAGGGCCCCACAGGCGTCAAGGCCCTGACGGCGGCTGGGGCTGGGCCGTGCTCTTCGGCTGTTT  
CGTCATCACTGGCTTCTCCTACGCCCTCCCCAAGGCCGTCAAGTGTCTTCTTCAAGGAGCTCATACAGGAGTTTG  
GGATCGGCTACAGCGACACAGCCTGGATCTCCTCCATCCTGCTGGCCATGCTCTACGGGACAGGTCCGCTCTGC  
AGTGTGTGCGTGAACCGCTTTGGCTGCCGGCCCGTCATGCTTGTGGGGGTCTCTTTGCGTCGCTGGGCATGGT  
GGCTGCGTCCTTTTGCCGGAGCATCATCCAGGTCTACCTCACCCTGGGGTCATCACGGGGTTGGGTTTGGCAC  
TCAACTTCCAGCCCTCGCTCATCATGCTGAACCGCTACTTCAGCAAGCGGCGCCCCATGGCCAACGGGCTGGCG  
GCAGCAGGTAGCCCTGTCTTCTGTGTGCCCTGAGCCCGCTGGGGCAGCTGCTGCAGGACCGCTACGGCTGGCG  
GGGCGGCTTCTCATCCTGGGCGGCTGCTGCTCAACTGCTGCGTGTGTGCCGCACTCATGAGGCCCTGGTGG  
TCACGGCCCAGCCGGGCTCGGGGCCGCGCAGCCCTCCCGGCGCCTGCTAGACCTGAGCGTCTTCCGGGACCGC  
GGCTTTGTGCTTTACGCCGTGGCCGCCTCGGTCAAGGTGCTGGGGCTCTTCGTCCCGCCGTGTTCTGTGGTGAG  
CTACGCCAAGGACCTGGGCGTGCCGACACCAAGGCCGCTTCTGCTCACCATCCTGGGCTTCATTGACATCT  
TCGCGCGGCCGCGCGGGCTTCGTGGCGGGGCTTGGGAAGGTGCGGCCCTACTCCGTCTACCTCTTCAGCTTC  
TCCATGTTCTTCAACGGCCTCGCGGACCTGGCGGGCTCTACGGCGGGCGACTACGGCGGCCTCGTGGTCTTCTG  
CATCTTCTTTGGCATCTCCTACGGCATGGTGGGGGCCCTGCAGTTCGAGGTGCTCATGGCCATCGTGGGCACCC  
ACAAGTTCTCCAGTGCCATTGGCCTGGTGCTGCTGATGGAGGCGGTGGCCGTGCTCGTCGGGCCCCCTTCGGGA  
GGCAAATCCTGGATGCGACCCACGTCTACATGTACGTGTTTCATCCTGGCGGGGGCCGAGGTGCTCACCTCCTC  
CCTGATTTTGTGCTGCTGGGCAACTTCTTCTGCATTAGGAAGAAGCCCAAAGAGCCACAGCCTGAGGTGGCGGCCG  
CGGAGGAGGAGAAGCTCCACAAGCCTCCTGCAGACTCGGGGGTGGACTTGCGGGAGGTGGAGCATTTCTGAAG  
GCTGAGCCTGAGAAAAACGGGGAGGTGGTTACACCCCCGAAACAAGTGTCTTGAGTGGCTGGGCGGGGCCGGCA  
GGCACAGGGAGGAGGTACAGAAGCCGGCAACGCTTGCTATTTATTTTACAACTGGACTGGCTCAGGCAGGGCC  
ACGGCTGGGCTCCAGCTGCCGGCCAGCGGATCGTCGCCCCGATCAGTGTGTTTGGAGGGGAAGGTGGCGGGGTGG  
GAACCGTGTCAATTCCAGAGTGGATCTGCGGTGAAGCCAAGCCGCAAGGTACAAGGCATCCTCACCAGGGGCC  
CGCCTGCTGCTCCCAGGTGGCCTGCGGCCACTGCTATGCTCAAGGACCTGGAAACCCATGCTTCGAGACAACGT  
GACTTTAATGGGAGGGTGGGTGGGCCGACAGGCTGGCAGGGCAGGTGCTGCGTGGGGCCCTCTCCAGCCCG  
TCCTACCCTGGGCTCACATGGGGCCTGTGCCACCCCTCTTGAGTGTCTTGGGGACAGCTCTTTCCACCCCTGG  
AAGATGGAAATAAACCTGCGTGTGGGTGGAGTGTCTCGTGCCGAATTCAAAAAGCTT

58/136

**FIGURE 47**

CCCACGCGTCCGCCACGCGTCCGCCGGGTCTGCGCGCTCCGGACTGAGGTGGCGTCCCTGGGCCGGACGGCG  
GTGTCCCGGCGTGGCGGGAAGCCGGCACTGGAGCGGGAGCGCACTGGGCGCGGGACCGGGAGGCGCAGGGACCG  
GACGGCTCCCGAGTCGCCACCTGACGGTACCGAGAGGGCGGCGCCCCCTCCGAGCAGAGCCGTCCCGGCCACTC  
CCCTGGGATCTGACTTGGCTCTTGCGGTGCGGGCACCGTGAAGCCCTGGGGTGTGCGTGGCTCCTCCTGGTAG  
GCGCCCTTTCCCGCGTCCGGCTTGGGGTGGTGGTGGCGTTGACTCCAGCCCCGCCTCTCCCTGGAGAGGAGGG  
CTCCACTCGCTCCTTCGGCTCCTCCCCTGGGGCCGAGCGACTCGGGCCGGCTTCTGCTTCCCTGCCTGCCG  
GCGGTCCCGCTGGCTAGAAGAAGTCTTCACTTCCCAGGAGAGCCAAAGCGTGTCTGGCCCTAGGTGGGAAAAGA  
ACTGGCTGTGACCTTTGCCCTGACCTGGAAGGGCCCAGCCTTGGGCTGAATGGCAGCACCCACGCCCCGCCGTC  
CGGTGCTGACCCACCTGCTGGTGGCTCTCTTCGGCATGGGCTCCTGGGCTGCGGTCAATGGGATCTGGGTGGAG  
CTACCTGTGGTGGTCAAAGAGCTTCCAGAGGGTTGGAGCCTCCCCTCTTACGTCTCTGTGCTTGTGGCTCTGGG  
GAACCTGGGTCTGCTGGTGGTGACCTCTGGAGGAGGCTGGCCCCAGGAAAGGACGAGCAGGTCCCCATCCGGG  
TGGTGCAGGTGCTGGGCATGGTGGGCACAGCCCTGCTGGCCTCTCTGTGGCACCATGTGGCCCCAGTGGCAGGA  
CAGTTGCATTCTGTGGCCTTCTTAGCACTGGCCTTTGTGCTGGCACTGGCATGCTGTGCCTCGAATGTCACTTT  
CCTGCCCTTCTTGAGCCACCTGCCACCTCGCTTCTTACGGTCATTCTTCCCTGGGTCAAGGCCTGAGTGCCCTGC  
TGCCCTGCGTGCTGGCCCTAGTGCAGGGTGTGGGCCGCTCGAGTGCCCGCCAGCCCCCATCAACGGCACCCCT  
GGCCCCCGCTCGACTTCTTGAGCGTTTTCCCGCCAGCACCTTCTTCTGGGCACTGACTGCCCTTCTGGTGC  
TTCAGCTGCTGCCTTCCAGGGTCTTCTGCTGCTGTTGCCGCCACCACCATCTGTACCCACAGGGGAGTTAGGAT  
CAGGCCTCCAGGTGGGAGCCCCAGGAGCAGAGGAAGAGGTGGAAGAGTCCTCACTGCAAGAGCCACCAAGC  
CAGGCAGCAGGCACCACCCCTGGTCCAGACCCTAAGGCCTATCAGCTTCTATCAGCCCGCAGTGCCTGCCTGCT  
GGGCCTGTTGGCCGCCACCAACGCGCTGACCAATGGCGTGCTGCCTGCCGTGCAGAGCTTTTCCCTGCTTACCCT  
ACGGGCGTCTGGCCTACCACCTGGCTGTGGTGCTGGGCAGTGCTGCCAATCCCCTGGCCTGCTTCTGGCCATG  
GGTGTGCTGTGCAGGTCCTTGGCAGGGCTGGGCGGCTCTCTCTGCTGGGCGTGTCTGTGGGGGCTACCTGAT  
GGCGCTGGCAGTCCTGAGCCCCTGCCCGCCCCCTGGTGGGCACCTCGGCGGGGGTGGTCCCTCGTGGTGCTGTGCT  
GGGTGCTGTGTCTTGGCGTGTCTCTCTACGTGAAGGTGGCAGCCAGCTCCCTGCTGCATGGCGGGGGCCGGCCG  
GCATTGCTGGCAGCCGGCGTGGCCATCCAGGTGGGCTCTCTGCTCGGCGCTGTTGCTATGTTCCCCCGACCAG  
CATCTATCACGTGTTCCACAGCAGAAAGGACTGTGCAGACCCCTGTGACTCCTGAGCCTGGGCAGGTGGGGACC  
CCGCTCCCCAACACCTGTCTTCCCTCAATGCTGCCACCATGCCTGAGTGCTGCAGCCAGGAGGCCCGCACA  
CCGGTACACTCGTGGACACCTACACACTCCATAGGAGATCCTGGCTTTCCAGGGTGGGCAAGGGCAAGGAGCAG  
GCTTGGAGCCAGGGACCAGTGGGGGCTGTAGGGTAAGCCCCTGAGCCTGGGACCTACATGTGGTTTGCCTAATA  
AAACATTTGTATTTAAAAA

59/136

**FIGURE 48**

GCCAGCACAGCTGCCCTCTGGACCCTGCGGACCCAGCCGAGCCCCTTCCTGAGTTCCACAGGCGCAGCCCCG  
GGCGGTGCGGCGGAGGGGTCCCCGGGGCGGTGCCAGGCGCAATCCTGGAGGGCGGCCGGGAGGAGGAGGTGCGC  
GCGGCCATGCACACCGTGGCTACGTCCGGACCCAACGCGTCCTGGGGGGCACCGGCCAACGCCCTCCGGCTGCCC  
GGGCTGTGGCGCCAACGCCCTCGGACGGCCCAGTCCCTTCGCCGCGGGCCGTGGACGCCTGGCTCGTGCCGCTCT  
TCTTCGCGGCGCTGATGCTGCTGGGCCTGGTGGGGAACTCGCTGGTCATCTACGTCACTGCGGCCACAAGCCG  
ATGCGGACCGTGACCAACTTCTACATCGCCAACCTGGCGGCCACGGACGTGACCTTCCTCCTGTGCTGCGTCCC  
CTTCACGGCCCTGCTGTACCCGCTGCCCGGCTGGGTGCTGGGCGACTTCATGTGCAAGTTCGTCAACTACATCC  
AGCAGGTCTCGGTGCAGGCCACGTGTGCCACTCTGACCGCCATGAGTGTGGACCGCTGGTACGTGACGGTGTTC  
CCGTTGCGCGCCCTGCACCGCCGCACGCCCCGCTGGCGCTGGCTGTCAGCCTCAGCATCTGGGTAGGCTCTGC  
GGCGGTGTCTGCGCCGTGCTCGCCCTGCACCGCCTGTCAACCGGGCCGCGCGCCTACTGCAGTGAGGCCTTCC  
CCAGCCGCGCCCTGGAGCGCGCCTTCGCACTGTACAACCTGCTGGCGCTGTACCTGCTGCCGCTGCTCGCCACC  
TGCGCCTGCTATGCGGCCATGCTGCGCCACCTGGGCCGGGTGCGCGTGCGCCCGCGCCCCGCCGATAGCGCCCT  
GCAGGGGCAGGTGCTGGCAGAGCGCGCAGGCGCCGTGCGGGCCAAGGTCTCGCGGCTGGTGGCGGCCGTGGTCC  
TGCTCTTCGCCGCTGCTGGGGCCCCATCCAGCTGTTCTGGTGCTGCAGGCGCTGGGCCCCGCGGGCTCCTGG  
CACCCACGCAGCTACGCCGCCTACGCGCTTAAGACCTGGGCTCACTGCATGTCTACAGCAACTCCGCGCTGAA  
CCCGCTGCTCTACGCCTTCCTGGGCTCGCACTTCCGACAGGCCTTCGCGCGCTGCCCCCTGCGCGCCGCGCC  
GCCCCGCGCCCCCGCCGGCCCCGGACCCCTCGGACCCCGCAGCCCCACACGCGGAGCTGCACCGCCTGGGGTCC  
CACCCGGCCCCCGCCAGGGCGCAGAAGCCAGGGAGCAGTGGGCTGGCCGCGCGCGGGCTGTGCGTCTGGGGGA  
GGACAACGCCCCCTCTTTGAGCGGACCCGGTGGGAATCCGAGCGGCTCCCTCGGGAGCGGGGACTGCTGGAACAG  
CGGCTATTCTTCTGTTATTAGTATTTTTTTTACTGTCCAAGATCAACTGTGGAATATTTTGGTCTCTTGTGAC  
GTTGCGGTGCAGTTTCGTTGTGAAGTTTGCTATTGATATTGAAATTATGACTTCTGTGTTTCCTGAAATTAAACA  
TGTGTCAACACAGGACTTTTTTGATCATTCCAGAAAGTGTGACACGTTTAAAAAAAAAAAAA

60/136

**FIGURE 49**

GGCGCGGGGCGCCATGGCACACCGAGCGGCTCCGTCTTCTGCTCCTCAGAGAGCCCGGCTGGCGGCCTGGGATG  
ACAAGATGTCTGGACTGCAATCCTGCACAGTTTTGAGAGGGAGATGACTTGAGTGGTTGGCTTTTATCTCCACA  
ACAATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTTTCAAACACAACCTGCCAGAC  
GGAAAACCGGCTTTCCGTATTTTTTTTTCAGTAATCTTCATGACAGTGGGAATCTTGTCAAACAGCCTTGCCATCG  
CCATTCTCATGAAGGCATATCAGAGATTTAGACAGAAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGCGGCCTG  
GTAATCACTGATTTCTTTGGCCATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCTGATAAAGAATG  
GATCCGCTTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTCTTCTGGTCTGTGCCAC  
TTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCAATATTTTCATTCTACGAAAATT  
ACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGCTTGTCTGCTGTTTTTCATAGCTTTGCTGCCCATCCT  
TGGACATCGAGACTATAAAATTCAGGCGTCGAGGACCTGGTGTCTTACAAACAGAAAGACATCAAAGACTGGG  
AAGATAGATTTTATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTCATTGTTGTGCAATGCA  
ATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGACAAGGCAGATCTCATCATTTGGA  
AATGGTAATCCAGCTCCTGGCGATAATGTGTGTCTCCTGTATTTGTTGGAGCCCATTTCTGGTTACAATGGCCA  
ACATTTGGAATAAATGGAATCATTCTCTGAAACCTGTGAAACAACACTTTTGTCTCTCCGAATGGCAACATGG  
AATCAAATCTTAGATCCTTGGGTATATATTTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAG  
TCAATGCTGTGGAGTGCATGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAATTCCTTAAAGGTTG  
CTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAGCTTAATAGGACAGTAAATCTGTGTGGG  
GCTAGAACAAAAATTAAGACATGTTTGGCAATATTTCAGTTAGTTAAATACCTGTAGCCTAACTGGAAAATTCA  
GGCTTCATCATGTAGTTTGAAGATACTATTGTCAGATTCAGGTTTTGAAATTTGTCAAATAAACAGGATAACTG  
TACATTTTCAACTTGTTTTTGGCAATGGGAGGTAGACACAATAAAATAATGCCATGGGAGTCACACTGAAAGCA  
ATTTTGAGCTTATCTGTCTTATTTATGCTTTGAGTGAATCATCTGTTGAGGTCTAATGCCTCTACTTGCCCTAT  
TTGCCAGAGAACATCTTAATGCAGCCTGCATAGTGAAATGGTTATTTTGAGATCACCGCTCTGTAGCTAACCT  
TATAAACTAGGCTCAGTAAATAAAGCACTCTTATTTTTTGATCTGGCCTATTTTGCCCTCATTGTGTAGCCT  
CAATTAACACATGCATGGTCATGACACCCAGAATTCATGATGGTTTTGTTATAACAACCTCTGCATATTCAGGT  
CTGGCAGACAGGTTGCCTGACCCTGCAATCCTATCTAGAATGGGCCATTCTTGTGCATTTGACAAATAGGAC  
TGCCTACATTTATTTATGAAGGTCGATTGTTGTTGGAAGTGTTTTTTCATGTCATAGATTAGCAATTTTCAA  
ATAATTATTTTTTCTCTGAAAATTTTGTGTGTGATTGCACAATAAATAATTTTTTAGAGAAACAAAGGCTCTTTC  
TCAGCACATTGATGGGCAACTAGAATTACAGCAGTTTCAAACCTCTACCATGGATAATGCAACAAACCGAAGCT  
ACATGCCAATGATAGGTGCAAAGAATATTGGCAAAAGGTGCTTTACCTTGAGCCATTATTTGTGTGAGAGAACA  
AAAGAAACAGAAATCAATATATAAATTCAAAGACTATCTGCAGCTAGTGTGTTTCTTCTTTACACACATATACAC  
ACAGACATCAGAAAATCTGTTGAGAGCAGGTTCAATTAATTTGTAAGATGGCATATTTCTAAAGCCTGTGCTAC  
CAGTACTAAGAGGGGAAGACTGGCAATTTGCCAAGCACTTGGGGATTATTATAACAATTAAGTAGGAGATCAAG  
AGATAATAATCTCTCCCCAAATTTTCCAATAATAATTGAGACTTTTTCTTTGCTTGTGTGTGTAATTCACCAA  
AAGAATTTCAATACCCATTCAAATTGTCCTAGGTCTATCAGAAATTAGGGAAGGTAGTCCTGCTTTATAATAGG  
AAAATGTATTTCTGTATAAGATTTCTTTGCTTTTCATTAATAATGGGATTCAATTAATAATTAATCTTTCCCTGT  
TAGGCTGATTTTCAGATTCTCTAGGAAATCTGGTGAAGTAACCAGAAGACTTTTCAGATGGTTTATTTGCTTTTCAG  
CAGAGAATTTATTTTCATACAGTTTACTTAAGAGTGTGATGTCTTGTGAACAGAGATATAAGGAACCATTTCCA  
TCCTTCCTTATCATGCTGGGTACAATGCTTCTATGAATATTTCCATGTATTTTGACTGGGGAGAGGCATGGAGA  
AGAACTCTCATTCAGGGGCTCCAGGATCCTTCTCCTTGAGGCTTCTAAATAAATGGCAGAATTTCTGCTGTAT  
TGCCATGATGTCACCCTGGCCATGTGTACTGACTTGAGGAGATCTTGCAACATGGCCATGTGCAAGGCTTTAAG  
GAGTGAGAGAGATGTGTACATATCTTAGGAGGGTTATCTATGTTATCTGAGTATATGTTTGGGTAAACCAATTG  
GTCTTAAAAATGATGTTAACCAAGAAGTAGACATCAAAAATTAAAAAAAAAAAAAAAAAA

61/136

**FIGURE 50A**

ATGTCACGCATGAGCCGGCATCCAGACAAGGACCTGGCCCAGGGTCCCTTCAACACCTGCTGTGGCTGCACCTT  
AATGGCTAGTCCTGCTAATCTCCCTCCGAACACTCAAGCAGCTGCAGAAAGGGCCCTTTCCAGAGCAGGTGGA  
AGAGGGTGCAAGTGCCCGCCCCGGCATCCCTGTCCCCTTTCCCACTGGCCATGGCTTCAGTTGCCTTCTGGATC  
AGCATCCTGATTGGCTGCGAGGAACAGACTCTCTGCAGAGGCTGGCGTAGCCCAGTCGGGGATGGCTGTGCTCA  
TGTGCCTCCCCAGGAGCGAGCGACCGCAGAGGCAGACCCTCCAGGGCGGTGCAGCACCTCCACGGCGTCGTCTA  
CCATCTGTGGCCTGTGGCATTGTCCCCACGGCTGCAGCTCCTCCACCTCTGCATTCCAGGCAGGGAGAAGAG  
TCGGGCAAACTGAGAAGGTGCTTCTCTGGGGAAGAGAGGGCCCTCCATGTGTGGAACCCGGAGTCCTGCAGCC  
CGATGTCCACGGCACCTCCAACCTGGGGAACCTGCTCCTTCTGCACGGCCTGGTTACGGCTCCCTCTTGTCCAC  
GGCGGGCGGGCGCCGAGCTGCTGAATTCTTTAGGAAGTCAGTTTGCCATTAGCCTTTTTGAAGTTCAGAGTGGA  
ACTGAGCCCAGCATTACAGGTGTGGCCACGTACAGGGCAGTGCAGGGCTATGCCACTGAAGCATTATCTCCTTTT  
GCTGGTGGGCTGCCAAGCCTGGGGTGAGGGTTGGCCTACCATGGCTGCCCTAGCGAGTGTACCTGCTCCAGGG  
CCTCCAGGTGGAGTGCACCGGGGCACGCATTGTGGCGGTGCCACCCCTCTGCCCTGGAACGCCATGAGCCTG  
CAGATCCTCAACACGCACATCACTGAACCTCAATGAGTCCCCGTTCTCAATATTTAGCCCTCATCGCCCTGAG  
GATTGAGAAGAATGAGCTGTGCGGCATCACGCCCTGGGGCCTTCCGAAACCTGGGCTCGCTGCGCTATCTCAGCC  
TCGCCAACAACAGCTGCAGGTTCTGCCATCGGCCCTCTCCAGGGCCTGGACAGCCTTGAAGTCTCTCCTTCTG  
TCCAGTAACCAGCTGTTGCAGATCCAGCCGGCCCACTTCTCCAGTGCAGCAACCTCAAGGAGCTGCAGTTGCA  
CGGCAACCACCTGGAATACATCCCTGACGGAGCCTTCGACCACCTGGTAGGACTCACGAAGCTCAATCTGGGCA  
AGAATAGCCTCACCCACATCTCACCCAGGGTCTTCCAGCACCTGGGCAATCTCCAGGTCTCCGGCTGTATGAG  
AACAGGCTCACGGATATCCCCATGGGCACCTTTGATGGGCTTGTTAACCTGCAGGAACCTGGCTCTACAGCAGAA  
CCAGATTGGACTGCTCTCCCCTGGTCTCTTCCACAACAACCAACCTCCAGAGACTCTACCTGTCCAACAACC  
ACATCTCCCAGCTGCCACCCAGCATCTTCATGCAGCTGCCCCAGCTCAACCGTCTTACTCTCTTTGGGAATTCC  
CTGAAGGAGCTCTCTCTGGGGATCTTCGGGGCCATGCCAACCTGCGGGAGCTTTGGCTCTATGACAACCACAT  
CTCTTCTCTACCCGACAATGTCTTCAGCAACCTCCGCCAGTTGCAGGTCTGATTCTTAGCCGCAATCAGATCA  
GCTTCATCTCCCCGGGTGCCCTTCAACGGGCTAACGGAGCTTCGGGAGCTGTCCCTCCACACCAACGCACCTGCAG  
GACCTGGACGGGAATGTCTTCCGCATGTTGGCCAACCTGCAGAACATCTCCCTGCAGAACCAATCGCCTCAGACA  
GCTCCCAGGGAATATCTTCGCCAACGTCAATGGCCTCATGGCCATCCAGCTGCAGAACCAACAGCTGGAGAAT  
TGCCCCCTCGGCATCTTCGATCACCTGGGGAACTGTGTGAGCTGCGGCTGTATGACAATCCCTGGAGGTGTGAC  
TCAGACATCCTTCCGCTCCGCAACTGGCTCCTGCTCAACCAGCCTAGGTTAGGGACGGACACTGTACCTGTGTG  
TTTCAGCCCAGCCAATGTCCGAGGCCAGTCCCTCATTATCATCAATGTCAACGTTGCTGTTCACAGCGTCCATG  
TACCTGAGGTGCCTAGTTACCCAGAAACACCATGTAACCCAGACACCCAGTTACCCCTGACACCACATCCGTC  
TCTTCTACCATCTAGCTAACCAGCCCTGTGGAAGACTACACTGATCTGACTACCATTCAGGTCACCTGATGACCG  
CAGCGTTTGGGGCATGACCATGCCCATAGCGGGCTGGCCATTGCCGCCATTGTAATTGGCATTGTGCGCCCTGG  
CCTGCTCCCTGGCTGCCTGCGTGGCTGTTGCTGCTGCAAGAAGAGGAGCCAAGCTGTCTGATGCAGATGAAG  
GCACCCAATGAGTGTTAAAGAGGCAGGCTGGAGCAGGGCTGGGGAATGATGGGACTGGAGGACCTGGGAATTTT  
ATCTTTCTGCCTCCACCCCTGGGTCCATGGAGCTTTCCCGTGATTGCTCTTTCTGGCCCTAGATAAAGGTGTGC  
CTACCTCTTCTGACTTGCTGATTCTCCCGTAGAGAAGCAGGTGCTGCCGGACCTTCTACAATCAGGAAGAT  
AGATCCAACCTGGCCATGGCAAAGCCCTGGGGATTTCCGATTACATACCCCTGGGCTTCTTCGAGAGGGCTCTT  
CCTCCAAATCCTCCCCACCTGTCTCCAAGAACAGCCTTCCCTGCGCCCAGGCCCCCTCCGGGCCTCTGTAGAC  
TCAGTTAGTCCACAGCCTGCTCACTTCGTGGGAATAGTTCTCCGCTGAGATAGCCCTCTCGCCTAAGTATTAT  
GTAAGTTGATTTCCCTTCTTTTGTCTCTTGTGCTATGGCTTGACCCAGCATGTCCCTCAAATGAAAG  
TTCTCCCCTTGATTTTCTGCTCCTGAAGGCAGGGTGAGTTCTCTCCTCAAAGAAGACTTCAAACCATTTAACTG  
GTTTCTTAAGAGCCGTCAATCAGCCTGGTTTTGGGGATGCTATGAAAGAGAGAAGGAAAATCATGCCGCTCAGT  
TCCTGGAGACAGAAGAGCCGTACATCAGTGTCTCACTTGTGATTTTTATCTGGAAAAGGAAGAAACACCCCAGCA  
CAGCAAGCTCAGCCTTTTAGAGAAGGATATTTCCAACTGCAAACTTTGCTTTGAAAAGTTTAGCCCTTTAAGG  
AATGAAATCATGTAGAATTTTGACTTCTAAAAACATTAAATCAGCTTATTAATACGGGATAGAGAAAGAAAT  
CTGGTGCCTGGGGGTCCCTGTGTTTACCCCTAGAGTTGTGTTTTAAATTTTAAATTGAAGCATGTGAAGTGTAC  
CTGCAGAAAAGTGGGAACATGATAGTGTATGGCTTGGTGGATTTTACAAACTGAACACTGACCTGTGTAATCAGC  
ATCTAGACCCAGACCCAGAGCGTCACAAATATCCCCCATCCTGGGCTTTTCCAGAGGAGATGGGGGCTTCTGA  
AGATGGACTTACCTGGGACCTGCCCCCATGAGCCAGGACGGTCCCCCACAGTCAGCCTGTGCAAAGGCCCG  
TGGCCAGGGGTGGAGGAGAATATGTGGGTGTGGACAGGATGGGAGACTGTGGCCTGAACAGGAGATTTTATTAT  
ATCTGGAGACCCTGAGAGACCCTGAGACCTGGGGCACCCCTGGCTGGCCAGGTGAGAAGCATCCTGACTGCAGAG  
GTCCGTGCAGCCACACCCCTCTTCCCTGCCAGCAAGCTGTCTGCGGCTCATCGGAGGCCCTCCGCTGGAGCCT  
TCTATGGACGTGATATGCCTGTATCTGTTTTTAATTTTCACTTCTTCACTTAGGGGAAGTGAAATCGCTCAGAGA  
TGAGATCCTTTAATTGAAAACGAAGTGTAACGGAATCTAGTGTCTTCTAATGTGGTAAAATTCTCCATCAACA

62/136

**FIGURE 50B**

TCACAGTCAGCTGGCAGCTGAACTTCAGAATCTCACTTACAGCAGGCGACACGGGGGTACACCGATGGGTCACA  
CTGGGTCTGGGGGCTCCCTGGAGCTCCTCCTGCGTGTGGTCTGGTTAGGAGTTGAGTTGTTTGCTCCAGGGTTA  
TTCTCCTCCTCGAGTCACAGTCACACGAATACCTGCCTTCTCTGGCTTTCTCTGCTATACACATATTCACATGGC  
GCTCAAGAAGTTAGGCTCATGGCAACGTGTGTCTTTCTCTGGACAACCTGGCCCAGTTTACAGTGAAATGGAGAA  
TTTCAGGTCTCCACGTCTGCCCAGGAAAGAACTTCAGCTGACTCCACGGGGATCTGGAAATCCACGACCAATCC  
CGATCGGCTCTTATTAGCTCCCCGCTCCACAAGACACCTGTGCTTTGGAAATCCACCACCAATCCCAGATCGGCT  
CTTATTAGCTCCCCGCTCCACAAGACACCTGTGATCTGGAAATCTACCACCAATCCCAGATCGGCTCTTATTAGC  
TCCCCGCTCCACAAGACACCTGTGACATCCTCCAGGGCCACAGGAGCACGTGCTGACCAGTTTTCCCTTCCAGT  
TCCTGCACAAAAAGTGTCCAGAGGGCTGTTTGCAAACTAGTGCACCTTTGTAGCTTTTCCACCTCTGTCCCAG  
GGAATCTAGGAGAGATGAGGCCCCGTCAGAGTCAAGAGATGTCATCCCCCAGGGTCTCCAAGGCATTTCCACAC  
TATTGGTGGCACCTGGAGGACATGCACCAAGGCTTGCCAGAGCCAACAGGAAGTGAGCCAGAGCATGGCACAT  
GAGCATACCCGCTGATGGTGGCCTGCTGTGCCTGGTGCCAACAGGGGCATCCCGGCCCATACCCCTCCAGACA  
GGAAGCATGGGTTTGCCACAGACCTGTCGGGTGCTCCTGTGAGTGGCCTCCAGATGTCTTTGTGCATAGGCAC  
AAGTGGGCCAGGGCTGGAGGGAGGTGGGAAACCTCATCATCCGGTGGGCCCTGCCAATCTTAACCCAGAACCCT  
TAGGTATTCCTGGCAGTAGCCATGACATTGGAGCACCTTCCTCTCCAGCCAGAGGCTGACCTGAGGGCCACTGT  
CCTCAGATGACACCACCCAGGAGCACCTAGGTGAGGGGTGAGGGCCCCCTTATGTGAACCTCTTGCCTCTTCC  
TTTCTCCCATCAGAGTGGTTGGATGGAGCCATTGGCCTCCTTTTCTTCAGCGGGCCCCTTCAACCTCTCTGCACC  
ATGTTGTCTGGCTGAGGAGCTACTAGAAAAGCTGAGTGGAGTCTCCTTTCCAACAGGATGATGCATTTGCTCAA  
TTCTCAGGGCTGGAATGAGCCGGCTGGTCCCCCAGAAAGCTGGAGTGGGGTACAGAGTTCAGTTTTCTCTCTG  
TTTACAGCTCCTTGACAGTCCCACGCCCATCTGGAGTGGGAGCTGGGAGTCAGTGTGGAGAAGAAACAACAAA  
AGCCAATTAGAACCCTATTTTTAAAAAGTGCTTACTGTGCACAGATACTCTTCAAGCACTGGACGTGGATTCT  
CTCTCTAGCCCTCAGCACCCCTGCGGTAGGAGTGCCGCTCTACCCACTTGTGATGGGGTACAGAGGCACTTGC  
TCTTCTGCATGGTGTTCATAGGCTGGGAGTTTTATTTATCTCTTCAAACCTTTGTACAAGAGCTCATGGCTTGT  
CTTGGGCTTTTCGTCATTAAACCAAAGGAAATGGAAGCCATTCCCCTGTTGCTCTCCTTAGTCTTGGTTCATCAGA  
ACCTCACTTGGTACCATATAGATCAAAAGCTTTGTAACCACAGGAAAAAATAAACTCTTCCATCCCTTAAAGAA  
TAGAATAGTTTGTCCCTCTCATGGGAATTGGGCTGTATGTATATTGTTCTTCTCCTTAGAATTTAGAGATACA  
AGAGTTCTACTTAGAACTTTTCATGGACACAATTTCCACAACCTTTCAGATGCTGATGTAGAGCTATTGGGAAA  
GAACTTCCAACTCAGGAAGTTTGACAGAGAGCAGACAGCTAGAGATAACTCGGGACCCAGAGTTGGTCGACAGA  
TGTTAGATGTATCCTAGCTTTTAGCTATAAACCCTCAAAGATTACAGCCCCAGATCCCACAGTCAGAACTGAA  
TCTGCGTTGTTGGGAAGCCAGCAGTGGCCTTGGGAAGGAAGCCATGGCTGTGGTTTCAGAGAGGGTGGGCTGGCA  
AGCCACTTCCGGGGAAAACTCCTTCCGCCCCAGGTTTCTTCTTCTTCTTAAGGAGAGATTATTTCTACCAACCCG  
CTGCCTTCATGCTGCCTTCAAAGCTAGATCATGTTTGCCTTGCTTAGAGAATTACTGCAAAATCAGCCCCAGTGC  
TTGGCGATGCATTTACAGATTTCTAGGCCCTCAGGGTTTTGTAGAGTGTGAGCCCTGGTGGGCAGGGTTGGGGG  
GTCTGTCTTCTGCTGGATGCTGCTTGTAAATCCATTTGG

63/136

**FIGURE 51A**

ATGGCGCCGCCGCCGCCGCCCGTGCTGCCCGTGCTGCTGCTCCTGGCCGCCGCCGCCGCCCTGCCGGCGATGGG  
GCTGCGAGCGGCCGCCCTGGGAGCCGCGCGTACCCGGCGGGACCCGCGCCTTCGCCCTCCGGCCCGGCTGTACCT  
ACGCGGTGGGCGCCGCTTGCACGCCCCGGGCGCCGCGGGAGCTGCTGGACGTGGGCGCGATGGGCGGCTGGCA  
GGACGTGCGCGCGTCTCGGGCGCGGGGCGCCCGCTGCCGCTGCAAGTCCGCTTGGTGGCCCGCAGTGCCCCGAC  
GGCGCTGAGCCGCCGCTGCGGGCGCGCACGCACCTTCCCGGCTGCGGAGCCCGTGCCCCGGCTCTGCGGAACCG  
GTGCCCGGCTCTGCGGGGCGCTCTGCTTCCCCGTCCCCGGCGGCTGCGCGGCCCGCGCAGCATTCGGCGCTCGCA  
GCTCCGACCACCTTACCCGCTGCCGCTGCCCGCCGCGCCCCAGGCCCGCTGTCCCGGCCGTCCCATCTGCCT  
GCCGCCGGGCGGCTCGGTCCGCCTGCGTCTGCTGTGCGCCCTGCGGCGCGCGGCTGGCGCCGTCCGGGTGGGAC  
TGGCGCTGGAGGCCGCCACCGCGGGGACGCCCTCCGCGTCGCCATCCCCATCGCCGCCCTGCCGCCGAACCTG  
CCCGAAGCCCGGGCGGGGCCGCGCGACGGGCCGGCGGGGCACGAGCGGCAGAGGGAGCCTGAAGTTTCCGAT  
GCCCCAATAACAGGTGGCGTTGTTTGAGAACGAACCGGCGGGCACCCCTCATCTCCAGCTGCACGCGCACTACA  
CCATCGAGGGCGAGGAGGAGCGCGTGAGCTATTACATGGAGGGGCTGTTGACGAGCGCTCCCGGGGCTACTTC  
CGAATCGACTCTGCCACGGGCGCCGTGAGCAGCGACGCTACTGGACCGCGAGACCAAGGAGACGCACGTCTC  
CAGGGTGAAGCCGTGGACTACGTACGCCGCGCGCTGCGCCACACCTACATCACTGTCTTGGTCAAAGACA  
CCAACGACCACAGCCCCGTCTTCGAGCAGTCGGAGTACCGCGAGCGCGTGCGGGAGAACCTGGAGGTGGGCTAC  
GAGGTGCTGACCATCCGCGCCAGCGACCGCGACTCGCCCATCAACGCCAACCTTGCGTTACCGCGTGTGGGGGG  
CGCGTGGGACGTCTTCCAGCTCAACGAGAGCTCTGGCGTGGTGAGCACACGGGCGGTGCTGGACCGGGAGGAGG  
CGGCCGAGTACCAGCTCCTGGTGGAGGCCAACGACCAGGGGCGCAATCCGGGCCCGCTCAGTGCCACGGCCACC  
GTGTACATCGAGGTGGAGGACGAGAACGACAATAACCCCAAGTTCAGCGAGCAGAACTACGTGGTCCAGGTGCC  
CGAGGACGTGGGGCTCAACACGGCTGTGCTGCGAGTGCGAGGCCACGGACCGGGACAGGGCCAGAACCGGGCCA  
TTACTACAGCATCCTCAGCGGGAACGTGGCCGGCCAGTTCTACCTGCACTCGCTGAGCGGGATCCTGGATGTG  
ATCAACCCCTTGGAATTTGAGGATGTCCAGAAATACTCGCTGAGCATTAAGGCCAGGATGGGGGCGCGCCCC  
GCTCATCAATTCCTCAGGGGTGGTGTCTGTGTCAGGTGCTGGATGTCAACGACAACGAGCCTATCTTTGTGAGCA  
GCCCCTTCCAGGCCACGGTGTGGAGAATGTGCCCTGGGCTACCCCGTGGTGCACATTCAGGCGGTGGACGCG  
GACTCTGGAGAGAACGCCCGGCTGCACTATCGCCTGGTGGACACGGCCTCCACCTTTCTGGGGGGCGGCAGCGC  
TGGGCCTAAGAATCCTGCCCCACCCCTGACTTCCCCTTCCAGATCCACAACAGCTCCGGTTGGATCACAGTGT  
GTGCCGAGCTGGACCGCGAGGAGGTGGAGCACTACAGCTTCGGGGTGGAGGCGGTGGACCACGGCTCGCCCCC  
ATGAGCTCCTCCACCAGCGTGTCCATCACGGTGTGACGTGAATGACAACGACCCGGTGTTCACGCAGCCAC  
CTACAGCTTCGTCTGAATGAGGATGCGGCCGTGGGAGCAGCGTGCTGACCTGCAGGCCCGCGACCGTGACG  
CCAACAGTGTGATTACCTACAGCTCACAGGCGGCAACACCCGAACCGCTTTGCACTCAGCAGCCAGAGAGGG  
GGCGGCCTCATCACCTTGGCGCTACCTCTGGACTACAAGCAGGAGCAGCAGTACGTGCTGGCGGTGACAGCATC  
CGACGGCACACGGTGCACACTGCGCATGTCTTAATCAACGTCACTGATGCCAACACCCACAGGCCTGTCTTTC  
AGAGCTCCCATTACACAGTGAGTGTGAGTGAGGACAGGCCTGTGGGCACCTCCATTGCTACCCCTCAGTGCCAAC  
GATGAGGACACAGGAGAGAATGCCCGCATCACCTACGTGATTACAGACCCCGTGCCGCGAGTTCCGCATTGACCC  
CGACAGTGGCACCATGTACACCATGATGGAGCTGGACTATGAGAACCAGGTGCGCTACACGCTGACCATCATGG  
CCCAGGACAACGGCATCCCGCAGAAATCAGACACCACCCCTAGAGATCCTCATCTCGATGCCAATGACAAT  
GCACCCAGTTCTGTGGGATTTCTACAGGGTTCATCTTTGAGGATGCTCCACCTCGACCAGCATCCTCCA  
GGTCTCTGCCACGGACCGGACTCAGGTCCCAATGGGCGTCTGCTGTACACCTTCAGGGTGGGGACGACGGCG  
ATGGGGACTTCTACATCGAGCCACGTCCGGTGTGATTGCGACCCAGCGCCGGCTGGACCGGGAGAATGTGGCC  
GTGTACAACCTTTGGGCTCTGGCTGTGGATCGGGGCGAGTCCCACTCCCTTAGCGCCTCGGTAGAAATCCAGGT  
GACCATCTTGGACATTAATGACAATGCCCCATGTTTGAGAAGGACGAACCTGGAGCTGTTTGTGAGGAGAACA  
ACCCAGTGGGGTCCGTGGTGGCAAAGATTCTGTGCTAACGACCCTGATGAAGGCCCTAATGCCCAGATCATGTAT  
CAGATTGTGGAAGGGGACATGCGGCATTTCTTCCAGCTGGACCTGCTCAACGGGGACCTGCGTGCCATGGTGG  
GCTGGACTTTGAGGTCCGGCGGGAGTATGTGCTGGTGGTGCAGGCCACGTGCGCTCCGCTGGTGAGCCGAGCCA  
CGGTGCACATCCTTCTCGTGGACCAGAATGACAACCCGCTGTGCTGCCGACTTCCAGATCCTCTTCAACAAC  
TATGTCACCAACAGTCCAACAGTTTCCCCACCGCGTGATCGGCTGCATCCCGGCCATGACCCCGAGCTGTC  
AGACAGCTCAACTACACCTTCGTGCAGGGCAACGAGTGCGCCGTGTTGCTGCTGGACCCCGCCACGGCGAAC  
TGCAGCTCAGCCGCGACCTGGACAACAACCGCCGCTGGAGGCGCTCATGGAGGTGTCTGTGTCTGATGGCATC  
CACAGCGTCACGGCCTTCTGCACCCCTGCGTGTCAACATCATCACGGACGACATGCTGACCAACAGCATCACTGT  
CCGCTGGAGAACATGTCCCAGGAGAAGTTCTGTCCCCGCTGCTGGCCCTCTTCTGAGGGGGGTGGCCGCCG  
TGCTGTCCACCACCAAGGACGACGTCTTCGTCTTCAACGTCCAGAACGACACCGACGTGAGTCCAACATCCTG  
AACGTGACCTTCTCGGCGTGTGCTGCTGGCGGCGTCCGCGGCCAGTTCTTCCCGTGGAGGACCTGCAGGAGCA  
GATCTACCTGAATCGGACGCTGCTGACCACCATCTCCACGCGAGCGGTGCTGCCCTTCGACGACAACATCTGCC  
TGCGCGAGCCCTGCGAGAATACTACATGAAGTGCCTGTCCGTCTGCGATTGACAGCTCCGCGCCCTTCTCAGC



64/136

**FIGURE 51B**

TCCACCACCGTGCTCTTCCGGCCCCATCCACCCCATCAACGGCCTGCGCTGCCGCTGCCCGCCCGGCTTCACCGG  
CGACTACTGCGAGACGGAGATCGACCTCTGCTACTCCGACCCGTGCGGCGCCAACGGCCGCTGCCGAGCCGCG  
AGGGCGGCTACACCTGCGAGTGCTTCGAGGACTTCACTGGAGAGCACTGTGAGGTGGATGCCCGCTCAGGCCGC  
TGTGCCAACGGGGTGTCAGAAGACGGGGGCACCTGCGTGAACCTGCTCATCGGCGGCTTCCACTGCGTGTGTCC  
TCCTGGCGAGTATGAGAGGCCCTACTGTGAGGTGACCACCAGGAGCTTCCCGCCCCAGTCCTTCGTACCTTCC  
GGGGCCTGAGACAGCGCTTCCACTTCACCATCTCCCTCACGTTTGCCACTCAGGAAAGGAACGGCTTGCTTCTC  
TACAACGGCCGCTTCAATGAGAAGCACGACTTCATCGCCCTGGAGATCGTGGACGAGCAGGTGCAGCTCACCTT  
CTCTGAGGCGAGACAACAACGACCGTGGCACCAGGTTCCAGTGGTGTGAGTGACGGGCGGTGGCACTCTG  
TGCAGGTGCAGTACTACAACAAGCCCAATATTGGCCACCTGGGCTGCCCATGGGCCGTCCGGGGAAAAGATG  
GCCGTGGTGACAGTGGATGATTGTGACACAACCATGGCTGTGCGCTTTGGAAAGGACATCGGGAACACAGCTG  
CGCTGCCAGGGCACTCAGACCGGCTCCAAGAAGTCCCTGGATCTGACCGGCCCTTACTCCTGGGGGGTGTCC  
CCAACCTGCCAGAAGACTTCCCAGTGCAACAACGGCAGTTCGTGGGCTGCATGCGGAACCTGTAGTCGACGGC  
AAAAATGTGGACATGGCCGATTTCATCGCCAACAATGGCACCCGGGAAGGCTGCGCTGCTCGGAGGAACCTTCTG  
CGATGGGAGGCGGTGTGAGAATGGAGGCACCTGTGTCAACAGGTGGAATATGTATCTGTGTGAGTGTCCACTCC  
GATTCCGGCGGGAAGAACTGTGAGCAAGCCATGCCTCACCCCCAGCTCTTCAGCGGTGAGAGCGTCTGTCTCTGG  
AGTGACCTGAACATCATCATCTCTGTGCCCTGGTACCTGGGGCTCATGTTCCGGACCCGGAAGGAGGACAGCGT  
TCTGATGGAGGCCACCAGTGGTGGGCCACCAGCTTTCGCCCTCCAGATCCTGAACAACACTACCTCCAGTTTGAGG  
TGTCACCGGCCCTCCGATGTGGAGTCCGTGATGCTGTCCGGGTTGCGGGTGACCGACGAGGAGTGGCACCAC  
CTGCTGATCGAGCTGAAGAATGTTAAGGAGGACAGTGAGATGAAGCACCTGGTCACCATGACCTTGGACTATGG  
GATGGACCAGAACAAGGCAGATATCGGGGGCATGCTTCCCGGGCTGACGGTAAGGAGCGTGGTGGTGGGAGGCG  
CCTCTGAAGACAAGGTCTCCGTGCGCCGTGGATTCCGAGGCTGCATGCAGGGAGTGAGGATGGGGGGGACGCCC  
ACCAACGTGCGCACCCCTGAACATGAACAACGCACCTCAAGGTGAGGTGAAGGACGGCTGTGATGTGGACGACCC  
CTGTACCTCGAGCCCCGTGTCCTCCCAATAGCCGCTGCCACGACGCTGGGAGGACTACAGCTGCGTCTGTGACA  
AAGGGTACCTTGAATAAACTGTGTGGATGCCTGTACCTGAACCCCTGCGAGAATATGGGGGCTGCGTGGCG  
TCCCCCGGCTCCCCGACGGGCTACGTGTGCGAGTGTGGGCCAGTCACTACGGGCGCTACTGTGAGAACAACCT  
CGACCTTCCGTGCCCGAGGGCTGGTGGGGGAACCCGCTCTGTGGACCCCTGCCACTGTGCCGTGAGCAAGGCT  
TTGATCCCGACTGTAATAAGACCAACGGCCAGTGCCAATGCAAGGAGAATTACTACAAGCTCCTAGCCAGGAC  
ACCTGTCTGCCCTGCGACTGCTTCCCCCATGGCTCCACAGCCGCACTTGCAGCATGGCCACCGGGCAGTGTGC  
CTGCAAGCCCGGCGTCATCGGCCGCACTGCAACCGCTGCGACAACCCGTTTGGCGAGGTACCACGCTCGGCT  
GTGAAGTGATCTACAATGGCTGTCCCAAAGCATTTGAGGCCGGCATCTGGTGGCCACAGACCAAGTTCGGGCAG  
CCGGCTGCGGTGCCATGCCCCAAGGGATCCGTTGGAATGCGGTCCGACACTGCAGCGGGGAGAAGGGCTGGCT  
GCCCCAGAGCTCTTTAACTGTACCACTCTCCTTCGTGGACCTCAGGGCCATGAATGAGAAGCTGAGCCGCA  
ATGAGACGCAGGTGGACGGCGCCAGGGCCCTGCAGCTGGTGAGGGCGCTGCGCAGTGCTACACAGCACACGGGC  
ACGCTCTTTGGCAATGACGTGCGCACGGCCCTACCAGCTGCTGGGCCACGTCTTCAGCACGAGAGCTGGCAGCA  
GGGCTTCGACCTGGCAGCCACGACGAGCCGACTTTACGAGGACGTCATCCACTCAGGCGACGCCCTCCTGG  
CCCCAGCCACCAGGGCGCGCTGGGAGCAGATCCAGCGGAGGAGGGCGGACGCGCAGGCTGCTCGGCGCTC  
GAGGGCTACTTCAGCAACGTGGCACGCAACGTGCGGCGGACGTACCTGCGGCCCTTCGTATCGTCACCGCCAA  
CATGATTCTTGCTGTGACATCTTTGACAAGTTCAACTTTACGGGAGCCAGGGTCCCGCGATTTCGACACCATCC  
ATGAAGAGTTCCCCAGGGAGCTGGAGTCTCCTTCCTTCCAGCCGACTTCTTCAGACCACCTGAAGAAAAA  
GAAGGCCCCCTGCTGAGGCCGGCTGGCCGAGGACACCCCGCAGACCACGCGCCCGGGGCTGGCACCAGAG  
GGAGGCCCCGATCAGCAGGCGGAGGCGACACCCCTGATGACGCTGGCCAGTTTCGCCGTGCTCTGGTCATCATTT  
ACCGCACCCCTGGGGCAGCTCCTGCCCCGAGCGCTACGACCCCGACCGTGCAGCCTCCGGTTGCCCTACCGGCC  
ATCATTAATACCCCGATGGTGAGCACGCTGGTGTACAGCGAGGGGGCTCCGCTCCCGAGACCCCTGGAGAGGCC  
CGTCTGGTGGAGTTCGCCCTGCTGGAGGTGGAGGAGCGAACCAAGCCTGTCTGCGTGTCTGGAACCACTCCC  
TGGCCGTTGGTGGGACGGGAGGTGGTCTGCCCGGGCTGCGAGCTCCTGTCCAGGAACCGGACACATGTCGCC  
TGCCAGTGCAGCCACACAGCCAGCTTTGCGGTGCTCATGGATATCTCCAGGCGTGAGAACGGGGAGGTCTGCC  
TCTGAAGATTGTACCTATGCCGCTGTGTCTTGTCACTGGCAGCCCTGCTGGTGGCCTTCGTCTCTCTGAGCC  
TGGTCCGCATGCTGCGCTCCAACCTGCACAGCATTACACAAGCACCTCGCCGTGGCGCTCTTCTCTCTCAGCTG  
GTGTTCTGTGATTGGGATCAACCAGACGGAACCCGTTTCTGTGCACAGTGGTTGCCATCCTCCTCCACTACAT  
CTACATGAGCACCTTTGCCCTGGACCCCTCGTGGAGAGCCTGCATGTCTACCGCATGCTGACCGAGGTGCGCAACA  
TCGACACGGGGCCCATGCGGTTCTACTACCTCGTGGCTGGGGCATCCCGCCATTGTACAGGACTGGCGGT  
GGCTGGACCCCCAGGGCTACGGGAACCCCGACTTCTGCTGGCTGTGCTTCAAGACACCCCTGATTTGGAGCTT  
TGCGGGGGCCATCGGAGCTGTATAATCATCAACACAGTCACTTCTGTCTATCTGCAAAGGTTTCTGCCAAA  
GAAAGCACCATATTATGGGAAAAAAGGGATCGTCTCCCTGCTGAGGACCGCATTCCTCCTGCTGCTGCTCATC

65/136

**FIGURE 51C**

AGCGCCACCTGGCTGCTGGGGCTGCTGGCTGTGAACCGCGATGCACTGAGCTTTCCTACTACCTCTTCGCCATCTT  
CAGCGGCTTACAGGGCCCCCTTCGTCTCCTTTTCCACTGCGTGCTCAACCAGGAGGTCCGGAAGCACCTGAAGG  
GCGTGCTCGGCGGGAGGAAGCTGCACCTGGAGGACTCCGCCACCACCAGGGCCACCCTGCTGACGCGCTCCCTC  
AACTGCAACACCACCTTCGGTGACGGGCCTGACATGCTGCGCACAGACTTGGGCGAGTCCACCGCCTCGCTGGA  
CAGCATCGTCAGGGATGAAGGGATCCAGAAGCTCGGCGTGCTCTGGGCTGGTGAGGGGCAGCCACGGAGAGC  
CAGACGCGTCCCTCATGCCCAGGAGCTGCAAGGATCCCCCTGGCCACGATTCCGACTCAGATAGCGAGCTGTCC  
CTGGATGAGCAGAGCAGCTCTTACGCCTCCTCACACTCGTCAGACAGCGAGGACGATGGGGTGGGAGCTGAGGA  
AAAATGGGACCCGGCCAGGGGCGCCGTCCACAGCACCCCCAAAGGGGACGCTGTGGCCAACCACGTTCCGGCCG  
GCTGGCCCGACAGAGCCTGGCTGAGAGTGACAGTGAGGACCCAGCGGCAAGCCCCGCTGAAGGTGGAGACC  
AAGGTGAGCGTGAGCTGCACCGCGAGGAGCAGGGCAGTCACCGTGAGAGTACCCCCCGGACAGGAGAGCGG  
GGGCGCAGCCAGGCTTGCTAGCAGCCAGCCCCAGAGCAGAGGAAAGGCATCTTGAAAAATAAAGTCACCTACC  
CGCCGCGCTGACGCTGACGGAGCAGACGCTGAAGGGCCGGCTCCGGGAGAAGCTGGCCGACTGTGAGCAGAGC  
CCCACATCCTCGCGCACGTCTTCCCTGGGCTCTGGCGGCCCGGACTGCGCCATCACAGTCAAGAGCCCTGGGAG  
GGAGCCGGGGCGTGACCACCTCAACGGGGTGGCCATGAATGTGCGCACTGGGAGCGCCAGGCCGATGGTCCG  
ACTCTGAGAAACCGTGAAGGCAAGCCCGTACCCACACAGGCTGCGGCATCACCTCAGACCTTGGAGCCCAAG  
GGGCCACTGCCCTTGAAGTGAGTGAGGGCCAGAGTGTTGGCGGTCCCATGGTGAGCAGCCCCCGACTGATCATC  
CAGACACAAAGGTCTTGGTCTCTCCAGGAGCTCAGGGCCTGTCAGACCTGGTGACAAGTGCCAAAGGCCACAGG  
CATGAGGGAGGCGTGAGCACTGGGCCAGCACCGCTGAGTCTTAAGACTGCAGTCAAAGCCAGAAGTGAGAGGG  
GACCCAGACTGGGCCAGAGGCTGGCCAGAGTTCAGGAACGCCGGGCACAGACCAAAGACCGCGGTCCAGCCC  
CGCCAGGCGGGCATCTCATGGCAGTGCGGACCCGTGGCTGGCAGCCCGGGCAGTCTTTGCAAAGGCACCCCT  
TGTCTTAAATCACTTCGCTATGTGGGAAAGGTGGAGATACTTTTATATATTTGTATGGGACTCTGAGGAGGTG  
CAACCTGTATATATATTTGCATTCGTGCTGACTTTGTATCCCGAGAGATCCATGCAATGATCTCTTGCTGTCTT  
CTCTGTCAAGATTGCACAGTTGTACTTGAATCTGGCATGTGTTGACGAAACTGGTGCCCCAGCAGATCAAAGGT  
GGGAAATACGTGAGCAGTGGGGCTAAAACCAAGCGGCTAGAAGCCCTACAGCTGCCTTCGGCCAGGAAGTGAGG  
ATGGTGTGGGCCCTCCCCGCCGGCCCCCTGGGTCCCCAGTGTTGCTGTGTGTGCGTTTGTCTCTGCTGCCAT  
CTGCCCCGGCTGTGTGAATTCAAGACAGGGCAGTGACAGCACTAGGCAGGTGTGAGGAGCCCTGCTGAGGTCACT  
GTGGGGCACGGTTGCCACACGGCTGTCAATTTTACCTGGTCATTCTGTGACCACCACCCCTCCCCCACCAGC  
CTCCAGGTGGCCCGGAGCTGCAGGTGGGGATGGCTTTGTCTTTGCTCCTGCTCCCGTGGGACCTGGGACC  
TTAAAGCGTTGCAGGTTCTGATTTGGACAGAGGTGTGGGGCCTTCCAGGCCGTTACATACTCCTGCCAATTC  
TCTAATCTCTGAGACTGCGAGGATCTCCAGGCAGGGTTCTCCCTCTGGAGTCTGACCAATTACTTCAATTTG  
CTTCAAATGGCCAATTGTGCAGAGGGACAAAGCCACAGCCACACTCTTCAACGGTTACCAAACTGTTTTTGAA  
ATTCACACCAAGGTGGGGCCCACTGCAGGCAGCTGGCACAGCGTGCCCGAGGGGGCTGTGGAACGGGTCCCGGA  
ACTGTGACACATGTTTGATTTTAGCGTTTCTTTGTTCTTCAAATCAGGTGCCCAAATAAGTGATCAGCACAGC  
TGCTTCCAAATAGGAGAAACCATAAAATAGGATGAAAATCAAGTAAAATGCAAAGATGTCCACACTGTTTTAAA  
CTTGACCCTGATGAAAATGTGAGCACTGTTAGCAGATGCCTATGGGAGAGGAAAAGCGTATCTGAAAATGGTCC  
AGGACAGGAGGATGAAATGAGATCCCAGAGTCTCACACCTGAATGAATTATACATGTGCCTTACCAGGTGAGT  
GGTCTTTTGAAGATAAAAACTCTAGTCCCTTTAAACGTTTGCCCCTGGCGTTTCTTAAGTACGAAAAGGTTTT  
TAAGTCTTGAACAGTCTCCTTTCATGACTTTAACAGGATTCTGCCCCCTGAGGTGTAATTTTTTTGTTCTATT  
TTTTTCCACGTACTCCACAGCCAACATCACGAGGTGTAATTTTTTAATTTGATCAGAACTGTTACCAAAAAACAA  
CTGTGAGTTTTATTGAGATGGGAAAAATGTAAACCTATTTTTATTACTTAAGACTTTATGGGAGAGATTAGACA  
CTGGAGGTTTTTAACAGAACGTGTATTTATTAATGTTCAAAACACTGGAATTACAAATGAGAAGAGTCTACAAT  
AAATTAAGATTTTTGAATTTGTACTTCTGCGGTGCTGGTTTTTCTCCACAAACACCCCCGCCCCCTCCCCATGCC  
CAGGGTGGCCGTGGAAGGGACGGTTTACGGACGTGCAGCTGAGCTGTCCGTGTCCCATGCTCCCTCAGCCAGTG  
GAACGTGCCGGAACTTTTGTCCATTCCCTAGTAGGCCTGCCACAGCCTAGATGGGCAGTTTTTGTCTTTCACC  
AAATTTGAGGACTTTTTTTTTTTTGCCATTATTTCTTCAGTTTTCTTTCTTGCACTGATCTTCTCCTCTCCTT  
CTGTGACTCCAGTGACTCAGACGTTAGACCTCTTGATGTTTTCCCACTGGTCCCTGAGGCTCTGTTT

66/136

**FIGURE 52**

CGGCCTAAGGTAGCGACGGGACTGGCCGGGGGCGGCAGGACCCGAAGGCGCTAGGCGGATTACCCGGATGGGAG  
TTGAATCGCGTCCCGGTCTTTCTAGCTGTGCCCCGAAATCGGGCGTGCGGGCAGCTACAGCAGAGAATCGGACA  
AGGAGGGAAGAAAGAGATGGTNNNGAAGTGAGTGCAAG  
AGGAGCCGGCTTAGCATCTAAACTGATTCTACCATCAGAAAAGAGGCCAAACTTCTATCATCATGGTGGATGTG  
AAGTGTCTGAGTGACTGTAAATTGCAGAACCAACTTGAGAAGCTTGGATTTTCACCTGGCCCAATACTACCTTC  
CACCAGAAAGTTGTATGAAAAAAGTTAGTACAGTTGTTGGTCTCACCTCCCTGTGCACCACCTGTGATGAATG  
GACCCAGAGAGCTGGATGGAGCGCAGGACAGTGATGACAGCGAAGAGCTTAATATCATTTTGCAAGGAAATATC  
ATACTCTCAACAGAAAAAAGCAAGAACTCAAAAAATGGCCTGAGGCTTCCACTAAACGCAAAGCTGTAGA  
TACCTATTGCTTGGATTATAAGCCTTCCAAGGGAAGAAGGTGGGCTGCAAGAGCACCAAGCACCAGAATCACAT  
ATGGGACTATCACCAAAGAGAGAGACTACTGCGCGGAAGACCAGACTATCGAGAGCTGGAGAGAAGAAGGTTTC  
CCAGTGGGCTTGAAGCTTGCTGTGCTTGGTATTTTCATCATTGTGGTGTGTTGTCTACCTGACTGTGGAAAATAA  
GTCGCTGTTTGGTTAAGTAAATTTAGGAGCAAAGCAATGCTCCAAGCGAGGCCTCCTGCTTCAGGAAAGAACCAA  
AACACTACCCTGAAGGGCCAGCCTAGCCTGCAGCCCTCCCTTGCCAGGGAGCCTTCCCTTGCACTGTGCTGCTCT  
CACAGATCGGTGTCTGGGCTCAGCCAGGTGGAAGGAACCTGCCTAACCAGGCACCTGTGTTAAGAGCATGATGG  
TTAGGAAATCCCCCAAGTCATGTCAACTCTCATTAAGGTGCTTCCATATTTGAGCAGGCGTCAAACAAGG

67/136

**FIGURE 53**

ACCGCTCCGGAGCGGGAGGGGAGGCTTCGCGGAACGCTCTCGGCGCCAGGACTCGCGTGCAAAGCCCAGGCCCG  
GGCGGCCAGACCAAGAGGGAAGAAGCACAGAATTCTCAACTCCAGTGTGCCCCATGAGTAAGAGCAAATGCTC  
CGTGGGACTCATGTCTTCCGTGGTGGCCCCGGCTAAGGAGCCCAATGCCGTGGGCCCCGAAGGAGGTGGAGCTCA  
TCCTTGTCAGGAGCAGAACGGAGTGCAGCTCACCAGCTCCACCCTCACCACCCGCGGCAGAGCCCCGTGGAG  
GCCCAGGATCGGGAGACCTGGGGCAAGAAGATCGACTTTCTCCTGTCCGTCAATTGGCTTTGCTGTGGACCTGGC  
CAACGTCTGGCGGTTCCCCCTACCTGTGCTACAAAAATGGTGGCGGTGCCTTCCTGGTCCCCCTACCTGCTCTTCA  
TGGTCATTGCTGGGATGCCACTTTTCTACATGGAGCTGGCCCTCGGCCAGTTCAACAGGGAAGGGGCCGCTGGT  
GTCTGGAAGATCTGCCCCATACTGAAAGGTGTGGGCTTACGGTTCATCCTCATCTCACTGTATGTCGGCTTCTT  
CTACAACGTCATCATCGCCTGGGCGCTGCACATATCTTCTCCTCCTTACCACGGAGCTCCCCCTGGATCCACT  
GCAACAACTCCTGGAACAGCCCCAACTGCTCGGATGCCATCCTGGTGAATCCAGTGGAGACAGCTCGGGCCTC  
AACGACACTTTTGGGACCACACCTGCTGCCGAGTACTTTGAACGTGGCGTGTGCACCTCCACCAGAGCCATGG  
CATCGACGACCTGGGGCCTCCGCGGTGGCAGCTCACAGCCTGCCTGGTGTGCTGGTTCATCGTGTGCTCTACTTCA  
GCCTCTGGAAGGGCGTGAAGACCTCAGGGAAGGTGGTATGGATCACAGCCACCATGCCATACGTGGTCTCTACT  
GCCCTGCTCCTGCGTGGGGTACCCCTCCCTGGAGCCATAGACGGCATCAGAGCATACCTGAGCGTTGACTTCTA  
CCGGCTCTCCGAGGCGTCTGTTTGGATTGACGCGGCCACCCAGGTGTGCTTCTCCTTGGGCGTGGGGTTCCGGG  
TGCTGATCGCCTTCTCCAGCTACAACAAGTTACCAACAACCTGCTACAGGGACGCGATTGTACCACCTCCATC  
AACTCCCTGACGAGCTTCTCCTCCGGCTTCGTCGTCTTCTCCTTCTTGGGGTACATGGCAGAGAAGCAGAGTGT  
GCCCATCGGGGACGTGGCCAAGGACGGGCCAGGGCTGATCTTCATCATCTACCCGGAAGCCATCGCCAGCTCC  
CTCTGTCTCAGCCTGGGCCGTGGTCTTCTTCATCATGCTGCTCACCCTGGGTATCGACAGCGCCATGGGTGGT  
ATGGAGTCAGTGATCACCGGGCTCATCGATGAGTTCCAGCTGCTGCACAGACACCGTGAGCTCTTACGCTCTT  
CATCGTCCGCGACCTTCTCCTGTCCCTGTTCTGCGTCACCAACGGTGGCATCTACGTCTTACGCTCCTGG  
ACCATTTTGCAGCCGGCACGTCCATCCTCTTTGAGTGCTCATCGAAGCCATCGGAGTGGCCTGGTTCTATGGT  
GTTGGGCACTTACGCGACGACATCCAGCAGATGACCGGGCAGCGGCCAGCCTGTACTGGCGGTGTGCTGGAA  
GCTGGTCAGCCCCCTGCTTTCTCCTGTTCGTGGTGTGGTGCAGCATTGTGACCTTCAGACCCCCCACTACGGAG  
CCTACATCTTCCCCGACTGGGCCAACGCGCTGGGCTGGGTTCATCGCCACATCCTCCATGGCCATGGTGGCCATC  
TATGCGGCCTACAAGTTCTGCAGCCTGCCTGGGTCCTTTCGAGAGAACTGGCCTACGCCATTGCACCCGAGAA  
GGACCGTGAGCTGGTGGACAGAGGGGAGGTGCGCCAGTTACGCTCCGCCACTGGCTCAAGGTGTAGAGGGAG  
AGAGACGAAGACCCCAGGAAGTCATCCTGCAATGGGAGAGACACGAACAAACCAAGGAAATCTAAGTTTCGAGA  
GAAAGGAGGGCAACTTCTACTCTTCAACCTCTACTGAAAACACAAACAAAGCAGAAGACTCCTCTCTTCTG  
ACTGTTTACACCTTTCCGTGCCGGGAGCGCACCTCGCCGTGTCTTGTGTTGCTGTAATAACGACGTAGATCTGT  
GCAGCGAGGTCCACCCCGTTGTTGTCCCTGCAGGGCAGAAAAACGTCTAACTTCATGCTGTCTGTGTGAGGCTC  
CCTCCCTCCCTGCTCCCTGCTCCCGGCTCTGAGGCTGCCCCAGGGGCACTGTGTTCTCAGGCGGGGATCACGAT  
CCTTGTAGACGCACCTGCTGAGAAATCCCCGTGCTCACAGTAGCTTCTAGACCATTTACTTTGCCCATATTTAA  
AAGCCAAGTGTCTGCTTGGTTTAGCTGTGCAGAAGGTGAAATGGAGGAAACCACAAATTCATGCAAAGTCTT  
TCCCGATGCGTGGCTCCCAGCAGAGGCCGTAATTTGAGCGTTTCACTTGACACATTGCACACAGCTGTGTTAG  
AGGCATTGGAGATGGGGTCTCTGGTATGTCTCACCAGGAAATCTGTTTATGTTCTTGTGAGCAGAGAGAAATA  
AAACTCCTTGAACACAGCTCAGGCTACTGCTCACTCAGGACGCTGTGGGTCTTGTGTGTAGGGAACGGCTG  
AGAGGAGCGTGTCTATCCCCGACGCATGCAGGGCCCCCACAGGAGCGTGTCTATCCCCGACGCATGCAGG  
GCCCCACAGGAGCATGTCTATCCCTGGACGCATGCAGGGCCCCCACAGGAGCGTGTACTACCCACAGACGCA  
TGCAGGGCCCCCACAGGAGCGTGTACTACCCAGGACGCATGCAGGGCCCCCACTGGAGCGTGTACTACCCAG  
GACGCATGCAGGGCCCCCACAGGAGCGTGTCTATCCCCGACCGGACGCATGCAGGGCCCCCACAGGAGCGTG  
TACTACCCAGGACGCATGCAGGGCCCCCACAGGAGCGTGTACTACCCAGGATGCATGCAGGGCCCCCACAGG  
AGCGTGTACTACCCAGGACGCATGCAGGGCCCCCATGCAGGCAGCCTGCAGACCAACACTCTGCCTGGCCTTG  
AGCCGTGACCTCCAGGAAGGGACCCCACTGGAATTTTATTTCTCTCAGGTGCGTGCCACATCAATAACAACAGT  
TTTTATGTTTGGCAATGGCTTTTTTAAATCATATTTACCTGTGAATCAAAACAAATTCAGAATGCAGTATCCG  
CGACCTTGCTTGTGATATTGCAGTTTTTGTTTACAAGAATAATTAGCAATACTGAGTGAAGGATGTTGGCCAA  
AAGCTGCTTTCCATGGCACACTGCCCTCTGCCACTGCAGGAAAGTGGATGCCATAGTTTGAATTCATGCCTCA  
AGTCGGTGGGCTTGCCTACGTGCTGCCCGAGGGCAGGGGCCGTGCAGGGCCAGTCATGGCTGTCCCTTGAAGT  
GGACGTGGGCTCCAGGGACTGGAGTGTAATGCTCGGTGGGAGCCGTGAGCCTGTGAAGTGCAGGCAGCTGCAG  
TTAGCACAGAGGATGGCTTCCCCATTGCCTTCTGGGGAGGGACACAGAGGACGGCTTCCCCATCGCCTTCTGGC  
CGCTGCAGTCAGCACAGAGAGCGGCTTCCCCATTGCCTTCTGGGGAGGGACACAGAGGACAGTTTCCCCATCGC  
CTTCTGGTTGTTGAAGACAGCACAGAGAGCGGCTTCCCCATCGCCTTCTGGGGAGGGGCTCCGTGTAGCAACCC  
AGGTGTTGTCCGTGTCTGTTGACCAATCTCTATTACGATCGTGTGGGTCCCTAAGCACATAAAAGACATCCA  
CAATGGAAAAAAGGAATTC

68/136

**FIGURE 54**

CGGACGCGTGGGTGAGCAGGGACGGTGCACCGGACGGCGGGATCGAGCAAATGGGTCTGGCCATGGAGCACGGA  
GGGTCTACGCTCGGGCGGGGGGCGAGCTCTCGGGGCTGCTGGTATTACCTGCGCTACTTCTTCTCTTCGTCTC  
CCTCATCCAATTCTCATCATCTGGGGCTCGTGCTCTTCATGGTCTATGGCAACGTGCACGTGAGCACAGAGT  
CCAACCTGCAGGCCACCGAGCGCCGAGCCGAGGGCCTATACAGTCAGCTCCTAGGGCTCACGGCCTCCAGTCC  
AACTTGACCAAGGAGCTCAACTTCACCACCCGCGCCAAGGATGCCATCATGCAGATGTGGCTGAATGCTCGCCG  
CGACCTGGACCGCATCAATGCCAGCTTCCGCCAGTGCCAGGGTGACCGGGTCATCTACACGAACAATCAGAGGT  
ACATGGCTGCCATCATCTTGAGTGAGAAGCAATGCAGAGATCAATTCAAGGACATGAACAAGAGCTGCGATGCC  
TTGCTCTTCATGCTGAATCAGAAGGTGAAGACGCTGGAGGTGGAGATAGCCAAGGAGAAGACCATTTGCACTAA  
GGATAAGGAAAGCGTGCTGCTGAACAAACGCGTGGCGGAGGAACAGCTGGTTGAATGCGTGAAAACCCGGGAGC  
TGCAGCACCAAGAGCGCCAGCTGGCCAAGGAGCAACTGCAAAAGGTGCAAGCCCTCTGCCTGCCCCCTGGACAAG  
GACAAGTTTGAGATGGACCTTCGTAACCTGTGGAGGGACTCCATTATCCACGCAGCCTGGACAACCTGGGTTA  
CAACCTCTACCATCCCCTGGGCTCGGAATTGGCCTCCATCCGCAGAGCCTGCGACCACATGCCCAGCCTCATGA  
GCTCCAAGGTGGAGGAGCTGGCCCCGAGCCTCCGGGCGGATATCGAACGCGTGGCCCCGCGAGAACTCAGACCTC  
CAACGCCAGAAGCTGGAAGCCCAGCAGGGCCTGCGGGCCAGTCAGGAGGCGAAACAGAAGGTGGAGAAGGAGGC  
TCAGGCCCCGGGAGGCCAAGCTCCAAGCTGAATGCTCCCGGCAGACCCAGCTAGCGCTGGAGGAGAAGGCGGTGC  
TGCGGAAGGAACGAGACAACCTGGCCAAGGAGCTGGAAGAGAAGAAGAGGGAGGCGGAGCAGCTCAGGATGGAG  
CTGGCCATCAGAACTCAGCCCTGGACACCTGCATCAAGACCAAGTCGCAGCCGATGATGCCAGTGTC AAGGCC  
CATGGGCCCTGTCCCCAACCCCCAGCCCATCGACCCAGCTAGCCTGGAGGAGTTCAAGAGGAAGATCCTGGAGT  
CCCAGAGGCCCCCTGCAGGCATCCCTGTAGCCCCATCCAGTGGCTCGAGGAGGCTCCAGGCCTGAGGACCAAGGG  
ATGGCCCCGACTCGGCGGTTTTCGGGAGGATGCAGGGATATGCTCACAGCGCCCGACACAACCCCCCTCCCGCCGCC  
CCCAACCACCCAGGGCCACCATCAGACAACCTCCCTGCATGCAAACCCCTAGTACCCTCTCACACCCGCACCCGC  
GCCTCACGATCCCTCACCCAGAGCACACGGCCGCGGAGATGACGTACGCAAGCAACGGCGCTGACGTACATA  
TCACCGTGGTGATGGCGTCACGTGGCCATGTAGACGTACGAAGAGATATAGCGATGGCGTCGTGCAGATGCAG  
CACGTGCGACACAGACATGGGGAACCTGGCATGACGTACACCGAGATGCAGCAACGACGTACGGGCCATGTC  
GACGTACACATATTAATGTCACACAGACGCGGCGATGGCATCACACAGACGGTGATGATGTCACACACAGACA  
CAGTGACAACACACACCATGACAACGACACCTATAGATATGGCACCAACATCACATGCACGCATGCCCTTTCAC  
ACACACTTTCTACCCAATTCTCACCTAGTGTCACGTTCCCCCGACCCTGGCACACGGGCCAAGGTACCCACAGG  
ATCCCATCCCCCTCCCGCACAGCCCTGGGCCCCAGCACCTCCCCTCCTCCAGCTTCTGGCCTCCAGCCACTTC  
CTACCCCCAGTGCCTGGACCCGGAGGTGAGAACAGGAAGCCATTACCTCCGCTCCTTGAGCGTGAGTGTTTC  
CAGGACCCCCCTCGGGGCCCTGAGCCGGGGGTGAGGGTCACCTGTTGTGCGGAGGGGAGCCACTCCTTCTCCCCC  
AACTCCCAGCCCTGCCTGTGGCCCGTTGAAATGTTGGTGGCACTTAATAAATATTAGTAAATCCTTAAAAAAA  
AAAAAAAAAAAAAAAAAAAAA

69/136

**FIGURE 55**

CGGACTTGGCTTGTTAGAAGGCTGAAAGATGATGGCAGGAATGAAAATCCAGCTTGTATGCATGCTACTCCTGG  
CTTTCAGCTCCTGGAGTCTGTGCTCAGATTCAGAAGAGGAAATGAAAGCATTAGAAGCAGATTTCTTGACCAAT  
ATGCATACATCAAAGATTAGTAAAGCACATGTTCCCTCTTGGAAGATGACTCTGCTAAATGTTTGCAGTCTTGT  
AAATAATTTGAACAGCCCAGCTGAGGAAACAGGAGAAGTTCATGAAGAGGAGCTTGTTGCAAGAAGGAAACTTC  
CTACTGCTTTTAGATGGCTTTAGCTTGGAAGCAATGTTGACAATATACCAGCTCCACAAAATCTGTCACAGCAGG  
GCTTTTCAACACTGGGAGTTAATCCAGGAAGATATTCTTGATACTGGAAATGACAAAAATGGAAAGGAAGAAGT  
CATAAAGAGAAAAATTCTTATATTCTGAAACGGCAGCTGTATGAGAATAAACCCAGAAGACCCTACATACTCA  
AAAGAGATTCTTACTATTACTTGAGAGAGAATAAATCATTTATTTACATGTGATTGTGATTCATCATCCCTTAATTA  
AATATCAAATTATATTTGTGTGAAAATGTGACAAACACACTTATCTGTCTCTTCTACAATTGTGGTTTATTGAA  
TGTGTTTTTCTGCACTAATAGAAATTAGACTAAGTGTTTTTCAAATAAATCTAAATCTTCAAAAAAAAAAAAAAA  
AAATGGGGCCGCAATT

70/136

**FIGURE 56**

CGCGGGGCGCGGAGTCGGCGGGGCGCTCGCGGGACGCGGGCAGTGCGGAGACCGCGGCGCTGAGGACGCGGGAGC  
CGGGAGCGCACGCGCGGGGTGGAGTTCAGCCTACTCTTTCTTAGATGTGAAAGGAAAGGAAGATCATTTTCATGC  
CTTGTTGATAAAGGTTTCAGACTTCTGCTGATTTCATAACCATTTGGCTCTGAGCTATGACAAGAGAGGAAACAAA  
AAGTTAACTTACAAGCCTGCCATAAGTGAGAAGCAAACCTTCCTTGATAACATGCTTTTTCGAAGTGCAGGAAA  
ATTAAATGTGGGCACCAAGAAAGAGGATGGTGAGAGTACAGCCCCACCCCCCGTCCAAAGGTCTTGCCTTGTA  
AATGCCACCACCATTGTCCAGAAGACTCAGTCAACAATATTTGCAGCACAGACGGATATTGTTTCACGATGATA  
GAAGAGGATGACTCTGGGTTGCCTGTGGTCACTTCTGGTTGCCTAGGACTAGAAGGCTCAGATTTTCAGTGTCG  
GGACACTCCCATTCTCATCAAAGAAGATCAATTGAATGCTGCACAGAAAGGAACGAATGTAATAAAGACCTAC  
ACCCTACACTGCCTCCATTGAAAAACAGAGATTTTGTGTTGATGGACCTATACACCACAGGGCTTTACTTATATCT  
GTGACTGTCTGTAGTTTGTCTTTGGTCCTTATCATATTATTTTGTACTTCCGGTATAAAAGACAAGAAACCAG  
ACCTCGATACAGCATTGGGTTAGAACAGGATGAACTTACATTCCTCCTGGAGAATCCCTGAGAGACTTAATTG  
AGCAGTCTCAGAGCTCAGGAAGTGGATCAGGCCTCCCTCTGCTGGTCCAAAGGACTATAGCTAAGCAGATTTCAG  
ATGGTGAAACAGATTGGAAAAGGTGCGTATGGGGAAGTTTGGATGGGAAAGTGGCGTGGCGAAAAGGTAGCTGT  
GAAAGTGTTCTTACCACAGAGGAAGCCAGCTGGTTCAGAGAGACAGAAATATATCAGACAGTGTGTATGAGGC  
ATGAAAACATTTGGGTTTCATTGCTGCAGATATCAAAGGGACAGGGTCTTGACCCAGTTGTACCTAATCACA  
GACTATCATGAAAATGGTTCCCTTTATGATTATCTGAAGTCCACCACCTAGACGCTAAATCAATGCTGAAGTT  
AGCCTACTCTTCTGTGCTAGTGGCTTATGTCAATTTACACACAGAAATCTTTAGTACTCAAGGCAAACCAGCAATTG  
CCCATCGAGATCTGAAAAGTAAAAACATTTCTGGTGAAGAAAAATGGAACCTTGTGTATTGCTGACCTGGGCCTG  
GCTGTTAAATTTTATTAGTGATACAAATGAAGTTGACATACCACCTAACACTCGAGTTGGCACCAAACGCTATAT  
GCCTCCAGAAGTGTTGGACGAGAGCTTGAACAGAAATCACTTCCAGTCTTACATCATGGCTGACATGTATAGTT  
TTGGCCTCATCCTTTGGGAGGTGCTAGGAGATGTGTATCAGGAGGTATAGTGAAGAATACCAGCTTCCTTAT  
CATGACCTAGTGCCCGAGTGACCCCTCTTATGAGGACATGAGGGAGATTGTGTGCATCAAGAAGTTACGCCCCCTC  
ATTCCCAAACCGGTGGAGCAGTGATGAGTGTCTAAGGCAGATGGGAAAACCTCATGACAGAATGCTGGGCTCACA  
ATCCTGCATCAAGGCTGACAGCCCTGCGGGTTAAGAAAACACTTGCCAAAATGTCAGAGTCCCAGGACATTAAA  
CTCTGATAGGAGAGGAAAAGTAAGCATCTCTGCAGAAAGCCAAACAGGTACTCTTCTGTTTGTGGGCAGAGCAAA  
AGACATCAAATAAGCATCCACAGTACAAGCCTTGAACATCGTCTGCTTCCCAGTGGGTTTCAGACCTCACCTTT  
CAGGGAGCGACCTGGGCAAAGACAGAGAAGCTCCCAGAAGGAGAGATTGATCCATGTCTGTTTGTAGGACGGAG  
AAACCGCTTGGGTAACCTGTTCAAGATATGATGCATGTTGCTTTCTAAGAAAGCCCTGTATTTTGTGATTGCCT  
TTTTTTTTTTTTTAAGATGCTTTCATTTTGCCAAAATAAAACAGATAATGTGGATGGTTTAAAGGTTATAGTATT  
ATAGTTTAAATAATAACAACAAAATTCTTCCAGGAACCTGCTGGAAGGTAAATTAATAACTTGTTTTTTCCA  
TTGGTAAAATATTGTGCACTCTGTGAACCAAAGACAGTCTAAGTTGGAGGACATAGAACGGAACCTCATCTTA  
AACATACTCCCCACCCGCTCTTGGCCTCCTCAGACCCTTTGGCCATCCCTGCATTTGGGGCCGCTATGGTAAT  
GTGAATGCACTGGGTACAAACACCGCCTGTCTAGGACCACATTTGGAATTCCTGCAGGTGGCCTTTTGCAGCTT  
CAGGCAATATGGAACAAATGAAGGTTTATGTGACTCTAATAGAAGTAATTGTTGATAGGTGTTTTTCAGATCCA  
CTTCTGTTTCTGATTGAGTTAGGCATCTCTTTCATGGTAAACCCCTTTTCATTAAACACAAAAAAGCTTTTTT  
TTTTTTTTTTTTTTTTTTTTTTTTTTTAAATGTGCAGAGGATTGACCTGTGCATGCTTTTGATCTCTCATTCAAAG  
GATCAATATTAAATAAAATTTGTCATGAGCTGTGTTGAAGACAGGGTGCTTTCAAATAGAGGTAATTTGCTCTTG  
TGTTGTAAGAGGAACATGTCAACAAAGATAGGAAATGAGGGTGATCGTGCAGATGGCTTGATCTTATATATGC  
AAAGGAGCCAATCTCAGAAGCACAAAGAAAAAAGTGTGCATACCTTATTTTGTACAGATAAAGATGATGTCTTT  
TTGTTATTGTCTGTCTGTTTTGTATGTGTCTGAGATAAGGGATAGAGAGGAAACATCCGTCAGGCTAATTTAAC  
TACATTTTATTTTAAAAATAGAGAAACATAACCTCTAGATGGGACAGCAGAGGACAGTTAGTAGAGGCCACAAA  
CTGTTATGGGCTGCTGTGTTTTGTTCTAAAATCAATATGGTTGGAGCATGTATATCTTAGGTGATCATTTTCACA  
TCTTAGGAATGCCTACTCATTTTATTTTATTCTAGTGATGCTCAATTCACATTTTAAATTTATTATATTTTCTCT  
TCTGTGGCACTTATACAAAATATCTCTTCACCTACTTAGTTCTACAGGGTTTTAACTTTGGAGCAACATGAATA  
AAATCATCGAGAAGGCCAATATTGTTTAGCAACATGAATACAATACAGTTTAAAGTTGTACACATCCTGCTCAA  
CTTTATTTCATATACATTTCCCTTCTGTGGTTTTCTTTTGTCTTCTAGAAATTCGTGTAGTGGTTAGTAAAGAAT  
TTGAAAGTACTTTCTCCTTGCTGTTTTTTTTTTTTTAAAGCATTTCTCCAGAACTCCTCCAGAGGGGCGAGTGT  
TTTAAAACACATTTTCCCCACTGGGTGATTGAAGGATGGAGGATTTTGAATAATTGACAGCTACATGAAACAT  
GAGAAAACATTTTCTCACTTCTGAAGTCGGTTTTGCAGCTGGTAACCTTGTTCATCCAGAAAACATTTCTAAAGCA  
ATGAGACTTTGTGAGCTGTGCTTACAGTTTGGGAGAATCATGAAGATTCTTTCTATATTTTGCATTTACTTCCC  
AGTGCTTCATAGCTGCATTTTG

71/136

**FIGURE 57**

MLRTAMGLRSWLAAPWGALPPRPPLLLLLLLLLLLLLLQPPPTWALSPRISLPLGSEERPFLRFEAEHISNYTALL  
LSRDGRTLYVGAREALFALSSNLSFLPGGEYQELLWGADAEEKKQQCSFKGKDPQRDCQNYIKILLPLSGSHLFT  
CGTAAFSPMCTYINMENFTLARDEKGNVLLEDGKGRCFPDPNFKSTALVVDGELYTGTVSSFQGNPAISRSQS  
LRPTKTESSLNLWLQDPAFVASAYIPESLGSLOGDDDKIYFFFSETGQEFEFFENTIVSRIARICKGDEGGERVL  
QQRWTSFLKAQLLCSRPDDGFPPNVLQDVFTLSPSPQDWRDTLFGVFTSQWHRGTTEGSAVCVFTMKDVQRVF  
SGLYKEVNRETQQWYTVTHPVPTPRPGACITNSARERKINSSLQLPDRVLNFLKDHFLMDGQVRSRMLLLQPQA  
RYQRVAVHRVPGLHHTYDVLFLGTGDGRLHKAVSVGPRVHIIIEELQIFSSGQPVQNLLLDTHRGLLYAASHGV  
VQVPMANCSLYRSCGDCLLARDPYCAWSGSSCKHVSlyQPQLATRPWIQDIEGASAKDLCSASSVVSPSFVPTG  
EKPCEQVQFQPNVTNLTACPLLSNLATRLWLRNGAPVNASASCHVLPTGDLLLVTQQLGEFQCWSLEEGFQQL  
VASYCPEVVEDGVADQTDEGGSVPVIIISTSRVSAPAGGKASWGADRSYWKEFLVMCTLFVLAVLLPVLFLLYRH  
RNSMKVFLKQGECASVHPKTCPVVLPPETRPLNGLGPPSTPLDHRGYQSLSDSPPGARVFTSEKRPLSIQDSF  
VEVSPVCPRPRV  
RLGSEIRDSVV

**Signal sequence.**

amino acids 1-37

**Transmembrane domain.**

amino acids 717-737

**N-glycosylation sites.**

amino acids 69-72, 96-99, 165-168, 410-413, 525-528, 630-633

**N-myristoylation sites.**amino acids 85-90, 205-210, 212-217, 251-256, 342-347, 351-356, 355-360,  
397-402, 431-436, 456-461, 467-472, 508-513, 626-631, 703-708, 709-714**Leucine zipper pattern.**

amino acids 12-33



72/136

**FIGURE 58**

MDCRKMARFSYSVIWIMAIKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWPQEEPAIRPRSSQRVPPMGIQH  
SKELNRTCCLNGGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPG  
CDGLVMDEHLVASRTPELPPSARTTTFMLVGICLSIQSY

**Transmembrane domain.**

amino acids 7-27

**N-glycosylation site.**

amino acids 79-82

**N-myristoylation sites.**

amino acids 26-31, 71-76, 92-97, 136-141, 179-184

**EGF-like domain cysteine pattern signature.**

amino acids 95-107

73/136

## **FIGURE 59**

MAARALCMLGLVLALLSSSSAE EYVGLSANQCAVPAKDRVDCGYPHVTPKEC NNRGCCFDSRIPGVPWC FKPLQ  
EAECTF

**Signal sequence.**

amino acids 1-21

**Tyrosine kinase phosphorylation site.**

amino acids 37-44

**N-myristoylation sites.**

amino acids 10-15, 26-31, 65-70

**P-type 'Trefoil' domain signature.**

amino acids 39-59

**Trefoil (P-type) domain.**

amino acids 31-72

74/136

**FIGURE 60**

MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETL  
PSKSNESHDMDDMDDEDDDDHVDSQDSIDSNDSDDDVDDTDDSHQSDESHHSDESDELVTDFPTDLPATEVFTP  
VVPTVDITYDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITSHMESEELNGAYKAIPVAQDLNAPSDWDSRGK  
DSYETSQLDDQSAETHSHKQSRLYKRKANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDK  
HLKFRISHELDASSEVN

**Signal sequence.**

amino acids 1-16

**N-glycosylation sites.**

amino acids 79-82, 106-109

**Tyrosine kinase phosphorylation site.**

amino acids 175-181

**N-myristoylation sites.**

amino acids 12-17, 200-205

**Cell attachment sequence.**

amino acids 159-161

**Osteopontin signature.**

amino acids 20-30

**Osteopontin.**

amino acids 1-314

75/136

**FIGURE 61**

MSRTAYTVGALLLLLLGTLTPAAEGKKKGSQGAIPPPDKAQHNDSEQTQSPQQPGSRNRGRGQGGRGTAMPGEEVL  
ESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGCNSRTIINRFCYGQCNSFYIPRHIRKEEGSFQSCSFCKPKK  
FTTMMVTLNCPQLQPPTKKKRVTRVKQCRCISIDL

**Signal sequence.**

amino acids 1-24

**N-glycosylation site.**

amino acids 42-45

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 26-29, 147-150, 168-171

**N-myristoylation site.**

amino acids 28-33, 61-66, 120-125, 136-141

**Amidation site.**

amino acids 23-26

**DAN domain.**

amino acids 58-184

76/136

**FIGURE 62**

MFLATLYFALPLLDLLLSAEVSGGDRLCDVKASDQCLKEQSCSTKYRTLRLQCVAGKETNFSLASGLEAKDECRS  
AMEALKQKSLYNCRCKRGMKKEKNCLRIYWSMYQSLQGNDLLEDSPYEPVNSRLSDIFRVVPFISVEHIPKGNN  
CLDAAKACNLDDICKKYRSAYITPCTTSVSNVDCNRRKCHKALRQFFDKVPAKHSYGMLFCSCRDIACTERRRQ  
TIVPVCSYEEREKPNCLNLQDSCKTNYICRSRLADFFFTNCQPESRSVSSCLKENYADCLLAYSGLIGTVMTPNY  
IDSSSLSVAPWCDSCNSGNDLEECLKFLNFFKDNTCLKNAIQAFGNGSDVTWQPAFPVQTTTATTTTALRVKN  
KPLGPAGSENEIPTHVLPPCANLQAQKLKSNVSGNTHLCISNGNYEKEGLGASSHITTKSMAAPPSCGLSPLL  
LVVTALSTLLSLTETS

**Signal sequence.**

amino acids 1-23

**Transmembrane domain.**

amino acids 434-454

**N-glycosylation sites.**

amino acids 59-62, 342-345, 401-404

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 220-223

**N-myristoylation sites.**

amino acids 205-210, 286-291, 343-348, 419-424

**GDNF receptor family.**

amino acids 1-415

77/136

**FIGURE 63**

MQHRGFLLLTLLALLALTSVAKKKKDKVKKGGPGSECAEWAWGPCTPSSKDCGVGFREGTCGAQTQRIRCRVPC  
NWKKEFGADCKYKFENWGACDGGTGTKVRQGLKKARYNAQCQETIRVTKPCTPKTKAKAKAKKGKGKD

**Signal sequence.**

amino acids 1-20

**N-myristoylation sites.**

amino acids 31-36, 34-39, 59-64, 92-97, 96-101

**PTN/MK heparin-binding protein family signature 1.**

amino acids 35-59

**PTN/MK heparin-binding protein family signature 2.**

amino acids 70-94

**PTN/MK heparin-binding protein family.**

amino acids 1-143

78/136

**FIGURE 64**

MWVLGIAATFCGLELLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEVMEQSAGIMYRKSCASS  
AACLIASAGYQSFCSPGKLNSVCISCCNTPLCNGPRPKKRGSSASALRPGLRRTTILFLKLALFSAHC

**Signal sequence.**

amino acids 1-22

**Transmembrane domain.**

amino acids 121-140

**N-glycosylation site.**

amino acids 45-48

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 113-116

**N-myristoylation sites.**

amino acids 5-10, 115-120, 124-129

79/136

**FIGURE 65**

MKNIGLVMeweIPEIICTCAKLRLPPQATFQVLRNGASVGTVLMFRCPSNHQMVGSGLLTCTWKGSIAEWSSG  
SPVCKLVPPHETFGFKVAVIASIVSCAIILLMSMAFLTCCLLKCVKKSKRRRSNRSACLWSQLKDEDLETVQAA  
YLGLKHFNKPVSGPSQAHDNHSFTTDHGESTSKLASVTRSVDKDPGIPRALSLGSSSSPQAQVMVHMANPRQP  
LPASGLATGMPQQPAAYALG

**Transmembrane domain.**

amino acids 93-113

**N-glycosylation sites.**

amino acids 128-131, 168-171

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 124-127

**N-myristoylation sites.**

amino acids 35-40, 37-42, 58-63, 74-79, 194-199, 227-232



80/136

**FIGURE 66**

DCTGDGPWQSNLAPSQLEYYASSPDEKALVEAAARIGIVFIGNSEETMEVKTGKLERYKLLHILEFDSDDRRRM  
SVIVQAPSGEKLLFAKGAESSILPKCIGGEIEKTRIHVDEFALKGLRTLCTIAYRKFTSKEYEEIDKRIFEARTA  
LQOREEKLA AVFQFIEKDLILLGATAVEDRLQDKVRETIEALRMAGIKVWVLTGDKHETAVSVSLSCGHFHRTM  
NILELINQKSDSECAEQLRQLARRITEDHVIQHGLVVDGTSLSLALREHEKLFMEVCRNCSAVLCCRMAPLQKA  
KVIRLIKISPEKPITLAVGDGANDVSMIQEAHVIGIGIMGKEGRQAARNSDYAIARFKFLSKLLFVHGHFYIIRI  
ATLVQYFFYKNVCFITPQFLYQFYCLFSQQTLYDSVYLTLYNICFTSLPILIYSLLEQHVDPHVLQNKPTLYRD  
ISKNRLLSIKTFLYWTILGFSAFIFFFGSYLLIGKDTSLGNGQMFGNWTFGTLVFTVMVITVTVKMALETHF  
WTWINHLVTWGSIIIFYFVFSLFYGGILWPFLGSQNMVFVFIQLLSSGSAWFATILMVVTCLFLDIIKKVFDRLH  
HPTSTEKAQLTETNAGIKCLDSMCCFPEGEAACASVGRMLERVIGRCSPTHISRSWSASDPFYTNDRSILTLST  
MDSSTC

**Transmembrane domains.**

amino acids 352-372, 369-389, 405-425, 453-473, 487-507, 503-523, 522-542,  
538-558, 561-581

**N-glycosylation sites.**

amino acids 281-284, 493-496

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 72-75, 128-131, 245-248

**N-myristoylation sites.**

amino acids 91-96, 261-266, 488-493

81/136

**FIGURE 67**

MWEEEDIAILFNKEPGKTENIENNLSSNHRRSCRRSEESDDDLDFDIGLENTGGDPQILRFISDFLAFLVLYNF  
IIPISLYVTVMQKFLGSFFIGWDLDLYHEESDQKAQVNTSDLNEELGQVEYVFTDKTGTLTENEMQFRECSIN  
GMKYQEINGRLVPEGPTPDSSEGNLSYLSSLSHLNLSHLTTSSSFRTSPENETELIKEHDLFFKAVSLCHTVQ  
ISNVQTDCTGDGPWQSNLAPSQLEY YASSPDEKALVEAAARYKLLHILEFDSDRRRMSVIVQAPSGEKL LFAKG  
AESSILPKCIGGEIEKTRIHVDEFALKGLRTL CIAYRKFTSKEYEEIDKRIFEARTALQQREEKLA AVFQFIEK  
DLILLGATAVEDRLQDKVRETIEALRMAGIKVWVLTGDKHETAVSVSLSCGHFHRMTMNILELINQKSDSECAEQ  
LRQLARRITEDHVIQHGLVVDGTSLSLALREHEKLFMEVCRNCSAVLCCRMAPLQKAKVIRLIKISPEKPITLA  
VG DGANDVSMIQEAHVIGIGIMGKEGRQAARNSDYAIARFKFLSKLLFVHG HFYYIRIATLVQYFFYKNVCFITP  
QFLYQFYCLFSQQTLYDSVYLTLYNICFTSLPILIYSLLEQHVDPHVLQNKPTLYRDISKNRLLSIKTFLYWTI  
LGFSHAFIFFFFGSYLLIGKDTSL LGNGQMFGNWTFTGLVFTVMVITVTVKMALETHFWTWINHLVTWGSII FYF  
VFSLFYGGILWPFLGSQNMYFVFIQLSSGSAWF AII LMVVTCLFLDI IKKVFDRLHPTST EKAQLTETNAGI  
KCLDSMCCFPGEAAACASVGRMLERVIGRCSPT HISRSWSASDPFYTNDRSILTLSTMD SSTC

**Transmembrane domains.**

amino acids 61-81, 575-595, 610-630, 658-678, 698-718, 727-747, 743-763,  
766-786

**N-glycosylation sites.**

amino acids 24-27, 113-116, 172-175, 184-187, 200-203, 486-489, 698-701

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 277-280, 333-336, 450-453

**N-myristoylation sites.**

amino acids 48-53, 296-301, 466-471, 693-698

**E1-E2 ATPases phosphorylation site.**

amino acids 130-136

**Haloacid dehalogenase-like hydrolase.**

amino acids 124-542

**E1-E2 ATPases phosphoryl.**

amino acids 105-142, 374-417, 516-539

82/136

## **FIGURE 68**

MKHVLNLYLLGVVLTLLSIFVRVMESLEGLLESPPGTSWTTRSQLANTEPTKGLPDHPSRSM

**Signal sequence.**

amino acids 1-18

**N-myristoylation sites.**

amino acids 11-16, 37-42

83/136

## **FIGURE 69**

MKTGLFFLCLLGTAAAIPTNARLLSDHSKPTAETVAPDNTAIPSLRAEDEENEKETAVSTEDDSHHKAEKSSVL  
KSKEESHEQSAEQGKSSSQELGLKDQXDSDGDL SVNLEYAPTEGTLDIKEDMSEPQEKNSQXH

**Signal sequence.**

amino acids 1-16

**N-myristoylation site.**

amino acids 12-17

84/136

**FIGURE 70**

MAPWAEAEHSALNPLRAVWLTLTAAFLLTLLLQLLPPGLLPGCAIFQDLIRYGKTKCGEPSRPAACRAFDVPKR  
YFSHFYIISVLWNGFLLWCLTQSLFLGAPFPSWLHGLLRILGAAQFQGGELALSAFLVLVFLWLHSLRRLFECL  
YVSVFSNVMIHVVQYCFGLVYYVLVGLTVLSQVPMDGRNAYITGKNLLMQARWFHILGMMMFIIWSSAHQYKCHV  
ILGNLRKNKAGVVIHCNHRIPFGDWFEYVSSPNYLAELMIYVSMVTFGFHNLTWWLVVTNVFFNQALSAFLSH  
QFYKSKFVSYPKHRKAFLPFLF

**Transmembrane domains.**

amino acids 20-40, 76-96, 118-138, 158-178, 193-213, 272-292

**N-glycosylation site.**

amino acids 274-277

**Tyrosine kinase phosphorylation sites.**

amino acids 143-149

**N-myristoylation sites.**

amino acids 38-43, 122-127

**3-oxo-5-alpha-steroid 4-dehydrogenase.**

amino acids 145-318

85/136

**FIGURE 71**

MPLLWLRGFLASCWIIIVRSSPTPGSEGHSAAPDCPSCALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDV  
TQVPVKAALLNAIRKLHVGVGKVGNGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLS  
VVERAEVWLFVKVPKANRTRTKVTIRLFQQQKHPPQGSGLDTGEEAAEEVGLKGERSELLLSEKVVDARKSTWHVFP  
VSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEEEGEGKKKGGGEGGAGADEEKEQSHRPFLMLQ  
ARQSEDHPPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHS  
TVINHYRMRGHSFPFANLKSCCVPTKLRPMSMLYYDDGQNIKKDIQNMIVEECGCS

**Signal sequence.**

amino acids 1-20

**N-glycosylation site.**

amino acids 165-168

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 214-217

**Tyrosine kinase phosphorylation site.**

amino acids 94-100

**N-myristoylation sites.**

amino acids 144-149, 184-189, 273-278, 274-279, 277-282, 360-365, 363-368

**Amidation sites.**

amino acids 107-110, 257-260, 268-271

**TGF-beta family signature.**

amino acids 339-354

**Transforming growth factor beta like.**

amino acids 318-426

**TGF-beta propeptide.**

amino acids 42-274

86/136

**FIGURE 72**

MAAAPLLLLLLLLVPVPLLPLLAQGPGGALGNRHAVYWNSSNQHLRREGYTVQVNVNDYLDIYCPHYNSSGVGPG  
AGPGPGGGAEQYVLYMVSRNGYRTCNASQGFKRWECNRPHAPHSPIKFSEKFQRYSAFSLGYEFHAGHEYYS  
TPTHNLHWKCLRMKVVFVCCASTSHSGEKPVPTLPQFTMGPNVKINVLEDFEGENPQVPKLEKSISGTSPKREHL  
PLAVGIAFFLMTFLAS

**Signal sequence.**

amino acids 1-30

**Transmembrane domain.**

amino acids 224-237

**N-glycosylation sites.**

amino acids 38-41, 67-70, 100-103

**Glycosaminoglycan attachment site.**

amino acids 69-73

**N-myristoylation sites.**

amino acids 26-31, 27-32, 30-35, 70-75

**Ephrin.**

amino acids 27-171

87/136

**FIGURE 73**

MGHSPPVLPLCASVSLLGGLTFGYELAVISGALLPLQLDFGLSCLEQEFVLVGSLLLGLLALLASLVGGFLIDCYGR  
KQAILGSNLVLLAGSLTLGLAGSLAWLVLGRAVVGFALSLSSMACCIYVSELVGPRQRGVLVSLYEAGITVGIL  
LSYALNYALAGTPWGRHMFGWATAPAVLQSLSLFLPAGTDETATHKDLIPLQGGEAPKLGPRPRYSFLDLF  
RARDNMRGRITTVGLGLVLFQQLTGQPNVLCYASTIFSSVGFHGGSSAVLASVGLGAVKVAATLTAMGLVDRAGR  
RALLLAGCALMALSVSGIGLVSEFAVPMDSGSPCLAVPNATGQTGLPGDSGLLQDSSLPIPRTNEDQREPIILST  
AKKTKPHPRSGDPSAPPRLALSSALPGPPLPARGHALLRWTALLCLMVFSAFSFGFGPVTWLVLSEIYPVEIR  
GRAFAFCNSFNWAANLFISLSFLDLIGTIGLSWTFLLYGLTAVLGLGFIYLEFVPETKGQSLAEIDQQFQKRRT  
LSFGHRQNSTGIPYSRIEISAAS

**Transmembrane domains.**

amino acids 11-31, 45-65, 83-103, 136-156, 168-188, 231-251, 265-285,  
296-316, 410-430, 456-476, 473-493

**N-glycosylation sites.**

amino acids 334-337, 526-529

**Glycosaminoglycan attachment site.**

amino acids 312-315

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 515-518

**N-myristoylation sites.**

amino acids 19-24, 57-62, 93-98, 133-138, 142-147, 146-151, 159-164, 188-193,  
265-270, 474-479, 502-507, 529-534

**Amidation sites.**

amino acids 72-75, 294-297

**Sugar (and other) transporter.**

amino acids 10-512



88/136

**FIGURE 74**

MAKATSGAAGLRLLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAPEEVPSFRLGQHLYG  
 TYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLTVYLKVFLSPTSLREGECCQWPGCARVYFS  
 FFNTSFPACSSSLKPRELCFPETRPSFRIENRPPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLE  
 VSTRWALDREQREKYELVAVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATL  
 RVFDADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNRNLSISENRTM  
 QLAVLVNDSDFQGPAGVLLLFHFNVSFLPVSLHLPSTYSLSVSRRARRFAQIGKVCVENCAAFSGINVQYKLHS  
 SGANCSTLGVTSAEDTSGILFVNDTKALRRPKCAELHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLS  
 CAVSKRRLECEECGLGSPGTGRCEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVETQDINICPDCLRGSI  
 VGHPEGEPRGIKAGYGTCCNCFPEEEKCFCEPEDIQDPLCDEL CRTVIAA AVLFSFIVSVLLSAFCIHCYHKFAHK  
 PPISSAEMTFRRPAQAAPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVK  
 ATAFHLKGRAGYTTAVKMLKENASPSSELRDLLSEFNVLKQVNHHPHVIKLYGACSDGPFLLLIVEYAKYGS  
 LRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKM  
 KISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFN  
 LLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAATPSDSLTYDDGLSEE  
 ETPLVDCNNAPLRALPSTWIENKLYGMSDPNWPGESPVPLTRADGTNTGFPYRPNDSVYANWMLSPSAAKLMD  
 TFDS

**Signal sequence.**

amino acids 1-23

**Transmembrane domains.**

amino acids 386-406, 633-653

**N-glycosylation sites.**amino acids 98-101, 151-154, 199-202, 336-339, 343-346, 361-364, 367-370,  
377-380, 394-397, 448-451, 468-471, 554-557, 834-837, 975-978, 1092-1095**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 312-315, 693-696

**Tyrosine kinase phosphorylation sites.**

amino acids 477-483, 897-905, 1089-1096

**N-myristoylation sites.**amino acids 28-33, 74-79, 275-280, 446-451, 453-458, 506-511, 514-519,  
535-540, 550-555, 588-593, 601-606, 607-612, 810-815, 828-833, 830-835,  
831-836, 1082-1087**Amidation site.**

amino acids 884-887

**Tyrosine protein kinases specific active-site signature.**

amino acids 870-882

**Protein kinase domain.**

amino acids 724-1005

**Cadherin domain.**

amino acids 172-261

89/136

**FIGURE 75**

MRTYRYFLLLFVWGQPYPTLSTPLSKRTSGFPAKKRALELSGNSKNELNRSKRSMWNQFFLLEEYTGSDYQYV  
GKLHSDQDRGDGSLKYILSGDGAGDLFIINENTGDIQATKRLDREEKPVYILRAQAINRRTGRPVEPESEFIIK  
IHDINDNEPIFTKEVYTATVPMSDVGTFFVQVTATDADDPTYGNSAKVVYSILQGQPYFSVESETGIIKTALL  
NMDRENREQYQVVIQAKDMGGQMGGLSGTTTNNITLTDVNDNPPRFPQSTYQFKTPESSPPGTPIGRIKASDAD  
VGENAEIEYSITDGEGLDMFDVITDQETQEGIIITVKLLDFEKKKVYTLKVEASNPHYVEPRFLYLGPFKDSATV  
RIVVEDVDEPPVFSKLAYILQIREDAQINTTIGSVTAQDPDAARNPVKYSVDRHTDMDRIFNIDSGNGSIFTSK  
LLDRETL LWHNITVIATEINNPKQSSRVPLYIKVLDVNDNAPEFAEFYETFVCEKAKADQLIOTLHAVDKDDPY  
SGHQFSFSLAPEAASGSNFTIQDNKDNTAGILTRKNGYNRHEMSTYLLPVVISDNDYPVQSSTGTVTVRVCACD  
HHGNMQSCHAEALIHPTGLSTGALVAILLCIVILLVTVVLFAALRRQRKKEPLIISKEDIRDNIVSYNDEGGGE  
EDTQAFDIGTLRNPEAIEDNKLRRDIVPEALFLPRRTPTARDNTDVRDFINQRLKENDTDPTAPPYDSLATYAY  
EGTGSVADSLSSLESVTTDADQDYDYLSDWGPFRFKKLADMYGGVDSKDSD

**Transmembrane domain.**

amino acids 611-631

**N-glycosylation sites.**

amino acids 49-52, 255-258, 399-402, 437-440, 455-458, 536-539, 723-726

**Glycosaminoglycan attachment sites.**

amino acids 93-96, 435-438

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 26-29

**N-myristoylation sites.**amino acids 42-47, 215-220, 242-247, 243-248, 246-251, 247-252, 284-289,  
403-408, 438-443, 534-539, 595-598, 610-615, 614-619, 782-787**Cell attachment sequence.**

amino acids 83-85

**Cadherins extracellular repeated domain signature.**

amino acids 147-157, 256-266, 476-486

**Cadherin cytoplasmic region.**

amino acids 638-784

**Cadherin domains.**

amino acids 58-150, 164-259, 273-375, 388-479, 492-589

90/136

**FIGURE 76**

MLTRNCLSLLLWVLFDGGLLTPLQPQPQQTlatePRENVihLPGQRSHFQrvKrgWvwnQffVleeyVGSEPQY  
VGKLHSDLDKGEgTVKYtLSGDGAGTVFTIDETTgDIHAIRSLDREEkPFYtLRAQAVDIETRkPLEPESEfII  
KVQDINDNEPKFLDGPYVATVPeMSPVGAYVLQVKATDADDPTyGNSARVVYSILQGQPYfSIDPKTGvIRTAL  
PNMDREVKEQYQVLIQAKDMGGQLGGLAGTTiVNITLTdVNDNPPRFpKSIFHLKVPeSSPIGSaIGRIRAVDP  
DFGQNAEIEYNIVPGDGGNLFdIVTDEDtQEGVIKLKKPLDFETKKAYtFKVEASNLHLDHRfHSAGPFKDTAT  
VKISVLDVDEFPVfSKPLYtMEVYEDTPVGtIIGAVTAQDLdVGSGAVRYfIDWKSdGDSYfTIDGNEGTIATN  
ELLdRESTAQYNfSIIASKVSNPLLTskVNILINVLdVNEFPPEISVPYETAVCENAKPGQIIQIVSAADRdLS  
PAGQQfSfRLSPEAAIKPNFTVRdFRNNTAGIETRRNGYSRRQqELYFLPVVIEDSSYPVQSSTNTMTIRVCRC  
DSDGTILSCNVEAIFLPVGLSTGALIAILLcIVILLAIVVLYVALRRQKKHtLMTSKEDIRdNVIHYDDEGGG  
EEDtQAfDIGALRNPKVIEENKIRRDIKPDSLCLPRQRPPMEDNTDIRdFIHQRLQENDVdPTAPPIDSLATYA  
YEGSGSVAESLSSIDSLTTEADQdYDYLTDWGPfRKVLADMFGEeESYNPDkVT

**Signal sequence.**

amino acids 1-25

**Transmembrane domain.**

amino acids 612-632

**N-glycosylation sites.**

amino acids 256-259, 456-459, 537-540, 545-548

**Glycosaminoglycan attachment site.**

amino acids 94-97

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 642-645

**Tyrosine kinase phosphorylation site.**

amino acids 159-165

**N-myristoylation sites.**amino acids 99-104, 216-221, 243-248, 244-249, 247-252, 248-253, 285-290,  
400-405, 404-409, 436-441, 439-444, 521-526, 596-601, 611-616, 615-620**Cadherins extracellular repeated domain signature.**

amino acids 148-158, 257-267

**Cadherin cytoplasmic region.**

amino acids 639-785

**Cadherin domain.**

amino acids 59-151, 165-260, 274-376, 389-480, 493-590

91/136

## **FIGURE 77**

MARPLCTLLLLMATLAGALASSSKEENRIIPGGIYDADLNDEWVQRALHFAISEYNKATEDEYYRRPLQVLRAR  
EQTFGGVNYFFDVEVGRITCKSQPNLDTCAFHEQPELQKKQLCSFEIYEVPWEDRMSLVNSRCQEA

**Signal sequence.**

amino acids 1-20

**Tyrosine kinase phosphorylation site.**

amino acids 57-64

**N-myristoylation sites.**

amino acids 17-22, 33-38

**Cystatin domain.**

amino acids 32-137

92/136

**FIGURE 78**

MTTSPILQLLLRLSLCGLLLQRAETGSKGQTAGELYQRWERYRRECQETLAAAEPSPGLACNGSFDMYVCWDYA  
APNATARASCPWYLPWHHHVAAGFVLRQCGSDGQWGLWRDHTQCENPEKNEAFLDQRLILERLQVMYTVGYSLS  
LATLLLALLILSLFRRLHCTRNYIHINLFTSFMLRAAAILSRDRLLPRLPGPYLGDQALALWNQALAAACRTAQIV  
TQYCVGANYSWLLVEGVYLHSLLVLVGGSEEGHFRYYLLLGWGAPALFVIPWVIVRYLYENTQCWERNEVKAIW  
WIIRTPILMTILINFLIFIRILGILLSKLRTRQMRCRDYRLRLARSTLTIVPLLVGVHEVVFAPVTEEQARGALR  
FAKLGFEIFLSSFQGFVSVLYCFINKEVQSEIRRGWHHCRLRRSLGEEQRLPERAFRALPSGSGPGGEVPTSR  
GLSSGTLPGPGNEASRELESYC

**Transmembrane domains.**

amino acids 1-20, 141-161, 169-189, 227-247, 259-279, 300-320, 338-358,  
377-397

**N-glycosylation sites.**

amino acids 62-65, 77-80, 230-233

**Glycosaminoglycan attachment sites.**

amino acids 433-436, 435-438

**N-myristoylation sites.**

amino acids 29-34, 58-63, 228-233, 250-255, 319-324, 434-439, 445-450,  
455-460

**G-protein coupled receptors family 2 signature 1.**

amino acids 61-85

**G-protein coupled receptors family 2 signature 2.**

amino acids 384-399

**7 transmembrane receptor (Secretin family).**

amino acids 134-399

**Hormone receptor domain.**

amino acids 58-123

93/136

**FIGURE 79**

MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETETGSRVGKLPEASRI  
LNTILSNYDHKLRLPGIGEKPTVVTVETIAVNSLGPLSILDMEYTTIDIFSQTWYDERLCYNDTFESLVLNGNVVS  
QLWIPDTFFRNSKRTHEHEITMPNQMVRIYKDGKVLTYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENE  
MIYKWENFKLEINEKNSWKLFQFDFTGVS NKTEIITTPVGDFMVMTIFFNVSRRFQYVAFQNYVPSSVTTMLSW  
VSFWIKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAVLNFLIYNQTK  
AHASPKLRHPRINSRAHARTRARSACARQHQAFCQIVTTEGSDGEERPSCSAQQPPSPGSPEGPRSLCSKL  
ACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRLDNYSRVVFPVTFFFFNVLYWLVLCLNL

**Signal sequence.**

amino acids 1-18

**Transmembrane domains.**

amino acids 305-325, 335-355, 351-371, 485-505

**N-glycosylation sites.**

amino acids 134-137, 252-255, 272-275, 367-370, 482-485

**N-myristoylation sites.**

amino acids 62-67, 144-149

**Neurotransmitter-gated ion-channels signature.**

amino acids 195-209

94/136

**FIGURE 80**

MEPRPTAPSSGAPGLAGVGETPSAAALAAARVELPGTAVPSVPEDAAPASRDGGGVRDEGPAAAGDGLGRPLGP  
TPSQSRFQVDLVSENAGRAAAAAAAAAAAAAAAAAAGAGAGAKQTPADGEASGESEPAKGSEEAKGRFRVNFVDPAA  
SSSAEDSLSDAAGVGVDGPNVSFQNGGDTVLESGSSLHSGGGGSGHHQHYYDTHNTNTYYLRTFGHNTMDAVP  
RIDHYRHTAAQLGEKLLRPSLAELHDELEKEPFEDGFANGEESTPTRDAVVITYAESKGVVKFGWIKGVLVRCM  
LNIWGVMLFIRLSWIVGQAGIGLSVLVIMMATVVTITITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGAIGL  
IFAFANAVAVAMYVVGFAETVVELLKEHSILMIDEINDIRIIGAITVVILLGISVAGMEWEAKAQIVLLVILL  
AIGDFVIGTFIPLESKKPKGFFGYKSEIFNENFGPDFREEETFFSVFAIFFPAATGILAGANISGDLADPQSAI  
PKGTLLAILITTLVYVGIASVSGSCVVRDATGNVNDTIVTELNTCTSAACKLNDFSSCESSPCSYGLMNNFQV  
MSMVSGFTPLISAGIFSATLSSALASLVSAPKIFQALCKDNIYPAFQMFAGYKGNNEPLRGYILTFLIALGFI  
LIAELNVIAPIISNFFLASALINFSVFHASLAKSPGWRPAFKYYNMWISLLGAILCCIVMFVINWWAALLTYV  
IVLGLYIYVITYKKPDVNWGSSTQALTYLNALQHSIRLSGVEDHVKNFRPQCLVMTGAPNSRPALLHLVHDFTKN  
VGLMICGHVHMGPRRQAMKEMSIDQAKYQRWLIKNNKMAFYAPVHADDLREGAQYLMQAAGLGRMKPNTLVLGF  
KKDWLQADMRDVMYINLFHDAFDIQYGVVVIRLKEGLDISHLQGQEELLSSQEKSPGTDVVSVEYSKKS  
DLDTSKPLSEKPITHKVEEEDGKTATQPLLKKEKSGPIVPLNVADQKLLEASTQFQKKQGKNTIDVWWLFDDGGLT  
LLIPYLLTTKKKWKDCKIRVFIGGKINRIDHRRAMATLLSKFRIDFSDIMVLGDINTKPKKENIIAFEEIIEP  
YRLHEDDKEQDIADKMKEDEPWRITDNELELYKTKTYRQIRLNELLKEHSSTANIIVMSLPVARKGAVSSALYM  
AWLEALSKDLPPILLVRGNHQSVLTFYS

**Transmembrane domains.**

amino acids 89-109, 315-335, 365-385, 402-422, 433-453, 484-504, 520-540,  
653-673, 670-690, 708-728, 724-744

**N-glycosylation sites.**

amino acids 168-171, 506-509, 553-556, 562-565, 690-693

**Glycosaminoglycan attachment site.**

amino acids 187-190

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 991-994

**N-myristoylation sites.**

amino acids 108-113, 131-136, 188-193, 189-194, 190-195, 316-321, 335-340,  
365-370, 369-374, 422-427, 500-505, 504-509, 521-526, 535-540, 585-590,  
606-611, 719-724, 796-801, 816-821, 925-930, 1059-1064, 1176-1181, 1202-1207

95/136

**FIGURE 81**

MATAVSRPCAGRSRDILWRVLGWRIVASIVWSVLFPLICTTVFIIIFSRIDLFHPIQWLSDFSFDLYSSYVIFYF  
LLLSVVIISIFNVEFYAVVPSI PCSRLALIGKIIHPQQLMHSFIHAAMGMVMAWCAAVITQGQYSFLVVPCT  
GTNSFGSPAAQTCLNEYHLFFLLTGAFMGYSYSLLYFVNNMNYLPFPITIQQYKFLRFRRSLLLLLVKHSCVESLF  
LVRNFCILYYFLGYIPKAWISTAMNLHIDEQVHRPLDTVSGLLNLSLLYHVWLCGVFLLTTWYVSWILFKIYAT  
EAHVFPVQPPFAEGSDECLPKVLNSNPPPIIKYLALQDLMLLSQYSPSRRQEVFSLSQPGGHPHNWTAISRECL  
NLLNGMTQKLILYQEAAATNGRVSSSY PVEPKKLNSPEETAFTQPKSSQMPRPSVPPLVKTSLFSSKLSTPDVV  
SPFGTPFGSSVMNRMAGIFDVNTCYGSPQSPQLIRRGPRLWTSASDQQMTEFSNPSPSTSISAEGKTMRQPSVI  
YSWIQNKREQIKNFLSKRVLIMYFFSKHPEASIQAVFSDAQMHIALEGLSHLVAASFTEDRFGVVQTTLPAIL  
NTLLTLQEAVDKYFKLPHASSKPPRISGSLVDTSYKTLRFAFRASLKTAIYRITTTTGEHLNAVQASAEHQKRL  
QQFLEFKE

**Transmembrane domains.**

amino acids 24-44, 68-88, 109-129, 126-146, 161-181, 178-198, 221-241,  
261-281

**N-glycosylation sites.**

amino acids 266-269, 361-364

**N-myristoylation sites.**

amino acids 125-130, 154-159, 173-178, 310-315, 448-453, 582-587



96/136

**FIGURE 82**

MGAPFVWALGLLMLQMLLFVAGEQGTQDITDASERGLHMQKLGSQSVQAALAEALVALPCLFTLQPRPSAARDAP  
RIKWTKVRTASGQRQDLPLILVAKDNVVRVAKSWQGRVSLPSYPRRRANATLLLGLPLRASDSGLYRCQVVRGIED  
EQDLVPLEVTGVVFHYRSARDRYALTFAEAQAEACRLSSAIIAAPRHLQAAFEDGFDNCDAGWLSDRTVRYPIQ  
SRPGCYGDRSSLPGVRSYGRNPNQELYDVYCFARELGGEVFFYVGPARRLTLAGARAQCRROGAALASVGQLHLA  
WHEGLDQCDPGWLADGSVRYPIQTPRRRCGGPAPGVRTVYRFANRTGFPSPAERFDAYCFRAHHPTSQHGDLT  
PSSGDEGEILSAEGPPVRELEPTLEEEVVTPDFQEPLVSSGEEETLILEEKQESQQTLSPTPGDPMLASWPTG  
EVWLSTVAPSPSDMGAGTAASSHTEVAPTDPMPRRRGRFKGLNGRYFQQQEPEPGLQGGMEASAQPPTSEAAVN  
QMEPPLAMAVTEMLGSGQSRSPWADLTNEVDMPGAGSAGGKSSPEPWLWPPTMVPPSISGHSRAPVLELEKAEG  
PSARPATPDFWSPLEATVSAPSPAPWEAFPVATSPDLPMAMLRGPKWMLPHPTPISTEANRVEAHGEATAT  
APPSPAAETKVYSLPLSLTPTGQGGEAMPTTPESPRADFRETGETSPAQVNKAHSSSSSPWPSVNRNVAVGFVP  
TETATEPTGLRGIPGSESGVFDTAESPTSGLQATVDEVQDPWPSVYSKGLDASSPSAPLGSQGVFLVPKVTNPL  
EPWVATDEGPTVNPMDSTVTPAPSDASGIWEPGSQVFEEAESTTLPQVALDTSIVTPLTTLEQGDKVGVPAMS  
TLGSSSSQPHPEPEDQVETQGTSGASVPPHQSSPLGKPAVPPGPTPTAASVGESASVSSGEPTVPWDPSSSTLLPV  
TLGIEDFELEVLGASPGVESFWEEVASGEEPALPGTPMNAAGAEVHSDPCENNPC LHGGTCNANGTMYGCSCDQ  
GFAGENCEIDIDDCCLCSPCENGCTCIDEVNGFVCLCLPSYGGSFCEKDTGECDRGWHKFQGHQCYRYFAHRRWE  
DAEKDCRRRSGLTSHVSPPEHSFINSFGHENTWIGLNDRIVERDFQWTDNTGLQFENWRENQPDNFFAGGEDC  
VVMVAHESGRWNDVPCNYNLPYVCKKGTVLCGPPPAVENASLIGARKAKNNVHATVRYQCNEGFAQHHVVTIRC  
RNSGKWDRPQIVCTKPRRSHRMRGHHHHHHQH HHQH HHKH KSRKERRKHKKHPTEDWEKDEGNFC

**Signal sequence.**

amino acids 1-22

**N-glycosylation sites.**

amino acids 122-125, 340-343, 1026-1029, 1223-1226

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 269-272, 1117-1120, 1209-1212

**Tyrosine kinase phosphorylation site.**

amino acids 131-138

**N-myristoylation sites.**

amino acids 45-50, 136-141, 284-289, 300-305, 459-464, 461-466, 499-504,  
502-507, 503-508, 533-538, 552-557, 554-559, 752-757, 755-760, 759-764,  
770-775, 789-794, 891-896, 909-914, 931-936, 997-1002, 1020-1025, 1021-1026,  
1027-1032, 1077-1082, 1087-1092, 1180-1185, 1211-1216, 1228-1233

**Amidation site.**

amino acids 240-243

**Aspartic acid and asparagine hydroxylation site.**

amino acids 1061-1072

**ATP/GTP-binding site motif A (P-loop).**

amino acids 553-560

**EGF-like domain cysteine pattern signature.**

amino acids 1032-1043, 1050-1061, 1070-1081

**C-type lectin domain signature.**

amino acids 1184-1208

**Extracellular link domain.**

amino acids 159-254, 260-356

**Lectin C-type domain.**

amino acids 1105-1210

**Sushi domain (SCR repeat).**

amino acids 1215-1271

**EGF-like domain.**

amino acids 1012-1043, 1050-1081

**Immunoglobulin domain.**

amino acids 52-142

97/136

**FIGURE 83**

MKFAEHLSAHITPEWRKQYIQYEAFKDMLYSAQDQAPSVEVTDEDTVKRYFAKFEEKFFQTCEKELAKINTFYS  
EKLAEAQRRFATLQNELQSSLDQKESTGVTTLRQRRKPVFHLSEERVQHRNIKDLKLAFSEFYLSLILLQNY  
QNLNFTGFRKILKKHDKILETSRGADWRVAHVEVAPFYTCCKINQLISETAVVTNELEDGDRQKAMKRLRVPP  
LGAAQPAPAWTTFRVGLFCGIFIVLNITLVLA AVFKLETDRSIWPLIRIYRGGFLLEFLFLLGINTYGWRQAG  
VNHVLIFEINPRSNLSHQHLFEIAGFLGILWCLSLACFFAPISVIPTYVYPLALYGFMVFFLINPTKTFYYKS  
RFWLLKLLFRVFTAPFHKVGFADFWLADQLNSLSVILMDLEYMICFYSLELKWDESKGLLPNNSEESGICHKYT  
YGVRAIVQCIPAWLRFIQCLRRYRDTKRAFPHLVNAGKYSTTFMVAFALYSTHKERGHSDTMVFFYLWIVFY  
IISSCYTLIWDLKMDWGLFDKNAGENTFLREEIVYPQKAYYYCAIIEDVILRFAWTIQISITSTLLPHSGDII  
ATVFAPLEVFRRFVWNFFRLENEHLNNGEFAVRDISVAPLNADDQTLLEQMMDQDDGVRNRQKNRSWKYNQS  
ISLRRPRLASQSKARDTKVLIEDTDDEANT

**Transmembrane domains.**

amino acids 235-255, 276-296, 314-334, 332-352, 348-368, 368-388, 438-458,  
475-495, 507-527

**N-glycosylation sites.**

amino acids 152-155, 248-251, 310-313, 432-435, 658-661, 664-667

**N-myristoylation sites.**

amino acids 238-243, 324-329, 428-433

**Crystallins beta and gamma 'Greek key' motif signature.**

amino acids 145-160

**EXS family.**

amino acids 439-617

**SPX domain.**

amino acids 1-180

98/136

**FIGURE 84**

MKFAEHLSAHITPEWRKQYIQYEAFKDMLYSAQDQAPSVEVTDEDTVKRYFAKFEEKFFQTCEKELAKINTFYS  
EKLAEAQRRFATLQNELQSSSLDAQKESTGVTTLRQRRKPVFHLSSHEERVQHRNIKDLKLAFSEFYLSLILLQNY  
QNLNFTGFRKILKKHDKILETSRGADWRVAHVEVAPFYTCKKINQLISETAVVTNELEDGDRQKAMKRLRVPP  
LGAAQPAPAWTTFRVGLFCGIFIVLNITLVLA AVFKLETDRSIWPLIRIYRGGFLLIEFLFLLGINTYGWRQAG  
VNHVLI FELNPRSNLSHQHLFEIAGFLGILWCLSLACFFAPISVIPTYVYPLALYGF MVFFLINPTKTFYYKS  
RFWLLKLLFRVFTAPFHKVGFADFWLADQLNSLSVILMDLEYMICFYSLELKWDESKGLLPNNSEESGICHKYT  
YGVRAIVQCIPAWLRFIQCLRRYRDTKRAFPHLVNAGKYSTTFMVTF AALYSTHKERGHSDTMVFFYLVWIFY  
IISSCYTLIIDLKMDWGLFDKNAGENTFLREEIVYPQKAYYYCAIIEDVILRFAWTIQISITSTTLLPHSGDII  
ATVFAPLEVFRFRVWNFFRLENEHLNNCGEFRAVRDISVAPLNADDQTLLEQMMDQDDGVRNRQKNRSWKYNQS  
ISLRRPRLASQSKARDTKVLIEDTDDEANT

**Transmembrane domains.**

amino acids 235-255, 276-296, 314-334, 332-352, 348-368, 368-388, 438-458,  
475-495, 507-527

**N-glycosylation sites.**

amino acids 152-155, 248-251, 310-313, 432-435, 658-661, 664-667

**N-myristoylation sites.**

amino acids 238-243, 324-329, 428-433

**Crystallins beta and gamma 'Greek key' motif signature.**

amino acids 145-160

**EXS family.**

amino acids 439-617

**SPX domain.**

amino acids 1-180

99/136

**FIGURE 85**

MSVGVSTSAPLSPTSGTSMSTFSIMDYVVFVLLLVLSLAIGLYHACRGWGRHTVGEELLMADRKMGCLPVALS  
LLATFQSAVAILGVPSEIYRFGTQYWFLGCCYFLGLLIPAHIFIPVFYRLHLTSAYEYLELRFNKTVRVC GTVT  
FIFQMVIYMGVVLVYAPSLALNAVTFGDLWLSVLALGIVCTVYTALGGLKAVIWTDFQTLVMFLGQLAVIIVGS  
AKVGGGLGRVWAVASQHGRI SGFELDPDPFVRHTFWTLAFGGVFMMLS LYGVNQAQVQRYLSSRTEKAAVLSCYA  
VFPPQQVSLCVGCLIGLVMFAYYQEYPMSIQQAQAAPDQFVLYFVMDLLKGLPGLPGLFIACLFSGSLSTISSA  
FNSLATVTMEDLIRPWFPEFSEARAIMLSRGLAFGYGLLCLGMAYISSQMGPVLQAAISIFGMVGGPLLGLFCL  
GMFFPCANPPGAVVGLLAGLVMAFWIGIGSIVTSMGFSMPSPSNGSSFSLPTNLT VATVTTL MPLTTFSKPTG  
LQRFYSLSYLWYSAHNSTTVIVVGLIVSLLTGRMRGRSLNPATIYPVLPKLLSLLPLSCQKRLHCRSYGQDHLD  
TGLFPEKPRNGVLGDSRDKEAMALDGTAYQGSSSTCILQETSL

**Transmembrane domains.**

amino acids 24-44, 64-84, 103-123, 140-160, 171-191, 206-226, 252-272,  
294-314, 339-359, 394-414, 423-443, 455-475, 491-511, 527-547, 557-577

**N-glycosylation sites.**

amino acids 138-141, 489-492, 498-501, 534-537

**N-myristoylation sites.**

amino acids 4-9, 16-21, 43-48, 184-189, 194-199, 272-277, 308-313, 353-358,  
362-367, 401-406, 455-460, 459-464, 463-468, 473-478, 490-495, 542-547,  
623-628

**Sodium:solute symporter family.**

amino acids 61-463

100/136

**FIGURE 86**

MALTGASDPSAEAEANGEKPFLLRALQIALVVSlywVTSISMVFLNKYLLDSPSLRLDTPIFVTFYQCLVTTLL  
CKGLSALAACCPGAVDFPSLRRLDLRVARSVLPLSVVFIGMITFNNLCLKYVGVAfYNVGRSLTTVFENVLLSYLL  
LKQTTSFYALLTCGIIIGGFwLGVDQEGAEGTlSWLGTvFGVLAslCVslNAIYtTKVLPavDGSIWRLTFYNN  
VNACILFLPLLLLLLgELQALRDLaQLGSAHFWGMMTLGGLFGfAIGYVTGLQIKFTSPLTHNVSGTAKACAQTV  
LAVLYYEETKSFLWWTSNMMVLGGSSAYTWVRGWEMKKTPEEPSPKDSEKSAMGV

**Transmembrane domains.**

amino acids 24-44, 61-81, 98-118, 139-159, 182-202, 220-240, 255-275

**N-glycosylation site.**

amino acids 284-287

**N-myristoylation sites.**

amino acids 162-167, 176-181, 185-190, 189-194, 260-265, 287-292, 319-324

101/136

**FIGURE 87**

MALTGASDPSAEAEANGEKPFLLRALQIALVVSLEYWVTSISMVFLNKYLLDSPSLRLDTPIFVTFYQCLVTTLL  
CKGLSALAACCPGAVDFPSLRRLDLRVARSVLPLSVVFIGMITFNNLCLKYVGVAFYNVGRSLTTVFENVLLSYLL  
LKQTTSFYALLTCGIIIGGFVLGVDQEGAEGTLSWLGTVFGVLASLCVSLNAIYTTKVLPAVDGSIWRLTFYNN  
VNACILFLPLLLLLLGGELQALRDFALGSAHFWGMMTLGGLFGFAIGYVTGLQIKFTSPLTHNVSGTAKACAQTV  
LAVLYYEETKSFLWWTSNMMVLGGSSAYTWVRGWEMKKTPEEPSPKDSEKSAMGV

**Transmembrane domains.**

amino acids 24-44, 61-81, 98-118, 139-159, 182-202, 219-239, 255-275

**N-glycosylation site.**

amino acids 284-287

**N-myristoylation sites.**

amino acids 162-167, 176-181, 185-190, 189-194, 260-265, 287-292, 319-324

102/136

**FIGURE 88**

MGSCSGRCALVVLCAFLVAALERQVFDFLGYQWAPILANFVHIIIVILGLFGTIQYRLRYVMVYTLWAAVWVT  
WNVFIICFYLEVGGLLQDSELLTFSLSRHRSWWRRERWPGCLHEEVPAVGLGAPHGQALVSGAGCALEPSYVEAL  
HSGLQILIALLLGFVCGCQVSVFTEEDSFDFIGGFDPFPLYHVNEKPSSLLSKQVYLP

**Transmembrane domains.**

amino acids 1-21, 34-54, 74-94, 147-167

**Glycosaminoglycan attachment site.**

amino acids 134-137

**Tyrosine kinase phosphorylation site.**

amino acids 24-32

**N-myristoylation sites.**

amino acids 2-7, 50-55, 125-130, 135-140

103/136

**FIGURE 89**

MGSCSGRCALVVLCAFQLVAALERQVFDFLGYQWAPILANFVHIIIIVILGLFGTIQYRLRYVMVYTLWAAVWVT  
WNVFIICFYLEVGGLLKDSELLTFSLSRHRSWWRRERWPGCLHEEVPAVGLGAPHGQALVSGAGCALEPSYVEAL  
HSCLQILIALLLGFVCGCQVVSVFTEEDSFDFIGGFDPFFPLYHVNEKPSSLLSKQVYLPA

**Signal sequence.**

amino acids 1-21

**Transmembrane domains.**

amino acids 34-54, 74-94, 147-167

**Glycosaminoglycan attachment site.**

amino acids 134-137

**Tyrosine kinase phosphorylation site.**

amino acids 24-33

**N-myristoylation sites.**

amino acids 2-7, 50-55, 125-130, 135-140



104/136

**FIGURE 90**

MGSCSGRCALVVLCAFAQLVAAALERQVFDFLGYQWAPILANFVHIIIVILGLFGTIQYRLRYVMVYTLWAAVWVT  
WNVFIICFYLEVGGLLKDSSELLTFSLSRHRSWWRRERWPGCLHEEVPAVGLGAPHGQALVSGAGCALEPSYVEAL  
HSCLQILIALLGFCGCVVSVFTEEDSCLRK

**Signal sequence.**

amino acids 1-21

**Transmembrane domains.**

amino acids 34-54, 73-93, 148-168

**Glycosaminoglycan attachment site.**

amino acids 134-137

**Tyrosine kinase phosphorylation site.**

amino acids 24-32

**N-myristoylation sites.**

amino acids 2-7, 50-55, 125-130, 135-140

105/136

**FIGURE 91**

MGSCSGRCALVVLCAFQLVAALERQVFDFLGYQWAPILANFVHIIIVILGLFGTIQYRLRYVMVYTLWAAVWVT  
WNVFIICFYLEVGGLLQDSELLTFSLSRHRSWWRRERWPGCLHEEVPAVGLGAPHGQALVSGAGCALEPSYVEAL  
HSQLQILIALLLGFVCGCQVVSFTEEDSCLRK

**Signal sequence.**

amino acids 1-21

**Transmembrane domains.**

amino acids 34-54, 73-93, 148-168

**Glycosaminoglycan attachment site.**

amino acids 134-137

**Tyrosine kinase phosphorylation site.**

amino acids 24-32

**N-myristoylation sites.**

amino acids 2-7, 50-55, 125-130, 135-140

106/136

**FIGURE 92**

MAVLFLLLFLCGTPQAADNMQAIYVALGEAVELPCPSPPTLHGDEHLSWFCSPAAGSFTTLVAQVQVGRPAPDP  
GKPGRESRLRLLLGNYSILWLEGSKEEDAGRYWCAVLGQHHNYQNWRVYDVLVLKGSQLSARAADGSPCNVLLCSV  
VPSRRMDSVTWQEGKGPVRGRVQSFQWGSEAALLLVCPGEGELSEPRSRRPRIIRCLMTHNKGVSFSLAASIDASP  
ALCAPSTGWDMPWILMLLLTMGQGVILALSIVLWRQVRGAPGRGNRMRCYNCGGSPSSSCKEAVTTCGEGRP  
QPGLEQIKLPGNPPVTLIHQHPACVAAHHCNQVETESVGDVTYPAHRDCYLGDLCSAVASHVAPAGILAAAAT  
ALTCLLPGLWSG

**Signal sequence.**

amino acids 1-15

**Transmembrane domains.**

amino acids 234-254, 354-374

**N-glycosylation site.**

amino acids 88-91

**Tyrosine kinase phosphorylation site.**

amino acids 97-104

**N-myristoylation sites.**amino acids 12-17, 56-61, 110-115, 128-133, 138-143, 175-180, 209-214,  
277-282, 278-283, 363-368

107/136

**FIGURE 93**

MSGGHQLQLAALWPWLLMATLQAGFGRTGLVLAAVESERSAEQKAVIRVIPLKMDPTGKLNLTLEGVFAGVAE  
ITPAEGKLMQSHPLYLCNASDDDNLEPGFISIVKLESPRRAPRPCLSLASKARMAGERGASAVLFDITEDRAAA  
EQLQQPLGLTWPVVLIIWGNDAEKLMEFVYKNQKAHVRIELKEPPAWPDYDVWILMTVVGTIFVIIASVLRIRC  
RPRHSRDPDPLQORTAWAISQLATRRYQASCRQARGEWPDSGSSCSSAPVCAICLEEFSEGQELRVISCLHEFHR  
NCVDPWLHQHRTCPLCVFNITEGDSFSQSLGPSRSYQEPGRRLHLIRQHHPGHAHYHLPAAYLLGPSRSASAVARPP  
RPGPFLPSQEPGMGPRHHRFPRAAHPRAPGEQQRLAGAHQHPYAQGWGMSHLQSTSQHHPAACPVPLRRARPPDSS  
GSGESYCTERSGYLADGPASDSSSGPCHGSSSDSVVNCTDISLQGVHGSSSTFCSSLSSDFDPLVYCSPKGDPO  
RVDMQPSVTSRPRSLDSVVPTGETQVSSHVHYHRHRHHYKKRFQWHGRKPGPETGVPQSRPPIPRTPQPEPP  
SPDQQVTGSNSAAPSGRLSNPQCPRALPEPAGPVDASSICPSTSSLENLQKSSLSARHPQRKRRGGPSEPTPG  
SRPQDATVHPACQIFPHYTPSVAYPWSPEAHPLICGPPGLDKRLLPETPGPCYSNSQPVWLCLTPRQPLEPHPP  
GEGPSEWSSDTAEGRPCPYPHCQVLSAQPGSEEELEELCEQAV

**Transmembrane domains.**

amino acids 5-25, 198-218

**N-glycosylation sites.**

amino acids 62-65, 92-97, 315-320, 481-486

**Glycosaminoglycan attachment site.**

amino acids 444-449

**Tyrosine kinase phosphorylation site.**

amino acids 171-177

**N-myristoylation sites.**amino acids 29-34, 67-72, 263-268, 445-450, 489-494, 492-497, 574-579,  
600-605**Amidation sites.**

amino acids 335-338, 565-568

**Zinc finger, C3HC4 type (RING finger).**

amino acids 272-312

108/136

**FIGURE 94**

MPLSLGAEMWGPEAWLLLLLLLLLASFTGRCPAGELETS DVVT VVLGQDAKLPCFYRGDSGEQVGQVAWARVDAGE  
GAQELALLHISKYGLHVSPAYEGRVEQPPPPRNPLDGSVLLRNAVQADEGEYECRVSTFPAGSFQARLRLRVLP  
PLPSLNPGPALEEGQGLTLAASCTAEGSPAPSVTDTEVKGTTSSRSFKHSRSAAVTSEFHLVPSRSMNGQPLT  
CVVSHPGLLQDQRITHILHVSFLAEASVRGLEDQNLWHIGREGAMKCLSEGQPPPSYNWTRLDGPLPSGVRVD  
GDTLGFPPLTTEHSGIYVCHVSNEFSSRDSQVTVDVLDPQEDSGKQVDLVSASVVVVG VIAALLFCLLVVVVVL  
MSRYHRRKAQQMTQKYEELTTLTRENIRRLHSHHTDPRSQPPEESVGLRAEGHPDSLKDNSSCSVMSEEPGRS  
YSTLT TVREIETQTELLSPGSGRAEEEEEDQDEGIKQAMNHFVQENGTLRAKPTGNGIYINGRHLV

**Signal sequence.**

amino acids 1-26

**Transmembrane domain.**

amino acids 348-368

**N-glycosylation sites.**

amino acids 281-284, 430-433, 489-492

**N-myristoylation sites.**amino acids 135-140, 162-167, 164-169, 189-194, 218-223, 311-316, 354-359,  
464-469, 477-482, 490-495, 500-505**Cell attachment sequence.**

amino acids 55-57

**Immunoglobulin domains.**

amino acids 45-129, 162-225, 263-317

109/136

**FIGURE 95**

MTQNKLKLCSEKAVYTEVPDGGWGWAVAVSFFFVEVFYTGIIKTFGVFFNDLMDSFNESNSRISWIISICVFVL  
TFSAPLATVLSNRFGHRLVVMLGGLLVSTGMVAASFSQEVSHMYVAIGIISGLGYCFSFLPTVTILSQYFGKRR  
SIVTAVASTGECFAVFAPAIMALKERIGWRYSLLFVGLLQLNIVIFGALLRPPIIRGPASPKIVIQENRKEA  
QYMLENEKTRTSIDSIDSGVELTTSPKNVPHTNLELEPKADMQQVLVKTSPRPSEKKAPLLDFSILKEKSFIC  
YALFGLFATLGFFAPSLYIIPLGISLGIDQDRAAFLLSTMAIAEVFGRIGAGFVLNREPIRKIYIELICVILLT  
VSLFAFTFATEFWGLMSCSIFFGFMVGTIGGLTFHCLLKMMSWALQKMSSAAGVYIFIQSIAGLAGPPLAGLLV  
DQSKIYSRAFYSCAAGMALAAVCLALVRPCKMGLCQRHHSGETKVVSHRGKTLQDIPEDFLEMDLAKNEHRVHV  
QMEPV

**Transmembrane domains.**

amino acids 23-43, 61-81, 85-105, 119-139, 148-168, 181-201, 293-313,  
325-345, 358-378, 389-409, 422-442, 452-472

**N-glycosylation site.**

amino acids 57-60

**Glycosaminoglycan attachment site.**

amino acids 125-128

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 146-149

**N-myristoylation sites.**

amino acids 40-45, 46-51, 98-103, 104-109, 122-127, 126-131, 241-246,  
301-306, 319-324, 384-389, 397-402, 460-465

**Amidation site.**

amino acids 144-147

110/136

## **FIGURE 96**

MLLWVILLVLAPVSGQFARTPRPIIFLQPPWTTVFQGERVTLTCKGFRFYSPQKTKWYHRYLGKEILRETPDNI  
LEVQESGEYRCQAQGSPLSSPVHLD FSSEMGFPHAAQANVELLGSSDLLT

**Signal sequence.**

amino acids 1-15

**N-myristoylation site.**

amino acids 89-94

111/136

**FIGURE 97**

MLLWVILLVLAPVSGQFARTPRPIIFLQPPWTTVFQGERVTLTCKGFRFYSPQKTKWYHRYLGKEILRETPDNI  
LEVQESGEYRCQAQGSPLSSPVHLDLFSSASLILQAPLSVFEGDSVVLRCRAKAEVTLNNTIYKNDNVLAFLNKR  
TDFHIPHACLKDNGAYRCTGYKESCCPVSSNTVKIQVQEPFTRPVLRASSFQPISGNPVTLTCTETQLSLERSDV  
PLRFRFFRDDQTLGLGWSLSPNFQITAMWSKDSGFYWCKAATMPHSVISDSPRSWIQVQIPASHPVLTLSPEKA  
LNFEGTKVTLHCETQEDSLRTLRYFYHEGVPLRHKSVRCEGASISFSLTTENSGNYICTADNGLGAKPSKAVS  
LSVTVPVSHPVNLNLSSPEDLIFEGAKVTLHCEAQRGSLPILYQFHHEDAALERRSANSAGGVAISFSLTAEHSG  
NYYCTADNGFGFPQRSAVSLITVPVSHPVLTLSAEALTFEGATVTLHCEVQRGSPQILYQFYHEDMPLWSSS  
TPSVGRVSFSFSLTEGHSGNYICTADNGFGFPQRSEVVSLFVTVPVSRPILTLRVPRQAQAVVGDLELHCEAPRG  
SPPILYWIFYHEDVTLGSSSAPSGGEASFNLSLTAEHSGNYSCEANGLVAQHSDTISLSVIVPVS RPILTFRAP  
RAQAVVGDLELHCEALRGSSPILYWIFYHEDVTLGKISAPSGGGASFNLSLTTEHSGIYSCEADNGPEAQRSEM  
VTLKVAVPVS RPVLTLRAPGTHAAVGDLELHCEALRGSPILYRFFHEDVTLGNRSSPSGGASLNLSLTAEHS  
GNYSCEADNGLGAQRSETVTLYITGLTANRSGPFATGVAGLLSIAGLAAAGALLLYCWL SRKAGRK PASDPARS  
PPDSDSQEPTYHNVPaweELQPVYTANPRGENVVYSEVRIIQEKKKHAVASDPRHLRNKGSPIIYSEVKVAST  
PVSGSLFLASSAPHR

**Signal sequence.**

amino acids 1-15

**Transmembrane domain.**

amino acids 851-871

**N-glycosylation sites.**amino acids 132-135, 383-386, 621-624, 631-634, 714-717, 795-798, 806-809,  
816-819, 843-846**Glycosaminoglycan attachment site.**

amino acids 707-710

**N-myristoylation sites.**amino acids 89-94, 162-167, 204-209, 236-241, 301-306, 338-343, 351-356,  
362-367, 394-399, 431-436, 444-449, 487-492, 537-542, 615-620, 630-635,  
708-703, 710-715, 723-728, 760-765, 802-807, 815-820, 826-831, 839-844,  
851-856, 854-859, 861-866**Amidation site.**

amino acids 877-880

**Immunoglobulin domains.**amino acids 37-87, 116-168, 204-262, 301-357, 394-450, 487-543, 580-636,  
673-729, 766-821



112/136

## **FIGURE 98**

MLLWCPPQCACSLGVFSPAPSFPVWGTRRSCEPATRVPEVWILSPLLRHGGHTQTQNHTASPRSPVMESPKKKNQ  
QLKVGILHLGSRQKKIRIQLRSQCATWKVICKSCISQTPGINLDLGSGVKVKIIPKEEHCKMPEAGEEQPV

**Signal sequence.**

amino acids 1-25

**N-glycosylation site.**

amino acids 56-59

**N-myristoylation sites.**

amino acids 14-19, 25-30

113/136

**FIGURE 99**

MRELAIEIGVRALLFGVFVFTEFLDPFQRVIQPEEIWLYKNPLVQSDNIPTRLMFAISFLTPLAVICVVKIIR  
TDKTEIKEAFLAVSLALALNGVCTNTIKLIVGRPRADFFYRCFPDGVNMSEMHCTGDPDLVSEGRKSFPSIHSS  
FAFSGLGFTTFYLAGKLHCFTESGRGKSWRLCAAILPLYCAMMIALSRMCDYKHHWQDSFVGGVIALIFAYICY  
RQHYPPPLGQHSLPO

**Transmembrane domains.**

amino acids 4-24, 47-67, 82-102, 145-165, 175-195

**Glycosaminoglycan attachment sites.**

amino acids 152-155, 171-174

**Tyrosine kinase phosphorylation site.**

amino acids 107-114

**N-myristoylation sites.**

amino acids 95-100, 120-125, 153-158, 210-215

**Amidation site.**

amino acids 137-140

**Tubulin-beta mRNA autoregulation signal.**

amino acids 1-4

**PAP2 superfamily.**

amino acids 82-230

114/136

**FIGURE 100**

MAELEFVQIIIIIVVMMVMVVVITCLLSHYKLSARSFISRHSQGRRREDALSSEGCLWPSESTVSGNGIPEPQV  
YAPPRPTDRLAVPPFAQRERFHRFQPTYPYLQHEIDLPTISLSDGEEPPPYQGPCTLQLRDPEQQLELNRESV  
RAPPNRTIFDSDLMDSARLGGPCPPSSNSGISATCYGSGGRMEGPPPTYSEVIGHYPGSSFQHQQSSGPPSLLE  
GTRLHHTHIAPLESAAIWSKEKDKQKGHPL

**Transmembrane domain.**

amino acids 7-27

**N-glycosylation site.**

amino acids 153-156

**Glycosaminoglycan attachment site.**

amino acids 65-68

**N-myristoylation site.**

amino acids 178-183

**Amidation site.**

amino acids 43-46

115/136

**FIGURE 101**

MAELEFVQIIIIIVVMMVMVVVITCLLSHYKLSARSFISRHSQGRRREDALSSEGCLWPSESTVSGNGIPEPQV  
YAPPRPTDRLAVPPFAQRERFHRFQPTYPYLQHEIDLPTISLSDGEEPPPYQGPCTLQLRDPEQQLELNRESV  
RAPPNRTIFDSLMDSARLGGPCPPSSNSGISATCYGSGGRMEGPPPTYSEVIGHYPGSSSFQHQQSSGPPSLLE  
GTRLHHHTHIAPLESAAIWSKEKDKQKGHPL

**Transmembrane domain.**

amino acids 7-27

**N-glycosylation site.**

amino acids 153-156

**Glycosaminoglycan attachment site.**

amino acids 65-68

**N-myristoylation site.**

amino acids 178-183

**Amidation site.**

amino acids 43-46

116/136

**FIGURE 102**

MGGAVVDEGPTGVKAPDGGGWAVLFGCFVITGFSYAFFKAVSVFFKELIQEFGIGYSDTAWISSILLAMLYGT  
GPLCSVCVNRFGCRPVMLVGGLFASLGMVAASFCSIQVYLTGTGVLGLALNFQPSLIMLNRYFSKRRPMA  
NGLAAAGSPVFLCALSPLGQLLQDRYGWRGGFLILGGLLLNCCVCAALMRPLVVTAQPGSGPPRPSRRLDLSV  
FRDRGFVLYAVAASVMVLGLFVPPVFVVSIAKDLGVPDTKAAFLLTILGFIDIFARPAAGFVAGLGKVRPYSVY  
LFSFSMFFENGLADLAGSTAGDYGGLVVFCIFFGISYGMVGALQFEVLMAIVGTHKFSSAIGLVLLMEAVAVLVG  
PPSGGKLLDATHVYMYVFILAGAEVLTSSLILLGNFFCIRKKPKPEQPEVAAAEEEEKLHKPPADSGVDLREVE  
HFLKAEPEKNGEVVHTPETS

**Transmembrane domains.**

amino acids 20-40, 55-75, 114-134, 146-166, 180-200, 223-243, 262-282,  
292-312, 318-338, 348-368, 385-405

**N-myristoylation sites.**

amino acids 54-59, 94-99, 95-100, 101-106, 119-124, 123-128, 125-130,  
150-155, 185-190, 257-262, 312-317, 329-334, 333-338, 405-410

117/136

**FIGURE 103**

MAAPTPARPVLTHLLVALFGMGSWAAVNGIWVELPVVVKELPEGWSLPSYVSVLVALGNLGLLVVTLWRRRLAPG  
KDEQVPIRVVQVLGMVGTALLASLWHHVAPVAGQLHSVAFLALAFVLALACCASNVTFLPFLSHLPPRFLRSFF  
LGQGLSALLPCVLALVQGVGRLECPPAPINGTPGPPLDFLERFPASTFFWALTALLVASAAAFQGLLLLLPPPP  
SVPTGELGSGLQVGAPGAEEEEVEESSPLQEPPSQAGTTPGPDPKAYQLLSARSACLLGLLAATNALTNGVLPA  
VQSFSCLPYGRLAYHLAVVLGSAANPLACFLAMGVLCRSLAGLGGLSLLGVFCGGYLMALAVLSPCPPLVG TSA  
GVVLVVL SWVLCLGVFSYVKVAASSLLHGGGRPALLAAGVAIQVGSLLGAVAMFPPTSIYHVFHSRKDCADPCDS

**Transmembrane domains.**

amino acids 9-29, 47-67, 81-101, 111-131, 146-166, 197-217, 272-292, 305-325,  
332-352, 368-388, 404-424

**N-glycosylation site.**

amino acids 129-132

**Protein kinase C phosphorylation sites.**

amino acids 273-275, 435-437

**N-myristoylation sites.**

amino acids 22-27, 88-93, 107-112, 150-155, 232-237, 236-241, 281-286,  
292-297, 346-351, 367-372, 400-405, 415-420

**Leucine zipper pattern.**

amino acids 149-170

118/136

**FIGURE 104**

MHTVATSGPNASWGAPANASGCPGCGANASDGPVPSRAVDWLVLFFAALMLLGLVGNSLVIYVICRHKPMR  
TVTNYFIANLAATDVTFLCCVPFTALLYPLPGWVLGDFMCKFVNYIQQVSVQATCATLTAMSVDRWYVTVFPL  
RALHRRTPRLALAVSLSIWVGSAAVSAPVLALHRLSPGPRAYCSEAFPSRALERAFALYNLLALYLLPLLATCA  
CYAAMLRLHLGRVAVRPAPADSALQGQVLAERAGAVRAKVSRLVAADVLLFAACWGPIQLFLVLQALGPAGSWHP  
RSYAAYALKTWAHCMSYSNSALNPLLYAFLGSHFRQAFRRVCPCAPRRPRRRPRRPGPSDPAAPHAELHRLGSH  
APARAQKPGSSGLAARGLCVLGEDNAPL

**Transmembrane domains.**

amino acids 42-62, 84-104, 125-145, 159-179, 202-222, 265-285, 307-327

**N-glycosylation sites.**

amino acids 10-13, 18-21, 28-31

**N-myristoylation sites.**

amino acids 14-19, 21-26, 24-29, 26-31, 56-61, 247-252, 255-260

**7 transmembrane receptor (rhodopsin family).**

amino acids 59-323

119/136

**FIGURE 105**

MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNLAIAILMKAYQRFRQSKASFLLLASGLV  
ITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCISIFGICMVFSGLCPLLLGSVMAIERCIGVTKPIFHSTKIT  
SKHVKMMLSGVCLFAVFIALLPILGHRDYKIQASRTWCFYNTEDIKDWE DRFYLLLF SFLGLLALGVSLLCNAI  
TGITLLRVKFKSQQHRQGRSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCTTLFALRMATWN  
QILD PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST

**Transmembrane domains.**

amino acids 29-49, 67-87, 108-128, 152-172, 201-221, 244-264

**N-glycosylation sites.**

amino acids 4-7, 19-22, 277-280

**Tyrosine kinase phosphorylation site.**

amino acids 194-201

**N-myristoylation sites.**

amino acids 40-45, 72-77, 126-131, 273-278

**7 transmembrane receptor (rhodopsin).**

amino acids 104-304



120/136

**FIGURE 106**

MSRMSRHPDKDLAQGPNTCCGCTLMASPANLPPNTQAAAERALSQSRWKRVQVPAPASLSPFPLAMASVAFWI  
SILIGCEEQTLCRGWRSPVGDGCAHVPPQERATAEADPPGRCSTSTASSTICGLWHLSPLRLQLLPPLHSRQGEE  
SGKTEKVLLWGREGLVHVKPGVLQPDVHGTSNLGNCSFLHGLVTAPSCPRRAGAEELNSLGSQFAISLFEVQSG  
TEPSITGVATSGQCRAMPLKHYLLLLVGCQAWGAGLAYHGCPSSECTCSRASQVECTGARIVAVPTPLPWNAMSL  
QILNTHITELNESPFNLISALIALRIEKNELSRITPGAFRNLGSLRYLSLANNKLQVLPIGLFGQLDSLESLLL  
SSNQLLQIQPAHFSQCSNLKELQLHGNHLEYIPDGAFDHLVGLTKNLGKNSLTHISPRVFQHLGNLQVLRLYE  
NRLTDIPMGTFDGLVNLQELALQQNQIGLLSPGLFHNNHNLQRLYLSNNHISQLPPSIFMQLPQLNRLTLFGNS  
LKELSLGIFGMPNLRRELWLYDNHISLDPNVFSNLRQLQVLILSRNQISFISPGAFNGLTELRELSLHTNALQ  
DLGDNVFRMLANLQNISLQNNRLRLQPLGNIFANVNGLMAIQLQNNQLENLPLGIFDHLGKLCELRLYDNPWRCD  
SDILPLRNWLLLNQPRLGTDTPVPCFSPANVRGQSLIIINVNAVPSVHVPEVPSYPETPWYPDTPSYDPTTSV  
SSTELTSPVEDYTDLTITQVTDDRSVWGMTHAHSGLAIAAIVIGIVALACSLAACVGCCCCCKRSQAVLMQMK  
APNEC

**Transmembrane domains.**

amino acids 57-77, 239-259, 775-795

**N-glycosylation sites.**

amino acids 183-186, 313-316, 607-610

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 803-806

**Tyrosine kinase phosphorylation site.**

amino acids 652-659

**N-myristoylation sites.**amino acids 209-214, 222-227, 229-234, 234-239, 255-260, 333-338, 357-362,  
453-458, 477-482, 573-578, 620-625, 769-774, 776-781, 798-803**Leucine zipper pattern.**

amino acids 344-365

**Leucine rich repeat N-terminal domain.**

amino acids 262-290

**Leucine rich repeats.**amino acids 316-339, 340-363, 364-387, 388-411, 412-435, 436-459, 460-483,  
484-507, 508-531, 532-555, 556-579, 580-603, 604-627, 628-651**Leucine rich repeat C-terminal domain.**

amino acids 661-713

121/136

**FIGURE 107A**

MAPPPPPVLPVLLLLAAAAALPAMGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRAPRELLDVGRDGRILA  
 GRRRVSGAGRPLPLQVRLVARSAPTALSRRRLRARTHLPGCGARARLCGTGARLCGALCFVPVGGCAAQHSALA  
 APTTLACRCPPRRPRCPGRPICLPVGGSVRLRLCALRRAAGAVRVGLALEAATAGTPSASPSPSPPLPPNL  
 PEARAGPARRARRGTSGRGSLSKFMPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERVSYMEGLFDERSRGYF  
 RIDSATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHSPVFEQSEYRERVRENLEVG  
 EVLTIRASDRDSPINANLRYRVLGGAWDVFLQNESSGVVSTRAVLDRREEAAEYQLLVEANDQGRNPGLSATAT  
 VYIEVEDENDNYPQFSEQNYVQVPEDVGLNTAVLRVQATDRDQGNAAIHYSILSGNVAGQFYHLHSLSGILDV  
 INPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVNDNEPIFVSSPFQATVLENVPLGYPVVHIQAVDA  
 DSGENARLHYRLVDTASTFLGGGSAGPKNPAPTDFPFQIHNSSGWITVCAELDREEVEHYSGFVEAVDHGSP  
 MSSSTSISITVLDVNDNDPVFTQPTYELRLNEDAAVGSSVLTQLQARDRDANSVITYQLTGGNTRNRFALSSQ  
 GGLITLALPLDYKQEQQYVLAVTASDGTSHTAHVLINVTDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSAN  
 DEDTGENARITYVIQDPVPQFRIDPDSTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDN  
 APQFLWDFYQGSIFEDAPPSTSIQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENV  
 VYNLWALAVDRGSPTPLSASVEIQVTILDINDNAPMFEKDELELFVEENNPGVSVVAKIRANDPDEGPNQIMY  
 QIVEGDMRHFFQLDLLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVDQNDNPPVLPDFQILFNN  
 YVTNKSNSFPTGVIGCIPAHDPDVSLSNYTFVQGNELRLLLLDPATGELQLSRDLDDNNRPLEALMEVSVSDGI  
 HSVTAFTCTLRVTIITDDMLTNSITVRLENMSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNQNDTVDSSNII  
 NVTFALLPGVGRGQFFPSEDLEQEQIYLNRTLTTISTQRVLPFDDNICREPCENYMKCVSVLRFDSSAPFLS  
 STTVLFRPIHPINGLRRCRCPGFTGDYCEIDEIDLCYSDPCGANRCRSREGGYTCECFDFTGEHCEVDARSGR  
 CANGVCKNGGTCVNLLIGGFHCVCPPGEYERPYCEVTTSTRSFPQSFVTFRGLRQRFHFTISLTFATQERNGLLL  
 YNGRFNEKHDFIALEIVDEQVQLTFSAGETTTTVAPKVPSPGVSDGRWHSVQVQYKNPNIGHGLPLHGSPSEKM  
 AVVTVDCCDTTMAVRFGKDIGNYSCAAQGTQTGSKSLDLTGPLLLGGVPNLPEDFPVHNRQFVGCMRNLSDVG  
 KNVDMAGFIANNGTREGCAARRNFCDGRRCCQNGGTCVNRWNMYLCECPLRFGGKNCEQAMPHPQLFSGESVSW  
 SDLNIIISVPWYLGLMFRTRKEDSVLMEATSGGPTSFRQLQILNNYLQFEVSHGPSDVESVMSGLRVTGDGEWHH  
 LLIELKNVKEDSEMKNLVTMTLDYGMQNKADIGGMLPGLTVRSVVVGASEDKVSVRRGFRGCMQGVRMGGTP  
 TNVATLNMNNAKVRVKDGDVDDPCTSSPCPPNSRCHDAWEDYSCVCDKGYLGINCVDACHLNPENMGACVR  
 SPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGNPVCPCCHCAVSKGFDPDCNKNTGQCCKENYKLLAQD  
 TCLPCDCFPHGSHSRTCDMATGQCACKPGVIGRQCNRCDNPFPAEVTTLGCEVIYNGCPKAFAEAGIWWPQTKFGQ  
 PAAVPCPKGSVGNVAVRHCSGEGKWLPELNFCTTISFVDLRAMNEKLSRNETQVDGARALQLVRLRSATQHTG  
 TLEFGNDVRTAYQLLGHVLQHESWQQGFDLAATQDADFHEVDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRRL  
 EGYFSNVARNVRRTYLRPFVIVTANMILAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSPADFFRPPEEK  
 EGPLLRPAGRRTPPTTRPGPGTEREAPISRRRRHPDDAGQFAVALVIYRTLGQLLPERYDPDRRSRLRPLHRP  
 IINTPMVSTLVYSEGAPLPRPLERPVLFVLEFALLEVEERTKPVCFWNHSLAVGGTGGWSARGCELLSRNRTHVA  
 CQCSHTASFAVLMDISRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQL  
 VFVIGINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYVVGWGIPIAVTGLAV  
 GLDPQGYGNPDCFWSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHYYGKKGIVSLRLTAFLLLLLI  
 SATWLLGLLAVNRDALSFHYLFAIFSGLQGPVLLFHCVLNQEVKHLKGVLGGRKLHLEDSATTRATLLTRSL  
 NCNTTTFGDGPDMLRDTDLGESTASLDSIVRDEGIQKLGVSGLVGRSHGEPDASLMPSRCKDPPGHDSDSSELS  
 LDEQSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDVANHVHPAGWPDQSLAESDSEDPGSKPRLKVET  
 KVSVELHREEQGSRRGEYPPDQESGGAARLASSQPPEQRKGILKNKVITYPPPLTLTEQTLKGRLEKLADCEQS  
 PTSSRTSSLGSGGPDCAITVKSPGREPGRDHLNGVAMNVRTGSAQADGSDSEKP

**Transmembrane domains.**

amino acids 4-24, 2235-2255, 2470-2490, 2504-2524, 2530-2550, 2571-2591,  
 2611-2631, 2651-2671, 2686-2706

**N-glycosylation sites.**

amino acids 403-406, 546-549, 634-637, 778-781, 1114-1117, 1139-1142,  
 1213-1216, 1249-1252, 1259-1262, 1287-1290, 1576-1579, 1623-1626, 1640-1643,  
 1979-1982, 2103-2106, 2122-2125, 2257-2260, 2415-2418, 2437-2440, 2523-2526,  
 2741-2744

**Glycosaminoglycan attachment sites.**

amino acids 80-83, 238-241

122/136

**FIGURE 107B**

cAMP- and cGMP-dependent protein kinase phosphorylation sites.  
amino acids 77-80, 234-237, 2304-2307

Tyrosine kinase phosphorylation sites.  
amino acids 363-370, 1379-1385, 1569-1577

N-myristoylation sites.  
amino acids 25-30, 37-42, 47-52, 124-129, 137-142, 138-143, 206-211, 303-308,  
407-412, 473-478, 489-494, 501-506, 613-618, 727-732, 741-746, 805-810,  
842-847, 933-938, 948-953, 1015-1020, 1122-1127, 1125-1130, 1268-1273,  
1383-1388, 1410-1415, 1416-1421, 1424-1429, 1521-1526, 1575-1580, 1583-1588,  
1587-1592, 1601-1606, 1619-1624, 1641-1646, 1662-1667, 1680-1685, 1734-1739,  
1766-1771, 1801-1806, 1811-1816, 1839-1844, 1843-1848, 1847-1852, 1848-1853,  
1927-1932, 1959-1964, 1983-1988, 2020-2025, 2054-2059, 2071-2076, 2081-2086,  
2146-2151, 2421-2426, 2424-2429, 2521-2526, 2587-2592, 2714-2719, 2775-2780,  
2779-2784, 2844-2849, 2898-2903, 2927-2932, 2972-2977, 2994-2999, 3002-3007

Amidation sites.  
amino acids 74-77, 1654-1657, 2302-2305, 2645-2648, 2717-2720

Aspartic acid and asparagine hydroxylation sites.  
amino acids 1664-1675, 1887-1898

EGF-like domain cysteine pattern signature.  
amino acids 1349-1360, 1387-1398, 1673-1684, 1896-1907, 1934-1945, 2022-2033

Cadherins extracellular repeated domain signature.  
amino acids 341-351, 447-457, 553-563, 675-685, 880-890, 987-997, 1089-1099

Cadherin domains.  
amino acids 250-344, 358-450, 464-556, 570-678, 692-780, 794-883, 897-990,  
1004-1092, 1110-1198

7 transmembrane receptor.  
amino acids 2465-2708, 2470-2710

EGF-like domains.  
amino acids 1876-1907, 1911-1945, 1653-1684, 1407-1440, 1307-1360, 1367-1398

Laminin G domains.  
amino acids 1470-1532, 1579-1632, 1719-1780, 1833-1852, 2003-2048

Latrophilin/CL-1-like GPS domain.  
amino acids 2407-2460

Hormone receptor domain.  
amino acids 2052-2109

123/136

**FIGURE 108**

MVDVKCLSDCKLQNQLEKLGFSPPILPSTRKLYEKKLVQLLVSPPCAPPVMNGPRELDGAQDSDDSEELNIIL  
QGNIIILSTEKSKLKKWPEASTTKRKAVDITYCLDYKPSKGRRWAARAPSTRITYGTITKERDYCAEDQTIESWR  
EEGFPVGLKLAVLGIFIIIVFVYLTVENKSLFG

**Transmembrane domain.**

amino acids 154-174

**N-glycosylation site.**

amino acids 176-179

**N-myristoylation sites.**

amino acids 60-65, 155-160

**Amidation site.**

amino acids 113-116

**LEM domain.**

amino acids 1-44

124/136

**FIGURE 109**

MSKSKCSVGLMSSVVAPAKEPNAVGPKVELILVKEQNGVQLTSSTLTNPRQSPVEAQDRETWGKKIDFLLSVI  
GFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMEALALGQFNREGAAGVWKICPILKGVGFTVILI  
SLYVGFFYNVIIAWALHYLFSSFTTELPWIHCNNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVL  
HLHQSHGIDDLGPPRWQLTACLVLVIVLLYFSLWKGVKTSQKVVWITATMPYVVLTAALLRGVTLPGAIDGIRA  
YLSVDFYRLCEASVWIDAATQVCFSLVGVGFGVLIASFSSYNKFTNNCYRDAIVTTSINSLTSFSSGFVVFSLGY  
MAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGIDSAMGGMESVITGLIDEFQLLHRH  
RELFTLFIVLATFLLSLFCVTNGGIYVFLLDHFAAGTSILFGVLI EAIGVAWFYGVGQFSDDIQQMTGQRPSL  
YWRLCWKLVSPCFLLFVVVVSIVTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLA  
YAIAPKDRDLVDRGEVRQFTLRHWLKV

**Transmembrane domains.**

amino acids 65-85, 98-118, 133-153, 149-169, 236-256, 272-292, 310-330,  
350-370, 393-413, 409-429, 445-465, 481-501, 520-540, 560-580

**N-glycosylation sites.**

amino acids 181-184, 188-191, 205-208

**N-myristoylation sites.**

amino acids 9-14, 39-44, 140-145, 203-208, 209-214, 258-263, 289-294,  
323-328, 327-332, 419-424, 425-430, 513-518

**Amidation site.**

amino acids 63-66

**Leucine zipper pattern.**

amino acids 440-461

**Sodium:neurotransmitter symporter family signature 1.**

amino acids 84-98

**Sodium:neurotransmitter symporter family signature 2.**

amino acids 166-186

125/136

**FIGURE 110**

MGLAMEHGGSYARAGGSSRGCWYYLRYFFLEFVSLIQFLIILGLVLFMVYGNVHVSTESNLQATERRAEGLYSQL  
LGLTASQSNLTKELNFTTRAKDAIMQMWLNARRDLDRINASFRQCQGDRIYITNNQRYMAAIIILSEKQCRDQFK  
DMNKSCDALLFMLNQKVKTLEVEIAKEKTICTKDKEVLLNKRVAEEQLVECVKTRELQHQERQLAKEQLQKVQ  
ALCLPLDKDKFEMDLRNLWRDSIIPRSLDNLYGYNLYHPLGSELASIRRACDHMPSLMSSKVEELARSLRADIER  
VARENSDLQRQKLEAQQGLRASQEAKQKVEKEAQAREAKLQAECSRQTQLALEEKAVLRKERDNLAKELEEEKR  
EAEQLRMELAIRNSALDTCTKTSQPMMPVSRPMGPVNPQPIDPASLEEFKRKILESQRPPAGIPVAPSSG

**Transmembrane domain.**

amino acids 28-48

**N-glycosylation sites.**

amino acids 83-86, 89-92, 113-116, 151-154

**Tyrosine kinase phosphorylation sites.**

amino acids 65-71, 248-255

**N-myristoylation sites.**

amino acids 8-13, 16-21, 76-81, 262-267, 314-319

126/136

**FIGURE 111**

MMAGMKIQLVCMALLAFSSWSLCSDSEEEMKALEADFLTNMHTSKISKAHVPSWKMTLLNVCSLVNNLNSPAEE  
TGEVHEEELVARRKLPTALDGFSLEAMLTYYQLHKICH SRA FQHWELIQEDILD TGNDKNGKEEVIKRKIPYIL  
KRQLYENKPRRPYILKRDSYYY

**Signal sequence.**

amino acids 1-23

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 164-167

**N-myristoylation site.**

amino acids 130-135

127/136

**FIGURE 112**

MLLRSA GK LNVG TKKEDGESTAPT PRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSGLGL  
EGSDFQCRDTPIPHQRRSIECCTERNECNKDLHPTLPPLKNRDFVDGPIHHRALLISVTVCSLLLVLIIILFCYF  
RYKRQETRPRYSIGLEQDETYIPPGESLRDLIEQSQSSGSGSGLPLL VQRTIAKQIQMVKQIGKGRYGEVWMGK  
WRGEKVAVKVFFTTTEEASWFRETEIYQTVLMRHENILGFIAADIKGTGSWTQLYLITDYHENGSLYDYLKSTTL  
DAKSMLKLAYSSVSGLCHLHTEIFSTQGKPAIAHRDLKSKNILVKKNGTCCCIADLGLAVKFISDTNEVDIPPNT  
RVGTRKRYMPPEVLDESLNRNHFQSYIMADMYSFGLILWEVARRCVSGGIVEEYQLPYHDLVPSDPSYEDMREIV  
CIKKLRPSFPNRWSSDECLRQMGKLMTECWAHNPASRLTALRVKKT LAKMSESQDIKL

**Transmembrane domain.**

amino acids 126-146

**N-glycosylation sites.**

amino acids 284-287, 343-346

**Glycosaminoglycan attachment sites.**

amino acids 186-189, 188-191

**N-myristoylation sites.**

amino acids 73-78, 187-192

**Serine/Threonine protein kinases active-site signature.**

amino acids 328-340

**Mitochondrial energy transfer proteins signature.**

amino acids 172-180

**Protein kinase domain.**

amino acids 204-491

**Activin types I and II receptor domain.**

amino acids 17-110



128/136

**FIGURE 113**

TTGAAGTGCATTGCTGCAGCTGGTAGCATGAGTGGTGGCCACCACCTGCAGCTGGCTGCCCTCTGGCCCTGGCT  
GCTGATGGCTACCCTGCAGGCAGGCTTTGGACGCACAGGACTGGTACTGGCAGCAGCGGTGGAGTCTGAAAGAT  
CAGCAGAACAGAAAGCTGTTATCAGAGTGATCCCCCTTGAAAATGGACCCACAGGAAACTGAATCTCACTTTG  
GAAGGTGTGTTTGCTGGTGTGCTGAAATAACTCCAGCAGAAGGAAAATTAATGCAGTCCCACCCGCTGTACCT  
GTGCAATGCCAGTGATGACGACAATCTGGAGCCTGGATTTCATCAGCATCGTCAAGCTGGAGAGTCCCTCGACGGG  
CCCCCACCCCTGCCTGTCACTGGCTAGCAAGGCTCGGATGGCGGGTGAGCGAGGAGCCAGTGCTGTCTCTTTT  
GACATCACTGAGGATCGAGCTGCTGCTGAGCAGCTGCAGCAGCCGCTGGGGCTGACCTGGCCAGTGGTGTGAT  
CTGGGGTAATGACGCTGAGAAGCTGATGGAGTTTGTGTACAAGAACCAAAAGGCCCATGTGAGGATTGAGCTGA  
AGGAGCCCCCGCCTGGCCAGATTATGATGTGTGGATCCTAATGACAGTGGTGGGCACCATCTTTGTGATCATC  
CTGGCTTCGGTGCTGCGCATCCGGTGCCGCCCCCGCCACAGCAGGCCGGATCCGCTTCAGCAGAGAACAGCCTG  
GGCCATCAGCCAGCTGGCCACCAGGAGGTACCAGGCCAGCTGCAGGCAGGCCCGGGGTGAGTGGCCAGACTCAG  
GGAGCAGCTGCAGCTCAGCCCCGTGTGTGTGCCATCTGTCTGGAGGAGTTCTCTGAGGGGCAGGAGCTACGGGTC  
ATTTCTGCCTCCATGAGTTCCATCGTAACTGTGTGGACCCCTGGTTACATCAGCATCGGACTTGCCCCCTCTG  
CATGTTCAACATCACAGAGGGAGATTCAATTTCCAGTCCCTGGGACCCTCTCGATCTTACCAAGAACCAGGTC  
GAAGACTCCACCTCATTGCGCAGCATCCCGGCCATGCCACTACCACCTCCCTGCTGCCTACCTGTTGGGCCCT  
TCCCGGAGTGCAGTGGCTCGGCCCCCACGACCTGGTCCCTTCTGCCATCCCAGGAGCCAGGCATGGGCCCTCG  
GCATCACCGCTTCCCCAGAGCTACACATCCCCGGGCTCCAGGAGAGCAGCAGCGCCTGGCAGGAGCCCAGCACC  
CCTATGCACAAGGCTGGGGACTGAGCCACCTCCAATCCACCTCACAGCACCTGCTGCTTGCCAGTGCCCTTA  
CGCCGGGCCAGGCCCCCTGACAGCAGTGGATCTGGAGAAAGCTATTGCACAGAACGCAGTGGGTACCTGGCAGA  
TGGGCCAGCCAGTGAATCCAGCTCAGGGCCCTGTATGGCTCTTCCAGTGACTCTGTGGTCAACTGCACGGACA  
TCAGCCTACAGGGGGTCCATGGCAGCAGTTCTACTTTCTGCAGCTCCCTAAGCAGTGACTTTGACCCCTAGTG  
TACTGCAGCCCTAAAGGGGATCCCCAGCGAGTGGACATGCAGCCTAGTGTGACCTCTCGGCCTCGTTCCTTGA  
CTCGGTGGTGGCCACAGGGGAAACCCAGGTTTCCAGCCATGTCCACTACCACCGCCACCGGCACCACCTACA  
AAAAGCGGTTCCAGTGGCATGGCAGGAAGCCTGGCCCAGAAACCGGAGTCCCCAGTCCAGGCCTCCTATTCT  
CGGACACAGCCCCAGCCAGAGCCACCTTCTCCTGATCAGCAAGTCACCAGATCCAATCAGCAGCCCTTCGGG  
GCGGCTCTCTAACCACAGTGCCCCAGGGCCCTCCCTGAGCCAGCCCTGGCCCAGTTGACGCCTCCAGCATCT  
GCCCCAGTACCAGCAGTCTGTTCAACTTGCAAAAATCCAGCCTCTCTGCCCCACACCCACAGAGGAAAAGGCGG  
GGGGTCCCTCCGAGCCCACCCCTGGCTCTCGGCCCCAGGATGCAACTGTGCACCCAGCTTGCCAGATTTTTC  
CCATTACACCCCCAGTGTGGCATATCCTTGGTCCCCAGAGGCACACCCCTTGATCTGTGGACCTCCAGGCCTGG  
ACAAGAGGCTGCTACCAGAAACCCAGGCCCTGTACTCAAAATTCACAGCCAGTGTGGTTGTGCCTGACTCCT  
CGCCAGCCCTTGAACACATCCACCTGGGGAGGGGCTTCTGAATGGAGTTCTGACACCGCAGAGGGCAGGCC  
ATGCCCTTATCCGCACTGCCAGGTGCTGTGGCCCCAGCCTGGCTCAGAGGAGGAACTCGAGGAGCTGTGTGAAC  
AGGCTGTGTGAGATGTTCAAGCCTAGCTCCAACCA

129/136

**FIGURE 114**

MSGGHHLLQLAALWPWLLMATLQAGFGRTGLVLAAVESERSAEQKAVIRVIPLKMDPTGKLNLTLEGVFAGVAE  
ITPAEGKLMQSHPLYLCNASDDDNLEPGFISIVKLESPPRRAPHPCLSLASKARMAGERGASAVLFDITEDRAAA  
EQLQQPLGLTWPVVLIIWGNDAEKLMEFVYKNQKAHVRIELKEPPAWPDYDVWILMTVVGTIFVIILASVLRIRC  
RPRHSRPDPLQQRTAWAISQLATRRYQASCRQARGEWPDSGSSCSSAPVCAICLEEFSEGQELRVISCLHEFHR  
NCVDPWLHQHRTCPLCMFNITEGDSFSQSLGPSRSYQEPGRRLLIRQHHPGHAHYHLPAAYLLGPSRSARPP  
RPGPFLPSQEPGMGPRHHRFPRATHPRAPGEQQRLAGAHQHPYAQGWGLSHLQSTSQHFAACPVPLRRARPPDSS  
GSGESYCTERSGYLADGPASDSSSGPCHGSSSDSVVNCTDISLQGVHGSSTFCSSLSSDFDPLVYCSPKGDPO  
RVDMPQSVTSRPRSLDSVVPGETQVSSHVYHRHRHHHYKKRFQWHGRKPGPETGVPQSRPPIPRTPQPEPP  
SPDQQVTRSNSAAPSGRLSNPQCPRALPEPAPGPVDASSICPSTSSLFNLQKSSLSARHPQRKRGGPSEPTPG  
SRPQDATVHPACQIFPHYTPSVAYPWSPEAHPLICGPPGLDKRLLPETPGPCYSNSQPVWLCLTPRQPLEPHPP  
GEGPSEWSSDTAEGRPCPYPHCQVLSAQPGSEEELEELCEQAV

**Signal sequence.**

amino acids 1-26

**Transmembrane domain.**

amino acids 198-218

**N-glycosylation sites.**

amino acids 62-65, 92-95, 315-318, 481-484

**Glycosaminoglycan attachment site.**

amino acids 444-447

**Tyrosine kinase phosphorylation site.**

amino acids 171-177

**N-myristoylation sites.**

amino acids 29-34, 67-72, 263-268, 445-450, 489-494, 492-497, 574-579

**Amidation sites.**

amino acids 335-338, 565-568

**Zinc finger, C3HC4 type (RING finger).**

amino acids 272-312

130/136

**FIGURE 115**

CCCTTTGAAGTGCATTGCTGCAGCTGGTAGCATGAGTGGTGGCCACCAGCTGCAGCTGGCTGCCCTCTGGCCCT  
GGCTGCTGATGGCTACCCTGCAGGCAGGCTTTGGACGCACAGGACTGGTACTGGCAGCAGCGGTGGAGTCTGAA  
AGATCAGCAGAACAGAAAGCTGTTATCAGAGTGATCCCCCTTGAAAATGGACCCACAGGAAAACCTGAATCTCAC  
TTTGGAAGGTGTGTTTGCTGGTGTGCTGAAATAACTCCAGCAGAAGGAAAATTAATGCAGTCCCACCCGCTGT  
ACCTGTGCAATGCCAGTGATGACGACAATCTGGAGCCTGGATTTCATCAGCATCGTCAAGCTGGAGAGTCCTCGA  
CGGGCCCCCGCCCTGCCCTGCTCACTGGCTAGCAAGGCTCGGATGGCGGGTGAGCGAGGAGCCAGTGCTGTCTCT  
CTTTGACATCACTGAGGATCGAGCTGCTGCTGAGCAGCTGCAGCAGCCGCTGGGGCTGACCTGGCCAGTGGTGT  
TGATCTGGGGTAATGACGCTGAGAAGCTGATGGAGTTTGTGTACAAGAACC AAAAGGCCCATGTGAGGATTGAG  
CTGAAGGAGCCCCCGCCCTGGCCAGATTATGATGTGTGGATCCTAATGACAGTGGTGGGCACCATCTTTGTGAT  
CATCTTGCTTCGGTGTGCGCATCCAGTGCCGCCCCCGCCACAGCAGGCCGGATCCGCTTCAGCAGAGAACAG  
CCTGGGCCATCAGCCAGCTGGCCACCAGGAGGTACCAGGCCAGCTGCAGGCAGGCCCGGGGTGAGTGGCCAGAC  
TCAGGGAGCAGCTGCAGCTCAGCCCCTGTGTGTGCCATCTGTCTGGAGGAGTTCTCTGAGGGGCAGGAGCTACG  
GGTCATTTCTGCTCCATGAGTTCCATCGTAACTGTGTGGACCCCTGGTTACATCAGCATCGGACTTGCCCCC  
TCTGCATGTTCAACATCACAGAGGGAGATTCAATTTCCAGTCCCTGGGACCCCTCTCGATCTTACCAAGAACCA  
GGTCGAAGACTCCACCTCATTGCCAGCATCCCGGCCATGCCACTACCACCTCCCTGCTGCCCTACCTGTTGGG  
CCCTTCCCGGAGTGCAGTGGCTCGGCCCCCACGACCTGGTCCCTTCTGCCATCCAGGAGCCAGGCATGGGCC  
CTCGGCATCACCGCTTCCCCAGAGCTGCACATCCCCGGGCTCCAGGAGAGCAGCAGCGCCTGGCAGGAGCCCAG  
CACCCCTATGCACAAGGCTGGGGACTGAGCCACCTCCAATCCACCTCACAGCACCCCTGCTGCTTGCCCACTGCC  
CCTACGCCGGGCCAGGCCCCCTGACAGCAGTGGATCTGGAGAAAGCTATTGCACAGAACGCAGTGGGTACCTGG  
CAGATGGGCCAGCCAGTGACTCCAGCTCAGGGCCCTGTGATGGCTCTTCCAGTGACTCTGTGGTCAACTGCACG  
GACATCAGCCTACAGGGGGTCCATGGCAGCAGTTCTACTTTCTGCAGCTCCCTAAGCAGTGACTTTGACCCCT  
AGTGTACTGCAGCCCTAAAGGGGATCCCCAGCAGTGGACATGCAGCCTAGTGTGACCTCTCGGCCTCGTTCTCT  
TGGACTCGGTGGTGCCACAGGGGAAACCCAGGTTTCCAGCCATGTCCACTACCACCGCCACCGGCACCAACAC  
TACAAAAGCGGTTCCAGTGGCATGGCAGGAAGCCTGGCCCAGAAACCGGAGTCCCCAGTCCAGGCCTCCTAT  
TCCTCGGACACAGCCCCAGCCAGAGCCACCTTCTCCTGATCAGCAAGTCACCAGATCCAACCTCAGCAGCCCTT  
CGGGGCGGCTCTCTAACCACAGTGCCCCAGGGCCCTCCCTGAGCCAGCCCTGGCCCAGTTGACGCCTCCAGC  
ATCTGCCCCAGTACCAGCAGTCTGTTCAACTTGCAAAAATCCAGCCTCTCTGCCCCACCCACAGAGGAAAAG  
GCGGGGGGGTCCCTCCGAGCCCACCCCTGGCTCTCGGCCCCAGGATGCAACTGTGCACCCAGCTTGCCAGATTT  
TTCCCCATTACACCCCCAGTGTGGCATATCCTTGGTCCCCAGAGGCACACCCCTTGATCTGTGGACCTCCAGGC  
CTGGACAAGAGGCTGCTACCAGAAACCCAGGCCCTGTTACTCAAATTCACAGCCAGTGTGGTTGTGCTGAC  
TCCTCGCCAGCCCCTGGAACCACATCCACCTGGGGAGGGGCCTTCTGAATGGAGTTCTGACACCGCAGAGGGCA  
GGCCATGCCCTTGTCCGCACTGCCAGGTGCTGTGCGCCAGCCTGGCTCAGAGGAGGAACCTCAGGAGCTGTGT  
GAACAGGCTGTGTGAGATGTTTCAGGCCTAGCTCCAACCA

131/136

**FIGURE 116**

MSGGHQLQLAALWPWLLMATLQAGFGRTGLVLAAAVESERSAEQKAVIRVIPLKMDPTGKLNLTLEGVFAGVAE  
ITPAEGKLMQSHPLYLCNASDDDNLEPGFISIVKLESPPRRAPRPCLSLASKARMAGERGASAVLFDITEDRAAA  
EQLQQPLGLTWPVVLWGNDAEKLMEFVYKNQKAHVRIELKEPPAWPDYDVWILMTVVGTIFVILASVLRIOC  
RPRHSRPDPLQQRTAWAISQLATRRYQASCRQARGEWPDSGSSCSSAPVCAICLEEFSEGOELRVISCLHEFHR  
NCVDPWLHQHRTCPLCMFNITEGDSFSQSLGPSRSYQEPGRRLLHRLRQHPGHAHYHLPAAYLLGPSRSARPP  
RPGPFLPSQEPGMGPRHHRFPRAAHPRAPGEQQRLAGAHQHPYAQGWGLSHLQSTSQHFAACPVPLRRARPPDSS  
GSGESYCTERSGYLADGPASDSSSGPCHGSSSDSVVNCTDISLQGVHGSSSTFCSSLSSDFDPLVYCSPKGDPO  
RVDMPQSVTSRPRSLDSVVPETGETQVSSHVHYHRHRHHHYKKRFQWHGRKPGPETGVPQSRPPIPRTPQPEPP  
SPDQQVTRSNSAAPSGRLSNPQCPRALPEPAPGPVDASSICPSTSSLFNLQKSSLSARHPQRKRGGPSEPTPG  
SRPQDATVHPACQIFPHYTPSVAYPWSPEAHPLICGPPGLDKRLLPETPGPCYSNSQPVWLCLTPRQPLEPHPP  
GEGPSEWSSDTAEGRPCPCPHCQVLSAQPGSEEELEELCEQAV

**Signal sequence.**

amino acids 1-26

**Transmembrane domain.**

amino acids 198-218

**N-glycosylation sites.**

amino acids 62-65, 92-95, 315-318, 481-484

**Glycosaminoglycan attachment site.**

amino acids 444-447

**Tyrosine kinase phosphorylation site.**

amino acids 171-177

**N-myristoylation sites.**

amino acids 29-34, 67-72, 263-268, 445-450, 489-494, 492-497, 574-579

**Amidation sites.**

amino acids 335-338, 565-568

**Zinc finger, C3HC4 type (RING finger).**

amino acids 272-312

132/136

**FIGURE 117**

TTGAAGTGCATTGCTGCAGCTGGTAGCATGAGTGGTGGCCACCACCTGCAGCTGGCTGCCCTCTGGCCCTGGCT  
GCTGATGGCTACCCTGCAGGCAGGCTTTGGACGCACAGGACTGGTACTGGCAGCAGCGGTGGAGTCTGAAAGAT  
CAGCAGAACAGAAAGCTGTTATCAGAGTGATCCCCCTGAAAATGGACCCACAGGAAAACCTGAATCTCACTTTG  
GAAGGTGTGTTTGCTGGTGTGCTGAAATAACTCCAGCAGAAGGAAAATTAATGCAGTCCCACCCGCTGTACCT  
GTGCAATGCCAGTGATGACGACAATCTGGAGCCTGGATTTCATCAGCATCGTCAAGCTGGAGAGTCCTCGACGGG  
CCCCCACCCCTGCCTGTCACTGGCTAGCAAGGCTCGGATGGCGGGTGAGCGAGGAGCCAGTGCTGTCTCTTTT  
GACATCACTGAGGATCGAGCTGCTGCTGAGCAGCTGCAGCAGCCGCTGGGGCTGACCTGGCCAGTGGTGTGAT  
CTGGGGTAATGACGCTGAGAAGCTGATGGAGTTTGTGTACAAGAACCAAAAGGCCCATGTGAGGATTGAGCTGA  
AGGAGCCCCCGGCTGGCCAGATTATGATGTGTGGATCCTAATGACAGTGGTGGGCACCATCTTTGTGATCATC  
CTGGCTTCGGTGCTGCGCATCCGGTGCCGCCCCGCCACAGCAGGCCGGATCCGCTTCAGCAGAGAACAGCCTG  
GGCCATCAGCCAGCTGGCCACCAGGAGGTACCAGGCCAGCTGCAGGCAGGCCCGGGGTGAGTGGCCAGACTCAG  
GGAGCAGCTGCAGCTCAGCCCCTGTGTGTGCCATCTGTCTGGAGGAGTTCTCTGAGGGGCAGGAGCTACGGGTC  
ATTTCTGCCTCCATGAGTTCCATCGTAACTGTGTGGACCCCTGGTTACATCAGCATCGGACTTGCCCCCTCTG  
CATGTTCAACATCACAGAGGGAGATTCATTTTCCAGTCCCTGGGACCCTCTCGATCTTACCAAGAACCAGGTC  
GAAGACTCCACCTCATTGCGCAGCATCCCGGCCATGCCACTACACCTCCCTGCTGCCTACCTGTTGGGCCCT  
TCCCGGAGTGACGTGGCTCGGCCCCCAGCACCTGGTCCCTTCTGCCATCCCAGGAGCCAGGCATGGGCCCTCG  
GCATCACCGCTTCCCCAGAGCTGCACATCCCCGGGCTCCAGGAGAGCAGCAGCGCCTGGCAGGAGCCCAGCACC  
CCTATGCACAAGGCTGGGGAATGAGCCACCTCCAATCCACCTCACAGCACCTGCTGCTTGCCAGTGCCCTTA  
CGCCGGGCCAGGCCCCCTGACAGCAGTGGATCTGGAGAAAGCTATTGCACAGAACGCAGTGGGTACCTGGCAGA  
TGGGCCAGCCAGTGAATCCAGCTCAGGGCCCTGTATGGCTCTTCCAGTGACTCTGTGGTCAACTGCACGGACA  
TCAGCCTACAGGGGGTCCATGGCAGCAGTTCTACTTTCTGCAGCTCCCTAAGCAGTGACTTTGACCCCTAGTG  
TACTGCAGCCCTAAAGGGGATCCCCAGCGAGTGGACATGCAGCCTAGTGTGACCTCTCGGCCTCGTTCTTGGGA  
CTCGGTGGTGCCACAGGGGAAACCCAGGTTTCCAGCCATGTCCACTACCACCGCCACCGGCACCACCACTACA  
AAAAGCGGTTCCAGTGGCATGGCAGGAAGCCTGGCCCAGAAACCGGAGTCCCCAGTCCAGGCCTCCTATTCTCT  
CGGACACAGCCCCAGCCAGAGCCACCTTCTCCTGATCAGCAAGTCACCAGATCCAACCTCAGCAGCCCTTCGGG  
GCGGCTCTCTAACCACAGTGCCCCAGGGCCCTCCCTGAGCCAGCCCTGGCCCAGTTGACGCCTCCAGCATCT  
GCCCCAGTACCAGCAGTCTGTTCAACTTGCAAAAATCCAGCCTCTCTGCCCCGACACCCACAGAGGAAAAGGCGG  
GGGGGTCCCTCCGAGCCCACCCCTGGCTCTCGGCCCCAGGATGCAACTGTGCACCCAGCTTGCCAGATTTTTTCC  
CCATTACACCCCCAGTGTGGCATATCCTTGGTCCCCAGAGGCACACCCCTTGATCTGTGGACCTCCAGGCCTGG  
ACAAGAGGCTGCTACCAGAAACCCAGGCCCCCTGTTACTCAAATTCACAGCCAGTGTGGTTGTGCCTGACTCCT  
CGCCAGCCCTTGAACACATCCACCTGGGGAGGGGCCTTCTGAATGGAGTTCTGACACCGCAGAGGGCAGGCC  
ATGCCCTTATCCGCACTGCCAGGTGCTGTGCGGCCAGCCTGGCTCAGAGGAGGAACTCGAGGAGCTGTGTGAAC  
AGGCTGTGTCAGATGTTTCAAGCCTAGCTCCAACCA

133/136

**FIGURE 118**

MSGGHHLLQLAALWPWLLMATLQAGFGRTGLVLAAVESERSAEQKAVIRVIPLKMDPTGKLNLTLEGVFAGVAE  
ITPAEGKLMQSHPLYLCNASDDDNLEPGFISIVKLESPRRAPHPCLSLASKARMAGERGASAVLFDITEDRAAA  
EQLQQPLGLTWPVVLIIWGNDAEKLMEFVYKNQKAHVRIELKEPPAWPDYDVWILMTVVGTIFVIILASVLRIRC  
RPRHSRPDPLQORTAWAISQLATRRYQASCRQARGEWPDSGSSCSSAPVCAICLEEFSEGQELRVISCLHEFHR  
NCVDPWLHQHRTCPLCMFNITEGDSFSQSLGPSRSYQEPGRRLHLIRQHHPGHAHYHLPAAYLLGPSRSAVARPP  
RPGPFLPSQEPGMGRHHRFPRAAHPRAPGEQQRLAGAQHPYAQGWGMSHLQSTSQHHPAACPVPLRRARPPDSS  
GSGESYCTERSGYLADGPASDSSSGPCHGSSSDSVVNCTDISLQGVHGSSSTFCSSLSSDFDPLVYCSPKGDPO  
RVDMPQSVTSRPRSLDSVVPETGETQVSSHVHYHRHRHHHYKKRFQWHGRKPGPETGVPQSRPPIPRTPQPEPP  
SPDQQVTRSNSAAPSGRLSNPQCPRALPEPAPGPVDASSICPSTSSLFNLQKSSLSARHPQRKRGGPSEPTPG  
SRPQDATVHPACQIFPHYTPSVAYPWSPEAHPLICGPPGLDKRLLPETPGPCYSNSQPVWLCLTPRQPLEPHPP  
GEGPSEWSSDTAEGRPCPYPHCQVLSAQPGSEEELEELCEQAV

**Signal sequence.**

amino acids 1-26

**Transmembrane domain.**

amino acids 198-218

**N-glycosylation sites.**

amino acids 62-65, 92-95, 315-318, 481-484

**Glycosaminoglycan attachment site.**

amino acids 444-447

**Tyrosine kinase phosphorylation site.**

amino acids 171-177

**N-myristoylation sites.**

amino acids 29-34, 67-72, 263-268, 445-450, 489-494, 492-497, 574-579

**Amidation sites.**

amino acids 335-338, 565-568

**Zinc finger, C3HC4 type (RING finger).**

amino acids 272-312

**FIGURE 119A**

[illegible]

135/136

**FIGURE 119B**

CTCTTGGACTGCTCCTGAGGAGGCCCTCTTTTCCAGTAGGAAGTTAGATGGGGGTTCTCAGAAGTGGCTGATTG  
GAAGGGGACAAGCTTCGTTTCAGGGGTCTGCCGTTCCATCCTGGTTCAGAGAAGGCCGAGCGTGGCTTTCTCTA  
GCCTTGTCACCTGTCTCCCTGCCTGTCAATCACCACCTTTCTCCAGAGGAGGAAAATTATCTCCCCTGCAAAGC  
CCGGTTCTACACAGATTTACAAATTGTGCTAAGAACCGTCCGTGTTCTCAGAAAAGCCCAGTGTTTTTGCAAAG  
AATGAAAAGGGACCCCATATGTAGCAAAAATCAGGGCTGGGGGAGAGCCGGGTTCAATCCCTGTCCTCATTGGT  
CGTCCCTATGAATTGTACGTTTCAGAGAAAATTTTTTTTCTATGTGCAACACGAAGCTTCCAGAACCATAAAAT  
ATCCCGTCGATAAGGAAAGAAAATGTCGTTGTTGTTGTTTTCTGGAACTGCTTGAAATCTTGCTGTACTATA  
GAGCTCAGAAGGACACAGCCCGTCCTCCCCTGCCTGCCTGATTCCATGGCTGTTGTGCTGATTCCAATGCTTTC  
ACGTTGGTTCCTGGCGTGGAAGTGTCTCCTTTGCAGCCCCATTTCCAAGCTCTGTTCAAGTTAACTTATG  
TAAGCTTTCCTGGCATGCGGGCGCGCACCCACGTCCCGCTGCGTAAGACTCTGTATTTGGATGCCAATCCA  
CAGGCCTGAAGAACTGCTTGTTGTGTATCAGTAATCATTAGTGGCAATGATGACATTCTGAAAAGCTGCAATA  
CTTATACAATAAATTTTACAATTCTTTGG



136/136

**FIGURE 120**

MHRLMGVNSTAAAAAGQPNVSTCNCKRSLFQSMEITELEFVQIIIIIVVMMVMVVVITCLLSHYKLSARSFIS  
RHSQGRREDALSSEGCLWPSESTVSGNGIPEPQVYAPPRPTDRLAVPPFAQRERFHRFQPTYPYLQHEIDLPP  
TISLSDGEEPPPYQGPCTLQLRDPEQQLELNRESVRAPPNRTIFDSDLMDSARLGGPCPPSSNSGISATCYGSG  
GRMEGPPPTYSEVIGHYPGSSFQHQSSGPPSLLEGTRLHHTHIAPLESAAIWSKEKDKQKGHPL

**Signal sequence.**

amino acids 1-16

**Transmembrane domain.**

amino acids 41-61

**N-glycosylation sites.**

amino acids 8-11, 19-22, 188-191

**Glycosaminoglycan attachment site.**

amino acids 100-103

**N-myristoylation sites.**

amino acids 6-11, 213-218

**Amidation site.**

amino acids 78-81

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number  
**WO 2003/024392 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 16/00**

(21) International Application Number:  
PCT/US2002/028859

(22) International Filing Date:  
11 September 2002 (11.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/323,268 18 September 2001 (18.09.2001) US  
60/339,227 19 October 2001 (19.10.2001) US  
60/336,827 7 November 2001 (07.11.2001) US  
60/331,906 20 November 2001 (20.11.2001) US  
60/345,444 2 January 2002 (02.01.2002) US  
60/369,724 3 April 2002 (03.04.2002) US  
60/404,809 19 August 2002 (19.08.2002) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way,  
South San Francisco, CA 94080-4990 (US).

(72) Inventors: **FRANTZ, Gretchen**; 135 San Benito Way,  
San Francisco, CA 94127 (US). **HILLAN, Kenneth,  
J.**; 64 Seward Street, San Francisco, CA 94114 (US).  
**PHILLIPS, Heidi, S.**; 15 Pine Avenue, San Carlos,  
CA 94070 (US). **POLAKIS, Paul**; 1449 Cortez Avenue,  
Burlingame, CA 94010 (US). **SPENCER, Susan, D.**; 2395  
Paradise Drive, Tiburon, CA 94920 (US). **WILLIAMS,  
P., Mickey**; 509 Alto Avenue, Half Moon Bay, CA 94019  
(US). **WU, Thomas, D.**; 113 Elsie Street, San Francisco,  
CA 94110 (US). **ZHANG, Zemin**; 876 Taurus Drive,  
Foster City, CA 94404 (US).

(74) Agents: **KRESNAK, Mark, T.** et al.; c/o Genentech, Inc.,  
MS49, 1 DNA Way, South San Francisco, CA 94080-4990  
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
21 October 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

(57) Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mam-  
mals and to methods of using those compositions of matter for the same.



WO 2003/024392 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/28859

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C07K 16/00 US CL : 530/387.1 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/387.1  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MPSRSCH		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	WO 00/12708A2, (GENENTECH, INC.), 09 March 2000. See entire document and MPSRCH sequence search report, 06 July 2004, pct-us02-28859-57.rag, pages 1-3.	1-5, 12-14 ----- 6-11, 15
X ---E Y	WO 00/78961 A1 (GENENTECH, INC.), 28 December 2000. See claim 6, and pages 497-498, and MPSRCH search report, 06 July 2004, pct-us02-28859-57.rag, pages 3-4.	1-5, 12-14 ----- 6-11, 15
X ---E Y	US 2003/0073129A1 (BAKER et al) 17 April 2003 (17.04.2003). See claims 17-20, and MPSRCH search report, 06 July 2004, pct-us02-28859-57.rapb, pages 1-3).	1-5, 12-14 ----- 6-11, 15
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<b>* Special categories of cited documents:</b>		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 08 August 2004 (08.08.2004)	Date of mailing of the international search report <b>30 AUG 2004</b>	
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571-273-1600)	Authorized officer MINH-TAM DAVIS Telephone No. 571-272-1600	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/28859

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-15, SEQ ID NO:57

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1-15, drawn to an isolated antibody that binds to the polypeptide of SEQ ID NO:57, or variants thereof, or extracellular domain thereof. Said antibody is a monoclonal antibody, an antibody fragment, or a chimeric or humanized antibody. Said antibody is conjugated to a growth inhibitory agent, a cytotoxic agent, or a detectable label. Said antibody is produced in bacteria or in CHO cell. Said antibody induces death to a cell to which it binds.

Group 2-60, claim(s) 1-15, drawn to an isolated antibody that binds to any one of the polypeptides of SEQ ID Nos: 58-112, 114, 116, 118 or 120, or variants thereof, or extracellular domain thereof. Said antibody is a monoclonal antibody, an antibody fragment, or a chimeric or humanized antibody. Said antibody is conjugated to a growth inhibitory agent, a cytotoxic agent, or a detectable label. Said antibody is produced in bacteria or in CHO cell. Said antibody induces death to a cell to which it binds.

An antibody binding to each of the polypeptides of SEQ ID Nos: 58-112, 114, 116, 118 or 120 constitutes a distinct invention.

The inventions listed as Groups 1-60 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

An international stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. When claims to different categories are present in the application, the claims will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and a process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said process; or (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, see PCT article 17(3) (a) and 1.476 (c), 37 C.F.R. 1.475(b) and (d). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d).)

Group 1, claims 1-15, an antibody that binds to the polypeptide of SEQ ID NO:57 form a single general inventive concept.

Groups 2-60 are not linked to the single general inventive concept of Group1 because the antibodies of groups 2-60 bind to the polypeptides of SEQ ID Nos: 58-112, 114, 116, 118 or 120, that do not share the same structure and function with the polypeptide of SEQ ID NO:57 to which the antibody of group 1 binds. Further, the antibodies of groups 2-60 bind to the polypeptides of SEQ ID Nos: 58-112, 114, 116, 118 or 120 which do not share the same structure and function.